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Bruton's tyrosine kinase (Btk) is a Tec family non-receptor tyrosine kinase found in 
platelets and B-cells. In platelets, Btk has demonstrated a role in facilitating both ITAM- 
and hemITAM-mediated platelet activation. Downstream of the B-cell receptor, Btk has 
been shown to induce signalling independently of its kinase domain, suggesting it may 
have a role as a scaffold protein.  
Aims 
To determine if Btk can act as an adaptor protein in platelets and to identify if there are 
differential roles of Btk downstream of GPVI and CLEC-2. 
Methods 
Indicators of platelet activity such as aggregometry, granule release and Ca2+ 
mobilisation, along with western blotting were used to study the effect of acalabrutinib, an 
inhibitor of Btk, downstream of GPVI and CLEC-2 mediated platelet activation. To identify 
a role for Btk kinase function downstream of GPVI and CLEC-2 signalling an NFAT-
Luciferase reporter assay was used, expressing wild type or a kinase dead Btk mutant in 
Btk-deficient cells. Total Internal Reflection Fluorescence Microscopy (TIRFM) and 
Stochastic optical reconstruction microscopy (STORM) was used to investigate the co-
localisation of Btk with other signalling proteins. 
Results  
At specific Btk inhibiting concentrations of acalabrutinib, platelet aggregation downstream 
of GPVI is normal despite loss of Btk pY223, an indicator of Btk activity and PLCγ2 pY759 
(PLCγ2 active site) phosphorylation. In a cell line model, GPVI mediated signalling is 
maintained despite inhibition with acalabrutinib or expression of a kinase dead mutant of 
Btk. However, Btk kinase function is essential for CLEC-2 mediated signalling at 
submaximal concentrations of rhodocytin in platelets and in a cell line model but can be 
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overcome at high concentrations of rhodocytin. Btk colocalised more with the 
transmembrane receptor LAT than either GPVI or CLEC-2 on collagen or rhodocytin, 
respectively. A proportion of Btk colocalised with GPVI, with the localisation and clustering 
of Btk unaltered in the presence of acalabrutinib. However, Btk inhibition altered the 
clustering of GPVI suggesting a kinase dependent role of Btk in the clustering of GPVI.  
Conclusions 
Platelets can aggregate without Btk pY223 phosphorylation downstream of GPVI showing 
a scaffolding role for Btk. Furthermore, Btk does not require kinase activity to signal 
downstream of GPVI in a cell line model. Localisation of Btk does not change when its 
kinase activity is inhibited with a Btk-specific dose of acalabrutinib, suggesting kinase 
independent recruitment of Btk, providing further evidence of adaptor protein function 
downstream of GPVI.  However, Btk kinase activity is required for signalling downstream 
of CLEC-2 at submaximal concentrations, as platelets fail to aggregate when Btk pY223 is 
lost. At high concentrations of rhodocytin when Btk is inhibited, platelets can still 
aggregate. Secondary feedback is likely mediating the aggregation of platelets. This 
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1. Platelets  
1.1.1 Platelets in haemostasis 
Platelets are small anucleate cells found in the blood stream. The primary role of platelets 
is to maintain haemostasis. Without platelets, there is an increased risk of haemorrhage 
as patients with thrombocytopenia (low platelet count) have an increased risk of bleeding 
(Lo et al., 2016).   
Within the healthy vasculature due to their size, shear forces and the presence of red 
blood cells, platelets flow near to the vessel wall. Factors including endothelial production 
of nitric oxide (NO) and prostacyclin (PGI2) ensure platelets are kept in an inactive state 
(Whittle et al., 1978). Thrombosis is initiated during the rupture of an atherosclerotic 
plaque or damage to vessel walls. This exposes extracellular matrix proteins including 
fibronectin, laminin and collagen which recruit and activate platelets. Plasma circulating 
von Willebrand factor (VWF) binds to exposed collagen through its A3 domain (Bonnefoy 
et al., 2006). The A1 domain of VWF then binds to Glycoprotein 1B, (GPIbα), one of the 
four subunits of the GPIb-IX-V complex upon the platelet surface. This decreases the 
velocity of the platelets causing them to roll at low speeds over the extracellular matrix 
(Savage et al., 2002). 
Reduced platelet speed increases the likelihood of direct interactions to occur, such as 
the binding of collagen receptors GPVI and α2β1 to collagen within the sub endothelium 
matrix. These contacts with collagen are stable and induce a tyrosine kinase signal 
transduction cascade which is discussed in more detail in Section 1.3.2.  
Tyrosine kinase signal transduction results in the mobilisation of calcium (Section 1.2.1), 
causing granule secretion (Section 1.2.2) which results in a secondary wave of activation, 
leading to the activation of platelet integrin αIIbβ3 (Section 1.2.3). Upon integrin activation 
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a stable thrombus is formed due to fibrinogen crosslinking between platelets (Ma et al., 
2007).  
 
1.1.2  Platelet ultrastructure 
Platelets are anucleate cells with a volume of 7-10.5µm3 and a diameter of between 1 and 
3.5µm (Giles, 1981, Tocantins, 1938).  
Platelet shape is maintained by its cytoskeleton which consists of microtubules and actin 
filaments. Consisting of α and β tubulins, microtubules are bundles which form a marginal 
ring, maintaining cell integrity and a resting discoid shape (Schwer et al., 2001). 
Furthermore, actin filaments are located outside the microtubule band and are 
concentrated beneath the plasma membrane further contributing to the discoid shape.  
Within the platelet cytoplasm are secretory granules – α-granules and dense granules. α 
granules are the most abundant type, with approximately 80 per cell. They contain 
molecules such as fibrinogen, von Willebrand factor (VWF) and P -selectin (Maynard et 
al., 2007). Furthermore, α granules contain coagulation factors, growth factors, 
chemokines and intracellular pools of several transmembrane receptors such as GPIb-V-
IX and αIIbβ3; therefore the levels of these receptors at the plasma membrane increase 
upon activation (Berger et al., 1996).  
Dense granules are far less abundant, with approximately 3-5 per platelet. They are larger 
and contain ATP, ADP, Ca2+, Mg2+ and serotonin (Meyers et al., 1982). The contents of 
dense granules are involved in regulating paracrine (same platelet) and autocrine 






1.2 Common platelet activation and thrombus formation 
1.2.1  Calcium release and granule release  
Calcium mobilisation is a downstream event common to all platelet receptors. In resting 
platelets, cytosolic calcium is maintained at approximately 100nM and this increases upon 
activation. At 1μM, calcium can initiate several processes within the platelet including, 
shape change, degranulation and inside-out activation of αIIbβ3 and therefore 
aggregation (Varga-Szabo et al., 2009). Elevation of calcium occurs from two major 
sources: release from intracellular stores and extracellular entry. 
Both methods require activation of a phospholipase C isoform (PLC), a key family of 
enzymes in the platelet. Different receptors activate one of the two isoforms within 
platelets, PLCγ2 and PLCβ. Upon activation of PLCγ2, phosphoinositide-4,5-
bisphosphate (PIP2) is hydrolysed to inositol-1,4,5-trisphosphate (IP3) and 1,2-diacyl-
glycerol (DAG) (Bird et al., 2004). IP3 induces Ca2+ release from its stores in the 
endoplasmic reticulum by activating the Ca2+ permeable ion channel IP3R. This results in  
the release of calcium from intracellular stores (O'Rourke et al., 1985). DAG activates 
protein kinase C (PKC) and together with the increase in calcium leads to degranulation 
and conformational change of αIIbβ3 (Kaibuchi et al., 1983, Shattil and Brass, 1987).  
After the initial wave of platelet activation, platelets release their granular contents as 
described in Section 1.3. The mechanism of platelet granule release is dependent on 
SNARE proteins – soluble NSF (an ATPase) attachment protein receptors (Blair and 
Flaumenhaft, 2009).  SNAREs are membrane associated proteins situated on platelet 
granules and the plasma membrane. The close interaction of the granule SNARE and 





1.2.2 Shape change and spreading 
As mentioned previously in Section 1.1.1, resting platelets are discoid in shape due to 
their actin and microtubule cytoskeleton. Both structures are polarised, meaning they 
dismantle from one end and grow in another. This is responsible for inducing platelet 
shape change.  
Upon activation, the platelet initially turns spherical. This change in shape from discoid to 
spherical is due to the dismantling of actin components to form filamentous actin 
structures. In fact, in resting platelets 60% of actin is not in the filamentous form and there 
is a large pool that can form rapid filament growth upon activation (Hartwig and DeSisto, 
1991).  
During early adhesion and spreading on fibrinogen and laminin, the filamentous actin (F 
actin) can also form nodules within the platelet. These are dense F actin regions that 
contain proteins such as Src family kinases and Wiskott-Aldrich syndrome protein 
(WASP) (Calaminus et al., 2008, Poulter et al., 2015). The dynamic actin structures grow 
at the polarised end to form spiky protrusions – filopodia. The platelet then flattens, with 
branched actin filaments formed called lamellipodia (Bearer, 1995). Granules and 
organelles then become central and the final morphology of the spread platelet resembles 
a fried egg. This increase in surface area may act to provide a larger area for secretion 
and therefore more receptors, including αIIbβ3 to get to the surface to bind fibrinogen 
(Moroi et al., 2020). Furthermore, a larger surface from spreading provides more 
membrane to interact with the coagulation cascade, with some steps of this cascade 
being membrane dependent (Wu, 2015).  
 
1.2.3  Release of ADP as a secondary mediator 
After initial activation, the release of ADP from dense granules can initiate a second wave 
of platelet activation in an autocrine and paracrine manner. This is due to ADP receptors, 
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P2Y1 and P2Y12 being present on the platelet surface. P2Y12 is more abundant, with 
P2Y1 only accounting for around 20 to 30% of total ADP binding sites (Savi et al., 1998).  
P2Y1 and P2Y12 are G-protein coupled receptors (GPCRs) and upon ADP binding 
induces signalling resulting in calcium mobilisation and aggregation (Jin and Kunapuli, 
1998). P2Y1 initiates ADP mediated shape change and platelet aggregation through Gq 
proteins initiating a transient rise in cytoplasmic Ca2+ (Jin et al., 1998). Whereas P2Y12 
receptors couple to Gi proteins, resulting in the amplification and stabilisation of the 
aggregation response (Jin and Kunapuli, 1998) . 
 
1.2.4  Thromboxane A2 production and release as a secondary 
mediator 
Many agonists have been shown to induce Thromboxane A2 generation (TxA2), including 
ADP (Jin et al., 2002) and collagen (Valles et al., 1991). TxA2 is produced from 
phospholipids by a multistep pathway. Initially, phospholipids are hydrolysed to 
arachidonic acid via phospholipase A2. Then the cyclooxygenase enzyme 1 (COX-1) 
catalyses the production of prostaglandin H2, and finally thromboxane A2 is produced 
from thromboxane synthase (Hamberg et al., 1975). Similarly to ADP, the thromboxane 
A2 receptor TP-α is a GPCR. This receptor facilitates a secondary wave of activation 
through Gq protein mediated activation of PLCβ (Hirata et al., 1996).  
 
1.2.5  Integrin shape change and fibrinogen binding 
On circulating platelets, the integrin αIIbβ3 is present in a ‘closed’ confirmation (Figure 
1.2.6.1). Made up of the αIIb subunit and the β3 subunit in a heterodimer, it is one of the 
most abundant proteins on the platelet surface with 60,000 – 80,000 copies (Burkhart et 
al., 2012). Resting αIIb is in a bent conformation, often likened to a knee joint. When the 
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‘knee’ is bent, the conformation of the integrin is closed and therefore has a low affinity to 
bind fibrinogen (Xiong et al., 2002).  
Upon platelet activation through either primary or secondary mediators, intracellular 
signalling results in the calcium flux and activation of Protein Kinase C. This results in 
activation of Talin and other cytoskeletal proteins to unclip the intracellular domain. This 
results in transformation of the extracellular domain (extension of the ‘knee’) into a high 
affinity state for ligands. This is termed inside-out signalling. The open confirmation of the 
integrin has an increased affinity to bind to arginine-glycine-aspartic acid (RGD)-
containing ligands, which include VWF, fibrin and the major ligand, fibrinogen (Springer et 
al., 2008). The binding of platelets to fibrinogen leads to crosslinked bridges between 
platelets, allowing the formation of aggregates and leading to platelet plug formation (Ma 
et al., 2007). 
Due to its vital role in stability and growth of a thrombus, αIIbβ3 is also a therapeutic drug 
target. The clinically used antagonist integrelin reversibly binds and inhibits the integrin by 
preventing the binding of its other agonists (O'Shea and Tcheng, 2002).   
 
1.2.6 Stable thrombus formation 
After the initiation of the platelet plug via previously discussed common platelet activation 
events (Section 1.2.1- 1.2.5), a final step must follow to stabilise the platelet plug into a 
thrombus. This prevents the disaggregation of platelets. Attachment of fibrinogen to 
αIIbβ3 initiates outside in signalling, and results in cytoskeletal reorganisation. This leads 
to the clot retraction, and resulting in increased stability of the haemostatic plug 
(Payrastre et al., 2000) (Section 7, Figure 1.2.6.1).  
Whilst platelet activation and plug formation is occurring, the coagulation cascade 
becomes active. This involves activation of coagulation factors ultimately leading to the 
stabilisation of the clot. Prothrombin is cleaved to thrombin, which can mediate the 
formation of soluble fibrinogen to long insoluble threads of fibrin. Thrombin is also a 
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powerful activator of platelets through the PAR1 receptor (Kim et al., 2009a). Fibrin forms 
a mesh like network on aggregated platelets, providing structural stability to the clot 





Figure 1.2.1 Schematic of haemostasis in response to vascular injury 
(1) Platelets, with the receptors shown on their surface, in circulation are maintained in a 
quiescent state by the released of NO and PGI2 from intact endothelial cells. (2) Injury to 
blood vessel exposes VWF and collagen present in the sub-endothelial matrix. At high 
shear rates, circulating platelets tether to the VWF through their GPIb-V-IX complex, 
which slows-down their movement. (3) This tethering facilitates platelet rolling along the 
sub-endothelium. (4) This reduced speed allows for GPVI to bind to collagen, which 
stimulates platelet signalling causing affinity upregulation of integrin αIIbβ3 and (5) 
secretion from α and dense granules. (6) Release of TxA2 and ADP and activate more 
platelets in an autocrine and paracrine manner. (7) Activated integrin αIIbβ3 present on 
the platelet surface can now bind to fibrinogen (shown in red), which results in a platelet 
















1.3 GPVI and FcRɣ  
After initial tethering of the platelet to the ECM, Glycoprotein VI, GPVI plays a major role 
in inducing platelet activation. GPVI is a receptor for collagen (Moroi et al., 1989), with 
around 9000 copies present upon the platelet surface (Burkhart et al., 2012). GPVI is 
constitutively associated with Fc receptor γ chain (FcRɣ) (Gibbins et al., 1997). The FcRɣ 
chain contains an immunoreceptor tyrosine-based activation motif (ITAM) - two YxxL/I 
sequences, with 7 amino acids between each of the two motifs (Reth, 1989).  
The targeting of GPVI as an anti-thrombotic therapy is desirable due to its exclusive 
expression on the platelet-megakaryocyte lineage (Watkins et al., 2009, Senis et al., 
2007).  
People deficient in GPVI either through genetic mutations (Matus et al., 2013), or 
autoimmune antibodies against GPVI have mild bleeding disorders such as bruising 
(Moroi et al., 1989). Bruising is a well-tolerated side effect that can indicate altered 
hemostasis. After capillary damage, hemostasis may take longer to initiate and this 
causes more blood to flood to the area, causing bruising. This side effect is favoured as 
opposed to life threatening bleeds or gastrointestinal bleeding (often a cause of diarrhoea) 
which has been observed with some antiplatelet therapies (Mauri et al., 2014). Therefore, 
targeting GPVI and its signalling pathway may provide clinical benefit.  
GPVI is a significant contributor to arterial thrombosis upon plaque rupture (Massberg et 
al., 2002).  Studies using patients naturally deficient in GPVI or using function blocking 
anti GPVI antibodies have identified that GPVI is indispensable for the formation of stable 
aggregates on collagen (Moroi et al., 1996). Genetically modified mice to be deficient in 
GPVI (GPVI null) or FcRɣ (FcRɣ null) animals using targeted gene deletion also have a 
drastically reduced thrombus volume on collagen (Kato et al., 2003). Taken together, 




GPVI is cleaved by the Metalloproteinases of the a disintegrin and metalloproteinase 
(ADAM) family (Bergmeier et al., 2004, Gardiner et al., 2007, Bender et al., 2010). Using 
antibodies to induce cleavage of GPVI, and therefore decreasing its expression in mouse 
models, has also further provided evidence that GPVI deficiency is protective against a 
model of arterial thrombosis, induced by either ferric chloride or laser injury in the carotid 
arteries (Massberg et al., 2003). GPVI deficiency through this method has also been 
shown to be protective against a model of thromboembolism, where a bolus of collagen 
and epinephrine is injected into the mouse. In untreated mice, the percentage of mice that 
survived the procedure was very low. All the JAQ1 (anti GPVI antibody) treated mice 
survived. It was hypothesised that this could be due to diminished platelet counts as 
transient thrombocytopenia occurs when mice are injected with JAQ1. However, the 
procedures were performed after the platelet counts had returned to normal, but there 
was still no expression of GPVI on platelets when assessed by western blot (Nieswandt et 
al., 2001).  
Mice deficient in GPVI via antibody depletion have a moderately increased bleeding time 
when compared to IgG treated mice. When compared against mice that have αIIbβ3 
depletion (using the same method, but a different antibody), the bleeding time is shorter, 
suggesting that GPVI is a more desirable anti-platelet to protect against thrombosis but 
not greatly alter hemostasis (Nieswandt et al., 2001).  
In contrast, a different group investigated the tail bleeding times of GPVI null mice. 
Compared to WT mice there is no significant difference in the bleeding time of these 
animals. Although, 3 of the 13 GPVI null  mice subjected to the assay had a bleeding time 
of over 600 seconds, whereas no WT mice did (Kato et al., 2003). This suggests that in 
some individuals, GPVI is pivotal for hemostasis, whereas for others it is not. Another 
group has also published tail bleeding times to assess hemostasis with the GPVI null 
mice. There is no significant difference in the bleeding time when compared to WT 
controls, although it is increased by approximately 30 seconds. Whereas similarly to 
antibody depletion experiments, β3 null mice do have a prolonged bleeding time (Lockyer 
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et al., 2006). The sample size used for these experiments is much larger and therefore 
likely to be more reliable. Only the averages for each data were published and therefore it 
would have been interesting to identify if there were any outliers (bleeding times of over 
600 seconds) as observed in the hands of Kato et al., 2003.  
In humans, patients that have naturally developed anti-GPVI antibodies and therefore 
depleted GPVI surface levels do experience altered hemostasis such as easy bruising, 
epistaxis and gingival bleeding (Sugiyama et al., 1987, Arthur et al., 2007). This is 
consistent with patients naturally deficient in GPVI experiencing a mild bleeding diathesis 
(Moroi et al., 1989).  Of note, these patients with autoimmune antibodies also have 
thrombocytopenia. This is because platelets that are coated with immunoglobulin G (IgG) 
are recognised and then phagocytosed by macrophages present within the spleen (Crow 
and Lazarus, 2003). The bleeding phenotype observed in these patients may be due to 
lack of platelets, as opposed to platelet function. Therefore, when developing antiplatelet 
therapies special care should be taken to ensure thrombocytopenia is not induced.  
Nonetheless, GPVI is a desirable therapeutic target. There is development of a soluble 
GPVI-Fc fusion protein, Revacept (Ungerer et al., 2011), and downstream tyrosine kinase 
inhibitors such as Btk (Busygina et al., 2018) and Syk (Eeuwijk et al., 2016) to inhibit 
GPVI mediated signalling. Platelet activation by atherosclerotic plaque material is blocked 
by Revacept and is currently in Phase II clinical trials (Schüpke et al., 2019). This is a 
promising clinical target, as it does not seem to cause a bleeding phenotype, or 
thrombocytopenia which has been observed in patients with auto-antibodies against GPVI 
(Schüpke et al., 2019) 
 
1.3.1 GPVI Ligands 
Collagen is the main endogenous ligand for GPVI and plays the major role in facilitating 
platelet activation under shear stress. Upon vessel damage, collagen acts as an adhesive 
protein for platelets either directly through GPVI, α2β1 or indirectly through GPIb-IX-V, as 
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well as an inducer of platelet aggregation. Collagen was identified as a mediator of 
thrombus formation as treatment of the sub-endothelium with collagenase, which 
denatures the collagen, prevents aggregation of platelets (Baumgartner and 
Haudenschild, 1972). Further cell line studies confirmed that collagen is a ligand for GPVI 
and that it promotes sustained signalling through this receptor (Tomlinson, et al 2007). 
Integrin α2β1 can also bind collagen. GPVI preferentially binds GPO amino acid 
sequences, whereas the integrin preferentially binds to GFOGER amino acid sequences 
(Jarvis et al., 2008). Using an α2β1 function blocking antibody, the platelet response to 
collagen was altered. However the response to CRP-XL, a GPVI specific agonist 
consisting of  GPO repeats, was not (Jarvis et al., 2002). The response to horm collagen 
(native type I fibrils from equine tendon and the collagen that was used in this study) was 
least affected by the function blocking antibody. Horm collagen was also confirmed to 
bind to GPVI, inducing activation and shape change, using FcRɣ chain deficient mice 
(Jarvis et al., 2002). The lack of response to any GPVI agonist observed in FcRɣ deficient 
mice is due the lack of expression of GPVI on the platelet surface, which is dependent on 
FcRɣ chain expression in vivo (Nieswandt et al., 2000, Kato et al., 2003). 
Fibrin is another endogenous ligand which causes similar tyrosine phosphorylation of the 
GPVI signalling cascade to collagen (Alshehri et al., 2015a) and can induce full spreading 
of murine platelets. Another independent group also identified that recombinant dimeric 
GPVI binds to fibrin, and further confirmed these results using GPVI deficient platelets as 
procoagulant activity (polymerisation of fibrinogen) was reduced (Mammadova-Bach et 
al., 2015). In those initial studies, neither group identified fibrinogen as being a ligand for 
GPVI using binding studies. Neither monomeric (shed from platelets) or recombinant 
dimeric GPVI became bound to fibrinogen (Alshehri et al., 2015a, Mammadova-Bach et 
al., 2015). Recently, it has been reported in human platelets that fibrinogen can bind and 
stimulate GPVI signalling as demonstrated using platelets deficient in GPVI not being able 
to spread on fibrinogen. Furthermore, platelets from mice expressing human GPVI fully 
spread whereas in contrast, WT mice do not (Mangin et al., 2018). Fibrinogen circulates 
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in plasma, which raised the question that if fibrinogen is a ligand for GPVI, why are 
platelets not constantly activated? However it has be theorised that binding of fibrinogen 
to monomeric GPVI would not induce the required clustering for activation, and therefore 
only when presented as a monolayer can it induce clustering and activation as evident in 
the work by Onselaer et al., 2017.   
Recent work has come out opposing plasma fibrin as a GPVI ligand. Fibrin formed from 
recombinant fibrinogen looks drastically different to fibrin formed in plasma when 
assessed using super resolution microscopy. Fibrin formed in plasma has incorporated 
plasma proteins that cause large differences in the thickness of the fibrin strands and may 
be blocking GPVI binding and activation (Zhang et al., 2020) 
GPVI does have exogenous ligands such as convulxin and collagen related peptide 
(CRP) respectively. Convulxin, a snake venom toxin, is able to induce platelet 
aggregation and adhesion (Francischetti et al., 1997, Jandrot-Perrus et al., 1997). It 
induces robust tyrosine phosphorylation in a cell line model (Tomlinson et al., 2007). CRP 
contains 10 repeats of Gly-Pro-Hyp, as this sequence is selectively bound by GPVI. It was 
found to induce potent platelet aggregation (Morton et al., 1995), however this only occurs 
after cross linking to induce a quaternary structure, mimicking collagen.  
 
1.3.2  Structure 
GPVI is approximately 62 kDa and belongs to the immunoglobulin superfamily. It has a 
total of 319 amino acids, with an additional N-Terminal 20 amino acids of signal sequence 
which is cleaved once GPVI reaches the membrane (Clemetson et al., 1999, Jandrot-
Perrus et al., 2000). It is constitutively expressed with the Fc receptor ɣ chain (FcRɣ) via a 
salt bridge between an Aspartic acid and an Arginine in the transmembrane domains of 
FcRɣ and GPVI respectively (Berlanga et al., 2002). The FcRɣ chain is a covalently linked 
homodimer, each chain containing an ITAM (Reth, 1989).  
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GPVI additionally contains a proline rich region where the Src family kinases Fyn and Lyn 
can bind via their SH3 domains (Ezumi et al., 1998, Suzuki-Inoue et al., 2002). It is 
hypothesised that some activated Lyn is constantly associated with the receptor 
(Schmaier et al., 2009). This ‘primed and ready to go’ complex enables fast initiation of 
signal transduction upon vessel injury; however it is unclear what prevents unwanted 
GPVI activation. It is suggested that the FcRɣ chain may be dephosphorylated at a rate 
quicker than phosphorylation, and only upon GPVI activation is this overcome (Senis et 
al., 2014) and the level of receptor clustering plays a part. 
On the surface of platelets, GPVI can be present as a monomer or a dimer (Miura et al., 
2002). The monomeric form is predominant on resting platelets, with this structure having 
a lower avidity for binding collagen (Jung et al., 2012). On an activated platelet, the 
dimeric form is more prevalent and Horii et al.¸ identified using molecular docking that the 
extracellular domains locate in a back to back dimeric structure which form the binding 
site for collagen (Horii et al., 2006). This study formed the basis for future work to identify 
that GPVI also expresses as a dimer upon the platelet surface in a resting state (Jung et 
al., 2009) and has a much higher affinity to binding collagen and CRP-XL (Jung et al., 
2012).  
Furthermore, it has been identified that GPVI can form oligomers on the platelet surface, 
with different GPVI agonists inducing a differing level of GPVI clustering (Poulter et al., 
2017). This offers another mechanism of platelet regulation. The formation of oligomers 
may help to recruit signalling molecules required for GPVI signalling transduction. 
The regulation of GPVI clustering is unknown. Tetraspanins are a family of 
transmembrane proteins which regulate lateral diffusion and clustering of proteins. 
Tetraspanin Tspan9 is expressed on platelets, and knockouts of this have impaired GPVI 
function so it was believed that Tspan9 may play a part in modifying clustering of GPVI 
(Protty et al., 2009). However, Tspan9 does not influence clustering when assessed using 
direct stochastic optical reconstruction microscopy (dSTORM) but does influence GPVI 
lateral diffusion when assessed using single particle tracking.  
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The clustering of GPVI is known to be Syk and Src family kinase independent. Using 
inhibitors at a concentration that inhibit phosphorylation and spreading, GPVI clusters 
were still able to be observed (Poulter et al., 2017).  
Further regulation of GPVI signalling may be down to lipid rafts. One group found a 
significant amount of GPVI confined to lipid rafts in resting platelets (Wonerow et al., 
2002). Whereas another independent group failed to identify any GPVI associated to lipid 
rafts in resting platelets, but large recruitment of GPVI to lipid rafts upon GPVI activation 
with convulxin (Locke et al., 2002). Recent proteomic analysis of lipid rafts from resting 
and GPVI stimulated platelets identified GPVI in lipid rafts in stimulated samples, and in 
basal samples but to a lesser extent (Izquierdo et al., 2019). 
 
1.3.3 Signalling 
Binding of Collagen or CRP-XL to GPVI initiates receptor clustering. This results in the 
phosphorylation of the ITAM within the FcRɣ chain by Src family kinases Fyn and Lyn 
(Ezumi et al., 1998, Quek et al., 2000). This phosphorylated ITAM then recruits Syk via its 
dual SH2 domains (Chen et al., 1996). Syk is then phosphorylated by SFK’s at position 
Y352 (Kurosaki et al., 1994), and is able to then undergo autophosphorylation at site 
Y525/6 (El-Hillal et al., 1997). The phosphorylation and activation of Syk enables 
phosphorylation of the adaptor protein Linker of Activated T Cells (LAT). Phosphorylated 
LAT, localised in lipid rafts (Wonerow et al., 2002) recruits Growth factor receptor-bound 
protein (Grb2), Grb2-related adapter protein downstream of Shc (Gads) and SH2 domain 
containing leukocyte protein of 76kDa (SLP-76) (Asazuma et al., 2000, Gross et al., 
1999a, Hughes et al., 2008), forming the LAT signalosome. The LAT signalosome is 
essential in recruitment of phospholipase C γ2 (PLCγ2), with phosphotyrosine residues in 
LAT providing docking sites for PLCγ2 via its SH2 domain (Watanabe et al., 2001). 
In addition to tyrosine kinases, lipid kinases are also activated downstream of GPVI. 
Phosphoinisitol 3 kinase (PI3K) is activated, which liberates PI(3,4,5)P3  (PIP3) from 
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PI(4,5)P2, (PIP2) (Pasquet et al., 1999a). PIP3 recruits Btk via its pleckstrin homology 
domain to lipid rafts present at the plasma membrane (Bolland et al., 1998, Várnai et al., 
1999). Within the lipid rafts, Btk can be phosphorylated by SFK Lyn and Syk (Park et al., 
1996, Rawlings et al., 1996). Additionally, both SFK’s and Syk can also phosphorylate 
PLCy2 (Liao et al., 1993, Rodriguez et al., 2001), however it is believed the major kinase 
regulating PLCγ2 phosphorylation is Btk (Quek et al., 1998). GPVI signalling can be 





Figure 1.3.1 Platelet GPVI signalling 
Collagen binds to GPVI and induces receptor clustering. This results in phosphorylation of 
the constitutively associated SFK’s, which phosphorylate the dual YxxL motifs (ITAMS) in 
the FcRɣ chain. This provides a site for Syk via its dual SH2 domains and Syk is 
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phosphorylated by SFK’s. Syk is responsible for phosphorylating LAT, which recruits 
adaptor proteins SLP-76, Gads and Grb2. PI3K becomes active and is recruited to the 
signalosome. It catalyses the production of PIP3 from PIP2, which recruits Btk and PLCγ2 
where they can now interact with LAT in the signalosome. Btk is phosphorylated by SFK’s 
or Syk, and together phosphorylated Syk and Btk mediate phosphorylation of PLCγ2 
resulting in PKC activation and calcium release. Kinases are shown in blue, adaptor 
proteins are shown in yellow and orange. Lipid metabolism shown with black arrows and 
tyrosine phosphorylation shown with green arrows.  
 
1.3.4  Non haemostatic functions  
Although its primary function is haemostasis, GPVI has been implicated in non-
haemostatic functions such as the advancement of cancer metastasis. Galectin, a protein 
present on colon cancer cells, has been shown to bind GPVI (Dovizio et al., 2013). 
Furthermore, recent work by the Nieswandt group has identified that inhibiting GPVI using 
a function blocking Fab fragment, efficiently impairs platelet-tumour cell interaction and 
tumour metastasis (Mammadova-Bach et al., 2020).  
Platelets are known to play a role in maintaining vascular integrity, as induced 
thrombocytopenic animals have endothelial thinning when analysed histologically. These 
animals also experience petechiae due to red blood vessel leakage via a more permeable 
endothelial layer (Hamberg et al., 1975, Kitchens and Weiss, 1975). This process is 
mediated by platelets and more specifically is maintained by platelet GPVI (Watson et al., 
2010). The original hypothesis was that as laminin and collagen, GPVI agonists, are 
embedded in the endothelial layer and upon rupture, GPVI can bind and become active. 
The intracellular signalling results in α granule secretion, which promotes angiogenesis 
and lymphatic endothelial cell growth to repair the damaged endothelial layer (Kisucka et 
al., 2006).  
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The working hypothesis for GPVI being a key player in the maintenance of vascular 
integrity has been expanded. It is known that platelets can protect against haemorrhage 
during inflammation, as thrombocytopenic mice have augmented intra-alveolar bleeding 
during lung inflammation. This observed bleeding is not a result of thrombocytopenia, as a 
low platelet count does not cause haemorrhage unless there is inflammation present 
(Goerge et al., 2008). The proposed mechanism is that platelets act to seal the breach 
within the vessel wall after binding via GPVI to prevent inflammatory bleeding which was 
investigated using GPVI knockout platelets (Goerge et al., 2008, Gros et al., 2015). Of 
note, more severe inflammatory bleeding occurs in GPVI and CLEC-2 double knockout 
platelets as opposed to single GPVI knockouts, as CLEC-2 can provide some protection 
in this model which will be discussed later (Rayes et al., 2018).  
Furthermore, it has been implicated that GPVI can play a protective role in another 
inflammatory condition – sepsis, induced by Klebsiella pneumonia. Using a mouse model 
and antibody induced GPVI deficiency, bacterial load in the lungs and some distant 
organs was increased following infection with K. pneumonaie (Claushuis et al., 2018). 
GPVI activation promotes platelet leukocyte interactions, leading to enhanced 
phagocytosis of the bacteria. Interestingly, although GPVI has been shown to mediate 
platelet activation in response to Staphylococcus aureus (Hu et al., 2011), there are 
currently no reports that K. pneumonaie directly activates GPVI.  
However, it is not clear whether GPVI can be protective in all methods of inducing sepsis. 
Using GPVI deficient mice in a cecal ligation and puncture model did not exacerbate 
clinical severity, whereas a receptor which has similar intracellular signalling as GPVI, 
CLEC-2, deficiency did (Rayes et al., 2017). The differences in bacteria and receptor 






1.4 ITAM signalling in other cells 
ITAM’s are not exclusive to platelets. ITAM’s are commonly expressed within the 
hematopoietic lineage including B and T lymphocytes, macrophages and dendritic cells 
(Underhill and Goodridge, 2007). The B cell receptor (BCR) and T cell receptor (TCR) 
also signal through ITAM motifs.  
The BCR signalling pathway is similar to GPVI signalling. BCR engagement induces 
phosphorylation of the ITAM by Src family kinases, creating docking sites for Syk via its 
SH2 domains (Rolli et al., 2002). PI3K is activated leading to recruitment of Btk via PIP3 
(Saito et al., 2001). The formation of a signalosome is mediated by the adaptor protein B 
cell-linker molecule (BLNK) as opposed to LAT used for GPVI signalling, and Btk is able 
to be phosphorylated by Syk or Lyn (Rawlings et al., 1996, Park et al., 1996, Yang and 
Desiderio, 1997). Recruitment of proteins to the signalosome enables phosphorylation 
and activation of PLCγ2, similarly to platelets.  
The TCR signalling is divergent from BCR and platelet GPVI signalling due to differential 
expression of proteins; such as Zap-70 as opposed to Syk, lymphocyte-specific protein 
tyrosine kinase, (Lck) as opposed to Lyn, IL2-inducible T-cell kinase – Itk as opposed to 
Btk.  
However, there are similarities. Upon TCR stimulation, Lck becomes active and 
phosphorylates the ITAMS present within the subunits of the receptor complex. This is 
comparable to how FcRɣ chain is phosphorylated after GPVI stimulation. This leads to 
recruitment of Zap-70, which is then able to phosphorylate LAT and SLP-76 to mediate 
the formation of the LAT signalosome. Itk is recruited via the production of PIP3 from 
activated PI3K and interacts with SLP-76 and LAT via its SH2 and SH3 domains. Itk is 






CLEC-2 is a 32 kDa type II transmembrane protein (Suzuki-Inoue et al., 2006) encoded 
for by the CLEC1B gene present on chromosome 12 (Navarro-Núñez et al., 2013).  
CLEC-2 is referred to as a (hem)ITAM, due to it containing one YxxL motif within its 
intracellular domain as opposed to the dual YxxL motif’s present in an ITAM receptor 
(Hughes et al., 2013).  
There are 2016 ± 239 copies of CLEC-2 present on the platelet surface as analysed by 
flow cytometry (Gitz et al., 2014), consistent with the Burkhart proteomic study which 
reported 3700 copies per platelet (Burkhart et al., 2012). In contrast, mouse platelets 
express a considerably larger amount of CLEC-2, despite their smaller size, 
(approximately 20x more copies) (Dunster et al., 2020). The discrepancies in copy 
number may be related to function. CLEC-2 signalling may be more important in 
maintaining hemostasis for murine platelets, and this will be discussed in later Sections.  
In contrast to GPVI, CLEC-2 expression is not limited to platelets and megakaryocytes 
(Jandrot-Perrus et al., 2000). CLEC-2 is expressed on liver sinusoidal endothelial cells 
(Chaipan et al., 2006), neutrophils and macrophages (Kerrigan et al., 2009). 
 
1.5.1  Ligands 
The first identified exogenous ligand, rhodocytin, was purified from Calloselasma 
rhodostoma (Shin and Morita, 1998). Before the identification of CLEC-2, rhodocytin was 
initially thought to interact with GPIbα on the platelet surface (Suzuki-Inoue et al., 2001). It 
was also originally called aggretin, and was also believed to interact with α2β1, as aggretin 
conjugated to sepharose was able to bind α2β1 loaded liposomes (Suzuki-Inoue et al., 
2001). Although this result is controversial as Eble et al., did not identify any binding 
between recombinant or WT α2β1 which had been purified from platelets and immobilised 
rhodocytin. CLEC-2 was confirmed as the specific receptor that the snake venom 
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activates using knockout mouse models and function blocking antibody studies 
(Bergmeier et al., 2001).  
Rhodocytin assembles as a tetramer composed of two α and two β chains (Shin and 
Morita, 1998). It induces tyrosine phosphorylation of CLEC-2 and many of the signalling 
molecules shared with the GPVI signal transduction pathway (Parguina et al., 2012). 
Rhodocytin induces activation of CLEC-2 by inducing clustering of the receptor, causing 
platelet aggregation with a lag phase (Nagae et al., 2014, Watson and O'Callaghan, 
2011). 
Fucoidan has also been proposed as a ligand for CLEC-2. Indeed, fucoidan does induce 
platelet aggregation and granule release (Manne et al., 2013). Phosphorylation of Syk, 
LAT, SFK and PLCɣ2 is also observed, and is lost when treated with an SFK and Syk 
inhibitor, suggesting this agonist behaves similarly to a (hem)ITAM agonist. FcRɣ chain 
knockout and CLEC-2 deficient mice were used to confirm that Fucoidan is an agonist for 
CLEC-2. Aggregation was lost at low fucoidan concentrations in the CLEC-2 knockout but 
maintained in the GPVI knockout (Manne et al., 2013). Further work using a higher 
concentration of fucoidan identified that CLEC-2 knockout mice can still undergo partial 
aggregation suggesting another receptor may also be partly responsible for mediating 
platelet activation. Indeed, using a double knockout model of GPVI and CLEC-2, no 
aggregation was observed in these mice even at high concentrations of fucoidan (Alshehri 
et al., 2015a). This demonstrates that Fucoidan can activate CLEC-2, but also partially 
activate other receptors.  
More recently, a study has identified that fucoidan does not match the phosphorylation 
profile of rhodocytin, with key sites on Syk and PLCɣ2 not being phosphorylated. 
Furthermore BAY 61-3606, a Syk inhibitor did not inhibit fucoidan mediated platelet 
aggregation (Kardeby et al., 2019). This is in contrast to previous studies which used the 
Syk inhibitors OXSI-2 and Go6976 which ablated the response to fucoidan (Manne et al., 
2013). Both papers identifying Syk as the target of these inhibitors were from the same 
group (Bhavaraju et al., 2008, Getz et al., 2011). Indeed, Go-6976 was originally a protein 
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kinase C inhibitor and OXSI-2 is not deemed to be specific (Bhavaraju et al., 2008, Yaron 
et al., 2016). Therefore the inhibition observed with these ‘Syk’ inhibitors led the authors 
to believe that fucoidan was activating CLEC-2 signalling through Syk (Manne et al., 
2013), when inhibition is likely to be due to off target effects.  
The endogenous ligand, Podoplanin (also known as aggrus), is present throughout the 
body such as on lymphatic endothelial cells, cancer cells, brain cells, lung endothelial 
cells and kidney podocytes (Astarita et al., 2012). Podoplanin is not found circulating in 
the blood, and podoplanin has minimal expression in the subendothelium in the inferior 
vena cava vessel wall.  However it is upregulated in the inflammatory condition deep vein 
thrombosis (DVT) (Payne et al., 2017). 
Podoplanin is a glycoprotein, and upon glycosylation can bind CLEC-2. It binds to CLEC-
2 in a similar way to rhodocytin (Nagae et al., 2014) and activates platelets leading to 
platelet aggregation (Suzuki-Inoue et al., 2007). Like rhodocytin, Podoplanin mediated 
aggregation also has a characteristic lag phase before inducing full aggregation in vitro 
(Chang et al., 2015, Christou et al., 2008). Platelet aggregation induced by cancer cells 
also has a characteristic lag phase and has been implicated in cancer metastasis (Kunita 
et al., 2007, Suzuki-Inoue et al., 2007). 
It has been recently discovered that a product of intravascular haemolysis, hemin (the 
ferric, Fe3+ form of heme) is an agonist of CLEC-2. It induces aggregation, granule 
release and αIIbβ3 activation. Platelets could still aggregate when hFc-GPVI was 
preincubated with hemin, but not when hFc-CLEC-2, identifying that this was the true 
receptor (Bourne et al., 2020). 
 
1.5.2 Structure   
CLEC-2 has a cytoplasmic N-terminal domain, a single transmembrane region and 
extracellular C-terminal domain. Encompassed within the extracellular domain is a stalk 
region and a carbohydrate-like recognition domain for binding carbohydrates.  
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The cytoplasmic region of CLEC-2 consists of 31 amino acids. Within the cytoplasmic 
domain there is a single YxxL sequence – the hemITAM.  
CLEC-2 is expressed on the surface as a homodimer (Figure 1.5.1), bringing two adjacent 
hemITAMs within close proximity (Watson et al., 2009).  Like GPVI, clustering of CLEC-2 
upon the surface determines the downstream signalling. Rhodocytin and podoplanin have 
two adjacent binding sites identified through crystallography (Hooley et al., 2008, Kato et 
al., 2008) and upon binding, it induces CLEC-2 clustering. Furthermore, evidence that the 
number of oligomerised CLEC-2 receptors increases upon activation with rhodocytin also 
supports this (Hughes et al., 2010b). 
CLEC-2 undergoes glycosylation in the platelet. However, the reason for this is unknown. 
recombinant unglysocylated CLEC-2 expressed in bacteria was still able to bind to 
rhodocytin suggesting glycosylation does not modify the binding of CLEC-2 to its snake 
venom ligand (Watson et al., 2007). 
 
1.5.3 Function in haemostasis 
Mouse models have been used to assess the controversial role of CLEC-2 in hemostasis. 
May et al. developed CLEC-2 deficient platelets by consistent exposure of mice with an 
anti-CLEC-2 antibody. This initially induces transient thrombocytopenia, however then 
platelets are produced lacking CLEC-2. Under high and intermediate shear rates (1700 
s−1 and 1000 s−1 respectively) CLEC-2 depleted platelets adhered to collagen but did not 
form a stable aggregate. Newly recruited platelets adhered but were released after a few 
seconds. This paper also identified that in CLEC-2 depleted mice there was an increase 
in tail bleeding time as a measurement of haemostasis. Furthermore, antibody treated 
CLEC-2 deficient platelets also had defective thrombus formation in a ferric chloride 
induced thrombus formation model as the time to occlude was significantly greater (May 
et al., 2009).   
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Initial work used a platelet specific CLEC-2 knockout mouse which was found to be 
embryonically / neonatally lethal (most pups die shortly after birth). This is due to 
cutaneous hemhorage and failure of the blood lymphatics to separate (Suzuki-Inoue et 
al., 2010). To overcome this, and to be able to assess the function of CLEC-2 in mouse 
models of thrombosis and hemostasis, chimeric mice were utilised. WT mice were 
subjected to radiation to induce bone marrow failure. Fetal liver cells from the platelet 
specific CLEC-2 mouse were then injected into the tail to rescue the bone marrow failure 
mouse and change the phenotype. The mouse then produces CLEC-2 deficient platelets, 
which respond normally to other agonists but have abolished response to rhodocytin 
(Suzuki-Inoue et al., 2010). This study demonstrated that thrombus formation under 
collagen is impaired in vitro, along with in vivo arterial thrombosis when assessed in 
mesenteric capillaries in a laser injury model. However these mice do not have a 
significant increase in their tail bleeding times (Suzuki-Inoue et al., 2010).  
Similarly, others report that CLEC-2 deficient mice do not have significantly different tail 
bleeding times using CLEC-2 chimeric mouse platelets (Hughes et al., 2010a). The 
methodologies are comparable to the work by Suzuki-Inoue and colleagues for the 
developing of platelets without CLEC-2. However, aggregation under flow was assessed 
at similar shear rates to May et al. and Suzuki-Inoue et al. In contrast to these two 
studies, the study by Hughes et al. identified that the platelets have normal aggregation 
on a concentration of collagen that is in between the two studies. 
The method of using anti CLEC-2 antibodies to induce CLEC-2 depletion was also utilised 
and once again, tail bleeding time and thrombus formation was assessed. CLEC-2 
depletion did not significantly increase tail bleeding times or have a significantly different 
thrombus size in vivo  (Bender et al., 2013). The methodology of assessing the formation 
was similar as to previously published, using ferric chloride and mesenteric arterioles 
(Suzuki-Inoue et al., 2010, May et al., 2009). However, to analyse the data, Bender and 
colleagues considered the size of the vessel, whereas it is unclear if previous work did 
this. It would be expected that a larger vessel would cause a larger thrombus in WT mice, 
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so considering this biological variation of vessel size is important when investigating size 
of thrombi.  
Lombard et. al., 2018 identified that human podoplanin can capture and activate human 
platelets under flow conditions, but not at physiological rates of shear. This alludes to a 
role for CLEC-2 in low shear and conditions at reduced flow. Indeed, CLEC-2 signalling is 
involved in deep vein thrombosis (DVT), which is a disease caused by a reduction and 
stasis of blood.  
Deep vein thrombosis (DVT) is a thromboinflammatory disorder caused by the stagnation 
of blood which then becomes hypoxic. This then induces the release of inflammatory 
mediators; therefore, it is a thromboinflammatory condition. Using platelet inducible 
CLEC-2 knockout mice, it was demonstrated by Payne et al., that CLEC-2 exacerbates 
DVT as these mice do not form thrombi in a stenosis model compared to WT controls. 
Furthermore, CLEC-2 deficient platelets or podoplanin inhibition by an antibody showed 
reduced recruitment to the vessel wall showing that the CLEC-2 - podoplanin interaction 
is critical for DVT.  
 
1.5.4  Signalling 
Overall, hemITAM mediated signalling is similar to ITAM mediated signalling with many of 
the kinases being employed in both.  
Similarly to GPVI signalling, upon either podoplanin (endogenous ligand) or rhodocytin 
(exogenous ligand) (Shin and Morita, 1998) stimulation, CLEC-2 dimers form oligomers 
(Hughes et al., 2010b). This recruits Syk to the hemITAMs where it is phosphorylated by 
Src family kinases (Mori et al., 2008), before it is able to undergo autophosphorylation 
similarly to ITAM signalling. Syk is essential in mediating CLEC-2 signal transduction 
(Severin et al., 2011, Spalton et al., 2009, Hughes et al., 2015) and when active, Syk is 
able to phosphorylate LAT, SLP-76, and SFK’s can phosphorylate Btk. These proteins 
then work synergistically to enable phosphorylation of PLCγ2, similarly to GPVI signalling. 
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Unlike GPVI signalling, it is known there is a requirement for secondary mediators to 
induce sustained CLEC-2 signalling (Pollitt et al., 2010, Manne et al., 2015b). ADP and a 
thromboxane A2 mimetic could not induce phosphorylation of CLEC-2 alone, whereas 
rhodocytin could. Using inhibitors that block TxA2 production (indomethacin) and 
scavenge ADP (apyrase), Pollitt et al., demonstrated that CLEC-2 phosphorylation is 
indirectly mediated by secondary mediators as CLEC-2 phosphorylation is greatly 
reduced in the presence of these inhibitors. 
Like the function of CLEC-2 in hemostasis, the location of the receptor is also 
controversial. In platelets, it was first described as being present in lipid rafts (Pollitt et al., 
2010). Using Brij – 58 as a detergent which disrupts the membrane but preserves lipid 
rafts, it was identified that the amount of CLEC-2 present in lipid rafts increases upon 
stimulation with rhodocytin. Furthermore, the amount of tyrosine phosphorylated CLEC-2 
(and therefore activated) was greatly increased in the presence of rhodocytin suggesting 
that CLEC-2 signals in lipid rafts.  
However Manne et al., argued that CLEC-2 was not found in lipid rafts. Using the same 
disruptor of lipid rafts as Pollitt et al., the same result of reduced platelet aggregation to 
rhodocytin was observed. It was hypothesised that the altered CLEC-2 signalling was due 
to the disruption required secondary mediators TxA2 and ADP which signal through 
GPCR’s (Pollitt et al., 2010, Hardy et al., 2004, Hirata et al., 1996). Using a synthetic 
analog of ADP, platelets did not aggregate in the presence of methyl-β-cytodextrin 
(MβCD), a cholesterol lowering agent which disrupts lipid rafts. This shows the 
dependency of ADP signalling on lipid rafts and it was therefore reasoned that this lack of 
aggregation to rhodocytin was due to the lack of required ADP signalling (Manne et al., 
2015b).  
To verify this, aggregation experiments were performed in the presence of a synthetic 
analog of ADP, MβCD and stimulated with rhodocytin to show that the response is the 
same. The experiments yield the same results of weak aggregation in the presence or 
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absence of ADP and from this, it is wrongfully concluded that the lack of aggregation is 
due to the disruption of ADP mediated G protein signalling.  
Manne and colleagues did not investigate if TxA2 signalling was altered with lipid rafts 
disrupted. TxA2 was previously identified as the majority requirement for CLEC-2 
signalling (Pollitt et al., 2010) and therefore it would have been interesting to see these 
results.  
In protein phosphorylation studies, Manne and colleagues omitted the use of αIIbβ3 
inhibitor integrelin and therefore had aggregating platelet conditions. It is known that 
granule release of fibrinogen occurs in response to CLEC-2 (May et al., 2009) and that 
the integrin could become active. Therefore, the observed phosphorylation of PLCγ2 in 
the presence of a lipid raft disruptor may be due to phosphorylation after outside in 
signalling (Huang et al., 2019). Another alternative explanation for the observed 
phosphorylation is the time point used to assess phosphorylation. Cells were lysed at 60 
seconds, and phosphorylation of both Syk and PLCγ2 is observed. This is unusually 
short, as it is known that CLEC-2 signalling has a characteristic lag time (Kato et al., 
2008, Suzuki-Inoue et al., 2007). Indeed in later work by the same group, there is no 
phosphorylation at 60 seconds (Badolia et al., 2017). Therefore, the observed 
phosphorylation in the absence of lipid rafts may have been due to platelet pre activation 
due to experimental methods.  
A more recent study could also not confirm the exact localisation of CLEC-2 (Izquierdo et 
al., 2019). This work stated that CLEC-2 was not found in lipid rafts. However four donors 
were assessed, with one donor presenting with CLEC-2 in the lipid raft fraction (stated in 
the supplementary materials), so it is not clear where CLEC-2 is localised. Membrane 
proteins are notoriously difficult to identify in proteomic studies due to their length and 





Figure 1.5.1 Platelet CLEC-2 signalling 
Rhodocytin or podoplanin binds to CLEC-2 and induces receptor clustering. This provides 
dual YxxL motifs for Syk to bind to via its dual SH2 domains. Syk is then phosphorylated 
by SFK’s. Syk is responsible for phosphorylating LAT, which recruits adaptor proteins 
SLP-76, Gads and Grb2. PI3K becomes active and is recruited to the signalosome. It 
catalyses the production of PIP3 from PIP2, which recruits Btk and PLCγ2 where they can 
now interact with LAT in the signalosome. Btk is phosphorylated by SFK’s or Syk, and 
together phosphorylated Syk and Btk mediate phosphorylation of PLCγ2 resulting in PKC 
activation and calcium release. Btk is also proposed to be upstream of Syk by Manne et 
al. Kinases are shown in blue, adaptor proteins are shown in yellow and orange. Lipid 





1.5.5 Non-hemostatic roles of CLEC-2 
1.5.5.1 Blood lymphatic development 
There is a crucial role for the podoplanin/CLEC-2 axis in embryonic development.  Global 
and platelet specific CLEC-2 knockout mice have blood lymphatic mixing and global KO’s 
are not viable at birth (Finney et al., 2012, Hess et al., 2014). Furthermore, a mouse that 
cannot signal via CLEC-2 due to an amino acid point mutation within its hemITAM (Y7A) 
(Haining et al., 2017a), and mice deficient in key CLEC-2 signalling proteins such as Syk 
(Turner et al., 1995), SLP-76 (Clements et al., 1999) and PLCγ2 (Ichise et al., 2009) also 
have a similar blood lymphatic mixing phenotype confirming that platelet CLEC-2 
signalling plays a role.  
Additionally, single knockouts of Btk or Tec have been reported to have normal blood 
lymphatic separation. However, the authors did not show WT controls for comparison 
making it difficult to confirm this result (Manne et al., 2015a). The authors of the same 
study also used double knockout mice, lacking both Btk and Tec, which did have  severe 
blood lymphatic mixing (Manne et al., 2015a) which is consistent with other CLEC-2 or 
Syk deficient mice (Bertozzi et al., 2010).  This suggests that Btk and Tec have a level of 
redundancy at that both must be absent for the phenotype to present itself. 
1.5.5.2  Inflammation  
Like GPVI, CLEC-2 plays a role in the prevention of haemorrhage induced by 
inflammation. HemITAM signalling plays a role in the thromboinflammatory disease, 
sepsis. Sepsis is a systemic inflammatory response which can result in multiple organ 
failure and death. In contrast to GPVI, in a cecal ligation and puncture model, CLEC-2 
deletion via a platelet specific knockout increases measures of clinical severity such as 
organ damage (Rayes et al., 2017). This organ damage occurs due to the increased 
bacterial load caused by the inefficient recruitment and activation of macrophages (Rayes 
et al., 2017). CLEC-2 absence also accelerates lung function decline in a model of acute 
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respiratory distress syndrome (ARDS) (Lax et al., 2017). Taken together, these show a 
protective role for CLEC-2 in inflammatory conditions. 
On the other hand it should be noted that CLEC-2 did not play a role in a sepsis model 
induced by K. pneumonia, and GPVI played the predominant protective role (Claushuis et 
al., 2018).  
1.5.5.3 Cancer 
Podoplanin is expressed on certain types of tumour cells including renal cell carcinoma 
and brain tumours (Shibahara et al., 2006). The interaction of platelet CLEC-2 and tumour 
podoplanin is believed to facilitate tumour metastasis, with increased podoplanin 
expression increasing malignancy. Blocking the podoplanin –platelet interaction using 
antibodies or depleting CLEC-2 reduces the metastasis of cancers. This implicates a role 















1.6 Differences in ITAM and HemITAM mediated 
signalling  
Although many of the components of (hem)ITAM mediated signalling are similar, there 
are some differences. These include the dependence of certain adaptors, actin 
polymerisation, and the requirement of lipid kinases.  
Aside from the obvious difference of GPVI containing two YxxL motifs, and CLEC-2 only 
one, there are also differences in the kinases that mediate the phosphorylation of these 
motifs. Downstream of GPVI, the phosphorylation of the ITAM is mediated by SFK’s 
(Ezumi et al., 1998, Quek et al., 2000, Suzuki-Inoue et al., 2002). The phosphorylated 
ITAMs then recruit Syk.  Whereas downstream of CLEC-2, it is mediated by Syk as 
demonstrated with the Syk inhibitor R406, or absence of Syk, inhibits CLEC-2 mediated 
phosphorylation (Spalton et al., 2009, Severin et al., 2011).  
One difference between GPVI and CLEC-2 mediated signalling is the requirement for 
actin polymerisation. Downstream of GPVI, aggregation is not blocked with high 
concentrations of an actin polymerisation inhibitor cytochalasin D. Whereas downstream 
of CLEC-2, aggregation was inhibited. Furthermore, phosphorylation of Syk and PLCγ2 
are inhibited in the presence of Cytochalasin D downstream of rhodocytin whereas they 
phosphorylation events are unaltered downstream of GPVI (Pollitt et al., 2010).  
The absolute requirement of certain adaptor proteins differs between the two pathways. 
SLP-76 is an absolute requirement for GPVI mediated signalling as SLP-76 knockout 
platelets do not respond to convulxin (Judd et al., 2002, Sebzda et al., 2006). This lack of 
aggregation is not rescued in the presence of high concentrations of agonist. Whereas 
aggregation can be induced in SLP-76 KO platelets with high concentrations of 
rhodocytin, suggesting that there is a difference in the need for SLP-76 between the 
different pathways (Suzuki-Inoue et al., 2006). This has further been confirmed using 
Jurkat cells and a luciferase reporter assay. Jurkat T cells lacking SLP-76 could mediate 
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CLEC-2 signalling but not GPVI signalling (Fuller et al., 2007). This corroborates that 
although the SLP-76 plays a role in both pathways, the absolute requirement is different.  
The necessity of PI3K activation is dissimilar downstream of GPVI and CLEC-2. PI3K is a 
lipid phosphatase that becomes active after GPVI (Lagrue et al., 1999) and CLEC-2 
(Manne et al., 2015a) activation. It can also become active after outside-in signalling via 
αIIbβ3 (Battram et al., 2017). PI3K is recruited to the LAT signalosome via SH2 domains 
in its regulatory subunit, p85, and this allows its activation (Gibbins et al., 1998). It is then 
able to catalyse PIP2 into PIP3, which can recruit other proteins via PH domains. 
Downstream of GPVI, PI3K activation is preferred as calcium flux is reduced in the 
presence of a range of PI3K inhibitors, but it is not abolished (Gilio et al., 2009). 
Furthermore, this has been demonstrated in aggregation also, where in the presence of 
pan PI3K inhibitors wortmanin and LY294002, GPVI mediated aggregation to convulxin is 
largely reduced. However, in response to rhodocytin, aggregation is abolished (Manne et 
al., 2015a). This further shows a difference between GPVI and CLEC-2 signalling. 
The requirement for secondary mediators in signal transduction is also different between 
the two receptors. CLEC-2 has an absolute requirement for secondary mediators ADP 
and TxA2 (Pollitt et al., 2010, Badolia et al., 2017, Izquierdo et al., 2020). Whereas whole 
cell tyrosine phosphorylation induced by convulxin is normal in the presence of ADP 
antagonists and inhibitors of TxA2 production (Atkinson et al., 2003b), demonstrating that 
GPVI does not depend on secondary mediators. 
The final difference between the GPVI and CLEC-2 signalling cascades is that it is 
proposed by Manne et al. that Syk is downstream of Btk in CLEC-2 stimulated platelets. 
This is novel compared to how it is typically thought of in GPVI signalling. The Kunapali 
group propose that as a Syk inhibitor did not affect Btk translocation to lipid rafts and that 
Syk phosphorylation is inhibited at a concentration that Btk phosphorylation is inhibited, 
that Btk is upstream of Syk. This highlights another potential difference between the GPVI 
and CLEC-2 pathways, as it is known that in GPVI signalling, Btk phosphorylation is 
below Syk (Quek et al., 1998). 
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1.7 Tec family kinases 
1.7.1  General  
Tec family kinases are a family of non-receptor tyrosine kinases expressed in a range of 
hematopoietic cells. They are one of the largest family of cytoplasmic tyrosine kinases, 
alongside SFKs (Akinleye et al., 2013). Named after the first identified member, Tec, 
there are 4 other kinases present within the family – Btk, Itk, Bmx and Txk. The proteins 
have a similar protein structure as Figure 1.7.1 illustrates. Two tec family kinases have 
been identified in platelets, Btk and Tec, with them playing roles in (hem)ITAM signalling 
(Manne et al., 2015a, Quek et al., 1998). 
 
Figure 1.7.1 Tec family kinase structure 
The TFK’s are made up of a pleckstrin homology (PH) domain which can bind 
phosphatidylinositol lipids, a Tec homology domain which contains the Btk motif and two 
proline rich regions, an Src Homology 3 (SH3) domain which binds proline rich regions, a 






1.7.2 Bruton’s Tyrosine Kinase (Btk) 
Bruton’s tyrosine kinase (Btk), discovered by Ogdon Bruton in 1952, is a 659 amino acid 
protein with its structure and key phosphorylation sites highlighted in Figure 1.7.2. Under 
resting conditions, Btk is unphosphorylated, unable to induce phosphorylation and is 





Figure 1.7.2 Domain structure of Btk 
Btk is 659 amino acids long and contains a PH, TH, SH3, SH2 and a kinase domain with 
key protein interactions denoted below and phosphorylation sites listed above.  
 
The N-terminal PH domain is required for translocation of Btk to the cell membrane upon 
production of PIP3 via PI3K (Várnai et al., 1999, Salim et al., 1996). Btk is one of the most 
abundant proteins that is bound to PIP3 when the PIP3 signalosome was investigated in 
platelets  (Durrant et al., 2017). PH domains have the ability to bind any phospholipids, 
but the Btk PH domain preferentially binds to PIP3 (Salim et al., 1996). The PH domain of 




Adjacent to the PH domain is the TH domain. Figure 1.7.1 shows that this domain 
contains the zinc finger Btk motif (BH on Figure 1.7.1) and proline rich regions (PRRs). 
The PRRs of Btk have been shown to interact with Phosphatidylinositol-4-phosphate 5-
kinase (PIP5K) (Saito et al., 2003). PIP5K is responsible for the catalysis of PtdIns[4]P 
(PIP) into PtdIns[4,5]P2 (PIP2).  Furthermore, the TH domain has been shown to provide 
the protein with stability (Vihinen et al., 1994a).  
Neighbouring the TH domain is the SH3 domain, which is known to bind proline rich 
regions. The Btk-SH3 domain can bind to the proline rich region within its own TH domain 
in vitro (Patel et al., 1997). This self-folding provides a possible regulatory mechanism of 
Btk. Additionally, the SH3 domain can bind to PI3K (Saito et al., 2001) and work as a 
scaffold protein to ensure a complete loop of phosphatidyl lipid signalling as shown in 
Figure 1.7.3.  
 
 
Figure 1.7.3 The interaction of Btk and phosphatidyl lipase signalling 
The interactions of Btk and phosphatidyl lipase signalling. Btk can interact with PIP5K 
through its PRR in the Tec homology domain (interactions shown with green arrows). Btk 
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can interact with PIP3 via interactions in its PH domain. Interaction of Btk and PI3K is 
through the Btk SH3 domain. Btk can mediate phosphorylation of PLCγ2. Lipid 
conversions are shown in Black and tyrosine phosphorylation is shown with red arrows.  
 
SH2 domains bind to phosphotyrosine residues. It has been proposed that Btk can dock 
with many of the LAT signalosome proteins (Figure 1.7.2). Upon recruitment to the LAT 
signalosome, Btk can be trans-phosphorylated on site Y551 in the activation loop of the 
kinase domain (Wahl et al., 1997). This transphosphorylation is mediated by SFK’s (Park 
et al., 1996, Rawlings et al., 1996, Dormann et al., 2001). Btk then undergoes 
phosphorylation at Y223 within the SH3 domain, rendering the kinase fully catalytically 
active. It is believed that this phosphorylation is mediated by self-phosphorylation 
(autophosphorylation) (Wahl et al., 1997), however it is unclear whether this 
phosphorylation could be mediated by another Btk molecule (Mohamed et al., 1999). 
Indeed, The PH of one Btk and the TH domain of another Btk have been shown to 
interact in a crystal structure forming the Saraste dimer (Hyvönen and Saraste, 1997). 
Recent work from two independent groups have provided strong evidence for PIP3 
mediated Btk dimerization and phosphorylation at Y223 being mediated by another 
molecule of Btk (Chung et al., 2019, Wang et al., 2019b). This is illustrated in Figure 
1.7.4.   
Function altering point mutations and domain deletion studies have shown that the SH2 
domain is essential for B cell signalling and calcium flux , however is not known if the 
same mechanisms play a role in Btk function in platelets (Fluckiger et al., 1998, 







Figure 1.7.4 Saratase dimer formation 
Btk is present in a closed inactive confirmation (lower left). The production of PIP3 (shown 
in purple) recruits Btk via its PH domain, where it forms an open shape and Btk can be 
transphosphorylated via SFK’s (pY551). The PH-TH domains can undergo dimerization, 
bringing two kinase domains in close contact with one another promoting 
transphosphorylation (pY223). This results in an active form of Btk with phosphorylation at 
pY223 and pY551.  
 
A domain that has been shown in some studies to be essential is the tyrosine kinase 
domain (Tomlinson et al., 2001). The kinase domain of Btk is comprised of approximately 
250 residues (Vihinen et al., 1994b). Key amino acid residues within the kinase domain 
include K430. This conserved lysine is the adenosine triphosphate (ATP) binding residue. 
Kinase inactive mutants have an amino acid with a different charge meaning the 
triphosphate cannot bind (Mao et al., 2001).  
Whether true Btk kinase activity is required to mediate signalling is controversial. It is 
known that Btk does have catalytic activity in vitro kinase assays and cell experiments. It 
has been shown that Btk can phosphorylate certain sites on PLCγ2 in B cells, but in the 
absence of Btk there is some residual phosphorylation (Kim et al., 2004). Furthermore, 
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using the chicken B cell line DT40 deficient in Btk, phosphorylation of PLCγ2 was reduced 
but not abolished. However, there is reduced IP3 production and calcium flux (Takata and 
Kurosaki, 1996). In platelets, Btk has been shown to phosphorylate PLCγ2 (partially) 
(Quek et al., 1998), Platelet endothelial cell adhesion molecule-1 (PECAM-1) (Tourdot et 
al., 2013) and suspected to phosphorylate β3 (Bye et al., 2017). This suggests that Btk 
does require its kinase activity. 
Phosphorylation of PLCγ2 occurs on 4 sites – Y753, Y759, Y1197 and Y1217 (Watanabe 
et al., 2001). Y753 and Y759 are in the SH2-SH3 domain of PLCγ2 whereas Y1197 and 
Y1217 fall within the C terminal region. Mutational studies of PLCγ2 in DT40 cells 
proposed that tyrosine phosphorylation of PLCγ2 in the SH2-SH3 region downstream of 
the BCR is partially required for activation; and these sites are mainly phosphorylated by 
Btk.  However Syk can play a role in phosphorylating PLCγ2 (Rowley et al., 1995, 
Rodriguez et al., 2001, Hashimoto et al., 1999a). Whereas the tyrosine phosphorylation in 
the C terminal (Y1197 and Y1217) is explicitly mediated by Btk (Watanabe et al., 2001). 
Another study has confirmed that Btk predominantly phosphorylates Y753 and Y759 in 
PLCγ2 in B cells, and these sites are required for activation (Humphries et al., 2004). Kim 
et al, also identified that phosphorylation of the SH2-SH3 region is required in B cells, and 
that this region is also phosphorylated in Ramos cells, Jurkats and Platelets (Kim et al., 
2004). Furthermore, there is no phosphorylation of Y1217 downstream of convulxin 
stimulated platelets, and that pY1217 is also largely independent of Btk.  
On the other hand, it has been proposed that kinase activity of Btk is not required. A 
recombinant oestrogen receptor bound version of Btk has been shown to mediate 
signalling with an inactive kinase (Tomlinson et al., 2001). Middendorp et al., 2003, also 
showed that a kinase inactive version of Btk is not required during B cell development to 
mediate PLCγ2 phosphorylation and calcium flux. Furthermore, there was a peak of 
calcium flux, albeit greatly reduced compared to wild type, in a kinase dead version of Btk 
downstream of the BCR (Takata and Kurosaki, 1996). This suggests that a kinase 
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inactive mutant can partially mediate PLCγ2 activation, and that therefore Btk could be 
possibly acting as a scaffold protein.  
A requirement for the kinase function of Btk has been demonstrated with its interaction 
with Wiskott Aldrich Syndrome protein (WASP) in B cells (Guinamard et al., 1998). The 
interaction occurs through the Btk SH3 domain (Guinamard et al., 1998, Kinnon et al., 
1997). In platelets, WASP is phosphorylated after GPVI stimulation (Oda et al., 2000, Oda 
et al., 1998) and this is blocked in the presence of wortmannin, a PI3K inhibitor. As 
production of PIP3 via PI3K is known to recruit Btk, it was hypothesised that this inhibition 
observed with wortmannin is due to the lack of Btk translocation. A study using Btk 
deficient (when assessed by western blot) X linked agammaglobulinemia (XLA) patients 
identified that phosphorylation of WASP is predominantly not mediated by Btk (Gross et 
al., 1999b, Oda et al., 2000). These patients do express Tec and it was proposed that this 
is mediating the phosphorylation of WASP as TFKs can have redundant roles (Atkinson et 
al., 2003a), however no other kinases were investigated in this study.  
Negative regulation of Btk is controlled by Protein Kinase C. Serine 180 within the Tec 
homology domain (Figure 1.7.2) is phosphorylated and this initiates translocation away 
from the plasma membrane (Kang et al., 2001). Further evidence for this mechanism is 
provided from B cells deficient in PKCβ which have prolonged and enhanced Btk tyrosine 
phosphorylation due to its close contact with tyrosine kinases (Leitges et al., 1996).  
 
1.7.3 Clinical relevance of Btk mutations  
The Btk gene is on the X chromosome, and gene mutations result in either total or partial 
deficiency and/or activity of Btk. This condition is called X-Linked Agammaglobulinemia 
(XLA). XLA is usually diagnosed during childhood as the affected children (most 
commonly males) manifest with reoccurring infections. Btk protein mutations / absence 
results in disrupted B cell signalling. This causes a reduction of mature B lymphocytes. 
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Less serum immunoglobulins are produced and consequentially, frequent infections 
occur. Therefore immunoglobulin transfusion is used as a treatment (Conley, 1985).  
Sequence analysis of Btk is used to identify if a patient has XLA. These mutations have 
been uploaded to the Btkbase – a mutation database containing the sequence variants 
(Vihinen et al., 1996, Väliaho et al., 2006). Over half of the pathogenic variants are 
premature stop codons and frameshift variants resulting in improper processing of Btk 
mRNA. This results in patients not expressing Btk when detected by western blotting or 
flow cytometry (Hashimoto et al., 1999b, Gaspar et al., 1998). 
Some patients express a ‘leaky’ phenotype, where the condition is not as severe, with 
some mature B lymphocytes circulating (Jones et al., 1996, Hashimoto et al., 1999b). 
Some ‘leaky’ patients have a mutation in the kinase domain causing reduced catalytic 
activity, therefore explaining the less severe phenotype (Gaspar et al., 2000). Further 
leaky patients have been identified, in which the mutations are not in the kinase domain. 
These patients have normal levels of Btk and Btk catalytic activity, but still have frequent 
albeit less severe infections. This suggests kinase function plays a large but not total role 
in the disease and other functioning Btk domains are required to prevent XLA.  
Interestingly, XLA patients do not report bleeding as a side effect, even though the role of 
Btk in platelets has been shown (Quek et al., 1998). Cardiovascular side effects in these 
patients, such as hypertension are believed to be related to the use of intravenous 
immunoglobulin (Späth et al., 2015).  
 
1.7.4 Tec 
Tec is another member of the Tec family kinases present in platelets, albeit at a much 
lower copy number than Btk (1,300 copies of Tec, 11,100 copies of Btk) (Burkhart et al., 
2012). It shares a similar structure to Btk (Figure 1.7.1) (Mohamed et al., 1999).  
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Tec has also been shown to directly phosphorylate PLCγ2 in vitro (Zwolanek et al., 2014, 
Humphries et al., 2004) but there is less extensive research on whether the kinase activity 
of Tec is required to mediate signalling in cell-based assays. Furthermore, the 
phosphorylation sites in PLCγ2 mediated by Tec are Y753 and Y759 which are the same 
as Btk (Humphries et al., 2004).  
It is known that Tec is able to partially mediate GPVI signal transduction. Btk-deficient 
platelets undergo shape change in response to CRP-XL, and aggregate to collagen. 
However they are less responsive and require a higher concentration of agonist to induce 
aggregation. Furthermore, in Btk-deficient platelets, PLCγ2 phosphorylation is not totally 
lost downstream of CRP-XL or collagen, alluding that Tec or other kinases such as Syk 
also have the ability to phosphorylate PLCγ2 (Quek et al., 1998, Atkinson et al., 2003a). 
Additionally, using single knockouts of either Btk or Tec, or double knockouts (platelet 
specific) suggests that Tec is able to compensate for Btk in this pathway and others, such 
as Tec being able to phosphorylate WASP in the absence of Btk (Oda et al., 2000).  
In contrast, downstream of CLEC-2, Tec is not believed to compensate in this pathway. 
The platelets of XLA patients do not aggregate even to maximal concentrations of 
rhodocytin (Nicolson et al., 2020). If Tec could compensate for Btk in CLEC-2 pathway, 
there would be some aggregation to this response. 
Furthermore, after using inhibitors of Btk, the work by Chen et al., 2018, proposed that 
biochemical activity of Tec, measured in a range of in vitro kinase assays, did not 
correlate with platelet aggregation downstream of GPVI. The inhibition of Btk in the kinase 
assays strongly correlated with the potency of the Btk inhibitors in platelet aggregation 
(Chen et al., 2018). This suggests that Tec does not play a predominant role in mediating 






1.8 Btk inhibitors 
As Btk plays a role in mediating B cell receptor signalling, it is used as a therapeutic target 
in a B cell malignancy, chronic lymphocytic leukaemia, CLL. Chromosomal alterations in 
tumour suppressor genes or proteins that cause apoptosis, but not Btk, result in an 
increased number of small, mature appearing lymphocytes in the blood, bone marrow and 
lymph (Scarfò et al., 2016).  
The B cell receptor signalling pathway is amplified in CLL and therefore inhibiting Btk is 
clinically beneficial. Ibrutinib, a first generation Btk inhibitor and acalabrutinib, a second-
generation inhibitor are both used clinically to treat CLL as seen in Figure 1.8.1.  
 
 
Figure 1.8.1 Structure of acalabrutinib and ibrutinib adapted from Byrd et al., 2016. 
 
1.8.1 Ibrutinib 
Ibrutinib (trade name Imbruvica, developed by Pharmacyclics) is a first generation Btk 
inhibitor that is used to treat CLL. It binds irreversibly to the Cys481 within the active site 
of Btk (Pan et al., 2007, Honigberg et al., 2010). After 4 hours, greater than 95% of Btk 
was occupied by ibrutinib in patients with B cell malignancies after oral administration at 
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most evaluated levels. Level of drug binding to Btk was determined using a fluorescently 
tagged derivative of ibrutinib (Honigberg et al., 2010).  This occupancy level is maintained 
for over 24 hours (Byrd et al., 2013), showing its irreversible binding.  
A number of studies have shown efficacy with ibrutinib by improving symptoms of CLL 
and it was approved for treatment of this disease in the UK in 2017 (Scheers et al., 2015, 
Byrd et al., 2013, Honigberg et al., 2010, Burger et al., 2015). Indeed, it is a very potent 
inhibitor of Btk, with IC50 values typically falling within the sub-nanomolar range in in vitro 
kinase assays (Pan et al., 2007, Liclican et al., 2020, Honigberg et al., 2010). Analysis of 
its potency in cell-based assays showed that for Btk pY223 and PLCγ2 phosphorylation 
downstream of the BCR, IC50s were still within the nM range (11 nM and 29 nM) 
respectively (Honigberg et al., 2010) showing that ibrutinib is a potent inhibitor of Btk.  
Ibrutinib therapy has also been reported to cause undesirable side effects including 
headaches, diarrhoea, atrial fibrillation and more dangerously, bleeding.  61% of patients 
receiving ibrutinib in one clinical trial experienced altered haemostasis and displayed a 
bleeding side effect (Byrd et al., 2015). The majority of these adverse bleeding side 
effects were grade 1 (48%) which is the formation of petechiae and contusions. However, 
7% of patients did have grade 3 bleeding events, which require transfusions and 
furthermore, 1 patient had a catastrophic bleed resulting in death. Although this occurred 
approximately 1 month after ibrutinib discontinuation and may have been related to the 
progression of the disease.  These haematological side effects can occur even with a 
normal platelet count (Lipsky et al., 2015, Shatzel, 2017).  
The side effects of ibrutinib are believed to be due to the non-specificity of the drug. In 
addition to Btk, other kinases are also inhibited by ibrutinib in vitro recombinant kinase 
assays, including Src (IC50 = 19nM ± 1), Tec (IC50 = 7.0nM ±2.5), Fyn (IC50 = 29nM ± 0) 
(Byrd et al., 2016). However different in vitro kinase assays can yield different results, with 
a recent paper reporting more potent inhibition of Tec (IC50 for Tec was 3.2nM) (Liclican et 
al., 2020). Furthermore, using in vitro kinases to assess the potency of an inhibitor may 
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not always be accurate as the kinase concentration and substrate can differ between 
groups and can therefore explain the differences observed.  
In platelets, ibrutinib has been characterised downstream of GPVI (Bye et al., 2017, Bye 
et al., 2015, Nicolson et al., 2018, Levade et al., 2014, Series et al., 2019) and 
downstream of CLEC-2 (Manne et al., 2015a, Nicolson et al., 2020) where it has been 
shown to disrupt platelet function and will be discussed in chapter 3.  
 
1.8.2 Acalabrutinib 
Acalabrutinib (trade name Calquence, developed by Acerta Pharma) is a second 
generation Btk inhibitor, and is reported to be more selective than ibrutinib (Barf et al., 
2017, Byrd et al., 2016, Patel et al., 2016). Similarly to ibrutinib, it is used for the treatment 
of CLL. The mechanism of action of acalabrutinib is the same as ibrutinib, with the drug 
binding to Cys481 within the binding loop of the active site, preventing ATP binding. This 
covalent binding is mediated by acalabrutinib’s unique reactive butynamide group. This 
butynamide group causes lower electrophilicity when compared to ibrutinib’s acrylamide 
group to bind to Cys481 and therefore may explain why acalabrutinib is more selective 
than ibrutinib (Barf et al., 2017, Patel et al., 2016).  
Like ibrutinib, acalabrutinib has anti-cancer effects in murine models of CLL and treatment 
is associated with a significant increase in survival (Herman et al., 2015). The 
effectiveness of this drug in the treatment of CLL has also been shown in patients in vivo 
and is licenced for use (Byrd et al., 2016, Isaac and Mato, 2020). 
In addition, acalabrutinib has also been proposed to cause similar side effects such as 
headaches and diarrhoea and albeit less frequently, atrial fibrillation (Isaac and Mato, 
2020, Barf et al., 2017).  Furthermore, acalabrutinib has been associated with a lower risk 
of bleeding than ibrutinib. Grade 3 bleeding events (gross blood loss, requiring 
transfusions) occurred in 8% of ibrutinib patients, whereas it was reported in 3% of 
patients taking acalabrutinib (Byrd et al., 2015, Furman et al., 2019). However, there are 
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no published results of clinical trials comparing the effectiveness of ibrutinib vs 
acalabrutinib in patients at treating CLL and their side effects (Isaac and Mato, 2020).  
In vitro kinase assays have been used to assess the potency and selectivity of 
acalabrutinib over ibrutinib. Acalabrutinib is slightly less potent than ibrutinib for inhibiting 
Btk (IC50 = 5.1nM ± 1 for acalabrutinib, IC50 = 1.5nM ± 0.2 for ibrutinib) whereas it is also 
less potent at inhibiting Tec (IC50 = 93nM ± 35) and Src (IC50 = >1000nM) (Byrd et al., 
2016). Others also confirmed that acalabrutinib was less potent at inhibiting Btk than 
ibrutinib. Acalabrutinib’s IC50’s for Btk being between 2.5-3nM (with ibrutinib being 
approximately 5x more potent) (Covey et al., 2015, Liclican et al., 2020). Nevertheless, 
acalabrutinib is less potent at inhibiting Tec and Src in vitro compared to ibrutinib (Barf et 
al., 2017, Covey et al., 2015). This increased selectivity for Btk (although lesser potency) 
and sparing of other kinases is an advantage of acalabrutinib over ibrutinib. 
Like ibrutinib, acalabrutinib has been utilised to study the role of Btk downstream of GPVI 
(Busygina et al., 2018, Bye et al., 2015, Dobie et al., 2019, Nicolson et al., 2018, Bye et 
al., 2017) and to a lesser extent CLEC-2 (Dobie et al., 2019, Nicolson et al., 2020). This 
will be discussed in more detail in chapter 3.  
 
1.8.3 Btk inhibitors in non-ITAM mediated signalling events and 
experiments under flow 
After patients taking ibrutinib for CLL were shown to have bleeding as a side effect, 
investigations into the role of this kinase inhibitor on platelet function were conducted. It 
was initially thought these bleeding side effects could be related to CLL. Some CLL 
patients have a lower platelet count, and the bleeding risk in thrombocytopenic individuals 
is increased already, independently of CLL. However, the association of reduced platelet 
aggregation to ristocetin and bleeding whilst taking ibrutinib is still significant regardless of 
platelet count (Kazianka et al., 2017). This highlighted the inhibition of platelet function is 
47 
 
responsible for the bleeding of ibrutinib patients and not the drop in platelet count, or the 
leukaemia itself.  
Indeed, ibrutinib does inhibit platelet function and these effects are not limited to ITAM 
mediated signalling pathways. Platelet rolling along VWF is preserved in the presence of 
ibrutinib whereas firm adhesion is reduced (Levade et al., 2014). This effect is dependent 
on GPIb as using a function blocking antibody to GPIb blocked the adhesion, consistent 
with Btk can play a role downstream of GPIb (Liu et al., 2006). This is also mirrored in 
patients taking ibrutinib having a reduced platelet surface area coverage on VWF. 
Although interestingly some donors did not have a reduced platelet surface area after 15 
days of treatment (Levade et al., 2014). Another platelet receptor that can be inhibited in 
the presence of ibrutinib is αIIbβ3. This integrin is crucial for aggregation and clot 
retraction functionality as in Section 1.2.6. Therefore, it is unsurprising that ibrutinib has 
been demonstrated to inhibit clot retraction (Bye et al., 2015, Dobie et al., 2019).  
Ibrutinib analogs have also been used to investigate the role of Btk in thrombus formation 
on collagen using shear flow conditions. The ibrutinib analog used in the study is a 
structurally similar variant of ibrutinib, that binds to Cys481 of Btk, with a similar IC50 value 
and selectivity profile as its parent drug. At a shear rate of 2,200s-1, which is the shear 
rate of stenosed arteries, the percent coverage was significantly decreased in the 
presence of the ibrutinib analog (Rigg et al., 2016). Whereas other work has shown that 
the surface coverage is not significantly different showing platelets adhere normally, 
however, the stability of the thrombus is significantly weaker t in the presence of ibrutinib 
(Bye et al., 2015).  
A study from an independent group used reconstituted blood to corroborate the finding 
that ibrutinib does not alter thrombus surface area, however, the stability of the thrombus 
was not shown (Nicolson et al., 2018). Recent work has also shown that ibrutinib also 
significantly inhibits thrombus formation in vitro on collagen, whereas other Btk inhibitors 
such as acalabrutinib or zanubrutinib do not (Bye et al., 2017, Dobie et al., 2019).  
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More physiologically relevant work using atherosclerotic plaque material extracted from 
human donors via endarterectomy as an agonist has recently been assessed. Plaque 
material contains morphologically different type I and type III fibres and induces platelet 
aggregation via GPVI but not the other collagen receptor α2β11 (Jamasbi et al., 2015).  
Multiple electrode aggregometry was initially assessed to identify if Btk inhibition could 
modulate the response to plaque material. When stimulated with homogenised plaque, 
aggregation was abolished by treatment of whole blood with ibrutinib and acalabrutinib 
(Busygina et al., 2018). However, the response was spared when stimulated with type 1 
collagen.  
At high shear, ibrutinib treatment (0.5μM) inhibited the platelet aggregate formation on 
plaque homogenate, but not collagen. This was also observed at low shear and with 
acalabrutinib. When samples treated with either ibrutinib (0.5μM) or acalabrutinib (1μM) 
were flowed over plaque homogenate at a shear rate of 600/s, there was a significant 
reduction compared to vehicle control. However, the response on type 1 collagen was not 
inhibited in the presence of ibrutinib or acalabrutinib. This sparing of aggregation on 
collagen was found to be α2β1 independent. Treatment with an α2β1-blocking antibody 
6F1, but not ibrutinib, blocked platelet adhesion to soluble type I. This demonstrates that 
α2β1 is required for aggregation on collagenous surfaces under arterial flow, but ibrutinib 
does not alter its downstream signalling.  
The authors propose that that the use of plaque tissue and the use of native type I 
collagen represent the pathological process of atherothrombosis and the physiological 
process of hemostasis, respectively.  
 
1.8.4 The platelet function of patients taking ibrutinib and 
acalabrutinib.  
All the research discussed so far used inhibitors exogenously added to healthy donor 
platelets. Studies have also examined the platelet function of patients taking these drugs 
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in the clinic as an anti-CLL therapy. Peak in vivo plasma concentrations of ibrutinib and 
acalabrutinib have been estimated at approximately 300nM and 1.7µM, respectively (Byrd 
et al., 2016, Advani et al., 2013). Platelet inhibition is typically seen at concentrations 
greater than this in ex vivo studies, however ex vivo and in vitro studies do not consider 
drug accumulation, metabolism, or plasma binding.  
Maximal platelet aggregation from patients taking ibrutinib was also assessed in response 
to collagen (3.3μg/mL). On ibrutinib therapy, not every patient has bleeding side effects. 
Using PRP, maximal aggregation was significantly inhibited in patients that do experience 
bleeding, along with platelet adhesion to VWF. This caused the authors to define the two 
groups and assess them differently. In patients experiencing bleeding, at day 15 of 60 
maximal platelet aggregation and surface coverage on VWF under flow was almost 
abolished, whereas U44619 and ADP mediated aggregation was normal. Whereas non 
bleeders do not have a significant inhibition of aggregation to any agonist or adhesion of 
VWF (Levade et al., 2014).  
Following on from the work of Levade et al., 2014, Kamel et al., also investigated platelet 
aggregation. This work showed that aggregation to both low and high doses of ADP were 
normal in patients taking ibrutinib, along with U46619 which induces platelet activation via 
the thromboxane A2 receptor. Before taking ibrutinib, patients have a high percent 
aggregation to low (2μg/ml) and high (10μg/mL) concentrations of collagen. Whilst taking 
the drug, the percentage aggregation drops by approximately half in response to high 
concentrations of collagen and by 75% to low concentrations of collagen (Kamel et al., 
2015) demonstrating that ibrutinib is a potent inhibitor of platelet aggregation. 
Thrombus formation under flow was also assessed in patients treated with ibrutinib and 
acalabrutinib.  The thrombus volume positively correlated with the platelet count of these 
patients treated with acalabrutinib. There was no significant correlation between thrombus 
volume and platelet count in ibrutinib patients further confirming in vitro experiments that 
ibrutinib causes unstable thrombi (Bye et al., 2015, Bye et al., 2017). Recent work has 
also confirmed this result that patients taking ibrutinib form unstable thrombi when 
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compared to healthy controls, whereas another second generation inhibitor, zanubrutinib, 
does not (Dobie et al., 2019).  
In the study by Busygina et al., patients on ibrutinib therapy had similar platelet counts to 
controls, and when multiple electrode aggregometry was assessed, aggregation was 
inhibited when stimulated with collagen or atherosclerotic plaque material consistent with 
their in vitro blood studies. When assessed under flow, ibrutinib patients had significantly 
decreased platelet coverage on plaque homogenate and tissue over a range of time 
points. On collagen, inhibition of thrombus formation was initially observed, however it 
was rescued and was not found to be significantly different at the end of the assay 
(Busygina et al., 2018).  
Ibrutinib inhibits thrombus formation when stimulated with atherosclerotic plaque, but it is 
not different from controls on response to collagen. From this, the authors hypothesise 
that thrombus formation in pathological settings (activation via plaque material), but not in 
normal haemostasis (activation via collagen), Btk inhibitors can be utilised as an anti-
platelet therapy (Busygina et al., 2018, Bye and Gibbins, 2018). 
Little has been published regarding patients taking Btk inhibitors downstream of CLEC-2. 
Recent work by collaborators has shown that patients taking both ibrutinib and 
acalabrutinib do not aggregate in response to rhodocytin over a range of concentrations 
of agonist. Unlike CRP-XL as an agonist, where there has been shown to have a 
difference in the platelet response between patients on ibrutinib or acalabrutinib (Nicolson 
et al., 2018), there is no difference in between the responses downstream of CLEC-2 







1.9 Aims and Hypothesis.  
1.9.1 Differences in ITAM and hemITAM signalling  
As discussed in Section 1.6, there are some differences in the GPVI and CLEC-2 
signalling pathways. These include differences in the requirements of secondary 
mediators, actin polymerisation and the requirement of PI3K activity. These are all 
dispensable for GPVI signalling, but essential for CLEC-2 signalling. However, the 
scaffold protein SLP-76 is required for GPVI, but not for CLEC-2, highlighting another 
novel difference between the pathways. 
One of the key differences is the position of Btk in the signalling cascades. It has been 
suggested that Btk is upstream of Syk in the CLEC-2 signalling pathway. This contrasts 
with GPVI signalling, where Btk is below Syk. Considering this difference it is not 
unreasonable to hypothesise that Btk may have a differential role downstream of GPVI 
compared to CLEC-2.  
 
1.9.2 Btk kinase activity in B cells  
Whether Btk behaves as an explicit kinase downstream of the BCR is debatable. 
Canonically it has been thought that Btk acts as a kinase downstream of the B cell 
receptor where it induces phosphorylation of PLCγ2 (Takata and Kurosaki, 1996, 
Watanabe et al., 2001, Humphries et al., 2004). The development of kinase inhibitors that 
are clinically successful in treating BCR mediated diseases also contributes to the notion 
that Btk acts as a kinase downstream of the BCR (Pal Singh et al., 2018).  
However, it has been shown that Btk may not act as an explicit kinase, as a kinase dead 
version of Btk can reconstitute BCR signalling (Tomlinson et al., 2001). Recently, non-
catalytic variants of Btk have been shown to mediate PLCγ2 activation (Wist et al., 2020).  
Furthermore, expression of non-catalytically active Btk causes a less severe phenotype of 
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XLA (Gaspar et al., 2000). This suggests that Btk can partially mediate BCR signalling in 
the absence of a functional kinase domain.  
Recently, a study has proposed dual roles for Btk, as a scaffold and a kinase in the 
formation of the antigen- triggered immune synapse. Btk scaffolding is important for the 
initiation of the formation of an immune synapse, whereas kinase activity controls the 
accumulation of the antigen within the cell (Roman-Garcia et al., 2018). This shows that 
within the same cell, Btk can mediate signalling through a catalytic or scaffolding role.   
1.9.3 Localisation of proteins 
Although studies have identified a role for Btk downstream of (hem)ITAM signalling, there 
has been no systematic studies investigating the localisation of Btk in relation to key 
signalling molecules. Studies using biochemical techniques of membrane fractions have 
identified that Btk translocates to the membrane after stimulation with convulxin and 
rhodocytin (Manne et al., 2015a). The localisation of GPVI and CLEC-2 on the surface 
has been studied using microscopy (Dunster et al., 2020, Pollitt et al., 2014, Poulter et al., 
2017), but has not yet been shown to interact with Btk.  
It has been proposed that Btk undergoes clustering in order to become catalytically active 
(Chung et al., 2019, Wang et al., 2019b, Hyvönen and Saraste, 1997). However, there is 










1.9.4 Aims and hypothesis 
While there are common mechanisms shared between GPVI and CLEC-2 mediated 
signalling there are differences. Btk is a kinase present in B cells, however, its kinase 
activity is not always required to mediate signalling. Patients taking a second generation 
Btk inhibitor do not experience bleeding as a side effect, suggesting that Btk may be 
playing a scaffolding or redundant role in platelets.  Furthermore, localisation of Btk and 
key hemITAM signaling molecules, which has not been extensively studied in platelets 
may help to elucidate if Btk plays a differential role downstream of GPVI and CLEC-2.  
The aims of this thesis are to:  
• Identify if there is a differential role of Btk downstream of GPVI and CLEC-2. 
• Investigate the role of the Btk kinase domain downstream of GPVI and CLEC-2 
• To determine if Btk can act as a scaffold protein independently of its kinase 
domain 
• To identify the localisation and clustering of Btk in relation to key signalling 
molecules in platelets.  
 
Hypothesis 
In platelets Btk plays a differential role downstream of GPVI and CLEC-2 by mediating 








2 Materials and methods  
2.1 Materials and Methods 
2.1.1 Agonists and inhibitors 
Collagen-related peptide (CRP-XL) was obtained from Professor Richard Farndale 
(University of Cambridge, Cambridge, UK). Type 1 Collagen was purchased from 
Nycomed (Munich, Germany). Rhodocytin was a kind gift from Dr Johannes Able 
(University of Münster, Münster, Germany). Fucoidan and ADP were purchased from 
Sigma Aldrich (Poole, UK). Ibrutinib and acalabrutinib were obtained from Medchem 
express (Sollentuna, Sweden). LY294002 was from Selleckchem (Houston, USA).  
2.1.2 Antibodies  
The antibodies used in this study are listed in Tables 2.1.1 and 2.1.2 
 
Table 2.1.1 The primary antibodies used in this study 















Mouse Flow cytometry 1:100 BD Biosciences 
(New Jersey, USA) 
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pY223 Btk Rabbit Western blotting 1:500 Abcam 
(Cambridge, United 
Kingdom) 
pY551 Btk Rabbit Western blotting 1:500 Abcam 
pY200 LAT Rabbit Western blotting 1:500 Abcam 




pY759 PLCγ2  Rabbit Western blotting 1:500 Cell Signalling 
Technology 



















PLCγ2 (Q-20) Rabbit Western blotting 
Immunofluorescence 
1:1000 
1 in 150 
Santa Cruz (Dallas, 
Texas) 
Btk (E-9) Mouse Western blotting 1:1000 Santa Cruz 
Btk (C-20) 
 
Goat Immunofluorescence 1:150 Santa Cruz 
Syk (N-19) Rabbit Immunofluorescence 1 µg/mL Santa Cruz 
LAT 
(FL-233) 
Rabbit Immunofluorescence 1:150 Santa Cruz 









Mouse Western blotting 2μg/mL  Dr Alice Pollitt 
Btk (BL7) Rabbit Western blotting 
Immunofluorescence 
1:1000 
1 in 150 
Dr Mike Tomlinson, 
University of 
Birmingham 
Tec (BL17) Rabbit Western blotting 1:1000 Dr Mike Tomlinson 
Tec (BL19) Rabbit Western blotting 1:1000 Dr Mike Tomlinson 
Tubulin Mouse Western blotting 1:2000 ProteinTech 
(Illinois, USA) 
















Table 2.1.2 Secondary antibodies used in this study 
Antibody Species Use Concentration Purchased 
from 
Alexa Fluor 647 
conjugated donkey 
anti-rabbit 








Alexa Fluor 488 
conjugated goat 
anti-mouse 





Alexa Fluor 555 
conjugated donkey 
anti-mouse 
Donkey STORM 1:500 Invitrogen 
Alexa Fluor 647 
conjugated donkey 
anti-goat 






Alexa Fluor 555 
donkey anti-goat 
Donkey STORM 1:500 Invitrogen 
 
2.1.3  Other reagents  
The Btk deficient DT40 cells, and plasmid constructs were a kind gift from Dr Mike 
Tomlinson (University of Birmingham, UK). FastDigest Bpil restriction enzyme and T4 
DNA Ligase were obtained from ThermoFisher (Massachusetts, USA). EcoRI-HF, Noti-
HF, BamHI-HF and T4 Polynucleotide kinase were from New England Biolabs 
(Massachusetts, USA). Phenol:Chloroform:Isoamyl Alcohol (24:24:1) was from 
ThermoFisher (Massachusetts, USA). Sybrsafe was purchased from Invitrogen 
(Massachusetts, USA). Fura-2-AM was from ThermoFisher (Massachusetts, USA). 
Unless stated, all other reagents were of chemical grade and purchased from Sigma 
Aldrich (Poole, UK).  
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2.2 Methods  
2.2.1 Human Washed Platelet Preparation 
50 mL of blood was drawn from drug free, consenting individuals using methodology 
approved by the University of Reading research ethics committee, into a syringe 
containing 5mL sodium citrate (4% w/v). 7.5 mL warmed Acid Citrate Dextrose, (ACD -85 
mM sodium citrate, 71mM citric acid and 110mM glucose) was added and centrifuged at 
102g for 20 minutes to obtain platelet-rich plasma (PRP). The PRP was decanted and 
10μL prostacyclin (PGI2 125μg/mL, solubilised in ethanol) was added and platelets 
pelleted by centrifugation at 1413g for 10 minutes. The pellet resuspended in 25mL of 
warmed Tyrode’s buffer (30°C) (134mM NaCl, 2.9mM KCl, 0.34mM Na2HPO4, 12mM 
NaHCO3, 20mM HEPES, 1mM MgCl2 and 5mM glucose; pH 7.3) and 3mL of ACD. The 
platelet count was determined using a Sysmex counter (Sysmex, UK), 10μL PGI2 was 
added and then following centrifugation at 1413g for 10 minutes, the platelet pellet was 
re-suspended to the appropriate cell density using Tyrode’s buffer. Platelets were rested 
for 30 minutes to recover.  
For ADP sensitive platelets, PRP was obtained from whole blood by centrifugation at 
102g for 20 minutes after addition of ACD. The PRP was then decanted and the platelet 
count was obtained. Centrifugation at 350g for 20 minutes pelleted the platelets. The 
platelet poor plasma was then removed gently, and the platelet pellet was resuspended to 
4x108 cells/mL in warmed Tyrode’s buffer. Platelets were used immediately. 
 
2.2.2 Light transmission aggregometry  
245μL of washed platelets at (4x108 cells/mL) were added to a siliconized glass cuvette 
and incubated for 5 minutes with vehicle (0.1% (v/v) DMSO final) or 2.5μL ibrutinib or 
Acalabrutinib (10µM – 0.01µM final) and then 2.5μL of CRP-XL (1μg/mL final) or 
rhodocytin (10-300nM final) was added and light transmission monitored for 5 minutes for 
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CRP-XL or 7 minutes for rhodocytin at 37oC with constant stirring (1200rpm) using an 
aggregometer (Helena biosciences, Gateshead UK). 
 
2.2.3 Western blot platelet sample production 
222.5μL Platelets (4x108 cells/mL) were incubated with indomethacin (10μM), apyrase 
(2U/mL) and integrelin (9μM) to induce non aggregating conditions for GPVI mediated 
signalling and integrelin (9μM) for CLEC-2 mediated signalling. Platelets were incubated 
with 2.5μL acalabrutinib (0.01 -10μM), ibrutinib (0.01-10μM) or vehicle control (0.1% (v/v) 
DMSO final) before addition of 25μL of agonists (1μg/mL CRP-XL, 100nM or 300nM 
rhodocytin final) under stirring conditions. GPVI stimulated samples were allowed to stir 
for 180 seconds at 37oC before lysis with 6X sample buffer (12% (w/v) Sodium Dodecyl 
Sulphate (SDS), 30% (v/v) glycerol, 0.15M Tris-HCl (pH 6.8), 0.001% (w/v) Brilliant Blue 
R, 30% (v/v) b-mercaptoethanol), whereas CLEC-2 stimulated samples were allowed to 
stir for 5 minutes before lysis with 6X sample buffer. Samples were heated at 95°C for 5 
minutes before freezing until SDS-PAGE.  
 
2.2.4 Immunoprecipitation 
445μL Washed platelets (8x108 cells/mL) under non-aggregating conditions were 
preincubated and stimulated with agonist as above. Platelets were preincubated with 5µl 
of the stated inhibitors or vehicle control for 5 minutes before stimulation with 50µl 300nM 
Rhodocytin for 3 minutes before lysis with an equal volume of 2x NP40 lysis buffer 
(100mM Tris, 300mM NaCl, 0.2% (w/v) SDS, 1% (w/v) Sodium deoxycholate, 1% (v/v) 
NP40) containing the protease inhibitors leupeptin (10μg/mL), AEBSF (200μg/mL), 
aprotinin (10μg/mL), Pepstatin (1μg/mL) and the phosphatase inhibitor sodium 
orthovanadate (5μM). Lysates were clarified by centrifugation at 15,000g for 10 minutes 
at 4°C before preclearing with 30μL protein A Sepharose beads for rabbit antibodies, or 
protein G for mouse antibodies for 30 minutes at 4°C. Lysates were incubated with 
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primary antibodies (concentrations stated within text), for 1 hour at 4°C before 25μL bead 
volume was added. Samples were incubated overnight at 4°C, before supernatant was 
removed. Beads were washed 1x in NP40 lysis buffer and then 3x in TBST (Tris buffered 
saline with Tween 20: 20mM Tris, 140mM NaCl, 0.1% Tween, pH 7.6) before elution into 
35μL of 2X Sample buffer. Samples were boiled at 95°C for 5 minutes before storage or 
SDS-PAGE immunoblotting. 
 
2.2.5 SDS-PAGE and Immunoblotting 
Proteins were separated by SDS-PAGE (Laemmli, 1970), using 10% SDS-PAGE Gels 
which were submerged in 1X Tris/Glycine/SDS buffer (25mM Tris, 192mM glycine, 0.1% 
(w/v) SDS, pH 8.3) within a Mini-PROTEAN tetra vertical electrophoresis cell (Bio-Rad, 
CA, USA). Electrophoresis was run at a constant voltage of 120V. 
Following protein separation, gels were removed from their plates. 2 pieces extra thick 
filter paper were soaked in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol, pH 8.3). A Section of polyvinylidene difluoride (PVDF) membrane was soaked 
in methanol and then in Towbin transfer buffer. Semi-dry western blotting was performed 
using a Trans-blot Turbo blotter semi-dry transfer cell (Bio-Rad, CA, USA). Proteins were 
transferred from the gel to the PVDF membrane for 40 minutes at 15V. PVDF membranes 
were then transferred into a 5% (w/v) solution of bovine serum albumin (BSA) dissolved in 
TBST (Tris buffered saline with Tween 20; 20mM Tris, 140mM NaCl, 0.1% (v/v) Tween, 
pH 7.6) to block the membrane for 1 hour at room temperature. Primary antibodies were 
diluted to a concentration as stated in Table 2.1.1 in a 5% (w/v) solution of BSA dissolved 
in TBST and membranes were incubated with these solutions overnight at 4°C on a 
rotator. Primary antibody solutions were removed from the PVDF membranes the next 
day and membranes were washed 3x for 10 minutes with TBS-T.  
Secondary antibodies (as stated in Table 2.1.2) were added 1:4000 to a 2.5% BSA 
(dissolved in TBS-T) solution, which was then added to PVDF membranes and incubated 
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in the dark at room temperature for 1 hour. PVDF membranes were washed 3x for 10 
minutes with TBS-T. PVDF membranes were scanned using a Typhoon Trio fluorescence 
imager (Amersham Biosciences, Buckinghamshire, UK) and analysed. Band intensity was 
analysed using Imagequant software.  
 
2.2.6 Calcium Flux 
Methods were adapted from Bye et al., 2018. Whole blood was centrifuged to prepare 
PRP as described previously in Section 2.2.1. FURA 2-AM was added to PRP to a final 
concentration of 2μM. Platelets were incubated for 1 hour at 37°C for 1 hour with gentle 
inversions. Platelets were then pelleted and resuspended to 4x108 cells/mL. 160μL of 
Fura-2 loaded platelets were incubated with inhibitors or vehicle for 5 mins at 37°C prior 
to addition of 40μL 5X concentration agonists (1μg/mL CRP or 300nM or 100nM 
rhodocytin final). Calcium fluorescence measurements with excitation at 340 and 380 nm 
and emission at 510 nm were recorded over a period of 5 minutes. The 340/380 ratio was 
plotted and the difference in the peak, area under the curve and time to peak of calcium 
was assessed. 
 
2.2.7 Flow cytometery  
In a flat-bottomed 96 well plate, 5μL of ADP insensitive washed platelets (4x108 cells/mL) 
were incubated with 5μL 10X drug or vehicle control, 0.5μL anti-P-selectin and 0.5μL anti-
fibrinogen antibody (stated in Table 2.1.1) for 5 minutes before the addition of 5μL 10X 
agonist, with a total reaction volume of 50μL made up with Tyrodes. The plate was 
incubated for 20 minutes in the dark before fixation with 150μL 0.2% formyl saline. Flow 
cytometric analysis was performed using a BD Accuri C6 flow cytometer (BD Biosciences, 
Oxford, UK) and data was collected from 10,000 events gated on platelets using side 
scatter (SSC) and forward scatter (FSC) measuring cell granularity and cell size, 




2.2.8 Platelet spreading microscopy 
Coverslips were coated with 300μL 100nM rhodocytin, 10μg/mL collagen or 200μg/mL 
fucoidan overnight at 4°C. Coverslips were washed 3x with PBS before being blocked 
with 5mg/mL heat denatured protease free bovine serum albumin in PBS for 45 minutes 
at room temperature. The wells were then washed 3x PBS to remove any excess blocking 
reagent. Washed platelets (2x107 cells/mL) were incubated with stated concentrations of 
inhibitor or vehicle control (0.1% DMSO (v/v)) prior for 5 minutes at room temperature. In 
experiments using LY294002, platelets were preincubated with LY294002 or vehicle 
control (0.1% ethanol (v/v)) for 5 minutes before the addition of acalabrutinib (1μM or 
0.1μM) or vehicle control (0.1% DMSO (v/v)). Platelets were allowed to spread for 45 
minutes at 37°C. Wells were washed 3x with PBS before platelets were fixed with 10% 
Formalin for 10 minutes at room temperature. Slides were mounted using Hydramount 
before Differential Interference Contrast (DIC) imaging on a Nikon Eclipse Ti2 100x lens. 
Platelet spreading analysis was performed using ImageJ cell counter plugin to assess the 
number of platelets in the field of view. Surface area of each individual platelet was also 
calculated by manually tracing the platelets and using the measure function on ImageJ.   
 
2.2.9 Cells and plasmids 
The DT40 chicken lymphoma cell line and the cell line rendered deficient in Btk (Takata 
and Kurosaki, 1996) was cultured in RPMI 1640 medium supplemented with 10% (v/v) 
Fetal bovine serum, 1% (v/v) chicken serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 20 mM glutamine and 50 μM 2β-mercaptoethanol. GPVI, FcRɣ and NFAT-
luciferase containing plasmids have been described previously (Tomlinson et al., 2007). 
The wild type (WT) and kinase dead (KD) K430E Btk plasmids have been previously 
described (Tomlinson et al., 2001). The mutations R307K and W124F have been 
described previously (Li et al., 1995).  
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Plasmids were dissolved in water and DH5α Escherichia coli were transformed. 
Competent cells were incubated with 1μL circular DNA for 30 minutes on ice. Cells were 
heat shocked at 37°C for 30 seconds and replaced on ice for 2 minutes to allow cells to 
recover. Cells were added to Luria broth (LB) and incubated at 37°C for 1 hour at 250 
rpm. 50μL of cells were then spread on agar plates containing 100μg/mL ampicillin, or 
50μg/mL kanamycin, depending on the selection cassette. Plates were incubated at 37°C 
overnight. Antibiotic resistant colonies were picked and used to inoculate 200mL Luria 
Broth supplemented with antibiotic (100μg/mL ampicillin, or 50μg/mL kanamycin) and 
shaken overnight at 250 rpm at 37°C to induce bacterial growth.  
Cultures were maxi prepped the following day using a GenElute maxiprep kit according to 
manufacturer’s instructions. The resulting yield was salt ethanol precipitated using sodium 
acetate (3M C2H3NaO2 pH 5.2) and 100% ethanol to precipitate the DNA. DNA was 
pelleted at 16,000g for 30 minutes at 4oC. The supernatant was discarded, and the pellet 
was washed in 70% ethanol. After pelleting, removal of all ethanol and air drying, the DNA 
pellet was resuspended in ultrapure ddH20 to achieve a concentration of 1μg/mL.   
 
2.2.10 Transfections and luciferase assay 
Cells were transfected in a volume of 0.4mL of serum free RPMI using a Gene Pulser II 
Electroporator (Bio-Rad) set at 350 V and 500 μF. Cells were transfected with 2 µg of 
both GPVI and FcRɣ or 10µg of CLEC-2, and 7.5 μg of NFAT-luciferase plasmids and 
where stated, either 5 µg WT or KD Btk plasmids or empty vector control. Twenty hours 
after transfection, live cells were counted by Trypan blue exclusion and diluted to 2x106 
live cells/mL. Cells (50μL) were stimulated with 50μL Horm collagen (10μg/mL final 
concentration) for GPVI or rhodocytin (50nM final) for 6 hours. As a positive control, cells 
were also treated with phorbol 12‐myristate 13‐acetate, PMA (50 ng/mL) plus ionomycin 
(1 μM). In experiments involving ibrutinib and acalabrutinib, cells were stimulated with 
collagen (10µg/mL final) or rhodocytin (50nM final) in the presence of ibrutinib (0.5-10µM), 
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acalabrutinib (0.5-10µM) or vehicle (0.1% (v/v) DMSO final) for 6 hours in the absence of 
serum as these drugs have a high degree of plasma binding (Levade et al., 2014). Cells 
were then lysed with 11μL of lysis buffer (10% (v/v) Triton X-100, 200 mM NaPO4 (pH 
7.8), and 4 mM dithiothreitol) and added to an equal volume of assay buffer (200 mM 
NaPO4, 20 mM MgCl2 and 10 mM ATP). Luciferase activity was measured using a 
NOVOstar plate reader (BMGLabtech) following the addition of 50μL of 1 mM D-luciferin. 
Luciferase assay values were recorded in triplicate and averaged for each experiment. 
 
2.2.11 Flow cytometry of DT40 cells  
To confirm receptor expression, following transfection 450μL cells (2x106 live cells/ mL) 
were pelleted and washed in FACS buffer (0.5% BSA/PBS) before resuspension in 10 
μg/mL 1G5 or AYP1 for GPVI and CLEC-2 transfected cells, respectively. Cells were 
washed 3 times with phosphate buffered saline and resuspended in Alexa Fluor 488-
conjugated goat anti-mouse antibody before washing. Cells were resuspended and 
stained with propidium iodide to enable gating of live cells before flow cytometry analysis 
using a BD Accuri C6 flow cytometer. 
 
2.2.12 DT40 Lysates and microscopy 
DT40 cells were washed 2x with 1x PBS. Cells were pelleted and resuspended in 1X 
RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 0.1% (w/v) SDS, 1% (w/v) Sodium 
deoxycholate, 1% (v/v) Triton) with protease and phosphatase inhibitors as previously 
described to 1x107 live cells/mL. Cells were lysed for at least 30 minutes on ice before the 
insoluble fraction of cytoskeletal components was removed by centrifugation at 16,000g 
for 10 minutes. The supernatant was removed and 6X sample buffer was added before 
western blotting as previously described in Section 2.2.5.  
Methods were adapted from (Tomlinson et al., 2004b). Coverslips were coated with Poly-
L-Lysine (0.01% (w/v)) before 1x washes in PBS and being allowed to dry. WT and Btk 
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KO DT40’s were washed 3x with 1x PBS. 1x106 cells were allowed to adhere to the 
coated coverslips at 37°C for 1 hour, before non-adhered cells were removed. Cells were 
fixed using 10% Formalin for 15 minutes before permeabillsation with 0.1% (v/v) Triton for 
7.5 minutes. Cells were blocked for 45 minutes at room temperature with heat denatured 
5 mg/mL BSA/PBS. Cells in individual wells were stained with primary antibodies against 
Btk (rabbit, BL7, 1 in 150), PLCγ2 (rabbit, Q- 20,1 in 150) or a rabbit IgG control (1 in 150) 
for 45 minutes at room temperature.  Following 3x washes in PBS cells were stained with 
Alexa fluor 488 conjugated goat anti rabbit secondary antibody (1 in 500; 4 µg/ml) for 45 
minutes at room temperature before 3x washes in PBS and 1x wash in ultrapure water. 
Cells were mounted using mounting medium containing DAPI (4′,6-diamidino-2-
phenylindole). Slides were imaged on a Nikon A1R fluorescence confocal microscope 
using the 60x lens.  
 
2.2.13 Creation of DT40 CRISPR Btk knockout.  
sgRNAs were designed using the online tool Deskgen (Hough et al., 2016). The first exon 
of Gallus gallus (chicken) Btk was selected in the software and the guide RNA sequences 
with the least off target effects were chosen. Additional bases were added (5’CACCG, 
3’CAAA) for overhangs to ensure ligation into vector backbone after digestion with Bpil. 
An additional guanine (G) was added to the start of the nucleotide guide as the U6 
promoter used to express the sgRNA prefers this nucleotide base to initiate the transcript.  
Methods were adapted from Ran et al 2013.  
1µg pSp-Cas9-2A-BB-Puro was digested with fast digest BpiI overnight at 37°C. The 
digested plasmid was run on a 1% agarose gel stained with 1x Sybrsafe for approximately 
1 hour at 120 volts. Linearised plasmid was excised from the gel and gel extracted using 
a GenElute gel extraction kit (Sigma Aldrich, UK) and eluted into 30µL ddH20. 
Forward and reverse oligos were ordered per each guide sequence as in Table 2.2.1 and 
resuspended to 100 µM. The oligonucleotides were annealed and phosphorylated using a 
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thermocycler as conditions shown in Figure 2.2.1 and the components listed in Table 
2.2.2. The annealed and phosphorylated oligonucleotides were diluted 1:200 before 
ligation into digested pSp-Cas9-2A-BB-Puro.  
 
Table 2.2.1 The primers used in this study 
Primer name Use  Sequence / Sequences 
SN1 Sequence W124F 5’ GAGGAGTCTAGTGAAATGGAA 
SN2 Sequence 
WW251/2LL 
5’ AGGTCGTGGCCCTTTATGATT  
SN3 Sequence R307K 5’ GTGATCCGCCATTACGTT  
SN7 Sequence K430E 5’ CTACGGCAGCTGGGAGATCGA  
 
U6 forward CRISPR Cas9 Guide  5’ GAGGGCCTATTTCCCATGATTCC  
SHN01 
SHN02 
Btk KO CRISPR 





Btk KO CRISPR 





Btk KO CRISPR 












































Table 2.2.2 Component mixture for oligonucleotide phosphorylation and annealing 
Component Volume (μL) 
10x Buffer A 2 
ATP (10mM) 2 
Guide oligo top strand (100μM) 1 
Guide oligo bottom strand (100μM) 1 
T4 polynucleotide kinase 1 






Figure 2.2.1 Thermocycling conditions used to phosphorylate and anneal single 
oligonucleotides   
 
Ligations were performed using 100ng of digested plasmid, 1µL of diluted oligos, 2X 
ligation buffer and 0.5µL T4 DNA Ligase made up to a total volume of 20µL with water. 
Ligation reactions occurred at 4°C overnight.  
DH5α Escherichia coli chemically competent cells were transformed using the ligation 
mixture. Competent cells were incubated with 5µL ligation mixture for 30 minutes on ice. 
Cells were heat shocked at 37°C for 30 seconds and replaced on ice for 2 minutes to 
allow cells to recover. Cells were added to Luria broth (LB, 1% tryptone, 0.5% yeast 
extract) and incubated for 1 hour as previously described in Section 2.2.9. 50μL Mixture 
was then spread on LB agar (LB and 1.5% w/v bacterial agar) containing 100µg/mL 
ampicillin and incubated at 37°C overnight.  
Single colonies from each plate were picked aseptically and used to inoculate 5mL LB 
broth supplemented with 100µg/mL ampicillin and incubated overnight as previously 
described in Section 2.2.9. Glycerol stocks were made with 250µL of culture and 250µL 
glycerol to act as a cyropreservative. The remaining culture was processed using Gen 
Elute Miniprep kit (Sigma, Poole UK) and eluted into ultrapure 50µL H20. DNA 
concentration was measured using a Nanodrop before sequencing with the U6 forward 




After verification of ligation of the guide RNA into pSp-Cas9-2A-BB-Puro, 200mL LB 
supplemented with ampicillin as previously described was inoculated with glycerol stocks 
made previously (as described in the above paragraph). Cultures were then processed 
using a GenElute maxiprep kit (Sigma, Poole UK) and salt ethanol precipitated as 
described in Section 2.2.9.  
WT DT40 cells were transfected using the previous method with the following adaptations 
based on (Abu-Bonsrah et al., 2016) – 30μg of guide containing plasmid and the 
electroporation conditions were modified to 300V and 900μF. Cells were left for 20 hours 
post transfection before stable selection. Serial dilution of cells was performed in the 
presence of 2µg/mL puromycin to isolate single-cell colonies. Cells were left for 7-10 days 
to ensure stable selection before colonies were expanded into 24 well plates and then into 
6 well plates. Lysates were made as in Section 2.2.12 and western blotted as in Section 
2.2.5 to confirm deletion of the protein.  
 
2.2.14 Creation of DT40 CRISPR Btk knockins 
Chicken (Gallus gallus, NP_989564.2), Mouse (Mus musculus, CH466598.2), Human Btk 
(Homo sapiens, Q06187.3), Zebrafish (Danio rerio, XP_697087.5) and beaver (Castor 
canadensis, JAV44149.1) were aligned using T-coffee (Notredame et al., 2000). 
Sequences were presented with ESPrit 3 (Robert and Gouet, 2014) to identify if key sites 
in Btk were exactly homologous or conserved.  
Guides were selected based on distance to mutation with the closest possible guides with 
the least amount of off target effects selected using Deskgen software and cloned into the 
pSpCas9-2A-BB-Puro plasmid as previously described (Section 2.2.13). Deskgen 
software (Hough et al., 2016) was also utilised to generate the donor sequence with the 
changed DNA codon to introduce a point mutation. Manual silent mutations were added 
into the donor sequence to remove the PAM site or mutate where the original guide would 
bind to prevent recutting. A further silent mutation of introducing or removing a restriction 
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enzyme site was introduced to allow for screening of mutants by restriction digestion. 
Donor sequences (Table 2.2.3) were ordered from Eurofins genomics in the pEX-A128 
and dissolved in ddH20 before transformation of E. coli.  
Initial experiments were performed with 15μg of guide DNA plasmid and 15μg of donor 
DNA plasmid at 300V and 900μF. Further experiments utilised 15μg of guide DNA 
plasmid and 15μg of linearized donor DNA plasmid. The donor plasmid was linearized 
using EcoRI-HF overnight at 37oC (20 units of enzyme per 1μg of DNA in a 50μL 
reaction). A sample was run on a 1% (w/v) agarose gel to ensure plasmid linearization 
compared to linearized DNA control. Linearized donor DNA was purified using Phenol 
chloroform extraction. One volume of Phenol:Chloroform:Isoamyl Alcohol (24:24:1) was 
added to the sample and shaken by hand for 20 seconds. The solution was centrifuged at 
room temperature for 5 minutes at 16,000g. The upper aqueous phase was removed, and 




















Table 2.2.3 Donor sequences used in CRISPR-Cas9 Btk KI experiments 







































2.2.15 DT40 DNA extraction and Touchdown PCR 
2.2.15.1 DNA extraction 
1mL of cells were pelleted and washed 1x in PBS and pelleted before being resuspended 
in 100μL DT40 lysis buffer (200 mM NaCl, 20 mM EDTA, 40 mM Tris–HCl, pH 8.0, 0.5% 
SDS, 0.5% 2-ME). 4μL of proteinase K was added (20μg/mL) and samples were digest 
overnight at 55°C. DNA was precipitated by the addition of 70μL of 5M NaCl and samples 
were shaken for 15 seconds before incubation on ice for 15 minutes. Samples were 
centrifuged at 12,000g for 30 minutes at 4°C and the supernatant removed. 250μL of 
100% ethanol was added to the supernatant and samples were span for 2 minutes at 4°C 
at 12,000g. The supernatant was removed and the DNA precipitate was washed with 
500μL of 70% ethanol before further centrifugation at 12,000g for 1 minute at 4°C. 
Supernatant was removed and samples were allowed to air dry for 5 minutes before 
resuspension in 15μL of ddH20.  
 
2.2.15.2 Touchdown PCR 
Extracted DNA was amplified using REDTaq (Sigma Aldrich, Poole UK). Reaction mixture 
contained 5 µl 10× REDTaq PCR Reaction Buffer, 1μL DNTPs (final concentration 200μM 
for each DNTP). 2.5 µl of both forward and reverse primers (10 µM), 10 ng template DNA, 
2.5μL of REDTaq DNA polymerase and ddH2O to a final volume of 50 µl. Reaction 
conditions were 94°C 1 minute, then cycles of 94°C 1 minute for denaturing, 65°C for 2 
minutes for annealing, 72°C for 3 minutes for extension with the annealing temperature 
dropping by 1°C each cycle to a final annealing temperature of 55°C. 20 cycles of 94°C 1 
minute, then cycles of 94°C 1 minute, 55°C for 2 minutes and 72°C for 3 minutes then 
followed. PCR mixture was resolved via agarose gel electrophoresis, resulting fragments 





2.2.16 Total internal reflection fluorescence microscopy (TIRFM) 
and Stochastic optical reconstruction microscopy (STORM) 
sample preparation 
Ibidi µ-slide wells were coated with 20µg/mL collagen overnight at 4°C, washed with PBS 
then blocked with 5mg/mL heat denatured protease-free bovine serum albumin in PBS 
(BSA/PBS) for 45 minutes at room temperature. The wells were washed 3 times with PBS 
before 200µL of washed platelets (2x107 cells/mL) were added and left to incubate for 45 
minutes at 37°C. Non adhered platelets were aspirated and the wells washed 3 times in 
PBS before cells were fixed with 200µL 10% Formalin for 10 minutes followed by 3 
washes in PBS. Cells were then permeabilised with 200µL 0.1% (v/v) Triton X-100 for 5 
minutes before being washed 3 times in PBS before being blocked with BSA/PBS as 
described previously before being incubated with primary antibodies. Primary antibodies 
used for staining can be found in Table 2.1.1. Platelets were stained with primary antibody 
for 45 minutes at room temperature then washed 3 times in PBS followed by incubation 
with appropriate secondary antibodies (1 in 500) for 45 minutes then finally washed 3x in 
PBS before being imaged in PBS using a Nikon TIRF system mounted on a Nikon Eclipse 
Ti inverted microscope, with a Nikon 100x NA 1.49 TIRF objective.  
 
2.2.17 TIRFM image analysis 
Microscopy analysis was performed using ImageJ. Btk spot analysis was performed by 
thresholding the image to 1% to remove background and select for Btk spots. Particles 
were counted using the ImageJ tool ‘Analyse Particles’. Particles between 0.1-10 microns 
and 0-1 circularity were included in the count. Colocalisation analysis was performed by 




2.2.18 STORM imaging 
Samples were imaged on a Nikon N-STORM system in dSTORM mode which is 
characterized by a Ti-E stand with Perfect Focus, using a 100x 1.49 NA TIRF objective.  
To allow fluorophore blinking, samples were imaged in a PBS based buffer consisting of 
enzyme solution (catalase 1 μg/ml, Tris (2-carboxyelthyl) phosphine hydrochloride 4 mM, 
glycerol 50%, KCl 25 mM, pH 7.5 Tris-HCl 20 mM, glucose oxidase 50 µg/ml), glucose 
solution (glucose 100 mg/mL, glycerin 10%) and reducing agent solution (100 mM MEA) 
(Metcalf et al., 2013).  
For dual colour STORM imaging (Alexa647 and Alexa555) the N-STORM emission cube 
was used. Images were obtained with continuous activation. The 405 (for 647) and 488 
(for 555) laser power was then increased by 5% every 30 seconds until maximum 
activation of 50% laser power during imaging to reactivate the fluorophores from the dark 
state. 20,000 frames per colour were captured using Nikon NIS Elements v4.5 software, 
and reconstructed using the Nikon STORM analysis module 3.2, applying the drift 
correction and the Gaussian rendering. 4 separate fields of view (FOV) from 3 
independent experiments were imaged. Individual fluorescent blinking events were 
identified and were filtered on photon count and only those with a count >400 was 
selected for further cluster analysis. 
 
2.2.19 STORM analysis 
Nikon localisation co-ordinates  were exported as a text file, and then separated into two 
colours and converted to a text file format using ‘ChriSTORM’ plug-in for ImageJ (Leterrier 
et al., 2015).  
2.2.19.1 LAMA 
Localisation microscopy analyser (LAMA) software (Malkusch and Heilemann, 2016) was 
used to assess cluster formation. Hierarchical cluster analysis was performed with 
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clustering analysis based on Density-based spatial clustering of applications with noise 
(DBSCAN). A cluster was defined as 10 points within a given observation radius (25nm, 
50nm, 75nm and 100nm).  
2.2.19.2 Plot profile 
To assess the localisations of GPVI and Btk along a collagen fibre, Nikon NIS Elements 
analysis software was used to perform plot profile analysis. A line was drawn along the 
collagen fibre and the fluorescence profile for each channel was generated. This was 
converted into arbitrary units due to differing lengths with varying staining fluorescence 
intensities of each fibre. The arbitrary units are 1 for Btk being present, 2 for GPVI being 
present and 3 for both being present at that individual locus. The percentage of 
localisations on the collagen fibre was assessed and analysed using GraphPad Prism. 
For images without collagen fibres, a random cross Section was drawn across the image 
over a range of platelets to generate the plot profile before it was analysed using excel 
and prism.  
 
2.2.19.3 ClusDoC: Cluster detection with degree of colocalization  
ClusDoc software (Pageon et al., 2016) was utilised to analyse colocalisation of clusters. 
At least 3 random regions of interest were selected for each field of view. Coordinate 
based colocalisation (CBC) is first used to assess the colocalisation of molecules of ‘A’ 
with ‘B’ and molecules of ‘B’ with ‘A’ within a defined diameter of 50 nm. ClusDoC utilises 
DBSCAN algorithms to analyse clusters. A cluster was defined as at least 10 points within 
50nm radius. The cluster contours are defined and overlaid on the CBC maps and 




2.2.20 Statistical analysis 
Data was analysed and where appropriate normalised to the vehicle control. GraphPad 
Prism 7 was used to perform statistical analysis by 1-way ANOVA with Dunnett’s or 
Tukey’s multiple comparison post-test, 2-way ANOVA with Dunnett’s or Tukey’s multiple 
comparisons test or a two-way T Test. The level of significance of p values is as follows, 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Data presented are mean +/- standard error of the 


















3 Btk inhibitors inhibit CLEC-2 mediated platelet functions 
more severely than GPVI mediated function. 
3.1 Introduction 
3.1.1 Btk deficient platelet function downstream of GPVI and 
CLEC-2  
The initial study that proposed a role for Btk downstream of GPVI was performed by Quek 
et al., 1998. Btk deficient XLA patients were compared to healthy donors and did not 
aggregate in response to CRP-XL at two doses (1μg/mL and 5μg/mL) and, although 
reduced, PLCγ2 phosphorylation was still present when assessed using western blotting. 
This can also be observed in Btk deficient mouse platelets as they do not aggregate to 
low concentrations of CRP-XL (1μg/mL and 3μg/mL) (Atkinson et al., 2003a). Human Btk 
deficient platelets did aggregate in response to collagen, albeit to a lesser extent. There 
was also calcium flux in response to this agonist, but not to CRP-XL.  
As PLCγ2 phosphorylation was not totally lost in these patients, it was hypothesised that 
Tec may be playing a compensatory role in mediating the phosphorylation (Atkinson et 
al., 2003a). A murine model of individual Btk and Tec knockouts, and a double knockout 
was used to investigate this hypothesis. When stimulated with collagen, PLCγ2 
phosphorylation was only reduced in the double knockout platelets. This is mirrored in 
aggregation experiments where individual Tec family kinase (TFK) knockouts have 
normal aggregation, whereas it is reduced in the double knockout (Atkinson et al., 2003a).  
When CRP-XL was used to ligate GPVI, high concentrations (10μg/mL) induced full 
aggregation in Tec knockouts, weak aggregation in Btk knockouts and no aggregation in 
double knockouts. Once again, this was mirrored in phosphorylation experiments with 
PLCγ2 phosphorylation being reduced in Btk deficient but not Tec deficient platelets. In 
double knockouts the levels of PLCγ2 phosphorylation were almost abolished at a high 
concentration of CRP-XL. This suggests Tec can compensate but not totally rescue the 
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platelet response in the absence of Btk, and only at high concentrations of agonist. At 
lower concentrations of agonist, Tec cannot play a compensatory role as aggregation is 
blocked in the absence of Btk for both human and mouse platelets (Quek et al., 1998, 
Atkinson et al., 2003a).  
It was initially believed that downstream of CLEC-2, Tec could also play a compensatory 
role. CLEC-2 deficient embryos have a blood lymphatic mixing (Finney et al., 2012, 
Suzuki-Inoue et al., 2010, Pollitt et al., 2014). Double knockout mice deficient in Btk and 
Tec display blood lymphatic mixing showing the role for Btk and/or Tec downstream of 
CLEC-2. Whereas single knockouts of either TFK result in a normal phenotype in vivo, 
suggesting redundancy between the two kinases, (Manne et al., 2015a). However, it is 
not clear which KO is presented in the paper and therefore difficult to ascertain which 
kinase plays the predominant role.  
 
3.1.2 Btk inhibitors downstream of GPVI 
The effect of ibrutinib on platelet aggregation induced by GPVI agonists has been 
characterised by numerous groups. Using intermediate and low concentrations of 
collagen as an agonist, ibrutinib can inhibit platelet aggregation in washed platelets 
(Alberelli et al., 2018, Bye et al., 2015). There are some discrepancies in the literature as 
to what concentration of ibrutinib is required to cause total inhibition of platelet 
aggregation to collagen. Differences between concentrations may be due to differing 
platelet preparations, agonist concentrations and the methods of assessing aggregation. 
In the work of Bye et al., aggregation was abolished at 1μM in response to 1μg/mL 
collagen in washed platelets. The same concentration of Ibrutinib (1μM) can also cause 
inhibition at higher concentrations of collagen (Alberelli et al., 2018, Levade et al., 2014).  
It has been shown that low concentrations of ibrutinib can be overcome by high 
concentrations of agonist, as using 10x the concentration of collagen required 10x the 
concentration of ibrutinib to inhibit the response (Lee et al., 2017). This may be due to the 
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redundancies in protein signalling or an increased amount of receptor clustering. For 
example, an increased amount of GPVI  receptor clustering may populate the local 
environment with FcRɣ chain associated SFK’s and Syk (Gibbins et al., 1996, Poole et al., 
1997). These kinases may be playing the predominant role in mediating aggregation 
compared to Btk.  
Similarly, to collagen, aggregation was inhibited in the presence of 1μM ibrutinib 
downstream of 1μg/mL CRP-XL. Spreading and adherence to CRP-XL was also greatly 
inhibited compared to vehicle control in the presence of 1μM ibrutinib. Whereas in 
contrast, only the spreading was inhibited on collagen, not the adherence (Bye et al., 
2015). Ibrutinib has also been shown to inhibit exogenous GPVI ligands such as convulxin 
mediated platelet aggregation (Manne et al., 2015a), in addition to CRP-XL mediated 
aggregation.  
Although ibrutinib has been studied in platelet aggregation, far less work has been 
published with acalabrutinib. Acalabrutinib is a more selective Btk inhibitor and does not 
inhibit Tec and other kinases including SFK at the same potency that ibrutinib does (Barf 
et al., 2017, Byrd et al., 2016, Herman et al., 2015). Therefore, it would be expected there 
would be less severe inhibition of platelet aggregation due to off target effects seen with 
Ibrutinib. Indeed, at 2μM, a clinically relevant dose, the level of inhibition of aggregation 
with 3.3μg/mL of collagen was not as severe as ibrutinib. However, higher concentrations 
of acalabrutinib were able to fully inhibit aggregation (Series et al., 2019). When a higher 
concentration of agonist is used, (100 or 75μg/mL), 0.6μM acalabrutinib did not appear to 
inhibit aggregation as severely, however no statistical analysis directly comparing to 
vehicle control was used (Chen et al., 2018).  
 
3.1.3 Btk inhibitors downstream of CLEC-2 
Compared to GPVI, the use of inhibitors to investigate the role of Btk downstream of 
CLEC-2 has been less extensively researched (Manne et al., 2015a, Lee et al., 2017, 
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Nicolson et al., 2020). The first initial study was performed by the Kunapali group using 
ibrutinib. It was proposed by this group that Btk is positioned upstream of Syk after CLEC-
2 stimulation as Syk phosphorylation is lost in the presence of ibrutinib (Manne et al., 
2015a). This is in contrast to the proposed canonical model of hemITAM signalling which 
suggests that Syk precedes Btk (Fuller et al., 2007, Hughes et al., 2010b, Pollitt et al., 
2014). 
Within the work by Manne et al, low concentrations of ibrutinib (10nM) ablated the CLEC-
2 mediated response to 10nM rhodocytin in mouse platelets.  This concentration (10nM 
ibrutinib) was also inhibitory to human platelets, at a range of concentrations of 
rhodocytin. Phosphorylation events using 300nM or 100nM rhodocytin and 10nM ibrutinib 
showed an inhibition of the Syk active site pY525 and PLCγ2 active site pY759, however 
the phosphorylation of Btk was not shown.  
In the study by Manne et al., aggregation was blocked 10nM. However, the authors did 
not show total cell phosphorylation, or investigate the Btk transphosphorylation site, 
pY551. Therefore, it is unknown whether Btk was initially phosphorylated by SFK’s which 
is required for it to be active (Wahl et al., 1997, Park et al., 1996). If the 
transphosphorylation site of Btk was shown, it would provide more convincing evidence 
that Syk lies downstream of Btk in CLEC-2 signalling.  
An alternative interpretation of the results by Manne et al., may be explained by the 
requirement of secondary feedback to reinforce CLEC-2 signalling. Indeed, Manne et al., 
show that at the concentration of ibrutinib (10nM) and rhodocytin (30nM), ATP secretion is 
totally abolished. This would suggest that the release of ADP and production of TxA2 is 
also inhibited under these conditions. It is known that the phosphorylation and 
reinforcement of CLEC-2 requires secondary messengers. The platelet preparation used 
by Manne et al would have prevented production of the secondary messenger TxA2 due 
to the use of aspirin in the preparation (Koessler et al., 2016). Positive feedback and Syk 
activation are required to initiate CLEC-2 phosphorylation (Pollitt et al., 2010, Hughes et 
al., 2015) and therefore signalling, so the absence of positive feedback may explain the 
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absence of Syk phosphorylation. Of note, the authors did also not show Src pY416, a 
marker of active Src, which is responsible for phosphorylating Syk, which in turn 
phosphorylates CLEC-2 (Hughes et al., 2015). Therefore, it is difficult to conclude if Btk 
lies upstream of Syk in the CLEC-2 stimulated pathway.  
A different study required 5μM of ibrutinib to block CLEC-2 mediated aggregation in 
mouse platelets, which is 50-fold higher than the concentration used by Manne et al., (Lee 
et al., 2017). The agonist used was podoplanin-Fc at 2μg/mL, and low concentrations of 
ibrutinib (0.5μM) did not cause inhibition of platelet aggregation. However, it is difficult to 

















3.2 Aims and hypothesis 
There are few studies on the role of Btk downstream of hemITAM signalling, aside from 
one study suggesting that it is upstream of Syk (Manne et al., 2015a). There is more 
literature published describing a role of Btk downstream of ITAM signalling, however there 
are some inconsistencies across studies, summarised below:  
1) Patients that have XLA and are deficient in Btk do not respond to CRP-XL but do 
respond to collagen (Quek et al., 1998). They do not experience bleeding side 
effects, likely to the compensation of Tec, but also other platelet stimulatory 
pathways (Atkinson et al., 2003a).  
2) Patients taking ibrutinib, a Btk inhibitor, experience bleeding as a side effect 
(Covey et al., 2015, Lipsky et al., 2015).   
3) Patients taking acalabrutinib, a second generation Btk inhibitor, are thought to 
experience less bleeding side effects. 
Taken together, it is not clear whether Btk’s catalytic activity is required to mediate GPVI 
signalling as no bleeding side effects are observed in XLA patients, or patients taking a 
more specific Btk inhibitor, acalabrutinib. 
The impact of ibrutinib on platelet aggregation suggests off target effects on platelet 
function. This is unlikely to be mediated through Btk, as acalabrutinib does not seem to 
replicate these effects, with acalabrutinib patients tending to not experience bleeding side 
effects.  
Downstream of CLEC-2, there are also unanswered questions in regard to Btk and its role 
within the signalling pathway (Manne et al., 2015a, Fuller et al., 2007, Hughes et al., 
2010b, Pollitt et al., 2014).  
The work published by Manne et al., uses ibrutinib, which can inhibit SFK phosphorylation 
(Patel et al., 2016). SFK inhibition would inhibit the release of secondary mediators and 
subsequently CLEC-2 phosphorylation (Severin et al., 2011).  Therefore, a more selective 
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Btk inhibitor, acalabrutinib, will be used to investigate the role of Btk downstream of 
CLEC-2.  
Aims 
• To identify if acalabrutinib causes platelet inhibition in a similar manner to ibrutinib  
• To characterise the effect of acalabrutinib downstream of GPVI and CLEC-2 using 
platelet aggregation, granule secretion and protein phosphorylation and to 
investigate where Btk lies in the CLEC-2 signalling cascade 
• To investigate if rhodocytin can support platelet spreading and if it can, to 
investigate if acalabrutinib can inhibit platelet adhesion and spreading to 
rhodocytin and to compare this with collagen  
 
Hypothesis 
Inhibition of Btk will inhibit CLEC-2 mediated platelet responses to a greater effect than 













3.3.1 Establishing conditions to assess CLEC-2 signalling in 
washed platelets  
Rhodocytin is a purified snake venom toxin, and within the literature it has been used at a 
range of concentrations from 3-300nM (Suzuki-Inoue et al., 2001, Bergmeier et al., 2001, 
Suzuki-Inoue et al., 2006, Suzuki-Inoue et al., 2007) . Furthermore, responsiveness to low 
concentrations of rhodocytin varies from donor to donor.  Therefore, washed platelet 
aggregation was performed to assess an appropriate concentration of rhodocytin to use 
for reproducible responses during this study.  
Washed platelets (4x108 cells/mL) were stimulated with 10-300nM rhodocytin for 7 
minutes. 300nM and 100nM induced maximal aggregation (90.1% ±4.5 and 89.7% ±7.0 
respectively) with there being a short lag/delay with 100nM of rhodocytin. 30nM of 
rhodocytin caused weak aggregation in some donors but not in others whereas 10nM did 
not induce aggregation. Therefore, 100nM and 300nM of rhodocytin were chosen as 
appropriate concentrations to reproducibly investigate CLEC-2 mediated platelet 
activation (Figure 3.3.1.B).  
To assess an appropriate time point for CLEC-2 signalling studies, washed platelets 
(4x108 cells/mL) were stimulated with 300nM rhodocytin for the stated time points in the 
presence of 9μM concentration integrelin. Samples were separated using SDS-PAGE 
before western blotting to assess total tyrosine phosphorylation using 4G10 antibody. As 
Figure 3.3.1.C shows, 0 and 30 seconds have minimal tyrosine phosphorylation, which 
increases at 60 seconds and is maintained up until 5 minutes where levels peak. 
Therefore, stimulation for 5 minutes was used to investigate signalling downstream of 






Figure 3.3.1 Washed platelets respond to rhodocytin at high concentrations and 
300 seconds is an appropriate time point to assess downstream CLEC-2 
phosphorylation. 
 (A, B) Washed platelets were stimulated with rhodocytin (10-300nM) for 7 minutes 
using light transmission aggregometry.  (A) shows the representative trace and (B) 
shows the % aggregation values from three independent experiments. statistical 
significance was calculated using a one-way ANOVA against vehicle control with a 
Tukey’s post-test. Graph represents mean ± SEM. Significance was taken at ***p ≤ 
0.001. (C) washed platelets in the presence of integrelin (9μM) were stimulated with 
100nM rhodocytin for the indicated times. Blots were probed with anti-phosphotyrosine 
antibody and tubulin antibody as a loading control.  (D) Densitometry analysis was 
performed using ImageQuant. Graph represents mean ± SEM, n=4. 
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3.3.2 Ibrutinib inhibits (hem)ITAM mediated washed platelet 
responses more severely than acalabrutinib, with hemITAM 
responses more severely inhibited  
Previous studies suggest that Btk is essential for GPVI and CLEC-2 mediated 
aggregation and granule secretion. Patients deficient in Btk do not aggregate in 
response to CRP-XL (Quek et al., 1998) and a low dose of ibrutinib (10nM) blocked 
platelet aggregation to a low concentration of rhodocytin (30nM) (Manne et al., 2015a). 
Some work using Btk inhibitors has been published investigating the role of Btk in 
platelet aggregation (Rigg et al., 2016, Kamel et al., 2015, Levade et al., 2014, Lee et 
al., 2017), further suggesting that Btk may be mediating the platelet response. 
Platelet α granule secretion is a common marker of platelet activation (Chen et al., 
2000, Blair and Flaumenhaft, 2009). These granules contain molecules that contribute 
to platelet regulation and thrombus formation via an auto and paracrine mechanism. P 
selectin (CD62P) is a transmembrane receptor that is present within α granules and is 
exposed on the surface of platelets during the release of granule contents (Koedam et 
al., 1992). Measuring the exposure of P-Selectin from platelets using flow cytometry 
indirectly measures the α granule secretion of the platelet. 
The activation of the integrin αIIbβ3 from its closed to open state is a critical process in 
platelet signalling. Inside-out signalling is the term for when the platelet becomes 
activated, transmits signals through the cell resulting in the opening of the integrin to 
its active state. Its ligand, fibrinogen, is then able to bind to the open confirmation and 
cause outside-in signalling leading to platelet aggregate formation (Woods et al., 1986, 
Springer et al., 2008).  The extent of fibrinogen binding to activated platelets was 
measured using flow cytometry, which provides an indirect estimation of the extent of 
integrin αIIbβ3 molecules present in the activated state on the platelet surface. This 
measure, together with α granule secretion show another readout of platelet activation. 
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Therefore, as ibrutinib has been shown to inhibit aggregation (Levade et al., 2014, Lee 
et al., 2017), these responses were also investigated, using acalabrutinib.  
For aggregation, washed platelets (4x108 cells/mL) were incubated with a range of 
concentrations of acalabrutinib, ibrutinib or vehicle control for 5 minutes before 
stimulation with 1μg/mL CRP-XL for 5 minutes or 100nM rhodocytin for 7 minutes. 
100nM rhodocytin was selected as opposed to 30nM used in the work by the Kunapali 
group as 30nM did not elicit a strong response in washed platelets in this study (Figure 
3.3.1).  Consistent with other studies 5 minutes was selected as the appropriate time 
for drug preincubation (Bye et al., 2015, Nicolson et al., 2018).  
For granule release and αIIbβ3 activation, flow cytometric analysis was performed.  
ADP insensitive washed platelets (4x108 cells/mL) were incubated with ibrutinib, 
acalabrutinib or vehicle control, anti-P-Selectin Cy5/PE conjugated antibody and FITC 
conjugated anti-fibrinogen antibody for 5 minutes before the addition of agonist 
(1μg/mL CRP-XL or 100nM rhodocytin). Platelets were incubated for 20 minutes in the 
dark and then fixed with 0.2% formyl saline prior to assessment using a BD Accuri C6 
flow cytometer (BD Biosciences, Oxford, UK).  Data was collected from 10,000 events 
gated on platelets using side scatter (SSC) and forward scatter (FSC), measures of 
cell granularity and cell size, respectively. 
Downstream of CRP-XL, only 10μM acalabrutinib inhibited aggregation and granule 
release (Figures 3.3.2 B and G), (p ≤ 0.001). αIIbβ3 activation was also inhibited at 10 
and 3μM acalabrutinib downstream of GPVI (p ≤ 0.001 and p ≤ 0.05).  At lower 
concentrations of acalabrutinib (1-0.1μM), responses to aggregation, granule secretion 
and αIIbβ3 activation were comparable to vehicle treated samples.  
1-0.1μM ibrutinib caused a significant reduction in platelet aggregation, with all values 
below 20% aggregation. Lower concentrations of ibrutinib did not inhibit aggregation in 
response to CRP-XL. This is also observed in granule secretion and αIIbβ3 activation 
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downstream of GPVI, with 1μM ibrutinib inhibiting the response (p ≤ 0.01) (Figures 
3.3.2.F and I). 
Figures 3.3.2.E, H and K compares the differences between the two drugs for the 
responses in aggregation, granule release and αIIbβ3 activation to CRP-XL. Ibrutinib is 
more potent at inhibiting aggregation, granule release and αIIbβ3 activation than 
acalabrutinib. This is reflected in the IC50 values, with the shift of the curve to the left 
for ibrutinib.  
At high concentrations of acalabrutinib (10 and 3μM), the aggregatory response to 
100nM rhodocytin was ablated (Figures 3.3.3.A, B) (p ≤ 0.001), as was granule 
release and αIIbβ3 activation (p ≤ 0.01) (Figure 3.3.3.G and J).  
1μM acalabrutinib significantly inhibited aggregation to rhodocytin on average to 30% 
(±14) (p ≤ 0.001), however, one donor had an almost normal response compared to 
the other donors which is reflected in the large error bars. 1μM acalabrutinib did not 
inhibit granule release downstream of CLEC-2 but did inhibit αIIbβ3 activation (p ≤ 
0.05). This shows responses are variable between donors at certain concentrations of 
inhibitor, which was also observed downstream of GPVI.  
Only the two lowest concentrations of ibrutinib tested (0.01μM and 0.03μM), did not 
cause inhibition of aggregation downstream of CLEC-2. 1, 0.3 and 0.1μM all caused a 
significant reduction in aggregation as Figures 3.3.3.C and 3.3.3.D show. Inhibition of 
aggregation responses were similar to granule release and αIIbβ3, as 0.3μM also 
significantly reduced the response (p ≤ 0.05).  
When comparing between the two drugs, there is a significant difference in the platelet 
aggregation at 0.3μM (p ≤ 0.001), 0.1μM (p ≤ 0.01) and 0.03μM (p ≤ 0.05), with 
ibrutinib being more inhibitory in CLEC-2 mediated responses.. The IC50 for 
acalabrutinib is 0.69μM (95% confidence interval, 0.36 to 1.13), and 0.02μM (0.01 to 
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0.04) for ibrutinib. This demonstrates that ibrutinib is more potent at inhibiting CLEC-2 
mediated aggregation.  
The more potent inhibition of platelet responses downstream of CLEC-2 (as measured 
by smaller IC50 values with both ibrutinib and acalabrutinib) compared to GPVI 
suggests that Btk inhibition is more detrimental to CLEC-2 mediated signalling than 






Figure 3.3.2 only high concentrations of Btk inhibitors inhibit GPVI washed 
platelets and Ibrutinib inhibits mediated α granule release and αIIbβ3 activation 
more than acalabrutinib mediated granule release 
(A-E) Washed platelets were incubated with (A,B) acalabrutinib (10-0.1μM), (C,D) 
ibrutinib (10-0.1μM) or vehicle control (0.1% DMSO (v/v)) for 5 minutes before 
stimulation with 1μg/mL CRP in light transmission aggregometry. (A, C) shows 
representative traces, and (B,D) shows the quantified values. (E) shows the % 
aggregation of both inhibitors. Graphs represent mean ± SEM, n=5. Statistical 
significance was calculated using a one-way ANOVA against vehicle control with a 
Dunnett’s post-test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. (H-J) Washed platelets (4x108 
cells/mL) were incubated with (F,H) ibrutinib, (G,I) acalabrutinib or vehicle control 
(DMSO, 0.1% (v/v) for 5 minutes, after which PE/Cy5 anti-human CD62P antibody and 
FITC-conjugated anti-fibrinogen were added to the sample prior to stimulation. 
Samples were stimulated with CRP-XL (1μg/mL) for 20 minutes before flow cytometric 
analysis. The Median fluorescence intensity was plotted against inhibitor concentration 
and analysed using one-way ANOVA with Dunnett’s post-test, ***p ≤ 0.001, **p ≤ 0.01 
and *p ≤ 0.05. Graphs represent mean ± SEM, n=4. The values were normalised to 









Figure 3.3.3 ibrutinib and acalabrutinib dose dependently inhibit CLEC-2 
mediated platelet functions however ibrutinib is more potent. 
 (A-E) Washed platelets were incubated with (A,B) acalabrutinib (10-0.1μM), (C,D) 
ibrutinib (10-0.1μM) or vehicle control (0.1% DMSO (v/v)) for 5 minutes before 
stimulation with 100nM rhodocytin in light transmission aggregometry. (A, C) shows a 
representative trace, and (B,D) shows the quantified values. (E) shows the % 
aggregation of both inhibitors. Graphs represent mean ± SEM, n=5. Statistical 
significance was calculated using a one-way ANOVA against vehicle control with a 
Dunnets post-test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. (H-J) Washed platelets (4x108 
cells/mL) were incubated with (F,H) ibrutinib, (G,I) acalabrutinib or vehicle control 
(DMSO, 0.1% v/v) for 5 minutes, after which PE/Cy5 anti-human CD62P antibody and 
FITC-conjugated anti-fibrinogen were added to the sample prior to stimulation. 
Samples were stimulated with rhodocytin (100nM) for 20 minutes before flow 
cytometric analysis. The Median fluorescence intensity was plotted against inhibitor 
concentration and analysed using one-way ANOVA with Dunnett’s post-test, ***p ≤ 
0.001, **p ≤ 0.01 and *p ≤ 0.05. Graphs represent mean ± SEM, n≥3. The values were 
normalised to vehicle control being 100% and the (H, J) IC50’s calculated.
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3.3.3 Platelets can aggregate at concentrations despite loss of 
the autophosphorylation site downstream of GPVI  
Granule secretion and aggregation are only inhibited by high concentrations of 
acalabrutinib (10μM) downstream of GPVI (Figure 3.3.2 B, G and J). The IC50 of 
acalabrutinib calculated in in vitro kinase assays using recombinant Btk are often 
within the nanomolar range (Liclican et al., 2020, Wu et al., 2016). Previous studies in 
platelets and B cells using acalabrutinib  have shown inhibition of Btk 
autophosphorylation at site pY223 at concentrations lower than 10μM (Series et al., 
2019, Herman et al., 2015). Consequently, it is not unreasonable to believe that Btk 
catalytic activity would be inhibited at concentrations where aggregation is normal. 
Therefore, protein phosphorylation studies were used to identify when there was 
inhibition of Btk autophosphorylation and how this inhibition related to aggregation and 
granule secretion.  
To examine the effect of acalabrutinib on GPVI-mediated protein phosphorylation, 
acalabrutinib treated washed human platelets were lysed after stimulation with CRP-
XL (1μg/mL) and lysates probed with phosphospecific antibodies. The time point used 
to asses phosphorylation was 180 seconds to be consistent with previous literature 
(Quek et al., 1998, Bye et al., 2017, Bye et al., 2015, Nicolson et al., 2018). 
Experiments were performed under non aggregating conditions with integrelin to block 
αIIbβ3 activation and in the presence of apyrase and indomethacin to identify the GPVI 
signalling response without any input of secondary mediators.  
Aggregation results from previously described (Figure 3.3.2) were overlayed for 
comparison. Total cell phosphorylation was assessed using anti-phosphotyrosine 
antibody 4G10. No striking differences were revealed in the total cell phosphorylation 
profile in the presence of acalabrutinib when compared to control lysates (Figure 
3.3.4.A, upper panel).  The phosphorylation of Src pY416 was not altered in the 
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presence of acalabrutinib (Figure 3.3.3.4.B). Syk pY525 phosphorylation was also 
unaltered when platelets were treated with acalabrutinib (Figure 3.3.3.4.B). 
Unsurprisingly, as the kinases mediate the phosphorylation of Btk were not inhibited, 
Btk pY551 was also not altered in the presence of acalabrutinib, Figure 3.3.3.4.B.  
The autophosphorylation site of Btk, pY223, was inhibited in the presence of 
acalabrutinib, with the IC50 value being calculated to 0.66μM (0.48 to 6.04). 10μM, 3μM 
and 1μM, all had significantly inhibited levels of phosphorylation at this site compared 
to the vehicle control (p ≤ 0.05). Indeed, phosphorylation is greatly reduced, in some 
donors at 1μM whereas aggregation is normal and not inhibited.  Similarly, 
acalabrutinib inhibits phosphorylation of PLCγ2 pY759, with the IC50 value being 
1.37μM, (0.69 to 2.74) with 1μM, 3μM, and 10μM acalabrutinib causing inhibition 
compared to vehicle control (Figure 3.3.4.B), p ≤ 0.05.  
The phosphorylation of Btk Y223 does not significantly correlate with aggregation, 
(p=0.104). Whereas there is a positive correlation between Btk pY223 phosphorylation 
and PLCγ2 pY759 phosphorylation, r=0.765 (P=0.027) suggesting some dependency 
on one another. However, correlation is not necessarily causative. There is also a 
significant correlation between PLCγ2 and aggregation as P=0.023, r=0.856.  
Taken together, these results suggest that in washed platelets stimulated with CRP-





Figure 3.3.4 Platelets can still aggregate downstream of GPVI when Btk and PLCγ2 
phosphorylation is lost 
 (A) ADP insensitive washed platelets at (4x108 cells/mL) in the presence of integrelin (9μM), 
apyrase (2units/mL) and indomethacin (10μM) were incubated with acalabrutinib or vehicle 
(DMSO 0.1% (v/v)) for 5 minutes prior to stimulation with 1μg/mL CRP-XL. Platelets were 
then lysed with 6X reducing sample buffer 180 seconds after addition of agonist. Whole cell 
lysates were then separated by SDS-PAGE and Western blots probed for whole cell 
phosphorylation or kinase specific phosphorylation with the stated antibodies. (A) 
Representative blot from 3 independent experiments. (B) Quantification of mean tyrosine 
phosphorylation levels ± SEM of 3 independent experiments. Statistical significance was 
calculated using two-way ANOVA with Dunnett’s post-test, with * in the colour of 
phosphorylation site / aggregation stated on the graph. * p ≤ 0.05. 
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3.3.4 CLEC-2 phosphorylation is only reduced in ADP sensitive 
washed platelets at high concentrations of ibrutinib, but not 
acalabrutinib.  
It is known that CLEC-2 phosphorylation is required to mediate signalling (Severin et 
al., 2011). The signalling components downstream of CLEC-2 and GPVI are strikingly 
similar, therefore it was hypothesised that a more severe effect of inhibition 
downstream of CLEC-2 may be related to inhibition of receptor phosphorylation. 
Furthermore, it is believed by Manne et al., that Btk lies upstream of Syk. 
Phosphorylation of CLEC-2 requires Syk and secondary feedback (Hughes et al., 
2015, Pollitt et al., 2010). If CLEC-2 phosphorylation was lost in the presence of 
acalabrutinib which inhibits Btk, it would provide evidence in favour of the hypothesis 
proposed by this group (Manne et al., 2015a).  
ADP sensitive and washed platelets were prepared to 8x108 cells/mL before 
preincubation with 1μM and 0.1μM ibrutinib, acalabrutinib or vehicle control for 5 
minutes before stimulation with 300nM of rhodocytin for 5 minutes. Cells were lysed 
with an equal volume of 2X NP40 lysis buffer with protease inhibitors before being 
subjected to immunoprecipitation with the anti-CLEC-2 antibody AYP1. After 
immunoprecipitation, samples were resolved using SDS-PAGE and Western blotted 
for tyrosine phosphorylation and CLEC-2. (Figure 3.3.5 A and B). Phosphorylation of 
CLEC-2 in vehicle treated platelets is significantly increased compared to resting 
platelets in both ADP sensitive and insensitive washed platelets (p ≤ 0.01), showing 
that CLEC-2 is phosphorylated in agonist stimulated samples (Severin et al., 2011, 
Pollitt et al., 2010, Mori et al., 2008), Figure 3.3.5.C.  When drug treated samples were 
compared to their vehicle treated samples, only 1μM ibrutinib treatment of ADP 
sensitive washed platelets had a significant reduction in CLEC-2 phosphorylation.  
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This inhibition observed in only one condition suggests that CLEC-2 phosphorylation is 
unlikely to be directly mediated by Btk. This suggests that the more severe inhibitory 
phenotype of Btk inhibitors downstream of CLEC-2 is likely to be mediated by 
intracellular kinase signalling not because of receptor phosphorylation. As Syk is the 
tyrosine kinase responsible for CLEC-2 phosphorylation, it also provides evidence that 







Figure 3.3.5 CLEC-2 phosphorylation is reduced in ADP sensitive washed 
platelets treated with ibrutinib but not acalabrutinib. 
(A) ADP sensitive or (B) ADP insensitive washed platelets (8x108 cells/mL) were 
preincubated with integrelin (9μM) and ibrutinib (0.1, 1μM) or acalabrutinib (0.1 or 
1μM) or vehicle control (0.1% DMSO (v/v)) for 5 minutes. Samples were stimulated for 
5 minutes with 300nM rhodocytin under stirring conditions. Reactions were lysed using 
2x NP40 lysis buffer with protease inhibitors. CLEC-2 was immunoprecipitated using 
anti-Clec-2 antibody AYP1 (2μg/mL). Samples were eluted into 2X sample buffer 
before SDS PAGE and western blotting. Membranes were incubated with anti-
phosphotyrosine antibody 4G10 and then incubated with Alexa Fluor 488 conjugated 
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goat anti-mouse. Gels were imaged, then stripped and reprobed for total CLEC-2 
using the anti-CLEC-2 antibody AYP2. (C) quantification was assessed using 
ImageQuant, graph represents mean ± SEM, n=4. Statistical testing was performed 
using a two-way ANOVA with Dunnett’s multiple comparison, *p ≤ 0.05, **p ≤ 0.01.
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3.3.5 Btk phosphorylation is inhibited downstream of CLEC-2 
in washed platelets 
CLEC-2 mediated aggregation is more severely inhibited by Btk inhibition compared to 
GPVI mediated aggregation. This effect is not mediated by a lack of CLEC-2 
phosphorylation and must be related to Btk or off target tyrosine kinase inhibition. 
However, it is not likely due to Syk or Src inhibition as this would reduce 
phosphorylation of CLEC-2 (Severin et al., 2011, Pollitt et al., 2010, Hughes et al., 
2015) . Therefore, protein phosphorylation downstream of rhodocytin stimulated 
platelets was investigated, (Figure 3.3.6). 
Washed platelets were incubated with acalabrutinib (10-0.01μM) for 5 minutes and 
then stimulated with 300nM or 100nM rhodocytin for five minutes in the presence of 
integrelin. Unlike experiments investigating GPVI signalling, these experiments were 
not performed in the presence of apyrase and indomethacin, as there is a requirement 
for secondary mediators to reinforce CLEC-2 signalling (Badolia et al., 2017, Izquierdo 
et al., 2020, Pollitt et al., 2010). 
In 300nM rhodocytin stimulated samples, there was a small reduction in total cell 
tyrosine phosphorylation in samples treated with acalabrutinib when compared to the 
vehicle control, (Figure 3.3.6.A, upper panel). Aggregation was inhibited at 10μM and 
3μM acalabrutinib when compared to vehicle control. Src pY416 was reduced to 52% 
(±8) of the vehicle control in the presence of 10μM acalabrutinib (p ≤ 0.001). 3μM and 
1μM acalabrutinib also caused a significant inhibition of Src pY416 (p ≤ 0.01 and p ≤ 
0.05) when compared to vehicle control, (Figure 3.3.6.B). 
On the other hand, Syk pY525 was not inhibited by acalabrutinib in either 300nM or 
100nM rhodocytin stimulated platelets. The Syk pY525 is still present in concentrations 
of acalabrutinib when Btk pY223 is lost (Figure 3.3.6 B upper and middle panels). This 
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suggests that Btk is downstream of Syk in the CLEC-2 signalling cascade, in contrast 
to the work of Manne et al.  
Btk pY551 is inhibited at the highest concentration of acalabrutinib (10μM, p ≤ 0.05), 
which is likely as Src pY416, is reduced. Src pY416 is a marker of SFK activity and a 
mediator of Btk phosphorylation at pY551.  
Btk pY223 was inhibited by acalabrutinib downstream of both concentrations of 
rhodocytin, with the IC50 being 0.88μM (0.44 to 1.42) for 300nM rhodocytin. 0.3μM 
acalabrutinib and higher caused inhibition of Btk pY223 phosphorylation (p ≤ 0.05). 
The phosphorylation of PLCγ2 Y759 was also inhibited by acalabrutinib downstream of 
CLEC-2, with the IC50 being 1.06μM (0.56 to 2.03). 10μM, 3μM and 1μM acalabrutinib 
caused significant decreases in this pY759 compared to vehicle control. 
Btk pY223 and PLCγ2 pY759 phosphorylation correlate to each other (r=0.928, p ≤ 
0.001), suggesting these may be dependent on each other, Figure 3.3.6.B. However, 
PLCγ2 pY759 correlates with aggregation (r = 0.762, p=0.028), whereas Btk pY223 
does not (r=0.691, p=0.058). This suggests that the aggregation downstream of CLEC-
2 at 300nM rhodocytin is not critically dependent on Btk phosphorylation, even though 
Btk’s substrate, pY759 on PLCγ2 is.  
Similarly, to 300nM of rhodocytin 10μM, 3μM and 1μM acalabrutinib all significantly 
inhibit aggregation when washed platelets are stimulated with 100nM rhodocytin. 
Phosphorylation of Btk pY223 is also significantly inhibited compared to vehicle control 
at these concentrations of acalabrutinib (p ≤ 0.01 and p ≤ 0.001), Figure 3.3.7.B. The 
data of aggregation and levels of Btk pY223 similarly overlap to each other, with 
aggregation being rescued at concentrations where Btk phosphorylation is also 
present (3.3.7.B).  
Acalabrutinib is more selective for Btk in in vitro kinase assays, with ibrutinib having 
inhibitory effects on SFK’s (Byrd et al., 2016). Therefore, the phosphorylation profile of 
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platelets treated with ibrutinib was also assessed downstream of CLEC-2. Samples 
were prepared as previously described except ibrutinib was used in place of 
acalabrutinib.  
As Figure 3.3.7 D-F demonstrates, ibrutinib more potently inhibits SFK’s over a range 
of concentrations when compared to acalabrutinib (p ≤ 0.01). Furthermore, ibrutinib 
inhibits phosphorylation of Syk pY525 to a greater extent when compared to 
acalabrutinib, which is consistent with the results of the Kunapali group where Syk 
phosphorylation is lost in the presence of ibrutinib. This allowed the authors to form the 
hypothesis of Btk to be upstream of Syk in the CLEC-2 signalling cascade. However, 
when a more specific Btk inhibitor, acalabrutinib is used, Syk phosphorylation is 
present when Btk phosphorylation is lost suggesting that Btk is downstream of Syk in 








Figure 3.3.6 CLEC-2 mediated aggregation can occur where Btk phosphorylation 
is lost 
(A) washed platelets at 4x108 cells/mL in the presence of 9 μM integrelin were 
incubated with acalabrutinib or vehicle (DMSO 0.1% (v/v)) for 5 minutes prior to 
stimulation with 300nM rhodocytin. Platelets were then lysed with 6X reducing sample 
buffer 5 minutes after addition of agonist. Whole cell lysates were then separated by 
SDS-PAGE and western blots were probed for whole cell phosphorylation or kinase 
specific phosphorylation sites. (A) Representative blot from 4 independent 
experiments. (B) Mean tyrosine phosphorylation levels ± SEM, n=4. Statistical testing 
was performed using a two-way ANOVA with Dunnett’s multiple comparison test, with 
* in the colour of phosphorylation site / aggregation stated on the graph. Significance 








Figure 3.3.7 Platelets cannot aggregate downstream of 100nM CLEC-2 when Btk 
phosphorylation is lost and there is a differential pattern of phosphorylation 
downstream of ibrutinib compared to acalabrutinib 
(A,D) washed platelets at 4x108 cells/mL in the presence of 9 μM integrelin were 
incubated with (A) acalabrutinib (0.1-10μM), (D) ibrutinib (0.1μM to 10μM) or vehicle 
control (DMSO 0.1% (v/v)) for 5 minutes prior to stimulation with 100nM rhodocytin. 
Platelets were then lysed with 6X reducing sample buffer 5 minutes after addition of 
109 
 
agonist. Whole cell lysates were then separated by SDS-PAGE and western blots 
were probed for whole cell phosphorylation or kinase specific phosphorylation sites. 
(A) Representative blot from 3 independent acalabrutinib experiments. (B, C) Mean 
tyrosine phosphorylation levels ± SEM, n=3. Statistical testing was performed using a 
two-way ANOVA with Dunnett’s multiple comparison test, with * in the colour of 
phosphorylation site / aggregation stated on the graph. Significance was taken at *p ≤ 
0.05, ** p ≤ 0.01 and *** p ≤ 0.001.  (D) Representative blot from 3 independent 
ibrutinib experiments. (D, F) Mean tyrosine phosphorylation levels ± SEM of 3 
independent experiments, significance was calculated using two-way ANOVA with 
Dunnett’s multiple comparisons test. *p ≤ 0.01 and **p ≤ 0.05 
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3.3.6 ADP Sensitive platelets are less severely inhibited by 
acalabrutinib downstream of GPVI and CLEC-2. 
Standard washed platelet experiments with rhodocytin show a stronger level of 
inhibition with acalabrutinib compared to CRP-XL (Figures 3.3.2 A, B and 3.3.3 A,B). It 
was hypothesised that as the platelets were ADP insensitive, less signalling was 
occurring due to reduced responses of secondary messengers and therefore resulting 
in a reduction in aggregation. Human platelet CLEC-2 signalling and activation is 
dependent on secondary mediators (Izquierdo et al., 2020, Badolia et al., 2017, Pollitt 
et al., 2010) and therefore it would be expected that if Btk was playing a similar role 
downstream of both CLEC-2 and GPVI the levels of inhibition in platelet aggregation 
would be the same in the presence of secondary mediators.  
The fast centrifugation of platelets during washing steps has been shown to 
desensitise the ADP receptors, with washed platelets having reduced responsiveness 
to ADP. The surface levels of the purinergic receptors paradoxically increase but the 
overall platelet response (as measured by aggregation) decreases, suggesting that 
they have reduced functional activity (Koessler et al., 2016). To prevent ADP 
desensitisation, platelets can be washed at a lower speed of centrifugation, which 
does not require the use of PGI2.  This allows the platelets to be used immediately 
reducing ADP receptor desensitisation, which occurs if platelets are stored without 
apyrase (Koessler et al., 2016). To firstly investigate the degree of how responsive 
platelets are to ADP, light transmission aggregometry was used. PRP, washed 
platelets prepared by the ADP sensitive method, and washed platelets centrifuged 
once with PGI2 and twice with PGI2 were stimulated with 0.1- 10μM ADP for 5 minutes 
and aggregation was compared, Figure 3.3.8.A-D.  
As Figure 3.3.8 E shows, at all concentrations of ADP tested, no significant differences 
in the aggregation can be observed between the methods of preparation. However, 
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Figure 3.3.8.F, shows there is a shift in the EC50 curves between the preparations of 
platelets in the response to ADP. For 2 washes, the EC50 was 45μM, 1 wash was 
0.08μM, ADP sensitive washed platelets 0.08μM and for PRP 0.04μM showing a large 
difference between the standard preparation of washed platelets (2 washes) compared 
to the other preparation methods. This shows that platelets respond differently to the 
secondary mediator ADP, which is required for CLEC-2 signalling, depending on how 
they were prepared. Therefore, a preparation using slower spins of platelets was used 
to maintain secondary mediator feedback. 
To investigate if ADP sensitivity plays a role in the response to aggregation, ADP 
sensitive platelets (4x108 cells/mL) were incubated with acalabrutinib (10-0.01μM) for 5 
minutes before stimulation with 1μg/mL CRP-XL for 5 minutes, or rhodocytin (100nM) 
for 7 minutes.  
When platelets are stimulated with CRP-XL, there is no significant inhibition of 
aggregation at any concentration of acalabrutinib tested. Similar results were observed 
for CLEC-2 stimulated platelets. However, in contrast to GPVI stimulated platelets, 
10μM acalabrutinib caused a significant reduction in rhodocytin induced aggregation 
compared to vehicle control (*p ≤ 0.05), Figure 3.3.8.J. 
This shows that ADP sensitive platelets are less severely inhibited by acalabrutinib 
compared to washed platelets. The level of inhibition is more severe downstream of 
CLEC-2 when compared to GPVI, as inhibition was only observed with high 






Figure 3.3.8 Platelet preparation effects their response to ADP and ADP 
sensitive platelets are less susceptible to Btk inhibition by acalabrutinib 
(A) PRP, (B) ADP sensitive washed platelets, (C) PRP span 1x with PGI2 at 1413g to 
obtain 1 washed platelet and (D) standard washed platelets were stimulated using 10-
0.1μM ADP or PBS (basal). Platelets were allowed to aggregate under constant 
stirring at 1200rpm for 5 minutes. (E) Statistical significance was calculated using a 
two-way ANOVA against each method of platelet preparation at a single concentration 
of ADP with a Tukey’s post-test with none found. (F) percentage aggregation was 
plotted to allow EC50 values to be calculated. Graphs represents mean ± SEM, n=3. 
ADP sensitive washed platelets (4x108 cells/mL) were incubated with (G-J) 
acalabrutinib or Vehicle (0.1% (v/v) DMSO) for five minutes before being stimulated 
with GPVI agonist (G,H) CRP-XL (1μg/mL) for 5 minutes or (I, J,) CLEC-2 agonist 
rhodocytin (100nM) for 7 minutes in light transmission aggregometry. (G, I) are 
representative traces and (H, J) are quantified values, n≥4. Statistical significance was 
calculated using a one-way ANOVA against vehicle control with a Dunnett’s post-test. 









3.3.7 ADP sensitive platelets are less susceptible to inhibition 
by acalabrutinib downstream of GPVI. 
Less severe inhibition of aggregation is seen in ADP sensitive platelets (Figure 
3.3.8.H). Residual plasma proteins may remain more in the samples prepared by this 
method, which can potentially bind to acalabrutinib. However, they are also more 
responsive to secondary mediators. To investigate if this less acute effect observed is 
due to plasma binding, phosphorylation downstream of GPVI was assessed. 
Experiments were performed in the presence of apyrase and indomethacin to allow for 
comparison with the experiments in Figure 3.3.4. This will help to deduce whether the 
less severe inhibition is related to plasma binding or secondary mediators. Therefore, if 
the effect is less strong, it may be due to the drug being plasma protein-bound, rather 
than the fact that the platelets are ADP sensitive.  
Similarly, to washed platelets, total cell tyrosine phosphorylation remained unchanged 
in the presence of acalabrutinib downstream of GPVI in ADP sensitive platelets. The 
IC50 value for aggregation was 17μM (11.30 to 26.43), which is much higher than ADP 
insensitive washed platelets in Section 3.3.2.  
Btk’s transphosphorylation site (pY551), mediated by SFKs and required for its full 
activation, is not inhibited in the presence of acalabrutinib in ADP sensitive washed 
platelets, similarly to the observed phosphorylation in ADP insensitive washed 
platelets. pY551 remains present, even at high concentrations of inhibitor and this can 
be observed in the very high IC50 value - 46μM.  Src pY416 is also not significantly 
reduced and has an IC50 value of 8.83μM (4.014 to 23.26).  
When compared to vehicle control, the inhibition of Btk pY223 is also inhibited in the 
presence of acalabrutinib at concentrations above 1μM (p ≤ 0.01 and p ≤ 0.05). 
Furthermore, Btk pY223 is reduced with an IC50 value of 0.57μM (0.26 to 1.20μM).  
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When compared to vehicle control, phosphorylation of PLCγ2 pY759 is also reduced in 
the presence of acalabrutinib at concentrations of 1μM or greater (p ≤ 0.05).  
Btk pY223 and PLCγ2 pY759 have a strong positive correlation (r=0.894, p=0.03) 
suggesting potential regulation with one another, however neither of the 
phosphorylation sites correlate with aggregation. This contrasts with ADP insensitive 
washed platelets, where PLCγ2 pY759 activity correlates with aggregation.  
There are similar IC50 values for both Btk pY223 in ADP sensitive and ADP insensitive 
washed platelets (Section 3.3.3), suggesting that the aggregation differences between 
platelet preparation in GPVI mediated aggregation is not related to Btk inhibition. 
Although GPVI signalling is not dependent on secondary mediators downstream of 
GPVI ligation, it may help to reinforce the signalling (Atkinson et al., 2003b). Therefore, 





Figure 3.3.9 Platelets can still aggregate downstream of GPVI when Btk and 
PLCγ2 phosphorylation is lost 
(A) ADP sensitive washed platelets at (4x108 cells/mL) in the presence of integrelin 
(9μM), apyrase (2units/mL) and indomethacin (10μM) were incubated with 
acalabrutinib or vehicle control (DMSO 0.1% (v/v) ) for 5 minutes prior to stimulation 
with 1μg/mL CRP-XL. Platelets were then lysed with 6X reducing sample buffer 180 
seconds after addition of agonist. Whole cell lysates were separated by SDS-PAGE 
and western blots were probed for whole cell tyrosine phosphorylation or kinase 
specific tyrosine phosphorylation. (A) Representative blot from 3 independent 
experiments. (B) Mean tyrosine phosphorylation levels ± SEM, n=3. Statistical testing 
was performed using a two-way ANOVA with Dunnett’s multiple comparison test, with 
* in the colour of phosphorylation site / aggregation stated on the graph. Significance 














3.3.8 Preparation of platelets depends on the degree on 
inhibition by ibrutinib and acalabrutinib to rhodocytin  
Btk inhibitors are less inhibitory of rhodocytin induced platelet aggregation in ADP 
sensitive platelets when compared to washed platelets (Figures 3.3.6 and 3.3.8). It is 
known that ADP sensitive platelets can respond to ADP more than normal washed 
platelets, but there is also residual albumin and fibrinogen present in the samples 
(Cazenave et al., 2004). This may be binding the drug and preventing it from binding 
and therefore inhibiting Btk as Btk inhibitors are highly plasma bound (Scheers et al., 
2015). To investigate if the reduced inhibition is mediated by the extra response to 
ADP or the amount of plasma protein present, different preparations of platelets were 
used to identify if the same concentration of drug can inhibit one preparation but not 
another due to the amount of drug binding.  
Traditional twice washed platelets (two fast spins with PGI2), once washed platelet (1 
fast spin with PG12) and PRP were preincubated with ibrutinib (0.01-10μM) for 5 
minutes before stimulation with 300nM rhodocytin for 7 minutes. Ibrutinib was used in 
these experiments as opposed to acalabrutinib for consistency with Nicolson et al., 
2020. Figure 3.3.10 shows that there is a difference in the potency of inhibition 
depending on the preparation of platelets. At 10μM ibrutinib, all the platelet 
preparations were inhibited. PRP aggregated at any ibrutinib concentration lower than 
10μM, whereas there are differences between the preparations at concentrations 3μM 
or lower. There was a statistically significant difference in aggregation between the 
preparations of platelets. The traditional 2 washed platelet did not undergo aggregation 
in the presence of 3μM or 1μM ibrutinib (aggregation of 16% ±2 and 13% ±2 
respectively) when compared to 1 wash and compared to PRP (aggregation of 
62%±18 and 94% ±1 for 1μM acalabrutinib for 1 wash and PRP respectively) (p ≤ 0.05 
and p ≤ 0.001). IC50 values were also calculated and as Figure 3.3.10.E shows, there 
is a clear shift to the left for 2 washed platelets showing more potent inhibition.  
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As there was no difference between one washed platelets and ADP sensitive platelets 
for the response to ibrutinib and overlapping EC50 curves in response to ADP (Figure 
3.3.10.E), only PRP, ADP sensitive platelets and washed platelets were used when 
the inhibitory effect of acalabrutinib on rhodocytin mediated effects. As Figure 3.3.11.D 
shows, there is a difference in response between preparations of platelets, with only 
washed platelets being inhibited in the presence of high concentrations of 
acalabrutinib.  
These results show that there is a difference in the levels of inhibition of platelet 
aggregation depending on the platelet preparation. Taken together with the ADP 
sensitivity work, this effect is related to the response in ADP sensitivity due to the EC50 




Figure 3.3.10 Platelet preparation effects their responses to rhodocytin in the 
presence of ibrutinib 
(A) PRP, (B) ADP sensitive washed platelets or (C) ADP insensitive washed platelets 
with 1 spin or (D) ADP insensitive platelets with two spins (standard washed platelets) 
were incubated with doses of ibrutinib (0.01-10µM) or vehicle control (0.1% DMSO v/v) 
for 5 minutes before stimulation with 300nM rhodocytin for 7 minutes and light 
transmission aggregometry was assessed for 5 mins at 1200rpm. (D) Values were 






Figure 3.3.11 Platelet preparation affects the response of their aggregation to 
rhodocytin in the presence of acalabrutinib 
(A) PRP, (B) ADP sensitive platelets or (C) washed platelets were incubated with 
doses of acalabrutinib (0.01-10µM) for 5 minutes before stimulation with 300nM 
rhodocytin for 5 minutes and light transmission aggregometry was assessed for 5 mins 
at 1200rpm (D), along with the (E) time taken to the initiation of aggregation following 
the addition of agonist. Statistical testing was performed using Two-way ANOVA using 
a Tukey’s post-test. Significance was taken at *p ≤ 0.05. **p ≤ 0.01, ***p ≤ 0.001. 




3.3.9 CLEC-2 mediated signalling of ADP sensitive platelets is 
not inhibited by acalabrutinib 
As platelets that are more responsive to ADP are less inhibited by Btk inhibitors in 
aggregation (Figures 3.3.8 I, J and 3.3.11) signalling in these platelets was assessed 
to identify if Btk phosphorylation levels were similar as to ADP insensitive platelets. 
Due to the normal aggregation, it was hypothesised that Btk phosphorylation would be 
less inhibited.   
Total cell tyrosine phosphorylation and aggregation are not inhibited in ADP sensitive 
CLEC-2 stimulated platelets samples, with aggregation not inhibited even at the 
highest concentrations of acalabrutinib (10μM) in contrast to ADP insensitive washed 
platelets (Figure 3.3.6). Furthermore, phosphorylation of Syk and LAT is not 
significantly inhibited when compared to vehicle control, Figure 3.3.12.B. Src pY416 is 
inhibited at 10μM acalabrutinib compared to vehicle control (p ≤ 0.05). However, Btk 
pY551 phosphorylation is reduced to 71% ±7 of vehicle control when treated with 
10μM acalabrutinib, but this is not statistically significant. As Btk pY551 and Syk 
phosphorylation is present when the amount of Btk pY223 is reduced, it further 
provides evidence that Btk is downstream of Syk in the CLEC-2 signalling cascade.  
Downstream of rhodocytin induced signalling phosphorylation of Btk at pY223 is 
reduced to 26% ± 4.6) of the vehicle control in the presence of 10µM acalabrutinib (p ≤ 
0.01), Figure 3.3.12.B upper panel. 3μM of acalabrutinib also leads to a reduction in 
pY223 phosphorylation (p ≤ 0.05) and the IC50 for 1.66μM (0.87 to 3.15) (Figure 
3.3.12.B).  
High concentrations of acalabrutinib also inhibit PLCγ2 pY759 phosphorylation, with 
10μM, 3μM and 1μM causing a significant reduction in phosphorylation when 
compared to vehicle control (p ≤ 0.01). This is reflected in the IC50, of 1.11μM (0.7 to 
1.75), similar to, but smaller than the Btk pY223 IC50.  
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Btk pY223 and PLCγ2 pY759 strongly positively correlate, (r= 0.890, p=0.003), but 
neither of these correlate to rhodocytin induced aggregation. This could potentially 
suggest that high concentrations of rhodocytin may be inducing aggregation 
independently of Btk and PLCγ2 phosphorylation. It is likely that this is mediated 
through secondary feedback mechanisms, as the platelets prepared through this 
method have a much stronger response to ADP (ADP Figure 3.3.8.) and drug treated 






Figure 3.3.12 ADP sensitive washed platelets can aggregate to rhodocytin in the 
presence of acalabrutinib when Btk phosphorylation is lost 
(A) ADP sensitive washed platelets at 4x108 cells/mL in the presence of integrelin 9 μM 
were incubated with acalabrutinib or vehicle (DMSO 0.1% (v/v)) for 5 minutes prior to 
stimulation with 300nM rhodocytin. Platelets were then lysed with 6X reducing sample 
buffer 5 minutes after addition of agonist. Whole cell lysates were then separated by 
SDS-PAGE and western blots probed for whole cell tyrosine phosphorylation or kinase 
specific phosphorylation sites. (A) Representative blots from 4 independent 
experiments. (B) Mean tyrosine phosphorylation levels ± SEM, n=4. Statistical testing 
was performed using a two-way ANOVA with Dunnett’s multiple comparison test, with 
* in the colour of phosphorylation site / aggregation stated on the graph. Significance 
was taken at *p ≤ 0.05 and ** p ≤ 0.01. 
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3.3.10 Calcium flux downstream of GPVI is only inhibited at the 
highest concentration of acalabrutinib whereas acalabrutinib 
dose dependently inhibits calcium flux downstream of CLEC-2.  
Calcium mobilisation is an essential step in platelet activation (Varga-Szabo et al., 
2009). It has been previously shown that calcium mobilisation is inhibited by ibrutinib 
(Bye et al., 2015), but at the time of starting this study, no work investigating the role 
with acalabrutinib had been published. The inhibition of calcium flux observed with 
ibrutinib may be related to the inhibition of SFK’s, as it is known that higher 
concentrations of ibrutinib inhibit SFK’s  (Figure 3.3.7.F and (Bye et al., 2015, Bye et 
al., 2017). Therefore, experiments using acalabrutinib, which has higher selectivity for 
Btk, were performed to investigate the role of the catalytic activity of Btk in these 
pathways.  
PRP with ACD, was incubated with the Ca2+ sensitive dye Fura-2 AM. Platelets were 
then pelleted and resuspended to 4x108 cells/mL. Platelets were incubated with 
acalabrutinib or vehicle control for 5 minutes before stimulation with 1μg/mL CRP, 
300nM or 100nM rhodocytin and calcium flux was assessed using a FlexStation, 
Figures 3.3.13.A and 3.3.14 A, B.  
When the area under the curve for 5 donors was calculated, vehicle treated samples 
(red dots) had a large increase in calcium flux downstream of GPVI as visible in Figure 
3.3.13.A, B. 10μM acalabrutinib significantly reduced the area under the curve when 
compared to vehicle control (*p ≤ 0.05). The differences between the peak at 380/340 
(the height of the peak – resting sample) ratio was also investigated. Using one-way 
ANOVA, only 10μM acalabrutinib caused a statistically significant reduction in the 
change of calcium flux compared to the vehicle control.  
The dynamics of calcium flux may also be quantified. It has been previously shown 
that ibrutinib delays the onset of calcium flux but does not block platelet aggregation 
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(Nicolson et al., 2018). Therefore, the time to reach the maximum value of 380/340 
was calculated for each concentration. If there was no peak due to a lack of calcium 
flux, the value was recorded as 300 seconds which was then end-point of the assay. 
The average time to peak for vehicle was 134±9.8 seconds, which increased to 295 
±84 seconds for 10μM acalabrutinib treated samples, however this was not statistically 
significant (p=0.0813).  
Downstream of CLEC-2, when the area under the curve was assessed, 300nM 
rhodocytin caused a greater calcium flux than 100nM rhodocytin in vehicle treated 
samples (Figure 3.3.14.D). When platelets were treated with 10μM or 3μM 
acalabrutinib, there is a significant inhibition in calcium flux when assessed by area 
under the curve (p ≤ 0.001).  
Similarly, when the change in peak was assessed, there was a difference between 
100nM and 300nM rhodocytin, with 300nM inducing a larger peak change (p ≤ 0.05). 
When comparing vehicle treated samples to drug treated samples, independent of 
their concentration of agonist, there was a significant inhibition in the amount of 
calcium that fluxes at 10μM, 3μM and 1μM acalabrutinib (p ≤ 0.001 and p ≤ 0.01), 
Figure 3.3.14.C .  
The time to peak was also inhibited for 10μM and 3μM acalabrutinib independent of 
their concentration of rhodocytin, Figure 3.3.14.E. This shows that 10μM and 3μM 
acalabrutinib ablate calcium flux in response to rhodocytin. 1μM has an inhibited 
response. 
The IC50 values for calcium flux in the presence of acalabrutinib downstream of CRP-
XL and both concentrations of rhodocytin are similar. The value for CRP-XL is 1.48μM, 
and 1.35μM and 1.51μM for 300nM and 100nM rhodocytin, respectively. These values 













































































































Figure 3.3.13 High concentration of acalabrutinib inhibits GPVI mediated calcium 
flux 
ADP sensitive washed platelets at 4x108 cells/mL were incubated with the calcium 
sensitive dye Fura-2 AM and then with acalabrutinib or vehicle (DMSO 0.1% (v/v)) for 
5 minutes. Platelets were then stimulated with 1μg/mL CRP-XL and calcium flux 
assessed in a FlexStation. (A) representative trace of calcium flux from 5 independent 
experiments. (B) the area under the curves of each representative trace was 
calculated, along with the difference in peak height flux (C) and the time taken to reach 
the peak (D). Graph displays mean ± SEM (n=5). Statistical significance was 
calculated using one-way ANOVA with Dunnett’s multiple comparisons test and 





Figure 3.3.14 High concentrations of acalabrutinib inhibit CLEC-2 mediated 
calcium flux 
ADP sensitive washed platelets at 4x108 cells/mL were incubated with the calcium 
sensitive dye Fura-2 AM followed by acalabrutinib or vehicle (DMSO (0.1% (v/v)) for 5 
minutes. Platelets were then stimulated with 100nM or 300nM rhodocytin and calcium 
flux assessed using a FlexStation. (A) representative trace of calcium flux stimulated 
with 100nM rhodocytin from 4 independent experiments. (B) representative trace of 
calcium flux stimulated with 300nM rhodocytin from 4 independent experiments. (C) 
The difference in peak height flux, (D) The area under the curves of each trace was 
calculated, and the time taken to reach the peak. Graphs display mean ± SEM, n=4. 
Statistical significance was calculated using two-way ANOVA with Dunnett’s multiple 




3.3.11 Platelets do not spread on fucoidan but spread weakly 
on rhodocytin. 
Fucoidan has been proposed as a CLEC-2 agonist (Manne et al., 2013, Martyanov et 
al., 2020, Buitrago et al., 2013). No previous work has been done identifying whether 
platelets can spread on fucoidan or the more well-established CLEC-2 ligand, 
rhodocytin.  Bye et al., have previously studied the effect of ibrutinib on platelet 
spreading on collagen and CRP-XL.  To determine if Btk played a role in platelet 
spread on CLEC-2 ligands it was first determined whether rhodocytin or fucoidan could 
support platelet spreading as there was a lack of CLEC-2 mediated spreading in the 
literature.   
Washed platelets were allowed to spread on fucoidan (200µg/mL), rhodocytin (100nM) 
or collagen (10μg/mL) coated coverslips for 45 minutes before fixation. Slides were 
mounted using Hydromount before imaging on a Nikon TiE2 microscope using 
differential phase contrast with a 100x objective. Analysis was performed using ImageJ 
to count the number of adhered platelets and spread surface area. 
As Figure 3.3.15.E shows, there are statistically fewer adhered platelets on fucoidan 
compared to collagen (p ≤ 0.05).  Although there is a trend for fewer platelets adhered 
on rhodocytin, this was not significant. The surface area of platelets spread on 
rhodocytin is also reduced, but this is not statistically significant when compared to 
collagen. As shown in Figure 3.3.15.F, platelets adhered to rhodocytin have an 
average surface area of 13.7µm2 ±4, whereas platelets spread more on collagen (with 
an average surface area of 43µm2 ±6). The platelets adhered to fucoidan do not 
undergo spreading and have a significantly smaller surface area compared to collagen 
(p ≤ 0.05).  
These results show for the first time that platelets spread on rhodocytin, and directly 
contradict the results of Martynov et al. showing that platelets spread on fucoidan. 
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Therefore, to investigate the role of Btk in CLEC-2 mediated spreading experiments, 






Figure 3.3.15 Platelets spread on collagen and rhodocytin but not fucoidan 
Washed platelets were spread on (A) collagen (10μg/mL), (B) rhodocytin (100nM), (C) 
Fucoidan (200µg/mL) or (D) BSA (5mg/mL) coated coverslips for 45 minutes and then 
fixed. Slides were mounted using Hydromount before imaging on a Nikon TiE2 
microscope with a 100x objective. Scale bar = 10μm. Analysis was performed using 
ImageJ to (E) count the number of platelets and to (F) determine surface area. 
Statistical testing was performed using one-way ANOVA using Tukeys post-test. 
Significance was taken at *p ≤ 0.05. Graphs represent mean ± SEM, n=3. 
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3.3.12 Platelet spreading on collagen or rhodocytin is not 
inhibited by acalabrutinib. 
Previous work has shown that ibrutinib inhibits platelet spreading, but not adhesion to 
collagen (Bye et al., 2015). Acalabrutinib was used to investigate if this observation 
was related to ibrutinib’s known off target effects or mediated by Btk. Furthermore, as it 
was determined that platelets could partially spread on rhodocytin, acalabrutinib was 
used to determine whether Btk inhibition can inhibit adhesion and spreading on this 
agonist. Previous work suggests that Btk activity is required downstream of CLEC-2 at 
submaximal concentrations of rhodocytin, and it would be expected that fewer platelets 
would adhere and/or fully spread on 100nM rhodocytin in the presence of 
acalabrutinib. 
Washed platelets (2x107 cells/mL) were incubated with acalabrutinib (0.1-10μM) for 5 
minutes before spreading on collagen (10μg/mL) or rhodocytin (100nM) for 45 
minutes. Cells were then fixed and mounted before imaging on a Tie2 microscope 
using differential phase contrast. ImageJ was used to analyse the surface area and to 
count the number of platelets per field of view. 
Preincubating the platelets with acalabrutinib did not inhibit the number of platelets 
adhered to either agonist compared to their vehicle controls (Figure 3.3.16.C). 
Although 10μM acalabrutinib reduced the average surface area of platelets spreading 
on rhodocytin (14.9μm2 ± 2.5 for 10μM acalabrutinib, compared to 25.1μm2 ± 7.5 for 
the vehicle control) it was not found to be statistically significant. Acalabrutinib did not 
inhibit the spreading on collagen, with all concentrations of acalabrutinib and vehicle 
having an average surface area within 7μm2 of each other. Surprisingly, this suggests 






Figure 3.3.16 Platelet spreading is not inhibited in the presence of acalabrutinib 
on collagen or rhodocytin 
Washed platelets were preincubated with acalabrutinib (0.1-10μM) or vehicle control 
for 5 minutes. Platelets were spread on (A) collagen (10μg/mL) or (B) rhodocytin 
(100nM) or BSA (5mg/mL) coated coverslips for 45 minutes and fixed. Slides were 
mounted using Hydromount before imaging on a Nikon TiE2 microscope with a 100x 
objective. Scale bar = 10μm. Analysis was performed using ImageJ to (E) count the 
number of platelets and to determine the (F) spread surface area. Statistical testing 
was performed using Two-way ANOVA using Dunnett’s post-test. Significance was 

















3.3.13 PI3K inhibition reduces platelet adhesion and spreading 
on collagen  
As adherence and spreading of platelets is not inhibited with 1μM acalabrutinib, a 
concentration that causes an inhibition of Btk phosphorylation, Btk is potentially playing 
a scaffolding role.  To investigate if the potential scaffolding role of Btk is related to its 
recruitment via PIP3, experiments were performed using a PI3K inhibitor and 
acalabrutinib in combination. This was to investigate if there is any further inhibition 
observed when Btk is not recruited to the signalosome compared to when Btk kinase 
activity is blocked.  
When treated with either concentration of acalabrutinib (1μM or 0.1μM), the number of 
platelets adhered to collagen is not significant different from vehicle treated samples, 
Figure 3.3.17.B. Additionally, when treated with either concentration of LY294002, 
there is no significant inhibition in the number of adhered platelets when compared to 
the vehicle control. The addition of LY294002 at either concentration to either 1μM or 
0.1μM acalabrutinib samples does not cause any further inhibition in the number of 
platelets adhered in the field of view.  
100μM LY294002 caused a reduction of surface area to 18.5μm2 ±1.5 which was 
significantly smaller than vehicle treated samples. The surface area of platelets treated 
with 1μM acalabrutinib is 43.7μm2 ±3.1. When the platelets are also treated with 
100μM LY294002 in addition to 1μM acalabrutinib, the surface area is significantly 
reduced to 13.7±1.1μm2), (p ≤ 0.05). This is also observed in 0.1μM acalabrutinib 
treated samples, with 100μM LY294002 and 0.1μM acalabrutinib causing an average 
platelet surface area of 14.5μm2 ±3.1 (p ≤ 0.001).  
This suggests that there is no further effect of Btk inhibition on platelet spreading due 
to kinase inhibition, and that the lack of spreading observed in these experiments is 





Figure 3.3.17 Addition of acalabrutinib does not further inhibit spreading with a 
PI3K inhibitor 
Washed platelets were preincubated with acalabrutinib (1 or 0.1μM), 100μM or 50μM 
LY294002 or vehicle control (DMSO 0.1% (v/v)) individually or in combination for 5 
minutes. (A) Platelets were spread on collagen (10μg/mL) or (B) BSA (5mg/mL) 
coated coverslips for 45 minutes before fixation. Slides were mounted using 
Hydromount before imaging on a Nikon TiE2 microscope with a 100x objective. Scale 
bar = 10μm. Analysis was performed using ImageJ to (B) count the number of adhered 
platelets and (C) to determine the surface area. Statistical testing was performed using 
Two-way ANOVA using Tukeys post-test. Significance was taken at *p ≤ 0.05. **p ≤ 
0.01, ***p ≤ 0.001. Graphs represent mean ± SEM, n=3.
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Table 3.3.1 Calculated IC50 values in this study 
 







IC50 (μM) 95% Confidence 
interval  










0.49 0.18 to 1.34 
  
1.40 0.83 to 2.37 
ADP insensitive 
platelets 
P selectin 0.55 0.11 to 2.85 
  
1.41 0.81 to 2.46 
ADP insensitive 
platelets 
Btk pY223 1.02 0.55 to 1.94 0.87 0.47 to 1.63 1.83 0.44 to 7.54 
ADP insensitive 
platelets 
PLCY pY759  
 
1.12 0.53 to 2.34 1.41 0.67 to 2.97 
ADP insensitive 
platelets 
Src pY416 39.93 15.86 to 1564 16.88 2.94 to 96.99 Uncalculatable  
ADP insensitive 
platelets 
Syk pY525  10.38 
 
2.05 to 190.6 Uncalculatable  Uncalculatable 
ADP insensitive 
platelets 









Btk pY223   1.66 0.87 to 3.150 0.57 0.19 to 1.65 
ADP sensitive 
platelets  
PLCY pY759   1.11 0.69 to 1.751 0.28 1.01 to 3.55 
ADP sensitive 
platelets  




Syk pY525    58.50 0.01 to 425988  
ADP sensitive 
platelets  





Using Btk inhibitors in a range of platelet functional assays the following aims were 
addressed  
3.4.1 Aim - To identify if acalabrutinib causes platelet inhibition to 
a similar manner to ibrutinib  
3.4.1.1 Ibrutinib inhibits both GPVI and CLEC-2 aggregation, granule release and 
fibrinogen binding more potently than acalabrutinib and CLEC-2 responses are 
more severely inhibited 
Downstream of GPVI, Figure 3.3.2 show that ibrutinib is more inhibitory than 
acalabrutinib. At 1μg/mL CRP-XL, only 10μM acalabrutinib caused inhibition of 
aggregation in washed platelets, whereas ibrutinib caused inhibition with concentrations 
as low as 0.1μM (Figures 3.3.2 B and D) consistent with previously published work (Dobie 
et al., 2019, Chen et al., 2018). The IC50 values are 2.7μM (1.7 to 4.26) for acalabrutinib 
and 0.06μM (0.05 to 0.09) for ibrutinib which agree with the IC50 values of Bye et al. 
However, larger IC50 values for ibrutinib and acalabrutinib downstream of CRP-XL were 
obtained when investigated by the Watson group (ibrutinib- 1.19μM, (0.73 to 1.95) and 
acalabrutinib 21.25μM (12.27 to 37.11) (Nicolson et al., 2018), but this is likely due to the 
higher concentrations of agonist used (10μg/mL of CRP-XL compared to 1μg/mL CRP-
XL). Nonetheless, this shows that ibrutinib is more potent at inhibiting platelet aggregation 
than acalabrutinib downstream of GPVI.  
Similar results can be observed downstream of CLEC-2. There is a shift to the left of 
ibrutinib’s IC50 curve compared to acalabrutinib’s (Figure 3.3.3 E, H, K), showing 
increased potency of ibrutinib. These values are in accordance with Nicolson et. al., 2020, 
and in direct contrast to the results on Manne et al, where 10nM ibrutinib abolished 
aggregation downstream of rhodocytin. Whereas in this study, 10nM ibrutinib does not 
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alter aggregation. Manne et al used 30nM of rhodocytin as an agonist which did not elicit 
a response in Figures 3.3.1.A and B.  
For both agonists, there is a significant difference in the amount of aggregation at 1μM (p 
≤ 0.01), with ibrutinib being more inhibitory (Figures 3.3.2B and 3.3.3.B). Indeed, at this 
concentration Src pY416 is not inhibited with acalabrutinib downstream of GPVI (Figures 
3.3.4.B). Downstream of CLEC-2 Src pY416 is inhibited at 1μM acalabrutinib, but not 
abolished, and levels are still approximately 50% (3.3.6.B lower panel). Furthermore, 
ibrutinib is more potent at inhibiting SFKs than acalabrutinib (Figure 3.3.7 D and F). This 
has also been confirmed in the literature (Bye et al., 2017).  
This suggests that aside from Btk and SFK inhibition, there are other kinases being 
inhibited by ibrutinib. Btk deficient XLA patients do experience inhibition of aggregation 
when treated with 70nM ibrutinib. This concentration concentrations thought to be 
inhibitory for Btk only (Tec and Src phosphorylation is unaltered in healthy donors at 
70nM ibrutinib) (Nicolson et al., 2018). This suggests that ibrutinib has other unknown 
targets that are mediating platelet inhibition. Because of the unknown off target effect of 
ibrutinib, acalabrutinib was used to further investigate the role of the Btk kinase in platelet 
responses to GPVI and CLEC-2 mediated signalling pathways.  
In line with this study, ibrutinib has been shown in the literature to inhibit α granule 
secretion downstream of GPVI. P-selectin exposure, a marker of platelet activation, is 
also greatly inhibited by 1µM of ibrutinib in response to 1μg/mL CRP-XL (Bye et al., 
2015). This has also been confirmed by another independent group, with 1μM ibrutinib 
inhibiting P-selectin exposure downstream of 0.25μg/mL of CRP-XL (Dobie et al., 2019). 
More recent work by Bye and colleagues has shown that acalabrutinib does not inhibit P-
selectin exposure as severely as ibrutinib downstream of CRP-XL (Bye et al., 2017). 
These findings are consistent with the findings of this study (Figure 3.3.2F-H). 
Fibrinogen binding downstream of 1μg/mL CRP-XL stimulated platelets is also 
significantly inhibited in the work by Bye et al., which is also consistent with the results in 
147 
 
this study (Figure 3.3.2.I). Also consistent with this study is that ibrutinib also inhibited 
fibrinogen binding more severely than acalabrutinib downstream of CRP (Bye et al., 
2017), Figure 3.3.3.I-K.  
Recent research has demonstrated that ibrutinib can cause shedding of αIIbβ3 in the 
absence of agonist in vitro and in vivo via ADAM17. It is believed this increased activity of 
ADAM17 is caused by off target effects as using a more selective, but still irreversible, Btk 
inhibitor Zanubrutinib did not modulate receptor levels (Dobie et al., 2019). This may be a 
potential reason for why there is a stronger inhibition of ibrutinib on fibrinogen binding 
compared to acalabrutinib. However as acalabrutinib was not used in the work by Dobie 
et al., it cannot be confirmed.  
The study by Dobie et al., also investigated granule secretion downstream of CLEC-2 in 
the presence of ibrutinib, however not for acalabrutinib. Concentrations of 0.5μM and 
higher of ibrutinib prevented the release of α and dense granules when stimulated with 
0.7μg/mL (23nM) rhodocytin. This is consistent with the results where concentrations 
greater than 0.3μM ibrutinib inhibit P-selectin exposure downstream of 100nM rhodocytin 
(Figure 3.3.3.F). An alternative Btk inhibitor, zanubrutinib, did not cause inhibition dense 
or α granule secretion at low concentrations. However, it did as the concentration 
increased, similarly to ibrutinib (Dobie et al., 2019).  
This group also investigate the activation of integrin αIIbβ3 downstream of rhodocytin. In 
contrast to this study, they assessed the active confirmation of the integrin using the PAC-
1 antibody which binds to active confirmation of αIIbβ3  (Joo et al., 2015). The opening of 
the integrin was inhibited using ibrutinib, similarly to our study (3.3.3.I). Zanubrutinib was 
still inhibitory at inhibiting PAC-1 binding when stimulated with 23nM rhodocytin, but to a 
lesser extent than ibrutinib (Dobie et al., 2019). The concentrations of inhibitor used in 
these experiments is not stated so it is difficult to compare to the results obtained in 




3.4.1.2 The phosphorylation of CLEC-2 is inhibited in the presence of ibrutinib but 
not acalabrutinib 
As there was a more severe effect of Btk inhibition on CLEC-2 mediated aggregation than 
GPVI mediated aggregation, it was investigated that the receptor itself was reduced in its 
phosphorylation which would prevent signalling. The SFK’s and Syk are responsible for 
the phosphorylation of CLEC-2 (Severin et al., 2011, Lorenz et al., 2015). Btk inhibition 
using acalabrutinib did weakly inhibit the phosphorylation of SFKs downstream of CLEC-2 
(Figure 3.3.6). However, 1μM ibrutinib has been proposed to inhibit SFK’s activity more 
potently (Figure 3.3.7.F) and published in literature (Bye et al., 2015, Nicolson et al., 
2020) which may explain why 1μM ibrutinib causes a reduction in CLEC-2 
phosphorylation whereas acalabrutinib does not. Interestingly however, this inhibition of 
phosphorylation is only in the ADP sensitive samples. This potentially may be due to the 
inhibition of the reinforced signalling by secondary mediators, that human CLEC-2 is 
dependent on, leading to a greater inhibitory effect.  
 
3.4.2 Aim - To characterise the effect of acalabrutinib 
downstream of GPVI and CLEC-2 using platelet aggregation, 
granule secretion and protein phosphorylation and to investigate 
where Btk lies in the CLEC-2 signalling cascade 
3.4.2.1 Dose dependent inhibition of platelet responses of acalabrutinib 
downstream of GPVI 
High concentrations of acalabrutinib is inhibitory on aspects of platelet function mediated 
via GPVI. These include inhibition of aggregation (Figure 3.3.2 A and B), granule 
secretion (Figure 3.3.2.G) and calcium mobilisation (Figure 3.3.13). However, there is no 
inhibition in these responses at 1μM acalabrutinib, which is shown to have lost 
phosphorylation of Btk at pY223, a site that shows Btk is catalytically active (Figure 3.3.4 
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and 3.3.9). Only 10μM acalabrutinib inhibited aggregation and calcium release (Figures 
3.3.2 A, B and 3.3.13B,C) which is consistent with two other studies (Bye et al., 2017, 
Nicolson et al., 2018). 
Calcium mobilisation was lost at 10μM acalabrutinib, along with aggregation, Btk and 
PLCγ2 phosphorylation. However, at 1μM acalabrutinib, calcium mobilisation was not 
inhibited despite inhibition of both Btk pY223 and PLCγ2 pY759 in ADP sensitive and 
ADP insensitive washed platelets (Figures 3.3.4 and 3.3.9). This suggests that catalytic 
activity of Btk and PLCγ2 phosphorylation at pY759 are not involved in calcium 
mobilisation. 
PLCγ2 has multiple phosphorylation sites, Y753, Y759, Y1197 and Y1217 (Kim et al., 
2004, Rodriguez et al., 2001). It is possible, that phosphorylation of another / multiple 
other sites, or an unknown mechanism such as serine phosphorylation is responsible for 
mediating calcium mobilisation downstream of GPVI. Mutagenesis studies mutating all 
four sites (Y753, Y759, Y1197 and Y1217) did not result in abolished calcium mobilisation 
in DT40 cells, suggesting an alternative mechanism of activation (Watanabe et al., 2001). 
Another PLCγ2 phosphorylation site, pY1217, which Btk has been proposed to 
phosphorylate in vitro (Watanabe et al., 2001), however it was not identified as 
phosphorylated in convulxin stimulated platelets (Kim et al., 2004). Western blotting was 
performed with this antibody; however it did not yield any results even in vehicle 
stimulated samples. Nonetheless, this suggests Btk catalytic activity at PLCɣ pY759 is not 
required downstream of GPVI mediated responses.  Although calcium flux was measured 
as an output of PLCγ2 activity, a more direct measure of PLCγ2 could be assessed to 
confirm these results. Measurement of IP3 or DAG could be performed to further ascertain 
this result.  
If Btk catalytic activity is not required downstream of GPVI, why is aggregation inhibited at 
10μM? Calcium mobilisation is inhibited at 10μM acalabrutinib and this is likely the reason 
for inhibition of aggregation in both ADP sensitive and ADP insensitive platelets. Indeed, it 
is not likely related to other kinases such as SFK and Syk as Btk’s pY551 site is still 
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present (suggesting it is transphosphorylated), and Syk pY525 and SFK pY416 are not 
significantly decreased at 10μM.  
A potential reason for this is Btk’s interaction with β3 (Soriani et al., 2006, Crosby and 
Poole, 2002). Indeed, the measure of the activated integrin in flow cytometry was inhibited 
at 10μM and 3μM acalabrutinib which matches the aggregation inhibition profile in 
washed platelets (Figure 3.3.2). It has been shown that acalabrutinib at these 
concentrations can inhibit pY773 β3 phosphorylation and that may be preventing full 
activation of the integrin. This would prevent a stable platelet aggregate forming (Bye et 
al., 2017). 
 
3.4.2.2 Dose dependent inhibition of platelet responses of acalabrutinib 
downstream of CLEC-2 and elucidating where Btk lies downstream of CLEC-2 
When platelets are stimulated with 100nM rhodocytin, acalabrutinib dose dependently 
inhibits the aggregation of ADP insensitive platelets, with 10μM, 3μM and 1μM causing 
inhibition of aggregation, calcium flux and α granule secretion. Btk pY223 phosphorylation 
is also inhibited across these concentrations. A strong positive correlation for Btk pY223 
phosphorylation and aggregation is observed. This suggests, but cannot totally confirm, 
that Btk pY223 is important for platelet aggregation at 100nM rhodocytin in ADP 
insensitive washed platelets. 
In 300nM rhodocytin stimulated ADP insensitive washed platelets, 0.3μM or greater of 
acalabrutinib caused inhibition of Btk pY223, whereas in ADP sensitive platelets 1μM 
acalabrutinib did not cause inhibition of Btk pY223. However, 10μM and 3μM 
acalabrutinib caused significant inhibition of pY223 (Figure 3.3.12).  Despite loss of pY223 
platelets still underwent aggregation.  Surprisingly, Src pY416, which is through to be 
important for CLEC-2 mediated signalling was also inhibited under these conditions. It is 
likely that enough SFK catalytic activity is present to mediate aggregation in these 
samples, particularly as the Src pY416 site is reduced, but not totally abolished.  
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The aggregation observed in ADP sensitive platelets at concentrations when Btk 
phosphorylation is lost may also be related to secondary feedback mechanisms. It is 
known that platelets prepared this way are more sensitive to ADP as there is a shift to the 
left in the EC50 curve when compared to washed platelets prepared by two fast spins 
(Figure 3.3.8 E, F). As a high concentration of rhodocytin was used in Figure 3.3.12, it 
could be reasoned that aggregation was mainly related to ADP and TxA2 being released 
and acting in an autocrine manner (Pollitt et al., 2010). Experiments using 100nM 
rhodocytin show that there is inhibition of aggregation at concentrations of acalabrutinib 
where phosphorylation Btk pY223 is blocked. It is likely that there is less ADP / TxA2 
released when platelets are stimulated with 100nM rhodocytin (as seen in the differing 
levels of calcium flux between 300nM and 100nM rhodocytin, Figure 3.3.14), and 
therefore the inhibition of aggregation is due to this.  
However, at high concentrations of rhodocytin, both ADP insensitive and ADP sensitive 
platelets still aggregate despite loss of Btk pY223 and PLCγ2 pY759 in the presence of 
acalabrutinib.  Aggregation occurs, despite the calcium mobilisation being blocked when 
assessed using the peak change during calcium flux. The differences in how these 
experimental assays are performed may be a reason why there is a discrepancy between 
aggregation and calcium mobilisation. The calcium assay is performed in a plate, whereas 
aggregation and the phosphorylation studies are performed under stirring conditions. This 
may impact the responsiveness to rhodocytin and therefore may explain the discrepancy. 
Furthermore, aggregation is generally viewed as an all or nothing assay. If platelets start 
to aggregate, it is rare that they will disaggregate. However, disaggregation of platelets 
can be observed when platelets are stimulated with weak agonists such as ADP 
(Wadowski et al., 2017), but has not been observed in rhodocytin stimulated platelets. 
High concentrations of rhodocytin (300nM) may induce such strong receptor clustering of 
CLEC-2 it may cause an increased recruitment of SFK and Syk to the signalosome 
(Martyanov et al., 2020, Pollitt et al., 2014, Watson and O'Callaghan, 2011). This may 
bypass the need for Btk catalytic activity in inducing phosphorylation of PLCγ2. In CLL 
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patients, resistance to ibrutinib has been observed, which are attributed to mutations in 
PLCγ2.  This suggests that downstream of the BCR there may be a Btk independent 
pathway of signalling at high agonist concentrations (Liu et al., 2015). 
Btk pY223 is more inhibited in ADP insensitive platelets than ADP sensitive platelets as 
shown by a smaller IC50 value for ADP insensitive platelets (1.74μM (0.02 to 0.46) for 
ADP sensitive and 0.4μM (0.24 to 0.65) for ADP insensitive).  
As ADP insensitive platelets are less potently inhibited it was hypothesised that this could 
be due to acalabrutinib becoming plasma bound (Scheers et al., 2015). Indeed, all the 
calculated IC50 values of phosphorylation sites are larger in ADP sensitive platelets, 
suggesting less potency of the drug (Figures 3.3.9, 3.3.12 and Table 3.3.1).  
Experiments adding in BSA at relevant physiological concentrations to platelets prepared 
by two washes may help to deduce if the less severe inhibition is related to residual 
plasma proteins or the lesser response to ADP. However, it is likely that lesser potency of 
acalabrutinib in ADP sensitive platelets is not mediated through the drug binding 
mechanism. The IC50 values for Btk pY223 downstream of GPVI are comparable between 
ADP sensitive and insensitive preparations (Figures 3.3.4 and 3.3.9). Therefore, it is likely 
to be related to the requirement of secondary feedback to reinforce CLEC-2 mediated 
signalling.  
Indeed, the observed aggregation at 10μM acalabrutinib in ADP sensitive CLEC-2 
stimulated platelets do have a significantly increased lag time to aggregate compared to 
vehicle treated samples. The delay in aggregation may be due to the time taken to 
produce and release TxA2 and ADP to activate the platelet and re-enforce the CLEC-2 
signalling. To verify these results, dense granule release of ATP using chronolume could 
be performed at the same time as aggregation to investigate the kinetics of dense granule 
release in the presence of inhibitor.  
It was proposed by the Kunapali group that Btk is upstream of Syk as Syk 
phosphorylation is lost in the presence of ibrutinib. We show here, using acalabrutinib, 
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that Syk is above Btk in the CLEC-2 signalling cascade. Firstly, the phosphorylation of 
CLEC-2 is mediated by Syk (Hughes et al., 2010b, Severin et al., 2011) and CLEC-2 
phosphorylation is maintained despite the inhibition of Btk (Figure 3.3.5)  
Other experiments, using western blotting further confirms that Syk is upstream of Btk. 
Specifically, that the phosphorylation of Syk pY525 (Syk activatory site) is present at 
concentrations of acalabrutinib where Btk pY223 (catalytic activity site) is lost. This 
provides evidence that Btk is not phosphorylating Syk. Further evidence is provided by 
the loss of the Btk transphosphorylation site, pY551. This is reduced at concentrations 
where Syk pY525 phosphorylation is normal, further providing evidence that in the CLEC-















3.4.3 Aim - To investigate if rhodocytin can support platelet 
spreading and if it can, to investigate if acalabrutinib can inhibit 
platelet adhesion and spreading to rhodocytin and to compare 
this with collagen 
3.4.3.1 Acalabrutinib does not inhibit GPVI or CLEC-2 mediated spreading or 
adhesion. 
Platelet spreading in the presence of a Btk inhibitor has been investigated in this study. 
Currently, no published studies have investigated the effects of acalabrutinib on platelet 
spreading, whereas ibrutinib has been studied. Bye et al., investigated the role of Btk 
during spreading and adhesion of platelets to CRP-XL and collagen using ibrutinib. 
Overall adhesion to collagen was not inhibited, whereas spreading was, as demonstrated 
by a decrease in the formation of lamellipodia. Lamellipodia formation was also inhibited 
on CRP-XL, but unlike collagen, platelet adhesion was also inhibited. This may be due to 
the compensatory role of α2β1 mediating the spreading on collagen as opposed to CRP-
XL (Jarvis et al., 2002).  
There has been no literature published investigating the ability of platelets to spread on 
rhodocytin. Experiments using podoplanin have been performed to show that platelets do 
adhere and spread via the CLEC-2 receptor (Pollitt et al., 2014). We show for the first 
time, that when compared to collagen, platelets adhere to rhodocytin. One experiment 
has been published with CLEC-2 and PEAR-1 receptor agonist fucoidan, where the 
platelets show very weak spreading (Martyanov et al., 2020), consistent with the results 
found in this study.  
Interestingly, when compared to their vehicle control, downstream of both GPVI and 
CLEC-2 there is no difference in the number of platelets adhered or their average area in 
the presence of acalabrutinib. However, in the average surface area of the platelets, there 
is not a significant difference in the vehicle treated samples between rhodocytin and 
collagen mediated spreading, but there is in drug treated samples (10μM, 3μM and 1μM 
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acalabrutinib). Platelets spread on a CLEC-2 agonist are more severely inhibited in their 
spreading than a GPVI agonist, suggesting that Btk’s catalytic activity may be more 
important downstream of CLEC-2 as opposed to GPVI.  
In contrast, spreading and adhesion to collagen is not inhibited when treated with 
concentrations of acalabrutinib that block Btk phosphorylation. There are two potential 
reasons for this. It may be that α2β1 may play a role in spreading on collagen when GPVI 
signalling is blocked (Gibbins, 2004, Jarvis et al., 2002, Jandrot-Perrus et al., 1997). 
However, using beads and a collagen sequence that specifically targets α2β1, it has been 
proposed that Btk is also essential downstream of this integrin (Lima et al., 2018). The 
other potential reason that platelets may adhere and spread normally on collagen may be 
due to the presence of Tec. In Btk knockout mice, platelet spreading on collagen is 
normal, likely due to the redundancy of Tec (Atkinson et al., 2003a). However, at 10μM 
acalabrutinib, Tec would also likely be inhibited (Nicolson et al., 2018) when spreading is 
not inhibited in this study, and in published literature (Bye et al., 2017).  
Taken together, this suggests that Btk and Tec may not play a significant role in mediating 
adhesion and spreading on collagen. Indeed, double knockouts of Tec and Btk have 
reduced but not total loss of spreading on collagen, and appear to adhere in a similar 
manner, however this is not quantified in the study (Atkinson et al., 2003a).  
 
3.4.3.2 The potential mechanism of Btk playing a dual scaffolding role 
It has been proposed in B cells that Btk can act as a scaffold through its interaction with 
PIP3, PIP5K and PLCγ2 (Saito et al., 2003, Pasquet et al., 2000, Scharenberg et al., 
1998). To investigate a potential mechanism for Btk’s possible scaffolding behaviour, 
experiments using the PI3K inhibitor LY294002 were performed. The aim being to prevent 
Btk recruitment to the membrane by preventing the production of PIP3 and inhibiting the 
kinase activity of Btk using acalabrutinib.  
156 
 
It has been previously shown that platelets treated with 50μM LY294002 had normal 
PLCY2 phosphorylation downstream of CRP-XL (Pasquet et al., 1999a), suggesting that 
recruitment of Btk may not be involved in the regulation of PLCγ2 phosphorylation. Of 
note, the phosphorylation is measured using immunoprecipitation and probed for total 
phosphotyrosine. Therefore it is possible that other sites compensate for Btk and it would 
have been interesting if Btk specific phosphosites had been assessed. Nonetheless, this 
suggests Btk independent activation of PLCγ2.  
When samples were treated with both the PI3K and Btk inhibitors, no additional inhibition 
of spreading was seen when compared to LY294002 alone (Figure 3.3.17.C, D). This 
suggests that Btk recruitment is more important than catalytic activity.  However, the 
concentration of PI3K inhibitor was likely also impacting the normal platelet response, as 
this would likely inhibit Akt which is required for spreading (Kim et al., 2009b). Although it 
has been used at this concentration (50μM) in the literature, with platelets aggregating to 
high concentrations of CRP-XL (Pasquet et al., 1999a). Experiments should be repeated 
with lower concentrations of LY294002 to modulate the recruitment of Btk without 
inhibiting the platelet spreading.  
An alternative approach to these experiments could be to use an inhibitor of Phosphatase 
and Tensin homolog (PTEN). This phosphatase is responsible for the removal of PIP3, 
and therefore it would increase Btk recruitment. Experiments could be performed with an 
inhibitor of PTEN, such as bpV(phen) (Pulido, 2018), in addition to acalabrutinib, to 
ensure Btk was present but catalytically inactive, to assess the potential scaffolding role of 
Btk (Myers et al., 1997).  
 
3.5 Conclusions 
Platelets can still aggregate and spread at concentrations where Btk phosphorylation is 
lost downstream of GPVI – this suggests a scaffolding role for Btk downstream of GPVI. 
At an intermediate concentration of rhodocytin, Btk cannot play a scaffolding role as 
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phosphorylation and platelet responses are inhibited when Btk phosphorylation is lost. 
However, at high concentrations of rhodocytin, Btk is not involved in the aggregation of 
these platelets, as aggregation occurs when phosphorylation of Btk is lost. This suggests 
other kinases and secondary feedback may play a role or a further potential scaffolding 
role downstream of CLEC-2. 
We show for the first time that platelets adhere too, and spread on the CLEC-2 ligand 
rhodocytin, and spreading is not inhibited by Btk inhibition. Spreading on GPVI agonist 
collagen is also not inhibited by acalabrutinib and potentially suggests a redundant role of 
















4 The use of the DT40 B cell line to investigate which 
functional Btk domains are required to convey GPVI and 
CLEC-2 signalling 
4.1 Introduction  
As platelets do not contain a nucleus, genetic modification of DNA is not possible using 
platelets directly. There is an emerging field of genetic manipulation of induced pluripotent 
stem (iPS) cells to make modified in vitro platelets (Moreau et al., 2016). However, 
currently platelet research is largely dependent on the genetic manipulation of animals. 
Animal work is slow due to time needed for the breeding of animals, cost ineffective and 
sometimes the genetic changes are not viable. For example, a mouse model with a 
double knockout of Btk and Tec is not viable beyond birth. This is due to the failure of the 
separation of the blood lymphatics and believed to be due to the disruption of the CLEC-2 
podoplanin signalling axis (Manne et al., 2015a).  
Therefore, research using model cell lines, genetic manipulation of DNA and the 
expression of mutant proteins using gene editing has been utilised to further unpick the 
role of proteins downstream of ITAM and hemITAM signalling.  
4.1.1 DT40 cells  
The DT40 cell line is a chicken (Gallus gallus domesticus) B cell line derived from Avian 
Leukosis Virus induced bursal lymphoma (Winding et al 2001). DT40 cells are used as a 
model cell line to investigate signalling pathways as they are easy to genetically 
manipulate. This is due to the increased ratio of targeted to random integration after 
transfection. The Kurosaki group were pioneers of genetic manipulation of this cell line, 
creating cell lines deficient in Syk, Lyn (Takata et al., 1994), PLCɣ2 (Takata et al., 1995) 
and Btk (Takata and Kurosaki, 1996) via homologous recombination. These cell lines 
have been vital in distinguishing the exact role of these proteins in ITAM mediated BCR 




DT40 cells do not endogenously express either of the platelet ITAM containing FcRɣ 
chain GPVI complex or the hemITAM containing CLEC-2 receptor (Fuller et al., 2007, 
Tomlinson et al., 2007). DT40 cells also endogenously express the signalling machinery 
needed for platelet (hem)ITAM receptor signalling, including Syk, Lyn and exclusively 
express the PLCγ2 isoform (Takata et al., 1995). The ease of receptor transfection into 
this cell line allows the BCR signalling proteins to be exploited to study platelet 
(hem)ITAM signalling.  
GPVI expression at the DT40 cell surface is only achieved when GPVI is co-transfected 
with FcRɣ (Tomlinson et al., 2007, Mori et al., 2008). This is consistent with the FcRɣ 
chain knockout mouse model which also has no GPVI detected at the surface of platelets 
using flow cytometry (Nieswandt et al., 2000). 
Fuller and colleagues used DT40 cells to analyse the CLEC-2 signalling pathway. The 
Nuclear factor of T cells (NFAT) and luciferase reporter assay, which is a measure of cell 
signalling, was used to identify that these cells do not express endogenous CLEC-2. 
Furthermore, this study identified that hemITAM signalling requires Syk and its dual SH2 
domains, Btk, PLCγ2 and phosphorylation of CLEC-2 to mediate signalling, whereas a 
Lyn knockout cell potentiated the response to rhodocytin (Fuller et al., 2007). A potential 
reason for this is that Lyn could be involved in terminating hemITAM signalling, as it is 
known to be involved in negatively regulating ITAM signalling in platelets (Quek et al., 
2000). This is due to Lyn’s role in phosphorylating immunotyrosine-based inhibitory motifs 
(ITIMs) such as Platelet–endothelial cell adhesion molecule-1 (PECAM-1) (Ming et al., 
2011, Tourdot et al., 2013). If no Lyn is present, once the response is initiated, it cannot 
be terminated, explaining the signal potentiation.  
4.1.2 The study of signalling pathways using the NFAT Luciferase 
assay  
The Nuclear factor of activated T cells (NFAT)-luciferase reporter assay is a sensitive 
assay to measure signalling induced within a cell. A reporter construct containing NFAT 
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which locates to the cytoplasm in a phosphorylated state, three copies of NFAT-activator 
protein-1 (AP-1) from the interleukin-2 gene promoter and a luciferase enzyme is 
transfected into the cell (Clipstone and Crabtree, 1992).  The appropriate agonist binds to 
its respective receptor to induce intracellular signalling causing an increase in cellular 
calcium. This increase in subcellular calcium causes activation of the serine-threonine 
phosphatase calcineurin, which can dephosphorylate NFAT. This allows exposure of 
NFAT’s nuclear localisation signal and thus allowing translocation to the nucleus (May et 
al., 2009). Additionally, AP-1 is phosphorylated by RAS/mitogen-activated protein kinase 
(MAPK), allowing nuclear translocation after activation of protein kinase C via PLCγ2. 
This occurs simultaneously with the phosphatase activity of calcineurin (Fuller et al., 
2007). 
Experiments are always performed with a positive control to verify successful transcription 
of the NFAT and AP-1 proteins. Post transfection, cells are treated with phorbol 12-
myristate 13-acetate (PMA) and ionomycin. These bypass the need for agonist binding 
and cell signalling by activating PKC and causing calcium flux, respectively. This allows 
nuclear translocation of the NFAT and AP-1 proteins. 
Following the translocation of NFAT and AP-1 proteins to the nucleus, luciferase can then 
be translated and transcribed (Figure 4.1.1.A), as the luciferase gene transcription is 
controlled by the NFAT and AP-1 proteins. The luciferase enzyme is then able to catalyse 
luciferin to produce luminescence in the presence of ATP (Figure 4.1.1.B). More cell 
signalling results in an increased amount of luciferase transcribed, and this corresponds 
to the amount of light produced.  
The use of the NFAT-luciferase assay is more favourable than measuring calcium flux 
due to the increased sensitivity of the assay. To maintain NFAT protein 
dephosphorylation, sustained calcineurin activation is required, and this is achieved with 
low continuous Ca2+ elevations (Dolmetsch et al., 1997). Sometimes, this low but 
sustained calcium flux is unmeasurable using fluorimetry or microscopy, and therefore the 
NFAT-luciferase assay is used (Tomlinson et al., 2007).  
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The NFAT luciferase assay has been utilised in cell signalling to elucidate both agonists, 
required proteins and protein domains involved in platelet signalling for both GPVI and 
CLEC-2 signalling (Mori et al., 2008, Tomlinson et al., 2007, Alshehri et al., 2015b, 







Figure 4.1.1 NFAT-Luciferase reporter assay  
(A) Agonist binds to the receptor to initiate cell signalling through tyrosine kinases. This results in calcium release which activates the 
serine/threonine phosphatase Calcineurin. This dephosphorylates NFAT proteins present in the cytoplasm exposing their nuclear localisation 
signal and they translocate to the nucleus. Concurrently, nuclear localisation signals on AP-1 proteins are also exposed through MAPK 
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signalling after the rise in calcium.  NFAT and AP-1 proteins then bind to promotors initiating transcription of the luciferase protein. (B) Luciferin 
in the presence of ATP, O2, Mg2+ and Luciferase is catalysed to Oxyluciferin and light, which is measured.
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4.1.3 CRISPR-Cas9  
Clustered regularly interspaced short palindromic repeats (CRISPR) – Cas9 technology 
utilises a microbial adaptive immune system to result in genome editing of the host cell. 
This system, originally present in prokaryotes, results in the cleavage of pathogen DNA 
and therefore pathogen death. This protects the bacteria from infection with viruses and 
plasmids. However, it has been exploited and developed to gene edit eukaryotes.  
The CRISPR-Cas9 system from Streptococcus pyogenes (SpCas9) has been widely 
utilised and consists of a Cas9 endonuclease and an oligonucleotide guide RNA which 
has been cloned into the same plasmid (see Figure 4.1.2). The guide sequence is 20-24 
nucleotides that guides the Cas9 to the target cut site and must be upstream of the 
protospacer adjacent motif (PAM). The PAM site is required in order for activation of the 
Cas9 protein. Now in its active state with the guide RNA bound, Cas9 will only cut if there 
is sufficient homology between the guide and the target sequence. DNA is nicked by the 
SpCas9 ~3-4 nucleotides upstream of the PAM sequence, where a double strand break is 
introduced. The cell can then repair the DNA by 2 methods; non homologous end joining 
(NHEJ) or homology directed repair (HDR) (Jinek et al., 2012, Ran et al., 2013, Shalem et 
al., 2014). 
Non-homologous end joining occurs after a double strand break and is the favoured 
method of DNA repair by cells (Mao et al., 2008). After the break, broken ends (typically 
with overhangs) are directly ligated without a homologous template. This is orchestrated 
by a variety of intracellular factors including ligases. Nucleotide bases are often added or 
deleted; however these bases are not always correct, due to its error prone nature. This 
often results in knockout or inactivation of the target protein, usually by the introduction of 
a frameshift (Lino et al., 2018). NHEJ usually destroys the PAM site due to the proximity 




Homology directed repair (HDR) is the alternative approach cells can take to repair their 
DNA after the induced double strand break. It is considered the more accurate 
mechanism of repair. It requires a donor template of the sequence to be repaired. The 
steps are shown in Figure 4.1.2. Briefly, a DSB is introduced and the repair template with 
homology arms lines up to near the area where the DSB is. The template is used to repair 
the double strand break by homology directed repair, integrating the template (which 
contains the desired mutations) into the DNA (Lino et al., 2018).  
HDR is far more complex than NHEJ. Firstly, the site of mutagenesis is limited by the 
presence of a PAM site. PAM sites are required for the DNA editing to take place, and the 
PAM site should be within 10 base pairs of the cut to increase the chances of HDR. This 
can often be restrictive if there are less PAM sites present within the sequence. 
Furthermore, the Cas9 will continue to cut the integrated DNA if there is still a PAM site 
present within the DNA after the HDR.  
Nevertheless, CRISPR-Cas9 has been employed experimentally to create knockouts 
(Shalem et al., 2014, Abu-Bonsrah et al., 2016), point mutation knock-ins (Zhang et al., 
2016) and introduced fluorescent tags to proteins (Khan et al., 2017). Therefore, it is a 
valuable and widely applicable experimental tool. Utilising CRISPR to create knock-ins is 
beneficial as it results in protein expression which is present under normal cellular control 
and regulation. Therefore, the expressed levels of protein are typically that of the 
endogenous protein, and experimental artefacts due to over expression levels can be 
disregarded. Any change in the expression of protein induced by the CRISPR-Cas9 





Figure 4.1.2 Mechanisms of DNA repair using CRISPR-Cas9 gene editing  
The guide RNA targets the Cas9 to the appropriate site where it induces a double strand 
break. The cell can then repair the DNA damage via non homologous end joining (NHEJ) 
where base insertions or deletions can lead to a frameshift in the DNA. Alternatively, a 
donor template with homologous arms and mutations (shown in yellow) can be used.  The 
cell can repair the DNA via homology directed repair, introducing specific mutations into 










4.1.4 Domains of Btk required for signalling  
There is conflicting literature in B cells as to which Btk domains are required to mediate 
signalling.  These are summarised in Table 4.1.1.  Furthermore, this research is limited to 
signalling downstream of the B cell receptor, with limited literature on the role of Btk 
domains in platelet (hem)ITAM receptor signalling using these models, or with any work 



















Table 4.1.1 Describes the Btk domain functions and evidence that they are or not required to mediate signalling 
Domain and 
 interaction 
Evidence that the domain and/or domain function is required Evidence that the domain and/or domain 
function is not required 
PH and TH –  
PIP3, produced by PI3K. 
Function altering point mutated Btk (R28C) did not undergo 
calcium flux in B cells in an overexpression model (Takata and 
Kurosaki, 1996). 
 
W124G point mutation reduces Btk signalling in a NIH 3T3 cell 
line (Li et al 1995).  
  
Btk activation dependent on PIP3 density at membrane (Chung et 
al., 2019) and PI3K inhibitors block Btk recruitment to the 
membrane fraction when platelets are stimulated with rhodocytin 
(Manne et al., 2015a) 
 
Multiple mutations in this domain have been identified as the 
cause of severe XLA in patients (Hyvönen and Saraste, 1997).  
PLCγ2 phosphorylation is not reduced in the 
presence of a PI3K inhibitor in Ramos cells, 
although Btk may not be the kinase responsible 
for PLCγ2 phosphorylation in these cells (Kim 
et al., 2004). 
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SH3 – proline rich 
regions 
Numerous identified mutations in this domain resulting in XLA 
(Väliaho et al., 2006). 
SH3 function of Tec is not required to mediate 
signalling in Jurkat cells when investigated 
using a functional altering point mutations 
(WW215/216LL) (Tomlinson et al., 2004b).  
 
SH3 domain is not required for signalling in a 
constitutively active Btk PH domain mutant (Li 
et al., 1995) 
SH2 - phosphotyrosine B cell signalling and flux blocked in function altering point 
mutation (R307K) and domain deletions  
(Fluckiger et al., 1998, Scharenberg et al., 1998). 
 
Several mutations in this domain have been identified as 
causative of XLA (Väliaho et al., 2006). 
Downstream phosphorylation of PLCγ2 is 
reduced but not abolished in B cells in function 
altering point mutation (R307G) (Takata and 
Kurosaki, 1996).  
 
Not required for oncogenic activity to transform 
colonies in NIH 3T3 cells in a PH activating Btk 
mutant (Li et al., 1995) 
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Kinase (SH1) – catalytic 
activity 
Btk can be responsible for tyrosine phosphorylation of PLCγ2 
(Watanabe et al., 2001). 
Kinase inhibitors ibrutinib and acalabrutinib that inhibit B cell 
signalling and are clinically successful for treatment of B cell 
malignancies (Patel et al., 2016, Isaac and Mato, 2020).  
Mutations in this domain lead to XLA, however it can be a less 
severe phenotype (Gaspar et al., 2000). 
Kinase inactive mutant (K430R) - Not required 
in B cell development (Middendorp et al., 2003)  
A kinase inactive mutant (K430E) can mediate 
signalling downstream of the oestrogen 
receptor in B cells (Tomlinson et al., 2001).  
There was a peak of calcium flux, albeit greatly 
reduced compared to wild type, in a kinase 
dead version of Btk downstream of the BCR 
(Takata and Kurosaki, 1996). 
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The above table shows that there is conflicting information within the literature about what 
Btk domain functions are required to mediate signalling. It is suggested by multiple reports 
that the PH domain is absolutely required in both platelets and B cells (Manne et al., 
2015, Pasquet et al., 2000), with little literature opposing this.  
It is contentious if the SH3 domain is required, as there have been multiple reports where 
this is not required to mediate BCR signalling. Whereas there are fewer reports verifying it 
is essential (Table 4.1.1). The function altering SH2 domain mutations at R307 in some 
reports abolish signalling (Fluckiger et al., 1998). Whereas in other reports, the PLCγ2 
phosphorylation is reduced but not abolished (Takata and Kurosaki, 1996). Both the SH3 
and SH2 domain functions would be difficult to block in platelets, as proline rich regions 
are endogenously expressed in proteins, and inhibiting tyrosine phosphorylation is likely 
to inhibit total platelet signalling (Watson et al., 2005).  
Whether the kinase function of Btk is required is controversial. There are some reports 
that kinase activity is required in one setting, but not in another, and this may even be in 
the same cell depending on the method of cell activation such as the role of Btk at the 
immune synapse (Roman-Garcia et al., 2018). Btk inhibitors have been used in platelets 
to inhibit kinase function with differing results depending on the publishing group, with 
some platelets undergoing full aggregation at Btk inhibiting concentrations, whereas 
others do not (Series et al., 2019, Levade et al., 2014, Nicolson et al., 2018, Bye et al., 
2015). In chapter 3, it was shown that Btk may be acting as a scaffold protein, and 








4.2 Aims of this chapter 
While the functional domains of Btk have been explored downstream of the BCR using 
the overexpression of proteins, little work has investigated the role of these domains 
downstream of GPVI and CLEC-2.  
As the DT40 cell line has been shown to be a valuable tool in investigating (hem)ITAM 
signalling, DT40 cells were utilised as a model to achieve the following aims: 
Aims 
• To elucidate which domains of Btk are required to mediate NFAT-Luciferase 
signalling downstream of GPVI and CLEC-2 using an overexpression model 
• To genetically modify Btk using CRISPR-Cas9 to generate mutants to verify 
overexpression experimental models. 
Hypothesis 
Btk will require PH and SH2 but not SH3 domain function to mediate signalling 
downstream of GPVI and CLEC-2. It may require a functional kinase domain downstream 












4.3 Results  
4.3.1 WT DT40 cells express Btk and PLCɣ2 whereas Btk 
Knockout cells only express PLCɣ2. 
To ensure that the batch of DT40’s was consistent with the literature, western blotting for 
the presence of key ITAM and hemITAM signalling proteins was assessed.  DT40 cells 
(1x107 cells/mL) were sampled periodically over two weeks before being washed in PBS 
and lysed in 1X RIPA buffer with protease inhibitors. Cells were lysed for a minimum of 30 
minutes before the appropriate volume of sample buffer was added before SDS-PAGE 
and western blotting.  
Consistent with previous work and proteomic studies, we found that WT DT40s express 
PLCɣ2 and Btk, and do not express GPVI, CLEC-2 or Tec (Rees et al., 2015). 
Furthermore, Btk KO cells (Dr Mike Tomlinson, University of Birmingham, UK) do not 
express Btk, and the level of PLCɣ2 is normal compared to WT cells (Figure 4.3.1). We 
did not see any evidence of Tec expression in WT DT40s nor a compensatory 
upregulation of Tec expression in the Btk KOs. Platelets were used as a positive control 




Figure 4.3.1 WT DT40's express Btk and PLCγ2 
(A) Platelets, WT DT40’s and Btk KO DT40’s were lysed using 1X RIPA before subjected 
to SDS-PAGE with western blotting to blot for PLCγ2, Tec, Btk.  Tubulin was using as a 
loading control. (B) Quantification was performed using Imagequant. Statistical 
significance was calculated using a two-way ANOVA with a Tukey's post-test. Graph 
represents mean ± SEM, n=3. Significance was taken at *p ≤ 0.05, **p ≤ 0.01. 
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4.3.2 WT DT40 cells express Btk and PLCγ2 when assessed using 
microscopy, whereas Btk deficient cells only express PLCγ2.  
After verifying that the antibody is suitable to assess the levels of Btk in western blotting, 
its use in immunofluorescence was then tested.  Another anti-Btk antibody in raised in a 
different host for future microscopy experiments was also assessed. 
To investigate the specificity of the antibodies, of Btk and PLCγ2, WT and Btk KO cells 
were adhered to poly-l-lysine-coated glass before fixation, permeabillsation and 
immunostaining with an anti-Btk antibody, an anti-PLCɣ2 antibody or IgG control. 
Samples were imaged using a Nikon A1R fluorescence confocal microscope. 
In line with the previous reports, Btk KO cells do not express Btk and this further provides 
verification of the antibody used in later chapters for microscopy as being specific to Btk 
as no signal can be seen in these cells. Figure 4.3.2.A shows that WT DT40 cells express 
abundant amounts of Btk and Btk appears to localise to the perimeter in the cell. This 
observation is consistent as to what is observed in the work by Tomlinson and colleagues.  
Furthermore, consistent with the western blotting, both WT and Btk deficient DT40s 
express PLCγ2 when analysed using microscopy, albeit to a lesser extent than Btk. This 
may be due to poor performance of the antibody or due to reduced expression of PLCγ2 








Figure 4.3.2 WT DT40's express Btk and PLCγ2 
WT DT40’s and Btk KO DT40’s were allowed to adhere to poly-L-Lysine before being 
fixed and permeabilised. Cells were stained with (A) rabbit anti-Btk, (B) rabbit IgG control, 
(C) rabbit anti-PLCγ2, (D) goat anti-Btk or (E) Goat IgG. Samples were stained with 
secondary antibody Alexa Fluor 647 conjugated donkey anti-rabbit or Alexa Fluor 647 




4.3.3 Btk does not require a functional kinase domain to signal 
downstream of GPVI. 
As mentioned above, B cell receptor signalling does not appear to require the kinase 
function of Btk in some experiments (Table 4.1.1).  We performed similar experiments to 
identify whether the kinase function was required for GPVI or CLEC-2 signalling.   
Kinase dead (KD) Btk has a point mutation at position 430, the ATP binding site (Vihinen 
et al., 1994b) which leads to a change from a lysine to a glutamic acid (Mahajan et al., 
1995) – K430E. The change from a basic side chain amino acid to an acidic amino acid 
prevents ATP binding and this renders the kinase catalytically inactive (Mahajan et al., 
1995, Tomlinson et al., 2001).  
WT and mutant Btk sequences were created previously and supplied in the pApuroII 
plasmid by Dr Mike Tomlinson. Samples were maxi prepped and WT and mutant Btk 
sequences were verified using Sanger sequencing (Eurofins genomics). The change in 
amino acid at site K430 to E can be visualised in Figure 4.3.3. Primers used for 
sequencing are listed in Table 4.3.1. 
Btk-deficient DT40 cells were transfected with WT or KD Btk, NFAT-luciferase and the 
appropriate receptors or empty vector controls. Cells were incubated for 6 hours in the 
presence or absence of collagen (10µg/mL), followed by lysis and an assay for 
luminescence (Figure 4.3.4). Btk-deficient cells transfected with GPVI, FcRɣ chain and 
NFAT-luciferase plasmids did not induce signalling when stimulated with collagen (data 
not shown). Cells were also stimulated with PMA and Ionomycin for 6 hours to verify 
transfection of the NFAT-luciferase construct (data not shown).  
Cells deficient in GPVI but transfected with WT Btk were unresponsive to collagen. 
Compared to the basal controls, a clear increase in signalling can be seen following 
collagen stimulation in the presence of WT Btk.  KD Btk also allows signalling by GPVI, at 




The level of WT and KD Btk expressed in the Btk deficient cells was analysed by SDS 
PAGE followed by western blotting. Both the WT and KD Btk were expressed at equal 
levels when the same amount of plasmid DNA was transfected into the cells (Figure 
4.3.4.B). Flow cytometry was also performed to assess the levels of GPVI on the surface 
to verify any differences in level of signalling was not related to receptor expression level. 
20 hours post transfection, cells were washed and stained with anti-GPVI antibody, 1G5 
before washing and then secondary staining with Alexa Fluor 488 goat anti-mouse 
antibody. Figure 4.3.4.C shows that there is no significant difference between the levels of 
the receptor between the two Btk constructs and therefore differing levels of signalling are 
related to the kinase function of Btk.  
 





Figure 4.3.3 K430E plasmid has the mutation 
K430E Plasmid was sequenced using primers listed in Table 4.3.1 using Sanger 
sequencing (Eurofins tubeseq sequencing service). The appropriate mutation was 
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confirmed by translating DNA into protein using EMBI EMBOSS Transeq (Rice et al., 





Figure 4.3.4 Kinase dead Btk is sufficient for GPVI signaling 
 (A) Btk deficient DT40 cells were transfected with GPVI, its binding partner FcRɣ and NFAT-luciferase plasmids. These cells were also 
transfected with either wild type (WT) or kinase dead (KD) Btk. Transfected cells were then stimulated with the GPVI agonist collagen (10 
μg/mL). Luciferase activity was compared using Two-way ANOVA with a Dunnett’s multiple comparisons post-test. **p ≤ 0.01. Graph 
represents mean ± SEM, n=4. (B) Representative western blot showing equal Btk expression in WT and KD transfected cells. (C) Post 
transfection as described in (A) Cells were washed and stained with 1G5 anti-GPVI antibody (10μg/mL) followed by secondary staining with 
goat anti-mouse Alexa Fluor 488 (1/500) and washing antibody to assess receptor levels post transfection using flow cytometry.  
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4.3.4 Btk requires a functional kinase domain to signal 
downstream of CLEC-2 
As shown in Figure 4.3.4, a functional kinase domain is not required to mediate signalling 
downstream of GPVI/FcRɣ, an ITAM containing receptor.  To investigate if an active Btk 
kinase domain is required for platelet hemITAM signalling the same experiment was 
carried out using CLEC-2.  
Btk deficient DT40 cells were transfected with the WT or KD Btk, NFAT-luciferase 
plasmids and the CLEC-2 plasmid or empty vector controls as previously described. Cells 
were stimulated for 6 hours in the presence of basal medium or rhodocytin (50nM) before 
lysis and luminescence assayed (Figure 4.3.5.A). Btk deficient cells transfected with 
receptor and NFAT-luciferase alone did not induce signalling when stimulated with 
rhodocytin (data not shown), consistent with the work of Fuller et al., 2007.  Flow 
cytometry was used to confirm equal expression of CLEC-2 and western blotting was 
used to show equal expression of WT and KD Btk constructs. Cells were also stimulated 
with PMA and Ionomycin for 6 hours to verify transfection of the NFAT-luciferase 
construct (data not shown).  
Cells deficient in Btk or which do not express CLEC-2 were unresponsive to rhodocytin. 
WT Btk allows signalling downstream of CLEC-2 (Figure 4.3.5.A) when compared to 
basal controls (transfected receptor and WT Btk, but no stimulation with agonist), with 
relative luciferase activity being significantly increased for the rhodocytin treated cells  
(***p ≤ 0.001). Kinase dead Btk does not induce signalling downstream of CLEC-2 when 
compared to basal treated cells. When compared to WT Btk + CLEC-2 and stimulated 
with rhodocytin there is a statistically significant reduction in the amount of signalling (***p 
≤ 0.001). This shows that in a cell line model, CLEC-2 signalling requires a functional Btk 
kinase domain.  
The level of Btk expressed in the cells post transfection was assessed by cell lysis, SDS 
PAGE and western blotting. Both the WT and KD Btk were expressed at equal levels 
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when the same amount of WT and KD plasmid DNA was transfected in (Figure 4.3.5.B). 
Flow cytometery was also performed to assess the levels of CLEC-2 receptor. Post 
transfection, cells were washed and stained with anti-CLEC-2 antibody, AYP1 before 
washing and then secondary staining with anti-mouse Alexa Fluor 488 antibody. Figure 
4.3.5.C shows that there is no significant difference between the levels of the receptor 
between the two Btk constructs and therefore differing levels of signalling are related to 





Figure 4.3.5 The kinase domain of Btk is required for CLEC-2 signalling 
(A) Btk deficient DT40 cells were transfected with CLEC-2 and NFAT-luciferase plasmids and either wild type (WT) or kinase dead (KD) Btk. 
Transfected cells were then stimulated with the CLEC-2 agonist rhodocytin (50nM). (A) Luciferase activity was compared using Two-way 
ANOVA with a Dunnett’s multiple comparisons post-test. ***p ≤ 0.001. Results shown are mean ± SEM, n=3. (B) Representative western blot 
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showing equal Btk expression in WT and KD transfected cells. (C) Cells were stained were washed and stained in AYP1 (10μg/mL) anti-CLEC-
2 antibody and anti-mouse Alexa Fluor 488 secondary antibody to assess receptor levels post transfection.  
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4.3.5 Ibrutinib and acalabrutinib do not inhibit GPVI mediated 
signalling. 
Ibrutinib and acalabrutinib are inhibitors of the kinase domain of Btk (Byrd et al., 2016, 
Byrd et al., 2013). We hypothesise that ibrutinib and acalabrutinib will render WT Btk 
kinase dead, verifying previous results (Figure 4.3.4). As cells with Btk KD already have 
no kinase function, if any further inhibition of signalling is observed in these cells, it may 
suggest alternative kinases are also being targeted by the drug; DT40s also express other 
potential ibrutinib targets, namely Fyn, Lyn and Syk (Watanabe et al., 2001, Takata et al., 
1995, Takata and Kurosaki, 1996). 
Btk deficient DT40 cells were transfected with WT Btk or KD Btk, as well as GPVI/FcRγ 
and NFAT luciferase plasmids as described in Section 4.3.3. Ibrutinib and acalabrutinib 
were incubated with the cells and collagen agonist for 6 hours.  Unlike the experiments 
above, serum free media was used to ensure that the drugs do not become protein bound 
(Scheers et al., 2015). 
High concentrations of ibrutinib (10µM) significantly inhibited signalling downstream of 
GPVI with both WT and KD Btk (**p ≤ 0.01). Similar reductions in relative luciferase 
activity were observed in kinase dead Btk transfected cells compared with vehicle treated 
cells, with ibrutinib treated values similar to basal responses (Figure 4.3.6.A). There was 
no difference in the signalling when the lower concentrations of ibrutinib were compared 
to vehicle for both the WT and KD versions of Btk. When unstimulated cells containing 
WT Btk were compared to lower concentrations of ibrutinib and collagen, 5μM and 0.5μM 
ibrutinib treated cells did elicit signalling when stimulated with collagen (*p ≤ 0.05 and **p 
≤ 0.01). This provides further evidence that Btk can signal independently of its kinase 
function downstream of GPVI. The inhibition seen with high concentrations of ibrutinib is 
likely mediated through off target effects on SFK’s (chapter 3) (Bye et al., 2017, Patel et 
al., 2016, Series et al., 2019). 
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In contrast to ibrutinib, acalabrutinib did not significantly inhibit NFAT signalling 
downstream of GPVI in WT and KD transfected cells even at high concentrations (Figure 
4.3.6.B). WT Btk transfected cells stimulated with collagen in the presence of 10μM and 
5μM or vehicle control acalabrutinib signalled approximately twice more than basal 
samples (*p ≤ 0.05), further providing evidence that Btk can signal independently of its 
kinase function. In the kinase dead Btk transfected cells, vehicle treated cells had a 
greater relative luciferase activity compared to basal (**p ≤ 0.01), as previously seen 





Figure 4.3.6 A high concentration of ibrutinib inhibits GPVI signalling wheras 
acalabrutinib does not in a cell line model 
(A) Btk deficient DT40 cells were transfected with GPVI, its binding partner FcRɣ and 
NFAT-luciferase plasmids. These cells were also transfected with either wild type (WT) or 
kinase dead (KD) Btk. Transfected cells were then stimulated with the GPVI agonist 
collagen (10 μg/mL) in the presence of ibrutinib, acalabrutinib (10µM- 0.5µM), or vehicle 
control (0.1% (v/v) DMSO) for 6 hours. Luciferase activity was compared using two-way 
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ANOVA with a Tukey’s post-test. Results shown are mean ± SEM of 3 independent 
experiments. 
 
4.3.6 Ibrutinib and acalabrutinib inhibit signalling downstream of 
CLEC-2 
Previous experiments using a kinase dead version of Btk suggested that catalytic activity 
is required to mediate signalling downstream of CLEC-2 (Figure 4.3.4). Ibrutinib and 
acalabrutinib were used to inhibit catalytic activity of Btk to verify these previously 
obtained results were not an artefact of an overexpression model.  
Experiments were performed as described above, but with CLEC-2 (replacing 
GPVI/FcRɣ) or empty vector was transfected into the cells. Cells were treated the same 
as Section 4.3.5 except for the stimulation was performed with 50nM rhodocytin as 
opposed to collagen.  
Downstream of CLEC-2, WT signalling was significantly increased when compared to 
basal controls, as expected. When treated with either Btk inhibitor, WT signalling was 
significantly reduced compared to vehicle control for both ibrutinib (10-0.5µM) (p ≤ 0.001 
and p ≤ 0.01) (Figure 5C) and acalabrutinib (10 – 5µM) (p ≤  0.01) (Figure 4.3.7). The 
lowest concentration of acalabrutinib did not significantly inhibit signalling in WT cells.  
There were no significant changes downstream of CLEC-2 for kinase dead Btk as vehicle 
treated cells do not signal when compared to basal treatment (Figure 4.3.7). This further 
verifies that Btk cannot induce signalling downstream of CLEC-2 without a functional 







Figure 4.3.7 Ibrutinib and acalabrutinib inhibit CLEC-2 signalling in a cell line model 
Cells were transfected as above and stimulated with the CLEC-2 agonist rhodocytin 
(50nM) in the presence of ibrutinib, acalabrutinib (10µM- 0.5µM), or vehicle control (0.1% 
(v/v) DMSO) for 6 hours. Luciferase activity was compared using two-way ANOVA with a 
Tukey’s post-test. Results shown are mean ± SEM of 3 independent experiments. 
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4.3.7 The PH, SH3 and SH2 domain of Btk are required to mediate 
signalling downstream of GPVI. 
As a functional kinase domain of Btk is not required to mediate signalling downstream of 
GPVI, experiments were performed to identify which other functional Btk domains are 
needed. It has been identified Tec needs both the PH and SH2 domain function to 
mediate signalling, but signalling could occur in a non-functional SH3 mutant (Tomlinson 
et al., 2004b). Therefore, it was hypothesised that like Tec, Btk requires its SH2 and PH 
domain activity to mediate signalling, but not its SH3 domain.  
Each domain was rendered non-functional using a point mutation. The phenylalanine 
substitution of a tryptophan at position 124 (W124F) induces a non-functional PH domain, 
which is no longer able to bind inositol phosphates (Figure 4.3.8.A). There is a double 
tryptophan residue within the SH3 domain that when switched to leucine (WW251/2LL) 
renders this domain inactive (Figure 4.3.8.B). This domain is no longer able to bind 
proline rich regions. At site 307, there is an arginine in WT Btk SH2 domain. To render the 
SH2 domain non-functional, and therefore unable to bind phosphotyrosines, a mutation 
from arginine to lysine is introduced (R307K) (Takata and Kurosaki, 1996), (Figure 
4.3.8.C).  These Btk mutations were provided in a plasmid from Dr Mike Tomlinson, and 
sequencing was performed using the primers listed in Table 4.3.1. 
Cells transfected with WT Btk, signal downstream of GPVI as shown above, when 
compared to basal treated cells. Cells that were transfected with any of the other domain 
mutants failed to signal downstream of GPVI when compared to basal (Figure 4.3.9.A). 
Furthermore, there was a significant inhibition of signalling compared to WT collagen 
treated cells (p ≤ 0.001).  
To verify that the lack of signalling was not down to differences in the level of protein 
expression, cells were lysed and protein expression was assessed by western blotting. 
Levels of the PH* and the SH3* mutant are similar. The SH2* mutant does not express as 
well as the others (Figure 4.3.9.B). 
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Taken together, these results suggest that to mediate signalling downstream of GPVI, 







Figure 4.3.8 PH, SH3 and SH2 domain mutant plasmids have the mutation expected 
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(A) W124F, (B) WW251/2LL and (C) R307k plasmids were sequenced using primers listed in Table what using Sanger sequencing (Eurofins 
tubeseq sequencing service). The appropriate mutation was confirmed by translating DNA into protein using EMBI EMBOSS Transeq (Rice et 





Figure 4.3.9 The PH, SH3 and SH2 domains of Btk are required to mediate GPVI signalling 
(A) Btk deficient DT40 cells were transfected with GPVI, FcRɣ chain and NFAT-luciferase plasmids. These cells were also transfected with 
either wild type (WT), PH (PH*), SH3 (SH3*) or SH2 (SH2*) domain inactivating mutants. Btk transfected cells were then stimulated with the 
GPVI agonist collagen (10 μg/mL).  Luciferase activity was compared using Two-way ANOVA with a Dunnett’s multiple comparisons post-test. 
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***, ****p ≤ 0.001. Results shown are mean ± SEM, n=4. (B) Representative western blot showing reduced expression of the SH2 domain 
mutant of Btk.  
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4.3.8 The PH, SH3 and SH2 domain of Btk are required to mediate 
signalling downstream of CLEC-2. 
As WT and KD Btk downstream of GPVI could mediate signalling, and all other functional 
domains were required (Figure 4.3.4 and Figure 4.3.9), this was also investigated 
downstream of CLEC-2. The kinase domain is absolutely required to mediate signalling, 
and therefore it was hypothesised that not all other functional domains may be required.  
Experiments were performed as previously described except for CLEC-2 being 
transfected as opposed to GPVI and its binding partner FcRɣ chain.  As seen previously, 
WT Btk in the absence of receptor did not induce signalling. When CLEC-2 is co-
transfected with WT Btk, there is a large increase of signalling compared to basal (p ≤ 
0.001). As seen with GPVI, none of the non-functional domain mutants induced signalling 
when compared to its own basal value. Furthermore, there is a significant decrease in the 
amount of signalling observed between the WT and different domain mutants when 
transfected in with CLEC-2 and stimulated with rhodocytin. This suggests that the PH, 








Figure 4.3.10 The PH, SH3 and SH2 domains of Btk are required to mediate CLEC-2 
(A) Btk deficient DT40 cells were transfected with CLEC-2 and NFAT-luciferase plasmids. 
These cells were also transfected with either wild type (WT) or PH (PH*), SH3 (SH3*) or 
SH2 (SH2*) domain inactivating mutants. Btk transfected cells were then stimulated with 
the CLEC-2 agonist rhodocytin (50 nM). Luciferase activity was compared using Two-way 
ANOVA with a Dunnett’s multiple comparisons post-test. ****p ≤ 0.001. Results shown are 

















































































4.3.9 Generation of a Btk deficient DT40 cell line using CRISPR-
Cas9 gene editing  
As the previous cell line work involved the overexpression of Btk in Btk deficient DT40 
cells, CRISPR-Cas9 genome editing was used to ensure the signalling observed is not 
due to overexpression of the protein. It also eliminated the requirement of a KO cell line 
and transfection of Btk back into the cells. Although DT40’s have been genetically 
modified using homologous recombination to create knockout cell lines (Takata and 
Kurosaki, 1996, Takata et al., 1995, Kurosaki et al., 1994, Takata et al., 1994), there is 
limited published research using CRISPR-Cas9 technology with DT40 cells (Abu-Bonsrah 
et al., 2016, Wang et al., 2019a, Costello et al., 2019). Prior to the use of CRISPR-Cas9 
to introduce point mutations into Btk, CRISPR-Cas9 was used to generate a Btk KO as a 
proof of concept and validate the Btk KO generated by Takata and Kurosaki (Takata and 
Kurosaki, 1996). 
Figure 4.3.11.A shows the design of the knockout guide RNA’s. Deskgen software was 
used to select a target (Hough et al., 2016). Targets were selected based on the lowest 
off-target effects, which is calculated using the Hsu algorithm (Hsu et al., 2013). If guides 
had an equal off-target effects, the guide with the increased activity was selected. Activity 
is defined as how likely the Cas9 nuclease is to induce double strand breaks when paired 
with the guide (Doench et al., 2016). As multiple transcripts were listed for Btk – exon 3 
was the first exon to have a consensus sequence, therefore guides were targeted there. 
For knockouts, guides are selected for early exons as the double stranded break (DSB) 
will be repaired by (non-homologous end joining) NHEJ causing an indel (insertion–
deletion mutations). This will result in a frameshift leading to a premature stop codon. 
Most likely, this will lead to no protein being translated, however if the protein is still able 




Guides are purchased as single stranded oligonucleotides termed SHN01, SHN02 up to 
SHN06 and were targeted to exon 3 and designed by adding compatible BpiL overhangs 
(5’CACCG, 3’CAAA) as displayed in Figure 4.3.11. The guides are annealed together and 
phosphorylated using T4 polynucleotide kinase using the thermocycling conditions shown 
in 4.3.11.B   
Once annealed together the guide oligos are cloned in the host plasmid pspCas9(BB)-2A-
Puro (Ran et al., 2013) (Figure 4.3.11.C), which was  digested overnight using BpiL 
before running on 1% agarose gel to confirm that the vector has been linearised (Figure 
4.3.11.D) before gel extraction. The host plasmid also contains antibiotic resistance for 
cells (puromycin) and E. coli (ampicillin) and the Cas9 protein (shown in purple in the 
plasmid).    
Guide RNA’s and host plasmid were annealed overnight before transformation into DH5α 
E. coli. Positive colonies were selected and sequenced using the U6 forward primer to 
ensure the guide RNA’s had been inserted as shown in Figure 4.3.12. These plasmids 
were termed SHN0102 and SHN0304. Guides were designed for SHN0506 but after 
sequence verification of multiple colonies, the guide was not present and therefore this 
plasmid was no longer used.  
According to the previous study where DT40 cells were genome engineered using 
CRISPR-Cas9 (Abu-Bonsrah et al., 2016), 30µg of each respective SHN plasmid was 
transfected into WT DT40 cells. Also, in line with the previous study, conditions for 
transfection were slightly different than the overexpression experiments due to the large 
amount of DNA being transfected – conditions were 300kV, 900μF.   
Cells were stably selected using puromycin, where cells with the integrated plasmid 
gained exhibiting resistance to this ribosome-inhibiting antibiotic, were expanded from 
single colonies. Initial selection was performed in 96-well plates with complete media 
supplemented with 2µg/mL puromycin, for approximately 1-2 weeks. If a single colony 
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was present, cells were expanded slowly (from a 24 well plate to a 6 well plate over 
approximately 2 weeks) until they could be sampled for protein expression.  
Lysates were made as previously described and samples were subjected to SDS-PAGE 
and western blotting for Btk. As Figure 4.3.13.A shows, guides SHN0102 and SHN0304 
resulted in a knockout of Btk.  
To verify the knockout behaved similarly to previous knockouts, the NFAT-luciferase 
assay was employed. SHN0102 clone 16 was transfected with 5µg of WT Btk or empty 
vector control, along with NFAT and the GPVI/FcRɣ constructs as previously described. 
Cells transfected with GPVI and FcRɣ chain and empty vector control did not signal 
downstream of GPVI, consistent with previous KO results (Section 4.3.3).  When the cells 
are transfected with WT Btk in addition to GPVI and FcRɣ, signalling does occur 
downstream of GPVI (4.3.13.B). This suggests that the cells were not damaged during the 
protein knockout process as it is known that CRISPR-Cas9 guides can have off target 






Figure 4.3.11 The CRISPR-Cas9 design strategy to create a Btk knockout 
Guides used to create a Btk knockout cell line were selected using Deskgen (Hough et 
al., 2016), and guides with the least off target effects were selected. (A) The first common 
exon across all variants was targeted to have the shortest chance of target effects despite 
their activity. BpiL overhangs were manually added to the oligos to ligate into the plasmid 
as shown in (C). (B) Oligos were annealed and phosphorylated using the thermocycling 
conditions, using T4 Polynucleotide Kinase (PNK). (C) pSp-Cas9(BB) plasmid has the 
BpiL site highlighted as to where the restriction enzyme will cut. (D) 1μg of plasmid shown 
in was digested with Bpil overnight at 37°C before running on a 1% agarose gel to confirm 




Figure 4.3.12 The cloning of the selected guides into the plasmid and verification 
by sequencing that the insert is present. 
The guides were selected based on their least off target effects, with all off target effects 
being above 80. Guides were cloned into psp-Cas9 as described above before being 




Figure 4.3.13 CRISPR-Cas9 can be utilised to generate Btk knockouts in DT40 cells 
and these knockouts behave as other Btk KO’s.   
(A) Stable cell mutants were lysed using 1x RIPA buffer and protease inhibitors before 
being subjected to western blotting. SHN0102 and SHN0304 guides produced knockout 
mutants when assessed for Btk. (B) SHN0102 clone number 16 was transfected with 5µg 
of WT Btk or empty vector control, along with NFAT and the GPVI/FcRɣ constructs as 
previous. Cells were then stimulated with the GPVI agonist collagen (10 μg/mL) or PMA 
and Ionomycin for 6 hours. Luciferase activity was compared using Two-way ANOVA with 
a Dunnett’s multiple comparisons post-test. **p ≤ 0.01. Results shown are mean ± SEM of 
two independent experiments. 
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4.3.10 Btk gene is evolutionary conserved and sites for function 
altering CRISPR-Cas9 knockin mutations are present in Chicken 
Btk.  
Previous experiments performed in this study and in the literature use overexpression of 
protein to investigate the role of Btk’s domains in cell signalling. Overexpression of protein 
can change the mechanism of cell signalling orchestrated by that protein for a variety of 
reasons (Moriya, 2015). Overexpression of a protein may alter normal protein:protein 
interactions therefore it may not be able to interact with its proposed partner. Using 
CRISPR-Cas9 gene editing involves the introduction of mutations into the protein without 
intentionally changing the expression levels. The protein expression remains under the 
control of the endogenous promoter. However, some changes to expression level may 
still be possible due to protein instability. This may result in a lower expression, but the 
protein is not being continually expressed as it would be in an expression plasmid. 
To induce function altering point mutations in each of Btk’s domains using CRISPR-Cas9 
knockins, sequences from multiple species were aligned. This was to confirm that the 
function altering mutations previously used in Sections 4.3.3 to 4.3.8 (W124F, 
WW251/2LL, R307K, and K430E) are also present in chicken Btk. This allowed for the 
appropriate sites to be selected for designing of guide RNAs.   
Btk protein sequences from a range of species were aligned using T-coffee (Notredame 
et al., 2000) and presented with ESPrit 3 (Robert and Gouet, 2014) to assess similarity 
between the sequences (Figure 4.3.14). Simple Module Architecture Research Tool 
(SMART) software was utilised to identify the location of each Btk domain (Letunic et al., 
2015).   
Btk is largely conserved across the species, with some minor differences between 
chicken (Gallus gallus) and Zebrafish (Danio rerio), such as a large area missing within 
the pleckstrin homology domain of Zebrafish. The key regulatory Btk tyrosine 
phosphorylation sites, Y223 and Y551 are shown inside a black box, highlighting their 
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conservation. Another key site in Btk is C481, which is highlighted by an arrow. This is 
where Btk inhibitors such as ibrutinib and acalabrutinib bind, and once again this is 
evolutionary conserved (Covey et al., 2015). Interestingly, although this site is conserved, 
patients can become resistant to these drugs due to mutation of this C suggesting that 
although it is important due to it being conserved, alternative amino acids can be 
substituted at this site (Johnson et al., 2016, Woyach et al., 2017, Wist et al., 2020). 
The sites of Btk function altering mutations previously used in above experiments 
(W124F, WW251/2LL, R307K and K430E) were generally found to also be conserved 
across species. WW251/2 is conserved in chicken, it is at WW249/250, due to slight 
length differences in the sequence between human, mouse, and chicken Btk. 
Nonetheless, the sites were conserved across human, mice and chickens, therefore these 










Figure 4.3.14 Btk is evolutionary conserved and CRISPR-Cas9 target sites are 
present in chicken Btk 
Btk sequence alignment was analysed with T-Coffee and presented with ESPrit 3. 
Domains were identified using SMART. Red areas are strict areas of common identity, 
areas in yellow are similarity of amino acids across groups. Blue boxes represent sites of 
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mutagenesis and black boxes are Btk phosphorylation sites. The arrow represents where 
ibrutinib and acalabrutinib bind to Btk.  
 
4.3.11 Design of CRISPR-Cas9 donor sequence for function 
altering knockin mutations in Chicken Btk  
After identifying the conserved targets of W124F, WW249/50LL, R307K and K430E 
through sequence alignment, guide RNA’s and donor sequences as the repair template 
for homologous recombination for knock-ins were designed.  
Deskgen software was used to generate the donor sequence with the changed DNA 
codons to cause a protein point mutation, such as changing from TGG (W) to TTC (F) 
(Table 4.3.2). A silent mutation was manually introduced to the donor sequence within the 
PAM site to destroy it. A silent mutation is when the nucleotide sequence of the DNA is 
altered but the amino acid sequence is not changed due to the redundancy of the triplet 
code. If the PAM site within the donor sequence is not mutated, the Cas9 protein will keep 
cutting the DNA resulting in a knockout. If the PAM site cannot be changed, the guide 
sequence can also be modified to prevent continuous cutting of the DNA. Furthermore, a 
silent mutation which created or destroyed a restriction enzyme site was introduced into 
the donor sequence. This was designed to enable a rapid method of screening mutants 
after DNA extraction and PCR amplification.  
Guides were picked as close to the point mutation as possible, as the greater the distance 
between the DNA cut to the position of the mutation leads to a reduction in efficiency. 
Guides were prepared as previously described (Section 4.3.9) and donor sequences were 
ordered from eurofins genomics and sequence verified. DH5α E. coli were transformed 
with 1μL of donor sequence plasmid and subsequent colonies were maxi prepped. 
A restriction enzyme digest was performed to verify that the plasmids contained the 
300bp donor sequences prior to transfection. Digests were performed overnight with KpnI 
and BamHI-HF. Figure 4.3.15 shows that there is an insert of 300bp.  
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Table 4.3.2 Donor sequences for Btk CRISPR-Cas9 knockins 
 
 
Figure 4.3.15 Donor plasmids contain the designed 300bp insert 
Plasmid DNA was digested overnight at 37°C with BamHI and KpnI before being run on a 
1% agarose gel stained with Sybrsafe. Images were taken on transilluminator (Syngene, 
Cambridge UK).   
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4.3.12 CRISPR-Cas9 did not induce function altering knock-ins in 
the Btk PH, SH3 pr kinase domain. 
For the initial knock-in experiments, DT40 cells were transfected with 15μg guide RNA 
plasmid, and 15μg of circular donor plasmid. All the stable cell colonies resulted in a Btk 
protein knockout. This is likely due to the transfection with a circularised donor plasmid 
which may fail to integrate into the cell as efficiently (Liu et al., 2018). The next approach 
was to linearize the donor plasmid in order to increase the efficiency of homology directed 
repair (Ran et al., 2013), as circular plasmids may be broken at random points within the 
plasmid in order to become integrated (Song and Stieger, 2017). This random breaking of 
plasmid may be in the area of the donor sequence and therefore disrupt the HDR.  
Donor plasmid was linearized with EcoRI-HF. DT40 cells were transfected with 15μg 
guide and 15μg linearized donor sequence. Subsequent plating out and stable clone 
selection was as previously described (Section 4.3.9). 
As Table 4.3.3 demonstrates, K430E and WW251/2LL knock-in experiments did not yield 
any stable cell colonies. The R307K KI strategy produced 11 potential mutant clones. 
Additionally, the PH domain mutation, W124F did also produce 3 potential mutant clones. 
Western blotting was performed to identify the presence of Btk before further analysis. 
These samples were analysed alongside a WT DT40 lysate, a platelet lysate and a Btk 
KO DT40 lysate to act as positive and negative controls, respectively.  
Figure 4.3.16 A+B shows that R307K KI strategy produced Btk knockouts with no Btk 
protein expression visible using western blotting in 9/11 cell lines (Figure A, B and data 
not shown). Only 3 stable cell line mutants were obtained in the time frame for W124F 
mutants with protein expression being undetectable by western blot (Figure 4.3.17.A). 
Mutants R307K 1D and 1H expressed full length Btk but to a lesser extent compared to 
WT cells. These clonal cell lines were taken forward and used in the NFAT luciferase 




Table 4.3.3 The number of viable cell colonies post stable selection 
Guide Number of stable cell colonies post transfection with linearised 
DNA 
Number of cell colonies that had Btk expressed when assessed by Western 
Blot.  
W124F 3 0 
WW251/2LL 0 0 
R307K 11 2 
K430E 0  0 
 
Figure 4.3.16 Expression of Btk post transfection with CRISPR-CAS9 R307K plasmids 
Lysates from single cell colonies were made by washing cells 1x in PBS before lysis in 1x RIPA buffer of a cell count of 1x107 cells. Cells were lysed 
for over 30 minutes before 6X SB was added and lysates boiled for 5 minutes before subjection to SDS-PAGE and western blotting with anti-Btk 
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antibody.  Anti-Tubulin antibody was used as a loading control. Lysates of colonies of cells that were transfected with plasmids to induce knockins of 
(A) W124F  or (A,B) R307K.
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4.3.13 An amino acid deletion in the SH2 domain renders Btk 
unable to signal downstream of GPVI. 
The intended CRISPR-Cas9 mutation was to substitute the amino acid arginine at 
position 307 to a lysine as described above. DNA was extracted from WT cells, and 
mutants 1D and 1H cells using alkaline lysis (Kambe, 2014, Laird et al., 1991). 
Touchdown PCR was performed to amplify the mutated region of interest using primers 
(R307KFWD, 5’ GTCACTTCCTCACAAATACCCC and R307KREV 5’ 
ATACAACGTAATGGCGGATCAT) and DNA electrophoresis was performed to confirm 
the band was at the correct size (286bp). After the PCR band was extracted using a gen 
elute gel extraction kit, the DNA was sequenced using the R307K FWD primer. 
Sequencing was performed by Eurofins genomics.  
The DNA sequencing results are presented in Figure 4.3.17.B, with the guide (labelled as 
guide) and the ordered donor (labelled as donor) sequence shown. The Black AAG in the 
donor sequence was the intended mutation, however, it was not present in the D or H 
cellular DNA. In D, 6 DNA bases were missing, and in H, 3 DNA bases were missing. The 
T in the donor Section was also the mutation of the PAM site which would have been a 
silent mutation, however that was also not integrated into the mutants’ DNA.  
When the resulting DNA is transcribed into amino acids, D is missing a serine and lysine, 
whereas in H, only the lysine is missing at sites homologous to human S310 and K311 
respectively (Figure 4.3.17.C). As there is more published literature on the role of human 
Btk than Chicken Btk, the homologous sites in humans was first investigated in Btkbase 
(Väliaho et al., 2006, Vihinen et al., 1996). There were no published mutations within 
Btkbase for these domains (Väliaho et al., 2006, Vihinen et al., 1996). 
Experiments were performed to identify whether if the SH2 domain mutations would 
cause a reduction or loss of signalling downstream of GPVI. NFAT-luciferase experiments 
were performed as previously described. Briefly, WT, D or H mutant cell lines were 
transfected with GPVI, FcRɣ chain and NFAT or empty vector controls. As shown in 
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Figure 4.3.17.D, only WT DT40 cells transfected with GPVI and FcRɣ chain were able to 
signal (p ≤ 0.001) compared to its basal control. No signalling was observed in either of 
the R307 mutants compared to its own basal value. R307 mutant H did have a slight 
increase in signalling in the presence of receptor and collagen, (2.04 ± 0.9) however, this 
was not found to be statistically significant. 
To verify the lack of signalling in the R307 mutants 1D and 1H cells was not due to 
differences in the surface expression levels of GPVI, flow cytometry analysis was used as 
previously described, (Section 4.3.3).  All transfected cells displayed similar levels of 
GPVI at the cell surface, Figure 4.3.17.E. This demonstrates that the lack of signalling in 
the mutants is not related to lack of GPVI receptor. 
To verify the process of CRISPR-Cas9 gene editing did not have any off-target effects 
and therefore explain the lack of observed signalling, experiments were performed by 
reconstituting Btk back into the cell. This would be expected to rescue the signalling 
downstream of GPVI. 
H mutant cells and WT cells were transfected with GPVI and FcRɣ and NFAT plasmids 
and 5μg of Btk or empty vector control. 5μg was selected as it was the amount previously 
utilised in the knockout experiments and it is known that this should induce a signal 
downstream of GPVI (Section 4.3.3). The NFAT luciferase assay was performed as 
previously descried. 
WT cells transfected with FcRɣ and GPVI signal well when stimulated with collagen, with 
the empty vector not reducing this signalling. Also like previous experiments, H did not 
signal when stimulated with collagen, despite receptor being transfected in. In mutant 
cells that were also transfected with Btk, signaling was restored in the presence of 
collagen (p ≤ 0.05) (4.3.17.F). Furthermore, this level of signalling was not significantly 
different to the amount of WT signalling observed. Increased expression of Btk was 






Figure 4.3.17 R307K KI strategy resulted in two amino acid deletions that render 
Btk inactive downstream of GPVI 
(A) WT, D and H DNA was extracted using alkaline lysis and then touchdown PCR was 
performed using primers R307KFWD, 5’ GTCACTTCCTCACAAATACCCC and 
R307KREV 5’ ATACAACGTAATGGCGGATCAT and resulting PCR was subjected to 
DNA electrophoresis. (B) Sequencing results of the PCR bands with the guide, D, H WT, 
and donor sequence of DNA present with the KI site, guide and PAM site labelled. (C) 
The transcribed protein sequence showing the absence of one or two amino acids in H or 
D, respectively. (D) SH2 domain CRISPR-Cas9 mutants (D, and H) were transfected with 
GPVI, FcRɣ chain and NFAT-luciferase plasmids.  Transfected cells were then stimulated 
with the GPVI agonist collagen (10μg/mL) or complete media (basal). Luciferase activity 
was compared using Two-way ANOVA with a Dunnett’s multiple comparisons post-test. 
****p ≤ 0.001. Results shown are mean ± SEM, n=3. (E) Surface GPVI levels were 
determined by staining transfected cells with 1G5 anti-GPVI antibody followed by 
secondary staining with Goat anti-mouse Alexa fluor 488. (F) WT cells and SH2 domain 
CRISPR-Cas9 mutant H were transfected with GPVI, FcRɣ chain and NFAT-luciferase 
plasmids. Mutants H were also transfected with WT Btk (5μg) or empty vector control. 
Transfected cells were then stimulated with the GPVI agonist collagen (10μg/mL), 
complete media (basal) or PMA (50ng/mL) plus ionomycin (1 μM). Luciferase activity was 
compared using Two-way ANOVA with a Dunnett’s multiple comparisons post-test. ****p 
≤ 0.001. Results shown are mean ± SEM, n=3. (G) Western blot of the cells post 









4.4 Discussion  
Using a cell line model for platelet signalling, the following aims were attempted to be 
addressed in this chapter.  
4.4.1 Aim -To elucidate which domains of Btk are required to 
mediate NFAT-Luciferase signalling downstream of GPVI and 
CLEC-2 using an overexpression model 
4.4.1.1 DT40’S as a model for platelet signalling 
DT40 cells are a useful model to investigate platelet signalling. They are cost-effective 
and easy to culture, with growth being rapid therefore experiments can be performed at a 
sensible speed. Furthermore, unlike platelets they contain a nucleus, so they are 
genetically tractable.  Despite being a B-cell line, they have strong similarities to platelets; 
they are suspension cells that can undergo spreading (Weber et al., 2008) and contain 
many of the proteins that are required in (hem)ITAM signalling (Kurosaki et al., 1994, 
Takata and Kurosaki, 1996, Takata et al., 1994).  
There is some controversy whether DT40 cells express Tec. Tec is present in B cells and 
in some human B cell lines, but not all. In one paper, Tec is believed to be expressed in 
DT40 cells (Tomlinson et al., 2004b), whereas in another paper by the same authors Tec 
is not believed to be expressed in these cells (Tomlinson et al., 1999). Furthermore, 
evidence has emerged that in some leukemic cell lines (not DT40s) expression of Btk and 
Tec are inversely correlated with each other (de Bruijn et al., 2017).   
The DT40 genome is published, however the genomic data is presented as scaffolds as 
opposed to whole genes. When Btk is searched, it is found as a scaffold with only one 
result and an E value of 0 which suggests it is present. Tec however similarly has a low E 
value but has some similar but not exact matches in the proteome. This may be due to the 
similarity of SH2 domains across different proteins. However, from the genomic data of 
this cell line it is also not clear that Tec is present in these cells.  
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In this research, Tec was undetectable in WT or Btk deficient DT40 cells using western 
blotting (Figure 4.3.1). This suggests that Tec is not expressed in the absence of Btk in 
these cells. Although these cells do not contain Tec like platelets (Figure 4.3.1), it does 
provide evidence that the signalling observed in later experiments is likely directly related 
to Btk and not compensation of Tec.  
 
4.4.1.2 The use of the NFAT luciferase assay to measure intracellular signalling 
downstream of GPVI and CLEC-2 
The NFAT- luciferase-reporter assay is a highly sensitive assay used to measure 
signalling when calcium flux may not be measurable following PLCγ2 activation in DT40 
cells (Tomlinson et al., 2007, Takata and Kurosaki, 1996, Tomlinson et al., 2001). The 
assay is a quantitative and relatively high throughput assay (i.e. 96-well plate format) after 
the cells have been transfected, allowing for multiple conditions to be tested at once, such 
as the treatment with ibrutinib and acalabrutinib observed in Figures 4.3.6 and 4.3.7.  
Other positives to the assay are that unlike fluorescence-based assays, there is a low 
background level, due to the presence or absence of light. Furthermore, the chemistry of 
the experiment (ATP + H20 -> Light) is relatively robust (Stecha et al., 2015). Failure of 
experiments tends to be at the transfection level such as the failure of receptor to be 
expressed on the surface of the cells, as opposed to the chemistry level. However, the 
use of the internal control, stimulation with PMA and ionomycin, which causes PKC 
activation and calcium flux, produces a large amount of light because of increased cell 
signalling when the cells are lysed. This ensures that the NFAT plasmid was successfully 
integrated into the cell, and low signalling values are not related to this and are related to 
the proteins mitigating the response.   
Although useful, the NFAT-luciferase assay does miss some interesting mechanics of 
signalling. The assay is an endpoint assay, over a long period of time when compared to 
platelet signalling. It is known that the location of Btk changes upon cell activation, but the 
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speed and dynamics are unknown (Bobe et al., 2001, Kang et al., 2001, Várnai et al., 
1999). As protein kinetics can have a valuable input to elucidating responses and roles, it 
would have been interesting to observe these experiments over a shorter time frame. The 
long-time frame is required to ensure proper transcription and translation of the luciferase 
plasmid before the cell assay is stopped by placing the assay plate at -80°C. An 
experiment with a shorter time frame, such as directly measuring Ca2+ flux may help to 
elucidate if the signalling can bypass Btk, for example, if PLCγ2 is independently recruited 
not via Btk. Although this is unlikely, as there is no signalling in the Btk deficient cells and 
receptor alone (Figure 4.3.11), so this suggests that signalling downstream of the 
hemITAM in this model requires Btk.  
4.4.1.3 What domains of Btk are needed to mediate signalling? 
In the Btk KO DT40 model of (hem)ITAM signalling, Btk is required. No NFAT-luciferase 
signalling is observed downstream of GPVI and CLEC-2 in its absence. This result is 
further confirmed by the CRISPR-Cas9 induced Btk KO’s in Figure 4.3.11. Furthermore, 
reconstitution of WT Btk back into these cells restores the signalling between basal and 
collagen when the receptor is present.  This suggests that Btk is required to mediate 
GPVI and CLEC-2 signalling in this cell line model.  
The pioneering structural biology work by the Andreotti group, discovered how Btk 
becomes active at the membrane. The structure of Btk is in a folded compact formation, 
and the SH2 domain has an acidic latch keeping the kinase domain in its inactive 
confirmation (Agnew and Jura, 2017, Joseph et al., 2017). The PH-TH domain module 
also contributes to this inactive and closed structure, and in this formation, the PH-TH 
domains are blocking the catalytic active site.  
Upon the production of phospholipids, where the PH-TH domains are recruited, the PH-
TH modules can spontaneously dimerize – so the PH-TH modules of one molecule of Btk 
binds to another PH-TH of another Btk molecule, and the PIP3 makes it more stable. This 
then enables the phosphorylation of one Btk molecule to another, to render it catalytically 
active (Chung et al., 2019). 
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For this mechanism of action to occur, a functional SH2, PH-TH and kinase domain are 
required, which is consistent with the results obtained in this study for CLEC-2. The SH3 
domain is required to keep the inactive confirmation but to a lesser extent, but it does 
suggest all domains of Btk are required to become active. Therefore, function altering 
point mutations in each Btk domain in an overexpression model were used to investigate 
this. 
 
4.4.1.4 The PH domain of Btk is required to mediate signalling downstream of 
GPVI and CLEC-2 
Trp124 is conserved across PH domains of Tec family kinases (Smith et al., 2001) and is 
required for the interaction of the Gβγ trimeric G proteins and phospholipids (Tsukada et 
al., 1994). The change of a tryptophan to phenylalanine renders this domain non-
functional (Li et al., 1995). Although both amino acids are aromatic, tryptophan has more 
polarbilisility than phenylalanine and can therefore bind other amino acids better.  
The recruitment of Btk to the signalosome is mediated by the PH domain of Btk in B cells 
(Fluckiger et al., 1998, Hyvönen and Saraste, 1997, Saito et al., 2001). Unsurprisingly, the 
results obtained in this study support this hypothesis as there is a lack of signalling 
observed in a function altering PH domain mutant. 
Indeed, there has been little work published suggesting that Btk signalling is independent 
of its PH domain in B cells, supported by numerous studies which show that the PH 
domain of Btk is essential (Li et al., 1995, Tsukada et al., 1994). 
The PH domain of Btk in mast cells and B cells can also interact with PKC (Johannes et 
al., 1999). A lack of NFAT signalling observed in these experiments (Sections 4.3.7 and 
4.3.8) may be related to this. Downstream of PKC signalling is MAPK signalling, which 
results in the activation of the AP-1 proteins which are required for NFAT signalling. In 
fact, Phorbol 12-myristate 13-acetate is used as a positive control to directly activate PKC 
for signalling (Clipstone and Crabtree, 1992, Dolmetsch et al., 1997). There may be a 
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required interaction for Btk and PKC via its PH domain to mediate signalling in the NFAT 
luciferase model, and in the mutant, this is abolished. This may also contribute to the lack 
of signalling observed in Figures 4.3.8 and 4.3.9. 
PH domain function has also been investigated indirectly in platelets and 
megakaryocytes. PIP3, produced by PI3K, is responsible for recruitment of Btk via its PH 
domain (Pasquet et al., 1999a, Laffargue et al., 1999, Bolland et al., 1998, Durrant et al., 
2017). It has been shown that Btk recruitment to the membrane fraction is dependent on 
PIP3 production, as using  PI3K inhibitors prevents translocation to the membrane 
fraction in GPVI (convulxin as an agonist) and CLEC-2 (rhodocytin as an agonist) 
stimulated platelets (Manne et al., 2015a). By preventing the interaction between PIP3 
and Btk, which results in reduced or abolished aggregation, it shows an indirect role for 
the PH domain downstream of GPVI and CLEC-2. These results in platelets that the PH 
domain is required validate the Btk overexpression model and strengthen the results that 
a functional PH domain is required for (hem)ITAM signal transduction. 
 
4.4.1.5 The SH3 domain of Btk is required to mediate signalling downstream of 
GPVI and CLEC-2.  
The double mutation of aromatic amino acid tryptophan to leucine at site 251/2 renders 
the SH3 domain of Btk non-functional. Tryptophan is an aromatic amino acid, whereas 
leucine is an aliphatic amino acid (Hashimoto et al., 1999a). This change from aromatic to 
aliphatic alters the binding capacity of Btk’s SH3 domain to proline rich regions.  
A functional Btk SH3 domain is required to mediate signalling downstream of both CLEC-
2 and GPVI (Figures 4.38 and 4.3.9). SH3 domains are responsible for mediating binding 
to proline rich regions, and it is believed that this is how Btk interacts with Lyn which is 
responsible for phosphorylation of Btk (Wahl et al., 1997). Btk needs to be phosphorylated 
to be catalytically active to mediate CLEC-2 signalling, therefore a functional SH3 domain 
is required (Figure 4.3.5). However, catalytically active Btk is not required to mediate 
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signalling downstream of GPVI (Figure 4.3.4). Therefore, it would not have been 
unreasonable to hypothesise that signalling would have been observed in the SH3 mutant 
downstream of GPVI, as it can act as a scaffold protein.   
In contrast to the results obtained here, work by Tomlinson and colleagues involving the 
related family member, Tec, identified that a functional SH3 domain of Tec is not required 
to mediate NFAT luciferase signalling downstream of the TCR (Tomlinson et al., 2004b). 
There was signalling observed in Jurkat cells transfected with a SH3 domain inactive 
version of Tec and stimulated with an anti-TCR antibody. This is in direct contrast to this 
work, as the SH3 domain mutant of Btk did not induce signalling downstream of hemITAM 
receptors (Figures 4.3.8 and 4.3.9). There are discrepancies between the experiments.  
Firstly, although Btk and Tec are within the same family of kinases, they can play different 
roles within the same cell. In mature B cells, Btk is thought to mediate PLCγ2 activation, 
whereas Tec is responsible for mediating Akt phosphorylation (de Bruijn et al., 2017), 
showing that the kinases can play different roles. Furthermore, the cell type used was 
different, as Jurkat cells were used as opposed to DT40’s and finally, the receptor used 
was different. As shown in Sections 4.3.3 – 4.3.6, the kinase domain is not required 
downstream of GPVI, whereas it is downstream of CLEC-2, so there may be differences 
downstream of the TCR also.  
The SH3 domain of Btk has also been proposed to be dispensable for PLCγ2 
phosphorylation in fibroblasts when cotransfected with Lyn. Deletion of this domain did 
not drastically alter the phosphorylation levels of PLCγ2 in these cells when compared to 
WT Btk. This suggests that PLCγ2 phosphorylation in fibroblasts is independent of the 
SH3 domain (Fluckiger et al., 1998). This is consistent with work using Tec by Tomlinson 
et al., but this finding is not consistent with the results obtained in this study. This may be 
related to the different cell models used. 
However, there is evidence that this domain may be essential in vivo, as fewer mutations 
within the SH3 domain have been identified in XLA patients (Väliaho et al., 2006, Vihinen 
et al., 1996). There are more mutations within the other domains. This suggests that the 
223 
 
domain cannot tolerate mutations as well and it may be essential for normal B cell 
function. Further evidence is provided for this as this Section of Btk is highly conserved 
across species (Figure 4.3.14).  
On the other hand, the reduced number of reported mutations within the SH3 domain 
could suggest that in vivo the domain does not participate in B cell signalling. If the SH3 
domain is not involved in regulation of signalling in B cells, there would be antibodies 
produced, and therefore there would be no symptoms of the disease. Typically XLA is 
diagnosed upon presentation of frequent infections, and therefore if signalling is regulated 
as normal, there would be no infections (Mohamed et al., 1999, Pal Singh et al., 2018, 
Väliaho et al., 2006).   
 
4.4.1.6 The SH2 domain of Btk is required to mediate signalling downstream of 
GPVI and CLEC-2 
The SH2 mutation of arginine to lysine at position 307 causes loss of function of the SH2 
domain of Btk (Li et al., 1995). This is due to the change in a positive polar side change 
from arginine, to the negative polar side chain of lysine.  The overall secondary structure 
is not changed by this mutation, however the function of binding to phosphotyrosines is 
lost (Mattsson et al., 2000).  
As Figures 4.3.9 and 4.3.10 demonstrate, the Btk SH2 domain is required downstream of 
CLEC-2 and GPVI. However, this mutant does not express as well as the other two Btk 
mutants (Figure 4.3.9.B).  This is consistent with data that this mutation of Btk does not 
express well in NIH 3T3 cells (Li et al., 1995). Mutations and deletions of the SH2 domain 
observed in XLA patients also affects Btk protein stability in vivo (Saffran et al., 1994).  
These results were further confirmed using endogenous of Btk as the SH2 mutation was 
introduced using CRISPR-Cas9 gene editing. Like the over-expression model, the SH2 
domain mutant expressed at a lower level compared to the endogenous WT protein 
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(Figure 4.3.9.B) and could not mediate signalling downstream of ITAM despite the 
presence of GPVI at the cell surface when assessed by flow cytometry.  
It is unsurprising that this domain is required, as the SH2 domain of Btk has been 
proposed to interact with phosphotyrosine residues on BLNK (homologous to LAT in 
platelets) (Hashimoto et al., 1999a), and therefore for signalling to occur, it makes sense 
that the functional SH2 domain is required. A functional SH2 domain has also been 
shown to be required for PLCγ2 phosphorylation in fibroblasts as there is a reduction in 
total PLCγ2 phosphorylation after transfection with R307K Btk and Lyn when compared to 
WT Btk (Fluckiger et al., 1998), however it is not totally reduced to basal levels. This is 
consistent with the work of Takata and Kurosaki, 1996, as phosphorylation of PLCγ2 is 
reduced but not abolished in B cells in this function altering point mutation (Takata and 
Kurosaki, 1996). This suggests that this domain plays a large but not total role in 
mediating PLCγ2 phosphorylation as some residual phosphorylation remains.   
 
4.4.1.7 The kinase function of Btk is required to mediate signalling downstream of 
CLEC-2 but not GPVI 
Kinase dead (KD) Btk has a point mutation at 430 from a lysine to glutamic acid (Mahajan 
et al., 1995), which is the ATP binding site (Vihinen et al., 1994a). The change from a 
basic side chain amino acid to an acidic amino acid prevents ATP binding. This renders 
the kinase inactive (Vihinen et al., 1994a, Tomlinson et al., 2001, Fluckiger et al., 1998). 
Btk does not require kinase function to induce calcium signalling downstream of GPVI in a 
cell line model (Figure 4.3.4). This observation is consistent with what has already been 
observed in B cells downstream of the B cell receptor (Tomlinson et al., 2001, 
Middendorp et al., 2003). Furthermore, there has been published data suggesting that 
PLCγ2 does not require phosphorylation at a known Btk phosphorylation site, Y1217, to 
induce lipase activity (Kim et al., 2004). The finding that the Btk kinase domain is 
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dispensable for GPVI signalling was confirmed when the assay was performed in the 
presence of ibrutinib and acalabrutinib (Figure 4.3.6).  
In the presence of ibrutinib, a less specific Btk inhibitor, only 10μM inhibited the NFAT 
luciferase signalling downstream of GPVI in WT and KD transfected cells (p ≤ 0.01). 
NFAT signalling was not significantly different from vehicle treated cells at lower 
concentrations of ibrutinib. Acalabrutinib did not inhibit signalling (Figure 4.3.6).  The 
inhibition of signalling seen in cells treated with high concentrations of ibrutinib but not 
acalabrutinib is likely due to the selectivity of the inhibitors. Ibrutinib is known to have off 
target effects and can inhibit Src family kinases (Figure 3.3.7.F  (Bye et al., 2017, Patel et 
al., 2016)), which are required for mediating signalling in GPVI/FcRɣ chain transfected 
DT40 cell line (Mori et al., 2008). 
In contrast, downstream of the hemITAM containing receptor CLEC-2, there is a 
requirement for a functional Btk kinase domain in a cell line model as shown in Figure 
4.3.5. The use of ibrutinib and acalabrutinib in the assay also verifies this result (Figure 
4.3.7). Previous work has also demonstrated that Btk requires its kinase function to 
mediate calcium signalling in Ramos cells downstream of the BCR (Fluckiger et al., 
1998), and that Btk can phosphorylate PLCγ2 in vitro (Watanabe et al., 2001). Therefore, 
CLEC-2 signalling requiring catalytic activity of Btk is not surprising.  
 
 
4.4.2 Aim - To genetically modify Btk using CRISPR-Cas9 to 
generate mutants to verify overexpression experimental models. 
4.4.2.1 CRISPR-Cas9 did not induce knock-ins for all the designed guides and 
donor sequences  
For CRISPR-Cas9 KI experiments that had no colonies (K430E and WW251/2LL), new 
guides should be designed. No colonies were obtained which was unusual, as if 
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homologous directed repair does not occur, it is likely that NHEJ would occur, resulting in 
a protein knockout. It is likely that there was a failure of cutting by Cas9. This can occur if 
the Cas9 enzyme binds but does not release. The release of Cas9 initiates the DNA 
double strand break. Therefore failure of dissociation of Cas9 would not induce a DSB for 
the cell to initiate repair (Knight et al., 2015) 
For the two guides that did yield colonies, with most cells being knockouts, there are 
multiple reasons to explain this. The efficiency of HDR in cells is very low, around 20% 
(Abu-Bonsrah et al., 2016), therefore it was not unexpected for protein KO to be induced 
in the majority of cases.  
A method to try and rectify the failure of these experiments would be to optimise the donor 
template. The donor template used in these experiments had equal homology arms 
(150bp either side of the mutation). Literature has suggested that unequal homologous 
arms may be beneficial and favoured by the cell to introduce HDR (Richardson et al., 
2016). The length of the homologous arms could also be changed, and as only one or two 
bases were being changed so altering the homology arm length may have improved 
efficiency (Liu et al., 2018)  
Efficiency can be improved by linearizing the donor plasmid.  The donor template was 
previously transfected in as a linearised and circular plasmid. To further improve 
efficiency, an alternate type of donor could be used. For example, some work has used 
single stranded oligonucleotides as the donor template for CRISPR with success (Jacobi 
et al., 2017). These could be commercially made, but they could also be PCR generated 
as dsDNA templates.  However the latter has been suggested by Jacobi et al that these 
may be toxic (Jacobi et al., 2017).  
4.4.2.2 CRISPR-Cas9 KI experiments resulted in amino acid deletions in the SH2 
domain of Btk, which renders it inactive 
After transfection and stable selection, two clones were obtained from CRISPR-Cas9 
gene editing. The mutation was within the SH2 domain. The expression of Btk in these 
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cells was slightly lower than WT cells when the same number of cells were loaded 
(Figures 4.3.16 and 4.3.17). This is consistent as to what is observed in the in the 
overexpression model NFAT experiments (Figure 4.3.9) and as to what has been 
published (Li et al., 1995).  
The deletion of either 3 or 6 bases (in mutants H and D respectively) suggests failure of 
HDR and by chance bases are deleted. Typically, deletion of bases via NHEJ results in a 
frameshift rendering the sequenced mismatched and therefore unstable (Ran et al., 
2013). Whereas in mutants D and H, exactly the number of bases that fall with the triplet 
code have been deleted during the process of NHEJ, causing the deletion of two amino 
acids. Further proof that the mutants did not undergo HDR was that the silent mutation 
within the PAM site was not integrated into the DNA (Figure 4.3.17.B).  
The two amino acids that have been deleted are Serine 310 and Lysine 311, near the 
start of the SH2 domain. S310 and K311 have not been identified as mutations in Btkbase 
(Väliaho et al., 2006). The S that is deleted (S310) is conserved in Src family kinases 
when aligned. It corresponds to S158 for Lyn, S178 for Fyn and S180 for Src. It has been 
proposed that mutation S178 in Fyn can contribute to rendering the SH2 domain inactive, 
but there were also other amino acid substitutions used to inactivate the SH2 domain in 
leukocytes (Bernardini et al., 2005). 
Experiments performed to assess the function of the mutation in the SH2 domain was 
similar to those observed in the over-expression model, which suggests that function of 
the SH2 domain is lost (Figures 4.3.9.A and 4.3.17.D). This is consistent with previous 
literature in that Btk requires its SH2 domain to mediate a large proportion of the 
phosphorylation of PLCγ2 in B cells, as in a function altering point mutation 
phosphorylation is reduced but not abolished (Takata and Kurosaki, 1996).  
Of note, each one of the domains of Btk aside from the kinase domain, inhibits the 
signalling downstream of GPVI so it cannot be said for certain that this mutation has 
caused specific SH2 inactivity (Figure 4.3.17). The mutation may have caused an 
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irregular structure of Btk and it may be unable to unfold to become active in its correct 
confirmation (Chung et al., 2019, Wang et al., 2019b). Misfolded protein is typically 
degraded (Hanna et al., 2019) and therefore this may be  related to the reduced 
expression of Btk in these mutants. To verify misfolded protein, modelling software such 
as Intfold (McGuffin et al., 2019) could be used to compare the protein structures.  
 
4.5 Conclusions  
In a knockout and over expression DT40 cell line model of platelet signalling, all Btk 
domains are needed to reconstitute CLEC-2 mediated signalling. Whereas downstream of 
GPVI, Btk requires a functional PH, SH3 and SH2 domain whereas it can mediate 
signalling independently of its kinase activity. The ability of a kinase dead mutant Btk to 
reconstitute signalling downstream of GPVI suggest that Btk can act as a scaffold protein 
downstream of GPVI signalling, whereas it cannot downstream of CLEC-2. This highlights 













5 Total internal reflection fluorescence microscopy to 
identify the localisation of Btk in relation to GPVI, LAT and 
CLEC-2.  
5.1 Introduction 
5.1.1 The location of Btk in platelets and B cells.  
Previous work using microscopy to study the location of Btk in platelets is limited. Most of 
the work to investigate localisation and protein-protein interactions is performed 
biochemically using immunoprecipitation and membrane fractionation. As platelets do not 
have a nucleus, they cannot be genetically transformed. Therefore, microscopy to 
investigate the localisation of proteins is limited to fixed samples and reliant on 
fluorescently labelled antibodies. Furthermore, microscopy requires specialist equipment 
and training when compared to immunoprecipitation and this may explain why there is 
less extensive research on Btk in platelets using microscopy.   
Btk has been shown to biochemically interact with some proteins and lipids in platelets 
including; PIP3 which is involved in Btk recruitment (Battram et al., 2017), Lyn which is 
proposed to phosphorylate Btk (Quek et al., 1998), Protein Kinase Cθ (Crosby and Poole, 
2002) and LAT which orchestrates GPVI and CLEC-2 signalling by the formation of the 
signalosome (Pasquet et al., 1999b). However, no published studies have identified an 
interaction between Btk and GPVI or CLEC-2 using coimmunoprecipitation in platelets.  
Furthermore, although co-immunoprecipitation have shown interactions biochemically, 
events are often difficult to identify due to the transient nature of some interactions or the 
disruption of weak interactions during the experimental process. Therefore, microscopy 
can evaluate where proteins are in relation to each other without the use of biochemical 
techniques and without the need for cell lysis.  
While microscopy has not been used to investigate the localisation of Btk within platelets 
it has been used to investigate the localisation of several over proteins and signalling 
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events. GPVI has been shown to cluster on collagenous surfaces such as horm collagen 
and CRP-XL (Poulter et al., 2017). Furthermore, GPVI and GPVI dimers have been 
shown to localise along collagen fibres (Poulter et al., 2017, Clark et al., 2019). 
Phosphotyrosine residues, stained with the phosphotyrosine specific antibody 4G10, were 
found to localise with some but not all GPVI molecules (Poulter et al., 2017) suggesting 
signalling primarily takes place along the collagen fibre. Enrichment of tyrosine 
phosphorylation has also been found in actin nodules using stochastic optical 
reconstruction microscopy (STORM). This suggests that nodules act as signalling hubs 
(Poulter et al., 2015).  CLEC-2 has been identified to form clusters at the platelet surface 
using TIRFM when indirectly imaged using podoplanin clustering.  However when 
investigated using STORM these clusters were found to be made up of smaller 
nanoclusters (Pollitt et al., 2014).   
The localisation of Btk and its relationship to other proteins has been studied to a greater 
extent in B cells than in platelets. The hemITAM containing receptor Dectin1 has been 
shown to interact with Btk using coimmunoprecipitation in macrophages during infection 
with Candida yeast (Strijbis et al., 2013). Furthermore, this was mirrored using 
microscopy, where Btk was also found to colocalise with PIP3 and actin during infection 
and phagocytosis, but not with DAG (Strijbis et al., 2013).  
Tec family kinases in B and T cells have been shown to form a punctate formation at the 
membrane in stimulated B and T cells  (Woods et al., 2001, Tomlinson et al., 2004b, Kane 
and Watkins, 2005). This observed punctate formation may be due to Btk directly 
changing its location and undergoing protein clustering in order to become catalytically 
active (Gustafsson et al., 2012, Mohamed et al., 2000, Chung et al., 2019, Agnew and 
Jura, 2017). It also may be an indirect effect, as it is known that PIP3 can form clusters at 
the membrane and Btk is recruited via its PH domain to PIP3 (Wang and Richards, 2012).  
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5.1.2 Total internal reflection fluorescence microscopy 
Total internal reflection fluorescence microscopy (TIRFM) is an advanced microscopy 
technique to illuminate within approximately 100nm of the coverslip. The idea of using 
reflection to visualise cells on the surface of glass was described in the 1950’s (Ambrose, 
1956), and then expanded by Axelrod in the 80’s (Axelrod, 1981). The resolution, which is 
the distance of which the microscope can distinguish two separate molecules, is 200nm 
for TIRFM (Kudalkar et al., 2016). 
The principle of TIRF is illustrated in Figure 5.1.1. Briefly, in standard florescent 
microscopy (on the left) light enters at a straight incident angle and illuminates the 
sample. In TIRFM, the incident light is directed at the sample at an angle. Most of this 
light is reflected away due to the coverslip, however a small portion is not. The non-
reflected light forms an evanescent wave through the sample, illuminating approximately 
100nm within the coverslip.  
TIRF is able to work due to the different refractive indices of the sample (N2) and the 
coverslip (N1). N2 (the sample contained in phosphate buffered saline) must have a lower 
refractive index than the N1 (the glass coverslip). The Snells law equation (listed below) 
states there is bending of light (refraction) when changing between two different mediums 
that have different refractive indices.  
The Snells law equation:  
𝑁1  𝑥 𝑠𝑖𝑛𝜃1 = 𝑁2 𝑥 𝑠𝑖𝑛𝜃2 
Where N1 = higher refractive index, N2 = lower refractive index, θ1 = angle of the incident 
beam in respect to the normal interface and θ2 = the refracted beam angle within the lower 
index medium.  
As the angle of θ1 continues, so will the θ2 which is the angle of refraction. When the θ2 is 
>90°, the critical angle (θc) is achieved (Figure 5.1.1). Any angle greater than the critical 
angle and no light with enter the sample – this is termed total internal reflection (Ambrose, 
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1956). An evanescent wave is generated at the point of total internal reflection and it 
exponentially decays whilst travelling through the sample. It excites fluorophores within 




Figure 5.1.1 Principles of TIRFM   
In conventional fluorescence microscopy, light enters vertically as seen on the left, with all 
of the depth of the sample being illuminated (lower left). In TIRFM the light enters at an 
angle (upper right). As the light is reflected away, an evanescent field is formed which 
refracts into the sample, illuminating within 100nm of the coverslip (lower right). The 
principles of Snells law are shown below. 
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TIRFM has been utilised to study a range of samples, including viruses, actin dynamics, 
cell substrate contact regions and intracellular signalling (Mattheyses et al., 2010). Within 
the platelet field, TIRFM has been utilised to identify platelet adherence to silica 
(Agnarsson et al., 2015), the cytoskeleton (Poulter et al., 2015) and receptor signalling 
and clustering (Pollitt et al., 2014, Poulter et al., 2017). 
TIRFM is a relatively quick method of microscopy. It also a greater signal to noise ratio 
than confocal microscopy due to a small Section being illuminated and therefore reducing 
background fluorescence (Simon, 2009). As Btk localises to the membrane upon GPVI 
and CLEC-2 stimulation when assessed using membrane fractionation and western 
blotting (Manne et al., 2015a), it is suitable for imaging GPVI, CLEC-2 and the 
transmembrane protein LAT. 
 
5.1.3  Colocalisation methods 
Colocalisation is the spatial overlap of two or more proteins when analysed using 
fluorescent labels. Each of the fluorophores used must have a separate emission 
wavelength to identify if the targets are located close to each other. The analysis provides 
a numerical value to identify how molecules relate to each other in microscopy images 
(Bolte and Cordelieres, 2006, Malkusch et al., 2012, Malkusch and Heilemann, 2016, 
Pageon et al., 2016). It can be calculated using a correlation-based method or a co-
occurrence-based method.  
Co-occurrence-based methods assess whether there is spatial overlap of two separate 
probes (Figure 5.1.2.A). Correlation based methods are when the probes overlay (as in 
co-occurrence), but also the number of probes increases in proportion to one another 
within the same structure (Figure 5.1.2.B). For example, as there is a higher proportion of 




Figure 5.1.2 Co-occurance and correlation based colocalisation analysis adapted 
from Aaron et al., 2018. 
(A) The image shows an example of high co-occurrence of green with red, a lower co-
occurrence of red with green but with low correlation as there is only one red molecule but 
numerous individual green molecules. (B) the image shown here displays a relatively low 
co-occurrence (only few yellow overlapping molecules) between the red and green 
channels. As there are a similar amount of green and red molecules the pixel intensities 
have a similar linear relationship, so there would be a high correlation value. 
 
5.1.3.1 Pearson correlation coefficient 
The original method of assessing colocalisation was developed by Pearson in 1896 (Dunn 
et al., 2011). Pearson correlation coefficient (PCC) is a statistical method of assessing 
colocalisation, measuring colocalisation as a correlation between the intensity of two 
imaged fluorophores. A range of values are produced between -1 to +1.  PCC values of -1 
are totally and inversely correlated images (as one probe increases, the other decreases 
in the same localisation), whereas values of +1 are totally correlated (both probes 
increase together). It is calculated by measuring the pixel by pixel covariance in the 




𝑃𝐶𝐶 =  
∑ (𝑀𝑖 − ?̅?) 𝑥 (𝐺𝑖 − ?̅?)𝑖
√∑ (𝑀𝑖 − ?̅?)
2 𝑥 ∑ (𝐺𝑖 − ?̅?)
2 𝑖  𝑖
 
Where 𝑀𝑖 and 𝐺𝑖 are the intensity of the magenta and green channels of pixel 𝑖 and ?̅? 
and ?̅? refer to the mean intensity of the two respective channels across the image (Dunn 
et al., 2011). The technique expects co-occurrence to be linear. However, this may not 
always be the case due to protein copy number differences and the stoichiometry of 
protein-protein interactions. 
PCC values between GPVI dimers and phosphotyrosine in the study of Poulter et al., on 
different GPVI activating ligands were below 0.3. They concluded from these values that 
some, but not all phosphotyrosine residues localise with GPVI due to the strong 
recruitment of GPVI at the collagen fibre (Poulter et al., 2017). A recent study has 
suggested values of equal to or greater than 0.4 are colocalised (Pallini et al., 2020).   
Therefore, a PPC of 0.4 was set as a threshold for determining if there is protein 
colocalization in this study.  
 
5.1.3.2 Manders colocalisation coefficient 
In contrast to PPC, Manders colocalisation coefficient (MCC) is based on co-occurrence 
rather than correlation. It was developed by Manders in response to hard to interpret 
negative PCC values.  It assesses the fraction of one protein that colocalises with a 
second protein.  The value of colocalisation is given between 0 (no co-occurrence) and 1 
(total co-occurrence) and calculated using the following equations: 
𝑀1 =  
Σ𝑖 𝑀𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙
Σ𝑖 𝑀𝑖,
  where 𝑀𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙 =  𝑀𝑖,   if 𝐺𝑖, > 0 and 𝑀𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙 = 0 if 𝐺𝑖, =  0 
𝑀1 =  
Σ𝑖 𝐺𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙
Σ𝑖 𝐺𝑖,
  where 𝐺𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙 =  𝐺𝑖,   if 𝑀𝑖, > 0 and 𝐺𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙 = 0 if 𝑀𝑖, =  0 
In contrast to PCC, MCC is independent of signal proportionality. It provides the fraction 
of fluorophore M with fluorophore G and the fraction of fluorophore G with M, which is 
excellent for assessing colocalisation without the need for a linear relationship which is 
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required for PCC. However, it is sensitive to background fluorescence and therefore 
images must be thresholded before processing (Bolte and Cordelieres, 2006, Dunn et al., 
2011). 
A value of equal to or greater than 0.4 suggest 40% of molecules of M are localised with 
molecule G. This value was selected as the value of colocalisation in this study (Pageon 
et al., 2016, Luo et al., 2018).  
 
5.2 Aims and Hypothesis 
To our knowledge the spatial localisation of Btk has not been studied in platelets. In B and 
T cells, it is known that Tec family kinases localise in a punctate formation in stimulated 
cells and this is mediated by their PH domains (Woods et al., 2001, Tomlinson et al., 
2004b, Kane and Watkins, 2005). Previous work has suggested that Btk may behave as a 
scaffolding protein downstream of the collagen receptor GPVI using platelet function 
assays, biochemical techniques, and a kinase dead mutant of Btk in a cell line reporter 
assay (chapters 3 and 4).  Therefore, the localisation of Btk to areas of GPVI mediated 
signalling was investigated in the presence and absence of Btk Kinase inhibitors.  If Btk 
acts as a scaffold it would be predicted that the localisation of Btk would not change in the 
presence of the inhibitors.      
Compared to GPVI, at submaximal concentrations of rhodocytin, a functional kinase 
domain is required to mediate signalling as shown using western blotting and cell line 
reporter assays.  Therefore, it would be expected that Btk would localise near the receptor 
due to its requirement. Additionally, Src and Syk are responsible for mediating CLEC-2 
clustering and therefore likely to localise near the hemITAM receptor. Due to the 
interactions of Btk and Syk and SFKs (Bobe et al., 2001, Mahajan et al., 1995), and its 
requirement in this pathway, it is not unreasonable to believe that Btk may be located 
near CLEC-2 when spread on rhodocytin. 
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Hypothesis: As Btk acts as a protein scaffold, it will localise along collagen fibres with 
GPVI and other signalling proteins.  This distribution will not change in the presence of 
Btk inhibitor. In comparison, Btk will localise to CLEC-2 when platelets are spread on 
rhodocytin, but due to the requirement of the kinase domain in mediating CLEC-2 
signalling. 
Aims of Chapter: 
• To investigate the distribution of Btk in platelets 
• To establish the localisation of Btk in relation to GPVI, LAT and CLEC-2 at the 
membrane using TIRFM 















5.3.1 Btk and GPVI do not colocalise on collagen fibres using 
TIRFM 
Initial experiments were performed to identify whether Btk colocalises with GPVI. It is 
known that platelet GPVI localises along collagen fibres, with the majority of GPVI dimer 
staining restricted to the fibre (Poulter et al., 2017, Clark et al., 2019). It has also been 
shown that phosphotyrosine residues localise at the collagen fibre (Poulter et al., 2017). 
Although not assessed numerically for colocalisation, the distribution of phosphotyrosine 
and GPVI look strikingly similar, with localisations along the collagen fibre. As Btk is 
tyrosine phosphorylated downstream of GPVI, it was hypothesised that it will also localise 
with GPVI along collagen fibres. Pearson correlation coefficient (PCC) and Manders co-
localisation coefficients (MCC) were used initially to assess colocalization of GPVI in 
relation to Btk.  
Washed platelets were spread on collagen for 45 minutes before being fixed and 
permeabilised. Platelets were then stained with a rabbit anti-Btk antibody and a mouse 
anti-GPVI antibody. Platelets were then incubated with Alexa Fluor 647 conjugated 
donkey anti-rabbit and Alexa Fluor 488 conjugated goat anti-mouse secondary antibodies 
before washing and imaging. Samples were imaged using TIRFM and analysed using the 
ImageJ Just Another Colocalization Plugin (JACoP) (Bolte and Cordelieres, 2006, 
Schneider et al., 2012).  
Btk forms a punctate pattern when platelets are spread on collagen. Some Btk puncta 
appear to be situated on the collagen fibre, however this is not evident throughout the 
image (Figure 5.3.1.A, magenta panel – Alexa fluor 647 staining). As previously reported 
in the work by Poulter and colleagues, staining of GPVI is mostly restricted to the collagen 
fibres (5.3.1.A, green panel, Alexa fluor 488 staining). When images are merged, areas of 
white suggest colocalization between Btk and GPVI.  While some areas display clear 
colocalisation, other areas do not.  To assess colocalisation PCC and MCC were used.  
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The PCC value between Btk and GPVI was 0.31 ± 0.01.  The MCC value for GPVI 
colocalising with Btk was 0.35 ± 0.02 and the value was 0.33 ± 0.02 for Btk localising with 
GPVI. All of these values are below the 0.4 threshold which suggests a lack of 
colocalization between Btk and GPVI (Bolte and Cordelieres, 2006, Dunn et al., 2011, 
Pageon et al., 2016)  
To confirm this result and to validate another antibody of Btk was used to assess for 
colocalisation between Btk and GPVI. In initial experiments, 100μg/mL of collagen was 
used which caused a high amount of fibres to be visualised in the DIC image (Figure 
5.3.1.A). As experiments were investigating the localisation of proteins at the collagen 
fibre, the collagen concentration was reduced to reduce overcrowding of the fibres.  
Experiments were performed as described previously with a goat anti-Btk antibody used 
in place of the rabbit anti-Btk antibody.  As seen previously, GPVI (Green channel; 
secondary staining with Alexa fluor 555) localises along the collagen fibre seen imaged 
using DIC (Figure 5.3.1.C). As seen with the Rabbit anti-Btk antibody, Btk staining with 
the Goat anti-Btk antibody also forms a punctate pattern in the platelet (Figure 5.3.1.C, 
magenta panel; secondary staining with Alexa fluor 647). The merged image shows areas 
of white, suggesting colocalisation between GPVI and Btk.  However, this is not uniform, 
suggesting colocalisation of some but not all of the Btk and GPVI molecules stained. 
When assessing colocalisation, the values obtained for this antibody were similar to the 
rabbit anti-Btk antibody. Although the average value for PCC is 0.43 ± 0.1, MCC for GPVI 
with Btk 0.44 ± 0.07, and the MCC for Btk with GPVI 0.41 ± 0.07 is slightly increased 
compared to the rabbit Btk there is no significant difference when analysed by two-way 
ANOVA (Figure 5.3.1). These values are over 0.4 suggesting that Btk does weakly 
colocalise with GPVI although it is not confirmed across two antibodies and therefore it is 
not convincing that Btk and GPVI significantly colocalise. This may be due to reagent 




Figure 5.3.1 Btk and GPVI weakly colocalise 
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(A, B) Washed platelets 2x10⁷ cells/mL were spread on collagen (100μg/mL) for 45 
minutes before fixation, permeabilization and staining with (A) rabbit anti-Btk and anti-
GPVI antibodies or (B) IgG controls. Wells were then stained with Alexa Fluor 647 
conjugated donkey anti-rabbit and Alexa Fluor 488 conjugated goat anti-mouse 
secondary antibodies. (C, D) Washed platelets (2x10⁷ cells/mL) were spread on collagen 
(10μg/mL) for 45 minutes before being stained with (C) goat anti-Btk and anti-GPVI 
antibodies or (D) IgG controls.  Note – this lower concentration of collagen was used for 
all subsequent microscopy experiments as this allowed easier visualisation of individual 
collagen fibres.  Samples were then with Alexa Fluor 555 conjugated donkey anti-mouse 
and Alexa Fluor 647 conjugated donkey anti-goat. Samples were imaged with Nikon TI-E 
100x TIRf lens. Analysis was performed using JACoP in ImageJ to quantify colocalisation 
between (E) Btk and GPVI to identify if GPVI and Btk colocalise using PCC and MCC, 
n≥3, Data represents mean ± SEM. Scale bar represents 10μm. Statistical testing was 














5.3.2 Btk kinase inhibitors do not alter the localisation of Btk 
The images taken above and colocalisation analysis suggested that Btk did not strongly 
colocalise with GPVI using TIRFM when platelets are spread on collagen. One 
catalytically active molecule of Btk has been suggested to phosphorylate of another 
molecule of Btk (Chung et al., 2019, Wang et al., 2019b).  This regulatory mechanism 
could explain the punctate pattern observed in the Btk staining.  Therefore, to investigate 
the role the Btk kinase domain has in the localisation and distribution of Btk, the kinase 
activity of Btk was inhibited using ibrutinib and acalabrutinib.  The localisation of Btk in 
relation to GPVI was assessed.  As previously shown in chapter 3 (Figure 3.3.4) the 
kinase activity of Btk, determined by the loss of the autophosphorylation site, is lost at 
1μM acalabrutinib. 1μM ibrutinib was selected to identify if there are any differences 
between the two drugs independently of their kinase inhibition. Furthermore, 1μM ibrutinib 
was selected as it inhibits Btk but does not reduce spreading on collagen (Bye et al., 
2015) so can be used to investigate the localisation of platelets without the artefact of less 
spreading.  
Washed platelets were pre-treated with ibrutinib or acalabrutinib (1μM) or vehicle control 
(0.1% (v/v) DMSO) for 5 minutes before spreading on collagen. Cells were fixed and 
staining was performed as previously described (Section 5.3.1). Btk puncta analysis was 
performed by thresholding the image to remove background and select for Btk puncta. 
Particles were counted using the ImageJ tool, analyse particles. Particles between 0.1-10 
microns and 0-1 circularity were included in the count. Colocalisation analysis was 
performed by thresholding the image and then using JACoP plug in (Bolte and 
Cordelieres, 2006). 
To determine the contribution the Btk kinase domain has in the punctate appearance, the 
number of puncta were quantified in platelets treated with acalabrutinib, ibrutinib or 
vehicle. Btk kinase inhibition did not impact the number of Btk puncta.  The average 
number of Btk spots per platelet which was 2 for each of the conditions (Figure 5.3.2.E).  
There is no significant difference in the number of puncta between vehicle and drug 
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treated samples. Furthermore, the average size and mean intensity of the puncta is not 
significantly different when platelets are treated with inhibitor showing that there is no 
change in the morphology and brightness of the puncta in the presence of Btk kinase 
inhibitor. 
There is no striking difference in the amount of colocalisation in the merged images 
between the treatment of drugs with some small areas of white being observed, however 
some areas are absent of white (Figure 5.3.2.A-C). No MCC or PCC values were over 
0.4, suggesting that Btk and GPVI do not colocalise. Furthermore, there was no change in 
the amount of colocalisation when comparing vehicle and drug treated samples. This 
suggests that kinase function does not regulate the distribution of Btk or its localisation in 
relation to GPVI. 
Taken together, these results suggest that Btk distribution and localisation in relation to 







Figure 5.3.2 Inhibition of the Btk kinase domain does not alter the distribution and 
colocalisation of Btk using TIRFM 
Washed platelets 2x10⁷ were treated with (A) vehicle, (B) ibrutinib (1µM), (C) 
acalabrutinib (1µM) or vehicle for 5 minutes before spreading on 100µg/mL collagen for 
45 minutes before fixation, permeabilization and staining with anti-Btk and anti-GPVI 
antibodies and secondary stained with Alexa Fluor 647 conjugated donkey anti-rabbit and 
Alexa Fluor 488 conjugated goat anti-mouse secondary antibodies respectively. Samples 
were imaged with Nikon TI-E 100x TIRf lens. Analysis was performed using (D) JACoP in 
ImageJ to quantify colocalisation between Btk and GPVI. N=3, data represents mean ± 
SEM. Statistical testing was performed with Two-way ANOVA with Dunnett’s multiple 
comparisons test, with no significance found. Scale bar represents 10μm. Analysis to 
count the (E) number of spots per platelet, (F) the size of the spots in μm2, and (G) and 
mean intensity of the spots was performed using ImageJ analyse particles tool. Graphs 
represent mean ± SEM. Statistical testing was performed with one-way ANOVA with 














5.3.3 Btk and GPVI are distributed throughout the platelet when 
spread on CRP-XL, and do not colocalise when imaged in TIRFM 
Btk did not directly colocalise with GPVI on collagen fibres. Strong GPVI localisation at 
the fibre is present (Figures 5.3.1 and 5.3.2), (Clark et al., 2019, Poulter et al., 2017). This 
may occlude Btk recruitment or be sterically preventing anti-Btk antibodies binding.  
Furthermore, another potential reason for using CRP-XL is the potential for GPVI 
clustering to be different on CRP-XL compared to collagen (Poulter et al., 2017). Each 
molecule of CRP-XL has 30 binding sites for GPVI and can potentially change the way 
GPVI clusters, for example, potentially larger clusters, (Smethurst et al., 2007). As no 
certain colocalisation was observed on collagen (Figure 5.3.1), CRP-XL was used to 
assess whether there is colocalisation on this ligand. 
CRP-XL is a non-fibrous ligand and has previously been used to assess spreading of 
platelets (Bye et al., 2015) and the localisation of GPVI (Poulter et al., 2017, Onselaer et 
al., 2020) and Syk (Dunster et al., 2020).  
Washed platelets were spread on CRP-XL (1μg/mL) coated surfaces for 45 minutes 
before fixation and permeabilization. Platelets were then stained with a rabbit anti-Btk 
antibody and a mouse anti-GPVI antibody followed by secondary staining with Alexa Fluor 
647 conjugated donkey anti-rabbit and Alexa Fluor 488 conjugated goat anti-mouse 
antibodies before washing and imaging. Samples were imaged using TIRFM and 
analysed using the ImageJ plugin JACoP (Bolte and Cordelieres, 2006).  
Both the MCC and PCC values were approximately 0.25, and there was no significant 
difference between the methods of colocalisation (Figure 5.3.3.B). The amount of Btk that 
colocalised with GPVI was identical to the amount of GPVI that colocalised with Btk when 
assessed using the MCC (0.27 ± 0.09 or 0.27 ± 0.1 respectively). Neither of these values 






Figure 5.3.3 Btk and GPVI do not colocalise on CRP-XL 
(A) Washed platelets were spread on CRP 1μg/mL for 45 minutes before being stained 
with anti-Btk (magenta panel, secondary antibody Alexa Fluor 647 conjugated donkey 
anti-rabbit), anti-GPVI (green panel, secondary antibody Alexa Fluor 488 conjugated goat 
anti-mouse). Samples were imaged in TIRFM.  (B) ImageJ JACoP was used to assess 
colocalisation using Pearson correlation coefficient and manders co-localisation 
coefficient of the amount of GPVI that colocalises with Btk and the amount of Btk that 
colocalises with GPVI. n=3. Data presented mean ± SEM. Statistical testing was 
performed using paired one-way ANOVA with Dunnett’s multiple comparison test with no 






5.3.4 Btk and phosphotyrosine residues do not colocalise in 
TIRFM. 
It is known that Btk is tyrosine phosphorylated downstream of GPVI (chapter 3, Figure 
3.3.4 and  (Atkinson et al., 2003a, Pasquet et al., 1999b, Quek et al., 1998). Therefore, it 
would be expected that Btk would localise with phosphotyrosine residues, stained for 
using the antibody 4G10. However, as there are more phosphotyrosine residues present 
than Btk molecules present, it is unlikely that there will be total colocalisation.  
Washed platelets were spread as previously described on collagen and stained with anti-
Btk and anti-phosphotyrosine (4G10) antibodies. Platelets were stained with Alexa Fluor 
647 conjugated donkey anti-rabbit and Alexa Fluor 488 conjugated goat anti-mouse 
secondary antibodies before washing and imaging using TIRFM. Colocalisation between 
Btk and phosphotyrosine was analysed using JACoP (Bolte and Cordelieres, 2006). To 
investigate whether the lack of localisation observed previously on collagen was due to 
the limit of TIRF, images were taken in and out of TIRFM (epifluorescence microscopy 
where the whole sample is illuminated). A collagen fibre can be up to 67nm in diameter 
(Orgel et al., 2006). If the fibre does not lie directly flat on the coverslip, the platelet 
membrane interaction may be out of the illumination of the evanescent wave (100nM) in 
TIRFM.  
Figures 5.3.4.B and C show that when compared to the DIC image, phosphotyrosines are 
enriched to the collagen fibre (pY - green panels), forming a similar pattern observed with 
GPVI (Figure 5.3.1). In agreement with earlier experiments, Btk does not directly localise 
to the fibre. When the images are merged, there is a small proportion of white, suggesting 
colocalisation between Btk and phosphotyrosines. A similar observation can be made 
when images are taken out of TIRF, however there appears to be some more white on 
the merged image. 
In TIRF, there is no significant difference between the amount of Btk that localises with 
phosphotyrosine or the amount of phosphotyrosine residues localising with Btk with 
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values are approximately 0.2 using MCC. The PCC value was similar. Neither of these 
values are ≥0.4 suggesting Btk does not localise with 4G10 in TIRF.   
This contrasts with the results out of TIRF, as all the colocalisation values are significantly 
larger compared to their TIRF counterparts (***p ≤ 0.001). All values are approximately 
0.4, suggesting more colocalisation of these two molecules occurs out of TIRF. This 
suggests that either Btk or phosphotyrosine residues are localised in a Z plane higher 











Figure 5.3.4 Btk and phosphotyrosines colocalise more out of TIRF than in TIRF 
Washed platelets were spread on collagen 10μg/mL for 45 minutes before being stained 
with anti-Btk (magenta), anti-phosphotyrosine 4G10 (green) and secondary stained with 
Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 488 conjugated goat anti-
mouse antibodies. Samples were imaged in (A) DIC, (B) in TIRF, or (C) out of TIRF. (D) 
ImageJ plugin JACoP was used to assess colocalisation using PCC and MCC coefficient 
of the amount of phosphotyrosines that colocalises with Btk and the amount of Btk that 
colocalises with phosphotyrosines n=4. Data presented mean ± SEM. Statistical testing 
was performed using paired 2-way ANOVA with Dunnett’s multiple comparison test ***p ≤ 





5.3.5  Btk and LAT colocalise when spread on collagen and 
imaged in TIRFM 
As Btk does not localise with GPVI in TIRFM it may be due to the fact Btk lies further 
downstream in the signalling cascade. LAT is a co-ordinator of GPVI signalling and many 
proteins are recruited to the signalosome (Hughes et al., 2008, Spalton et al., 2009, 
Pasquet et al., 1999b, Gibbins et al., 1998). Although Btk phosphorylation is not reduced 
in LAT deficient platelets (Pasquet et al., 1999b), it is hypothesised that Btk is recruited to 
the signalosome (Baba et al., 2001). Btk has been shown to co-immunoprecipitate with 
LAT in CRP-XL stimulated platelets (Pasquet et al., 1999b).  Therefore, it is not 
unreasonable to hypothesise they will localise with each other spatially.  
Btk and LAT localisation were assessed using TIRFM in platelets spread on collagen. As 
previously described, platelets were spread on 10μg/mL collagen for 45 minutes. Platelets 
were fixed, permeabilised and stained with anti-LAT and anti-Btk antibodies followed by 
secondary staining with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 
555 conjugated donkey anti-goat antibodies.  Images were taken using TIRFM with 
colocalisation analysed in JACoP. 
Btk, as shown previously, forms a punctate distribution. LAT is also distributed in a similar 
manner (Figure 5.3.5.A). The merged image shows a large proportion of white suggesting 
high levels of colocalisation between Btk and LAT when analysed using PCC and MCC.  
All average colocalisation values are greater than the 0.4 threshold, showing that there is 
some colocalisation between Btk and LAT, and values over 0.4 suggest that ≥40% of 
molecules overlap with each other. There is no significant difference between the amount 
of Btk that colocalises with LAT and the amount of LAT that colocalises with Btk. It would 
be expected that more LAT would overlap with Btk than Btk with LAT as there are 
approximately half as many copies of LAT as there are Btk (Zeiler et al., 2014, Burkhart et 
al., 2012). However, this assumes all protein copies are localised in a way that would 
allow imaging, such as not being in tight complex or the epitope being blocked. 
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Nonetheless, Btk and LAT look to somewhat colocalise on collagen, as expected as it has 














Figure 5.3.5 Btk and LAT colocalise in platelets when spread on collagen 
Washed platelets were spread on collagen (10μg/mL) for 45 minutes before fixation and 
permeabilization. Platelets were stained with (A) anti-Btk (magenta) and anti-LAT (green) 
antibodies or (B) IgG controls and secondary stained using Alexa Fluor 555 conjugated 
donkey anti-goat and Alexa Fluor 647 conjugated donkey anti-rabbit.  Images were taken 
in (A) TIRFM or DIC. Images were analysed using ImageJ JACoP to calculate the (C) 
PCC, and MCC to assess the visual colocalisation shown in the merged image. n=3, 





5.3.6  Syk and GPVI colocalise when spread on collagen and 
imaged in TIRFM 
Syk is known to precede Btk in the GPVI signalling cascade. It has been shown to directly 
interact with GPVI in GPVI pull down assays (Houck et al., 2019, Gibbins et al., 1997). 
Consequently, it was hypothesised that Syk would localise with GPVI. These experiments 
were performed as a positive control to further verify the lack of colocalisation between 
Btk and GPVI.  
Washed platelets were spread on collagen for 45 minutes before being fixed and 
permeabilised as previously described. GPVI was stained using 1G5 as previous (Figure 
5.3.1), and Syk was stained using N-19 as in Dunster et al., 2020. Samples were 
incubated with secondary antibodies Alexa Fluor 555 conjugated donkey anti-mouse and 
Alexa Fluor 647 conjugated donkey anti-rabbit. Images were taken using TIRFM.  
Figure 5.3.6 confirms that Syk and GPVI colocalise when imaged using TIRFM. With 
colocalisation shown in white in the merged image, there is a clear area of colocalisation 
along the diagonal collagen fibre. When this was analysed using MCC after thresholding 
as described previously, the value for Syk with GPVI was 0.5 ± 0.03 and for GPVI with 










Figure 5.3.6 Syk and GPVI colocalise when platelets are spread on collagen 
Washed platelets were spread on collagen for 45 minutes before being fixed, 
permeabilised and stained with (A) anti-Syk (magenta) and anti-GPVI (green) antibodies 
followed by secondary staining with Alexa Fluor 555 conjugated donkey anti-mouse and 
Alexa Fluor 647 conjugated donkey anti-rabbit antibodies. (B) ImageJ with JACoP plug in 
was used to assess colocalization between GPVI and Syk. n=3, graph represents mean ± 








5.3.7  Btk and CLEC-2 colocalise when imaged in TIRF and 
spread on rhodocytin 
As shown in the previous chapter platelets spread weakly on rhodocytin (Figure 3.3.15). 
Experiments to investigate the localisation of Btk in relation to CLEC-2 were performed. It 
is known that CLEC-2 undergoes clustering which is mediated by Src and Syk family 
kinases in platelets (Pollitt et al., 2014). As Btk has been shown to interact with Syk and 
Src, it could be hypothesised that Btk may be localised near CLEC-2 (Oda et al., 2000, 
Wahl et al., 1997). Furthermore, as previous data suggests that there is a stronger 
requirement for Btk kinase function downstream of CLEC-2 than GPVI (chapter 3 and 
chapter 4), it is likely that Btk could be localising with CLEC-2 as opposed to GPVI.  
Washed platelets were spread on rhodocytin (100nM) for 45 minutes before fixation. 
Samples were then stained with anti-Btk as previously described and anti-CLEC-2 (AYP1) 
or IgG controls followed by secondary staining with Alexa Fluor 647 conjugated donkey 
anti-rabbit and Alexa Fluor 555 conjugated donkey anti-mouse antibodies. Samples were 
then imaged using TIRFM. 
Figure 5.3.7.A shows that Btk (magenta panel) forms a punctate distribution in a similar 
manner as seen previously when platelets are spread on GPVI ligands. CLEC-2 (green 
panel) is distributed over the platelet. When merged, there is areas of white, suggesting a 
large amount of colocalisation between Btk and CLEC-2. 
A numerical value of colocalisation was calculated using ImageJ. Using MCC and PCC 
the mean colocalisation values were greater than 0.65 (Figure 5.3.7.C). This suggests a 









Figure 5.3.7 Btk and CLEC-2 colocalise when spread on rhodocytin 
Washed platelets were spread on rhodocytin (100nM) for 45 minutes before being fixed, 
permeabilised and stained with (A) anti-Btk (magenta) and anti-CLEC-2 (green) or (B) IgG 
controls and then secondary stained with Alexa Fluor 647 conjugated donkey anti-rabbit 
and Alexa Fluor 555 conjugated donkey anti-mouse antibodies. Images were merged and 
(C) colocalization assessed using the ImageJ plugin JACoP n=3, Graph represents mean 
± SEM. Scale bar represents 10μm. 
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5.3.8  Btk and LAT colocalise when spread on CLEC-2 ligand 
rhodocytin and imaged in TIRFM  
Btk and CLEC-2 look to colocalise more than Btk and GPVI. However in GPVI stimulated 
platelets, Btk looks more likely to localise with LAT. In T cells, the T cell receptor and LAT 
form distinct ‘protein islands’ which is where the proteins cluster and are separated by 
actin (Lillemeier et al., 2010). Therefore, it was investigated if Btk also localises with LAT 
when platelets spread on a CLEC-2 ligand to see if the protein islands theory is applicable 
to platelets. It was also to identify if Btk is recruited to the LAT signalosome and if it can 
be visualised microscopically.  
As previously described, washed platelets were spread on rhodocytin for 45 minutes.  
Platelets were fixed, permeabilised and stained with anti-LAT and anti-Btk antibodies 
followed by secondary staining with secondary antibodies (Section 5.3.5). Images were 
taken using TIRFM. When the platelets were spread on rhodocytin, Btk was found to have 
a punctate distribution (Figure 5.3.8.A). LAT was seemingly localised all over the platelet 
as was observed previously in GPVI mediated spreading (Figure 5.3.5). The merged 
image does show a large proportion of white suggesting colocalisation.  
Colocalisation was assessed using the ImageJ plugin JACoP.  The mean PCC value is 
0.54 ± 0.14, suggesting colocalization of Btk and LAT. Using MCC there is no difference 
in the amount of Btk that colocalises with LAT, and the amount of LAT that overlaps with 
Btk, with both values being approximately 0.55, again, suggesting colocalisation between 







Figure 5.3.8 Btk and LAT colocalise when spread on rhodocytin 
Washed platelets were spread on rhodocytin for 45 minutes before being fixed, permeabilised and stained with (A) anti-Btk (magenta) and anti-
LAT (green),or (B) IgG controls and secondary stained with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 555 donkey anti 
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goat antibodies. (C) Images were merged and (C) colocalization assessed using the ImageJ plugin JACoP n=3 Graph represents mean ± SEM.  




Using TIRFM the following aims were addressed 
5.4.1 Aim - To investigate the distribution of Btk in platelets 
5.4.1.1 Btk forms a punctate pattern when imaged in TIRFM  
Btk forms a punctate pattern in spread platelets when imaged using TIRFM (Figures 
5.3.1, 5.3.2, 5.3.5, 5.3.7). The punctate appearance also lines up with the collagen fibre in 
some instances as shown in Figure 5.3.1.C. In other cell types, punctate subcellular 
localisation patterns can arise from proteins localised to membrane bound organelles, 
such as apoptotic proteins accumulating in the mitochondria (Wolter et al., 1997), or from 
macromolecular complexes of sufficient size such as LAT protein islands seen in T cells 
(Lillemeier et al., 2010).  
It is unlikely that Btk forms a punctate pattern in platelets due to localisation of membrane 
bound organelles, as there is no evidence to show that it is recruited to the mitochondria 
or is present in α or dense granules (Maynard et al., 2010, Maynard et al., 2007, Meyers 
et al., 1982). It is more likely that the observed formation of Btk puncta imaged in TIRFM 
is due to the formation of macromolecular complexes and protein clustering. To support 
this, Btk has been shown to form a punctate distribution in B cells which is similar to the 
pattern seen in platelets (Tomlinson et al., 2004b). 
Btk’s punctate formation may also be related to the localisation of PI3K and the 
production of PIP3 when platelets are activated downstream of GPVI and CLEC-2. PI3K 
is expressed at a relatively low level (2,100 copies) per human platelet, as opposed to Btk 
(11,100 copies) (Burkhart et al., 2012). The punctate pattern of Btk may be due to it 
localising with the few copies of this protein as it produces PIP3. Furthermore, PI3K and 
Btk have been shown to co-immunoprecipitate (Battram et al., 2017), suggesting there is 
an interaction, however it is unknown whether this is directly, or through PIP3.  PI3K itself 
forms cytoplasmic punctate patterns in other cell types, namely NIH-3T3, A431 and MCF-
7 cells (Gillham et al., 1999), and PIP3 has been shown to spontaneously cluster (Wang 
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et al., 2015).  The punctate distribution of GFP-Tec is also dependent on the production of 
PIP3 in D10 mouse T cells (Kane and Watkins, 2005). An inhibitor of PI3K, to block the 
production of PIP3, caused a reduction in the density of the GFP-Tec clusters. Therefore, 
recruitment of Btk to areas of concentrated PIP3 via its PH domain may explain the 
punctate appearance of Btk in platelets using TIRFM. 
A good direction to take this work and further investigate the puncta formation of Btk in 
platelets would be to verify the puncta formation is not related to the limited resolution of 
TIRFM. To do this, a more advanced microscopy technique such as STORM should be 
used. PI3K inhibitors could also be added to platelets whilst spreading to prevent PIP3 
production, and this would help deduce if the punctate formation of Btk is PIP3 
dependent.  
 
5.4.2 Aim - To establish the localisation of Btk in relation to GPVI, 
LAT and CLEC-2 at the membrane using TIRFM 
5.4.2.1 Distribution of Btk in platelets spread on GPVI ligands. 
Btk does not colocalise with GPVI when platelets are spread on CRP-XL.  Values for 
colocalisation were less than 0.4 which was the threshold value for colocalization set 
(Figure 5.3.3). In contrast, when spread on collagen, the data suggests that Btk and GPVI 
may localise, with one species of antibody giving colocalization values greater than 0.4. 
However, another species of antibody does not, but these values are not statistically 
significant from each other (Figure 5.3.1.E). The resolution limit of TIRFM may not allow 
for the localisation for Btk and GPVI to be fully confirmed. 
However, there is a significant difference in the localisation of Btk and phosphotyrosine 
residues when imaged in and out of TIRF (p ≤ 0.01). All the phosphotyrosine residues 
within the cell could be stained with 4G10 and therefore it may be that more of the 
phosphotyrosines are present out of the 100nm imaging area. It is known that proteins 
can move within the Z plane such as LAT in T cells (Griffié et al., 2017), and therefore 
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some of the phosphotyrosine residues may be above the TIRF illumination limit when the 
platelet was fixed. These residues may be the opposite cell membrane, which has 
continuously phosphorylated proteins present such as Lyn (Schmaier et al., 2009, Aquino 
et al., 2011). An alternative approach would be to use phosphospecific antibodies. 
There appears to be some areas along the collagen fibre that Btk is localised where GPVI 
is not. This can be visualised in Figure 5.3.1.C. Proteins can be recruited, perform their 
role and then be in the process of returning to their normal location, such as Syk 
recruitment to the ITAM containing BCR and then subsequently leaving (Zhou et al., 
2006). Therefore, the areas where Btk is absent may be where Btk has left the fibre after 
performing its role when the cells are fixed.   
However, Btk may not localise with GPVI. A recent study using B cells has demonstrated 
that phosphorylated Btk (assessed using phosphospecific antibodies) does not strongly 
colocalise with the BCR when assessed using confocal microscopy, with PCC values 
below 0.4 (Jing et al., 2020). As Btk does not directly localise with the ITAM containing B 
cell receptor, this is consistent with the data presented in this chapter. 
When spread on collagen, Btk and LAT show some colocalisation, with MCC and PCC 
values being greater than 0.4. A potential reason that Btk may colocalise with LAT as 
opposed to GPVI is the position Btk lies in the signalling pathway. It has been shown in T 
cells that LAT and the TCR form distinct ‘protein islands’ which are signalling complexes 
separated by actin (Lillemeier et al., 2010). While LAT has been shown to colocalise with 
the adaptor proteins SLP-76 and Grb2 in T cells using TIRFM (Zhang et al., 2018, 
Balagopalan et al., 2018), there have been no studies demonstrating that Tec family 
kinases and adaptor proteins (LAT and BLNK in T and B cells respectively) colocalise 
using microscopy.  It is unknown whether protein islands form in platelets, but it may 




5.4.2.2 Distribution of Btk in platelets spread on a CLEC-2 ligand 
When spread on a CLEC-2 agonist, Btk and CLEC-2 have high colocalisation values 
when imaged in TIRFM (Figure 5.3.7). More CLEC-2 localises with Btk as opposed to Btk 
localising with CLEC-2 (p ≤ 0.01). This may be related to differences in copy number as 
there are ~6 fold more copies of Btk present in platelets than copies of CLEC-2 (Burkhart 
et al., 2012, Dunster et al., 2020, Gitz et al., 2014). 
Similarly high colocalisation values, when assessed by PCC and MCC, were observed for 
Btk with LAT when platelets were spread on rhodocytin. However, in the representative 
images, some platelets spread to a greater extent than others on rhodocytin.  The higher 
values of colocalisation may be related to the degree of platelet spreading as molecules 
maybe densely localised in unspread platelets compared to spread platelets. 
 
5.4.2.3 Possible reasons for the lack of colocalization between of Btk and other 
proteins in this study 
Using two methods of assessing colocalisation, MCC and PCC, Btk did not strongly 
colocalise with GPVI, but did with CLEC-2 (Figures 5.3.1 and 5.3.7). In a recent study 
using biochemical methods, Btk was found to be absent from lipid rafts following platelet 
stimulation with both GPVI and CLEC-2 agonists.  Therefore it unsurprising that it did not 
colocalise with GPVI which was found to be present in lipid rafts (Izquierdo et al., 2019). It 
is controversial whether CLEC-2 is present in lipid rafts, with reports of CLEC-2 being 
present (Pollitt et al., 2010), and absent from lipid rafts (Manne et al., 2015b). As Btk does 
not localise in lipid rafts (Izquierdo et al., 2019), it is not unreasonable that it is localising 
with CLEC-2 as it also may not be in lipid rafts. However, Btk does appear to localise with 
LAT, which is known to be present in lipid rafts (Locke et al., 2002, Bodin et al., 2003, 
Izquierdo et al., 2019), so this hypothesis may not be correct.  
In order to test this hypothesis, experiments could be performed to gently disrupt lipid 
rafts, but this may impact spreading (Lier et al., 2005). Or, alternative experiments to stain 
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for Btk in conjunction with cholesterol may identify if Btk is localising to lipid rafts, where 
GPVI signalling is known to take place (Locke et al., 2002).  
Another possible explanation for the lack of colocalisation of Btk and other proteins may 
be related due to the copy numbers. Perfect colocalisation (MCC score of 1) is very 
unlikely in studies between Btk, and phosphotyrosines due to the large variations of copy 
number within the platelet. There is not an exact number of phosphotyrosines present 
within a stimulated platelet, but it would be expected it to be significantly larger than the 
11,100 copies of Btk (Burkhart et al., 2012). There are 9600 copies of GPVI and 4800 of 
LAT. As there are more copies of Btk, the ratios of these proteins are not 1:1, which may 
explain why there is a low level of colocalisation.  
The use (or not) of phosphospecific antibodies may have also altered the results. In the 
recent pre-publication by Pallini et al 2020, a phosphospecific Syk antibody  and a Syk 
antibody which binds regardless of phosphorylation (referred to as total-Syk) were used to 
investigate the localisation of Syk in relation to the collagen fibre. The total-Syk antibody 
labels the entire platelet in confocal microscopy, whereas the phosphospecific Syk 
antibody appears to localise along the collagen fibre. This is also mirrored when 
antibodies for phosphospecific LAT and total-LAT are used.  
A further possible reason may be that the time point of 45 mins was too short. Indeed, 
Pallini et al demonstrated that while there is some phosphorylated LAT that colocalises 
with GPVI in confocal microscopy in this time frame, the level of colocalization is greatly 
increased after 3 hours of spreading (Pallini et al., 2020). This suggests that LAT is 
recruited to the fibre at a slower rate, or prolonged signalling may mediate the recruitment 
of different proteins. This may be happening to Btk.  
As Btk has been to co-immunoprecipitate with LAT (Pasquet et al., 1999b), it is not 
unreasonable to believe that more Btk may be present at the fibre at a later time point. 
However, the biochemical studies are much shorter in time frame, so it may not be 
applicable to reason that Btk would be present at a later time point due to its interaction 
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with LAT in a short biochemical experiment. Nonetheless, experiments could be 
performed using a longer time point, or shorter time points such as stimulating in 
suspension, to investigate this further.  
 
5.4.3 Aim - To identify changes in Btk localisation in the presence 
of a Btk inhibitor 
The punctate distribution of Btk did not change in the presence of the Btk kinase inhibitors 
ibrutinib and acalabrutinib (Figure 5.3.2). In B cells and platelets, the recruitment of Btk is 
mediated by the PH domain of Btk and its interaction with the lipid PIP3 (Saito et al., 
2001, Várnai et al., 1999, Salim et al., 1996, Durrant et al., 2017, Patel et al., 2019). This 
mechanism is not believed to be kinase dependent, therefore it is consistent with the 
results in this study that the localisation does not change in the presence of a Btk inhibitor.  
Interestingly, when investigating the clustering of GFP-Tec in T cells using TIRFM, a Src 
inhibitor caused a greater inhibition of Tec clustering density when compared to a PI3K 
inhibitor. This suggests that catalytic activity of Tec is required for its clustering, as SFK’s 
are responsible for the phosphorylation of Tec family kinases (Park et al., 1996, Wahl et 
al., 1997). However, SFKs are not just responsible for phosphorylation of TFK’s, they also 
phosphorylate ZAP-70, which mediates the phosphorylation of LAT. The inhibition of SFK 
catalytic activity may prevent Tec clustering through a reduction in LAT signalosome 
tyrosine phosphorylation. Therefore Tec may not be recruited to the LAT signalosome via 
its SH2 domain interactions (Palacios and Weiss, 2004).  
Although the platelets are pre-treated with ibrutinib and acalabrutinib it is difficult to know 
if the drug is bound to the platelets. There has been a study using a fluorescent version of 
ibrutinib to image tumour cells. The fluorescently labelled ibrutinib colocalised strongly 
with a fluorescently tagged Btk. It was less efficacious than unlabelled ibrutinib, as a 
higher concentration was required in order to cause Btk inhibition in a cell free assay than 
unlabelled ibrutinib (Turetsky et al., 2014, Kim et al., 2015). Nonetheless, the use of 
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fluorescently tagged ibrutinib would allow for the confirmation that the drug is entering the 




Using TIRFM, Btk does not strongly colocalise with GPVI when platelets are spread on 
CRP-XL. There is a suggestion of weak colocalization of Btk and GPVI on collagen and 
Btk may localise to areas of the collagen fibre in areas that GPVI is not absent through an 
unknown mechanism.  Btk and LAT look to colocalise more strongly than Btk and GPVI 
on collagen. 
When spread on rhodocytin, Btk looks to localise with CLEC-2, LAT and phosphotyrosine 
residues but this may be an artefact due to the lack of full spreading in the platelets.  
The resolution, which is the distance of which the microscope can distinguish two 
separate molecules, is limited at 200nm for TIRFM (Kudalkar et al., 2016). This may 
conceal true results of colocalisation. Therefore alternative methods to assess 
colocalisation should be used to confirm the results obtained. Stochastic optical 
reconstruction microscopy, has a greater optical resolution limit of approximately 20-50nm 
(Rust et al., 2006). This allows for more accurate distinguishing of molecules and was 
used in the next chapter to further investigate the localisation of Btk in relation to GPVI, 
LAT and CLEC-2. It also allows for the assessment of protein clustering which can act as 







6 Investigating the localisation and clustering of Btk, GPVI, 
LAT and CLEC-2 using Stochastic optical reconstruction 
microscopy. 
 
The distance of which two separate molecules can be distinguished is limited at 200nm 
for TIRFM (Kudalkar et al., 2016). This may have concealed or potentiated true results of 
colocalisation in chapter 5. Stochastic optical reconstruction microscopy (STORM) was 
used to further investigate the localisation of Btk in platelets. STORM allows for increased 
fluorophore localisation and therefore can be used to investigate colocalisation and 
protein clustering more accurately due to the higher resolution (Metcalf et al., 2013, 
Ovesný et al., 2014, Rust et al., 2006).  
6.1 Introduction  
6.1.1 Protein clustering as a mechanism of regulation  
Protein clustering provides an extra layer of regulation upon signal activation. Large 
protein clusters are connected to enhanced signalling as it brings kinases closer to their 
targets, reducing the space that molecules need to move or diffuse too. This makes the 
signalling more efficient (Cebecauer et al., 2010). In platelets, clustering of GPVI and 
CLEC-2 is required for the initiation of signalling (Pollitt et al., 2014, Poulter et al., 2017). 
Clustering has also been demonstrated to play a role in signal termination, such as 
clustering of the TCR and the phosphatase CD45 has been implicated in terminating 
signalling in T cells (Varma et al., 2006)  
GPVI clustering is determined by the ligand that the platelet is interacting with and is a  
level of regulation for GPVI mediated signalling and platelet activation (Poulter et al., 
2017, Dunster et al., 2020). Although platelet spreading and adherence to a variety of 
GPVI ligands is reduced in the presence of a Syk or SFK inhibitor, clustering of GPVI is 
still present when assessed using TIRFM (Poulter et al., 2017). Therefore, the mechanism 
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which regulates GPVI clusters in unknown but appears to be Src and Syk kinase 
independent.  
Losartan has been proposed to inhibit GPVI clustering. This molecule is an angiotensin II 
receptor antagonist, and it inhibits platelet aggregation to collagen and CRP-XL, but it is 
not a GPVI antagonist. FcRɣ chain phosphorylation was inhibited in the presence of 
losartan in stimulated samples so it was hypothesised that the GPVI clustering was being 
inhibited. Indeed, using the proximity ligation assay Duolink, it was identified that losartan 
did inhibit GPVI clustering via an unknown mechanism (Jiang et al., 2015). Work from 
another group did corroborate that aggregation to collagen was inhibited. However, when 
GPVI clustering was assessed using STORM the cluster density (number of clusters per 
μm2) and the cluster area were unaltered in the presence of losartan, suggesting that 
losartan did not alter GPVI clustering (Onselaer et al., 2020). Both studies used the same 
GPVI ligands and losartan concentrations, so the differences may be due to experimental 
methods.  
The concept of receptor clustering providing a level of regulation is not limited to GPVI in 
platelets.  CLEC-2 has also been demonstrated to undergo clustering following ligand 
engagement with Podoplanin (Watson et al., 2009, Pollitt et al., 2014).  However, SFK’s 
and Syk tyrosine kinases regulate the clustering of CLEC-2 (Pollitt et al., 2014).  
Furthermore, if the receptor were to cluster, clustering of the intracellular tyrosine kinases 
responsible for mediating signalling would also be expected. This has been observed in B 
cells with Btk recruited to microclusters (0.5 to 1μm in size) and larger clusters (average 
surface area of 16μm2) during BCR signalling (Fleire et al., 2006). In addition to Btk, these 
clusters consist of other phosphorylated proteins including Syk, BLNK and PLCγ2 (Weber 
et al., 2008). Disruption of clusters through a lack of protein recruitment can result in 
immunodeficiencies (Wang et al., 2014), highlighting the importance of protein clustering. 
In B cells, Btk is not thought to be directly responsible for mediating the clustering of the 
BCR, however, it is indirectly involved. Btk deficient B cells have reduced actin 
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polymerisation when assessing the amount of free actin monomers (G actin) over time 
when stimulated (Sharma et al., 2009).  This suggests that in B cells, Btk is involved in 
actin remodelling, which contributes towards the merging of BCR microclusters (Liu et al., 
2011). Microclusters move towards the centre of the cell in in vitro 2D experiments. Actin 
decreases around individual BCR clusters and remodels around the outer edge of the 
central BCR cluster, resulting in centripetal movement of the cluster (Liu et al., 2016). The 
centripetal large BCR cluster is known as the immune synapse (IS), which forms at the 
interface between the antigen presenting cell and the B cell. Btk contributes to IS 
formation via shuttling and scaffolding other proteins but also by its catalytic activity 
(Roman-Garcia et al., 2018).  
 
6.1.2 Microscopy techniques and analysis methods used in this 
study 
6.1.2.1 Stochastic optical reconstruction microscopy     
Stochastic optical reconstruction microscopy (STORM) is a single molecule localisation 
method of microscopy that yields quantitative and qualitative data (co-ordinates and an 
‘image’). First described by Rust et al., 2006, it is a technique that utilises individually 
tagged fluorescent molecules to generate an image. It has far superior imaging resolution 
compared to TIRFM, with a resolution of up to 20nm (Rust et al., 2006). 
Direct STORM (DSTORM) is the most widely used form of STORM due to its relative 
simplicity compared to other types.  Images can be used to generate a 3D image to 
investigate the axial location of molecules within a cell. Or images can be taken within 
TIRF to investigate proteins close to the plasma membrane.  Images are taken in a fixed 
sample, identifying the location of proteins of interest using fluorescently labelled 
antibodies.  High laser power in a redox buffer initiates the stochastic switching of 
fluorophores. This is often referred to as blinking. Immediately before imaging, the liquid 
present in the well is removed and replaced with chemicals and enzymes that stabilise the 
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blinking by regulating the photophysical properties of the fluorophores. The chemicals 
include reducing agents to induce the dark state and oxygen scavengers to ensure the 
fluorophore spends the correct amount of time in each state (Heilemann et al., 2008).  
Figure 6.1.1.A shows the limits of conventional fluorescence microscopy, with different 
fluorophores overlapping. The advantage to STORM is that fluorophore molecules are 
individually turned on and off in a sequential stochastic fashion repeatedly during a user 
defined number of frames. During the reconstruction phase, algorithms within the 
software use the point spread function (Figure 6.1.1.B) to pinpoint the location of the 
fluorophore for each of the blinks. This generates a super-resolved reconstructed image 
(Figure 6.1.2) and the co-ordinates of the blinks as an output (Poulter et al., 2018).  
STORM microscopy is a quantitative method of microscopy. The fluorophore co-ordinates 
enable analysis of data such as protein clustering and colocalisation with a greater 
resolution than traditional methods. STORM has been used in platelets to investigate the 
structure of actin nodules (Poulter et al., 2015) and the clustering of proteins such as 
GPVI, CLEC-2 and Syk (Pollitt et al., 2014, Poulter et al., 2017, Haining et al., 2017b, 





 Figure 6.1.1 Principles of STORM 
(A) Traditional conventional fluorescence microscopy cannot distinguish fluorophores 
closer than 200nm (far left). STORM involves the stochastic switching on (in green) and 
off (in grey) of fluorophores to create a reconstructed image with greater resolution. (B) 
Fluorophores emit light in an airy disk where there is a bright centre with (dark green) with 
decreasing intensity around it (airy disk). Below is the fluorescence profile representations 
of the refraction pattern which is the point spread function (B, dark crosses in A). The 
sequential blinking and STORM algorithm the centre of the point spread function of the 
fluorophore as shown by the crosses, which allows for distinct fluorophores to be viewed 
with a greater resolution. (C) in conventional microscopy (Figure A, first panel) the 
overlapping point spread functions does not distinguish between PSF (black arrow). 
Whereas in STORM generates a reconstructed image with (D) increased resolution as the 





Figure 6.1.2 Reconstructed STORM image of platelets 
A reconstructed STORM image with a zoomed in Section to show that the resolution 
allows for single molecule localisation and clustering. Each dot represents a blink Scale 
bar 10μm and 1μm. 
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6.1.3 Coordinate based colocalisation 
Coordinate based Colocalisation (CBC) is a method to assess the amount of 
Colocalisation seen in super resolution co-ordinate files (Malkusch et al., 2012, Malkusch 
and Heilemann, 2016, Pageon et al., 2016). CBC is a measure of how molecule A is 
distributed throughout the cell in relation to molecule B within a certain defined radius, as 
shown in Figure 6.1.3. Each point is assigned a density gradient of the number of 
molecules of the opposite species are present. Once each molecule has a density 
gradient, the output values are ranked using Spearman’s correlation coefficient. This 
gives each localisation a CBC value between -1 and +1. A CBC of -1 means that the 
localisations of the two molecules are segregated, a value of 0 is random distribution, and 
a value of +1 defines localisations that are totally colocalised. These localisations would 
be stacked upon each other if the images were overlayed. Values >0 is deemed to be 
more colocalised than would randomly occur, but 0.4 is defined as the threshold to 
identify colocalisation suggested Pageon and colleagues.  
 
 
Figure 6.1.3 Principles of CBC analysis 
 (A), (E), are the single molecule localisations of two different molecules, represented as 
magenta and green dots. (B), (F), each localisation of either colour, the distribution of the 
neighbour localisations of the same species is calculated as the radius (black circles) 
increases in user defined increments, this creates the density gradient for each individual 
channel (C), (G), in the second step the density gradient (distribution of neighbour 
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localizations) from centre of the radius of the alternate colour is calculated. (D), (H), Each 
local density is tested for correlation using Spearman’s correlation coefficient, with +1 
values shown in orange being colocalised and blue values being anti colocalised. Each 
single molecule localisation of each different molecule is given an individual colocalisation 
value. Figure adapted from Malkusch et al., 2012.  
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6.1.4 Density based spatial clustering of applications with noise 
(DBSCAN) 
DBSCAN is an algorithm that clusters data based on distance and a number of minimum 
points required to form a cluster. A schematic is shown in Figure 6.1.4. It is a propagative 
cluster method (the clusters are not set to a particular size). Localisations are connected 
to form a cluster if the number of neighbouring point (minimum points) is above the 
threshold within a particular radius (r). Both parameters are user defined. Localisations 
are recruited to the propagating cluster until the parameters are no longer fulfilled 
(Malkusch and Heilemann, 2016, Pageon et al., 2016). DBSCAN also identifies noise 
localisations – molecules that do not cluster and are not on the propagative edge which is 
beneficial (Pageon et al., 2016). DBSCAN is also advantageous as it can detect arbitrary 
shaped clusters, whereas other clustering methods such as Ripley’s K function cannot.  
 
Figure 6.1.4 Schematic of DBSCAN 
DBSCAN is a propagative cluster detection method where connectivity between 
localisations is established if the number of neighbouring localisations is above a certain 
threshold (e.g. 2 in the diagram) within a radius r (e.g. 20 nm). The connection is 
propagated if the parameters are fulfilled (green dots) and stops when the parameters are 
no longer fulfilled (yellow dots). This method can also identify any remaining isolated 







6.1.5 Software used in this study  
6.1.5.1 ChriSTORM  
ChriSTORM is a series of ImageJ macros and scripts (Leterrier et al., 2015) that allow 
translation of Nikon N-STORM output files to be in the correct format to analyse data 
using ThunderSTORM (Ovesný et al., 2014). In addition, the scripts allow for the two 
colours to be separated into individual colours in order to be processed in LAMA 
(Malkusch and Heilemann, 2016).  
6.1.5.2 LocAlisation Microscopy Analyser - LAMA 
LAMA software, designed by Malkusch and Heilemann, 2016, is a freely available 
software that extracts quantitative information from single molecule data. The software 
concentrates on producing biologically relevant information such as clustering, CBC and 
localisation accuracy (Malkusch and Heilemann, 2016).  
Clustering analysis is performed using DBSCAN (Section 6.1.4). In addition to DBSCAN, 
it implements a polygon-based morphology algorithm to provide information on the 
individual cluster side and number of localisations to cluster.  
 
6.1.5.3 Cluster detection with a degree of colocalisation -ClusDoC 
Published after LAMA, ClusDoC combines both cluster detection using DBSCAN and 
CBC to achieve more detailed analysis (Pageon et al., 2016). The software runs through 
MATLAB and allows data to be subclassified for a detailed analysis to give the number of 
clusters that are colocalised. The typical workflow is shown in Figure 6.1.5 below.  
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It is split into two Sections – the CBC analysis (Section 6.1.3 and shown in red in Figure 
6.1.5), whilst simultaneously clustering the localisations using DBSCAN (shown in green, 
Figure 6.1.5). The ClusDoC module (shown in blue) compiles the previous Sections by 
amalgamating cluster detection information and CBC values to distinguish between 
colocalised clusters and non-clustered molecules.  
 
 
Figure 6.1.5 The analysis workflow taken in this study. ClusDoC workflow from 
Pageon et al., 2016 
A Nikon reconstructed image is loaded into ChriSTORM and separated into two colour co-
ordinates for LAMA. LAMA then uses DBSCAN analysis to provide clustering parameters 
of the two separate channels. ClusDoC was used to investigate co-clustering. The CBC 
values for each individual localisation in a user defined radius (visualised in red) are 
calculated. Meanwhile, clustering analysis is performed using DBSCAN to yield 
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information about clustering and cluster maps (green Section). The final Section complies 
the data from the CBC and DBSCAN. The output is the amount of colocalised and non-
colocalised clusters and their parameters.  The reconstructed image from the co-ordinates 
was analysed in Nikon NIS elements using plot profile to assess for colocalization 
 
 
6.2 Aims and Hypothesis 
Little is known about the distribution and localisation of Btk in platelets. Previous 
experiments, using TIRFM, suggested that Btk may be weakly localised with GPVI and 
LAT. There is stronger evidence that Btk is localising with LAT and CLEC-2 when spread 
on rhodocytin. However, the resolution offered with TIRF cannot confirm these 
observations. 
Irrespective of ligand, Btk forms a punctate distribution in platelets (chapter 5, Figure 
5.3.1), similarly to the distribution observed in immune cells (Kane and Watkins, 2005, 
Tomlinson et al., 2004b). This alludes to the ability of Btk to cluster. Furthermore, using 
modelling studies, it is believed that Btk would undergo protein clustering due to the 
phosphorylation of one molecule of Btk by an already active molecule of Btk (Chung et al., 
2019). Therefore, it is likely that Btk will undergo clustering when platelets are active. 
More clustering may be observed on rhodocytin due to the stronger requirement of Btk in 
CLEC-2 mediated signalling (chapter 3 and 4).  
Hypothesis: Btk will cluster when platelets are spread on GPVI and CLEC-2 ligands. Btk 
will colocalise with LAT on both rhodocytin and collagen but is less likely to localise with 
GPVI. Btk will localise with CLEC-2. 
Aims  
• To investigate the clustering of Btk on collagen, CRP-XL and rhodocytin. 
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• To confirm if Btk recruitment is independent of its kinase function as suggested 
using TIRFM. 
• Identify if clustering of GPVI is dependent on Btk kinase activity using 
acalabrutinib 
• To verify the colocalisation results in chapter 5 using dSTORM, a greater 





6.3.1 Investigating protein clustering analysis using STORM and 
LAMA 
GPVI and CLEC-2 are present on the surface of platelets as dimers, and form clusters 
following activation (Clark et al., 2019, Pallini et al., 2020, Poulter et al., 2017, Martyanov 
et al., 2020, Pollitt et al., 2014). Btk forms a punctate formation in platelets (chapter 5, 
Figures 5.3.1 onwards), alluding to cluster formation. Hence, the clustering of Btk and 
other proteins was investigated on GPVI and CLEC-2 ligands.  
Cluster analysis was performed using LAMA software on reconstructed STORM 
coordinates. A cluster was defined as 10 points across a range of radii (25 to 100 nm) to 
investigate the degree of clustering, and to identify an appropriate cluster diameter. Each 













6.3.1.1 Btk and GPVI cluster on collagen  
Btk has not been shown to cluster using dSTORM, whereas clustering of GPVI on 
collagen is required for signalling and has been described in the literature (Poulter et al., 
2017, Dunster et al., 2020, Onselaer et al., 2020, Pallini et al., 2020, Clark et al., 2019). 
Initial experiments were performed to confirm that the clustering approaches applied in 
this study were consistent with the literature.  
Washed platelets were spread on collagen (10μg/mL). Cells were fixed and stained with 
anti Btk and anti GPVI, before staining with secondary antibodies Alexa Fluor 555 
conjugated donkey anti-mouse and Alexa Fluor 647 conjugated donkey anti-goat. 
Samples were imaged using a Nikon N-STORM system in blinking buffer to induce 
fluorophore blinking (Metcalf et al., 2013). 20,000 frames per fluorophore were captured 
and reconstructed using Nikon NIS-Elements STORM analysis module, applying drift 
correction and gaussian rendering. Individual fluorescent blinking events were filtered on 
photon count and only those with a count >400 were selected for further analysis. 
Clustering analysis was performed using LAMA and DBSCAN, to obtain the clusters in 
the field of view and the cluster size (Malkusch and Heilemann, 2016). A cluster was 
defined as the minimum radius (25 to 100nm) and having a minimum of 10 points 
consistent with the work of Poulter and colleagues who selected 10 points within 50nm.  
For Btk clusters, as the radius increases, both the cluster size and the number of 
localisations to a cluster positively correlate with each other (p ≤ 0.01), Figure 6.3.1.C. For 
GPVI as the radii increases, the cluster size also increases (p ≤ 0.05), whereas the 
number of localisations to a cluster does not (Figure 6.3.1.D). The number of clusters gets 






Figure 6.3.1 GPVI and Btk cluster on collagen 
Washed platelets 2x10⁷ cells /mL were spread on 10µg/mL collagen for 45 minutes 
before fixation, permeabilization and staining with (A) Anti-Btk and (B) Anti-GPVI 
antibodies followed by secondary staining with Alexa Fluor 555 conjugated donkey 
anti-mouse and Alexa Fluor 647 conjugated donkey anti-goat . Samples were imaged 
using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 
20,000 frames were captured and reconstructed using Nikon NIS-Elements STORM 
analysis module, applying drift correction and gaussian rendering. 3 fields of view from 
3 independent experiments were imaged. Individual fluorescent blinking events were 
filtered on photon count and only those with a count >400 were selected for further 
analysis. Cluster analysis was performed using DBSCSAN algorithm in LAMA 
software, with a cluster being defined as 10 localisations within 25nm, 50nm, 75nm 
and 100nm. Correlation analysis was performed using GraphPad Prism 8 with the 
significant R values of correlation being stated on the graph for (C) Btk clusters and 













6.3.1.2 Btk and GPVI cluster on CRP-XL  
After Btk was shown to cluster on collagen, similar experiments were performed with 
CRP-XL. This was to identify if Btk clustering is a result specific to the fibrous ligand of 
collagen, and to discount for any interplay of the integrin α2β1. It is known that there is 
differences in the level clustering of GPVI on CRP-XL as opposed to collagen (Poulter 
et al., 2017), and it is not unreasonable to hypothesise that Btk clustering could be 
different.  
Washed platelets were spread on CRP-XL (1μg/mL) for 45 minutes. Platelets were 
then fixed, permeabilised and stained with antibodies as previously described (Section 
5.3.3). Samples were imaged and analysed as described in Section 6.3.1.1. 
When the radii is increased, the number of Btk clusters and the size of the Btk clusters 
both strongly positively correlate as r values are both almost 1 (0.997 and 0.993 for 
number and size of clusters respectively, p ≤ 0.01) (Figure 6.3.2.C). 
 For GPVI, as the parameter of the cluster radii increased, so did the cluster size (r = 
0.995, **p ≤ 0.01). This is consistent to as what has been observed in other 
experiments and is also is what is observed as to what happens on collagen. In 
contrast, as radii increases, the number of clusters is negatively correlated. The r value 
is -0.953, p ≤ 0.05, suggesting strong negative correlation. The number of localisations 
per cluster strongly positively correlates, indicating these correlations are likely due to 







Figure 6.3.2  Btk and GPVI cluster on CRP-XL 
Washed platelets 2x10⁷ cells /mL were spread on 1µg/mL CRP-XL for 45 minutes before 
fixation, permeabilization and staining with anti-Btk (magenta, A) and anti- GPVI (green, 
B) followed by secondary staining with Alexa Fluor 555 conjugated donkey anti-mouse 
and Alexa Fluor 647 conjugated donkey anti-goat. Samples were imaged using a Nikon 
N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 frames were 
captured and reconstructed using Nikon NIS-Elements STORM analysis module applying 
drift correction and gaussian rendering. ≥3 fields of view from 3 independent experiments 
were imaged. Individual fluorescent blinking events were filtered on photon count and only 
those with a count >400 were selected for further analysis. Cluster analysis was 
performed using DBSCSAN algorithm in LAMA software, with a cluster being defined as 
10 localisations within 25nm, 50nm, 75nm and 100nm. Correlation analysis was 
performed using GraphPad Prism 8 with the r value of correlation being stated on the 
graph for (C) Btk clusters and (D) GPVI clusters.  Graphs represent mean ± SEM. Scale 













6.3.1.3 Inhibition of Btk catalytic activity does not impact Btk clustering but does 
impact GPVI clustering  
Initial TIRFM experiments suggested that the punctate distribution of Btk is not altered in 
the presence of the Btk inhibitor acalabrutinib (Section 5.3.2).  However, as Btk has been 
proposed to cluster due to transphosphorylation (Chung et al., 2019), dSTORM was used 
to quantify Btk cluster parameters, to identify changes in the presence of acalabrutinib.  
This approach may identify changes in Btk cluster size and density which cannot be 
visualised with the resolution of TIRFM. 
1μM blocks Btk’s kinase activity as determined by a loss of autophosphorylation using 
biochemical assays (Chapter 3) and therefore this and a lower concentration were used to 
inhibit Btk kinase activity. Washed platelets were treated with either 1μM acalabrutinib, 
0.1μM acalabrutinib or vehicle control before being spread on collagen (10μg/mL) for 45 
minutes. Samples were fixed, permeabilised, stained and imaged as previously described 
(Section 6.3.1.1). Clustering analysis was performed using LAMA software, with a cluster 
being defined as 10 points within 50nm (Malkusch and Heilemann, 2016). These 
parameters were selected to be consistent with Poulter et al., 2017.  
Compared to control treated platelets, the average number of Btk clusters does not 
change in the presence of acalabrutinib. However, 1µM of acalabrutinib treatment 
resulted in a significant decrease in the number of GPVI clusters (Figure 6.3.3.B).  This 
effect was lost at 0.1µM of acalabrutinib.  While there was a decrease in the number of 
GPVI clusters, there was an overall increase in the size of GPVI clusters, suggesting that 
clusters were merging. 
In summary, the kinase activity of Btk is not required for Btk clustering as quantified using 
DSBCAN and cluster parameters of a minimum 10 points per 50nm but is involved in the 





Figure 6.3.3 High concentrations of acalabrutinib inhibit the number of GPVI but 
not Btk clusters compared to vehicle control 
(A) Washed platelets 2x10⁷ cells/mL were treated acalabrutinib (1µM or 0.1μM) or 
vehicle (0.1% DMSO (v/v)) for 5 minutes before spreading on 10µg/mL collagen for 45 
minutes then fixed, permeabilised and stained with anti-Btk and anti-GPVI followed by 
secondary staining with Alexa Fluor 555 conjugated donkey anti-mouse and Alexa 
Fluor 647 conjugated donkey anti-goat before being imaged using a Nikon N-STORM 
system in blinking buffer to induce fluorophore blinking. 20,000 frames were captured 
and reconstructed using Nikon NIS-Elements STORM analysis module, applying drift 
correction and gaussian rendering. 3 fields of view from 3 independent experiments 
were imaged. Individual fluorescent blinking events were filtered on photon count and 
only those with a count >400 selected for further analysis. Cluster analysis was 
performed using DBSCAN algorithm in LAMA software, with a cluster being defined as 
10 localisations within 50nm. (B) The number of clusters of Btk and GPVI were 
analysed along with the (C) cluster size and (D) number of localisations per cluster. 
Graphs represents mean ± SEM. Statistical testing was performed using Two-way 
ANOVA with Dunnett’s post-test. Scale bar represents 5μm.
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6.3.1.4 Btk and LAT cluster on collagen  
Experiments using TIRFM suggested weak colocalisation for Btk and LAT (Section 5.3.5).  
LAT has been shown to cluster in T cells (Lillemeier et al., 2010), and therefore it was 
investigated if it undergoes clustering when spread on collagen.  
Washed platelets were spread on collagen (10μg/mL) for 45 minutes. Platelets were 
fixed, permeabilised and stained with anti-LAT and anti-Btk followed by secondary 
staining with Alexa Fluor 647 conjugated donkey anti rabbit and Alexa Fluor 555 
conjugated donkey anti goat. Imaging and analysis was performed as previously 
described (Section 6.3.1.1).  
When the radii cluster parameter is increased, the number of LAT clusters decreases, 
with the r value being -0.997 (p ≤ 0.01), Figure 6.3.4.C. However, the size of the LAT 
clusters and the number of localisations per cluster both strongly positively correlate with r 
values being almost 1 almost 1 (0.989 and 0.958 for number of localisations to a cluster 
and size of clusters respectively).This is statistically significant (p ≤ 0.05). This is likely 
due to the larger radii incorporating smaller clusters into larger clusters leading to a 
decrease in the overall number of clusters as the radius increases.  
The increase in cluster radii leads to a decrease in the number of LAT clusters is also 
mirrored for Btk clusters (r = -0.992, **p ≤ 0.01) (Figure 6.3.4.D). In contrast, as the radius 
increases, the size of the clusters strongly positively correlates with the cluster size with 
the r value being 0.998 (***p ≤ 0.001).  Furthermore, the number of localisations per 





Figure 6.3.4 Btk and LAT cluster on collagen 
Washed platelets were spread on collagen for 45 minutes before being fixed, 
permeabilised and stained with (A) anti-Btk  (magenta),or (B) anti-LAT (green) and 
secondary stained with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 
555 donkey anti goat antibodies. Samples were imaged using a Nikon N-STORM system 
in blinking buffer to induce fluorophore blinking. 20,000 frames of each colour were 
captured and reconstructed using Nikon NIS-Elements STORM analysis module, applying 
drift correction and gaussian rendering. ≥3 separate fields of view from 3 independent 
experiments were imaged. Individual fluorescent blinking events were filtered on photon 
count and only those with a count >400 were selected for further analysis. Cluster 
analysis was performed using the DBSCSAN algorithm in LAMA software, with a cluster 
being defined as 10 localisations within 25nm, 50nm, 75nm and 100nm. Correlation 
analysis was performed using GraphPad Prism 8 with the r value of correlation being 
stated on the graph for (C) LAT clusters and (D) Btk clusters.  
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6.3.1.5 Btk and CLEC-2 cluster when platelets spread on rhodocytin 
Btk is distributed as a punctate pattern on GPVI ligands.  It was investigated to see if Btk 
formed a similar distribution when platelets were spread on a CLEC-2 ligand rhodocytin  
Washed platelets were spread on 100nM rhodocytin for 45 minutes before fixation, 
permeabilization and staining with anti-Btk and anti-CLEC-2 followed by secondary 
staining with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 555 
conjugated donkey anti-mouse as in Section 5.3.7 Imaging and cluster analysis were 
performed as previously described (Section 6.3.1.1).  
Similarly, as to when platelets spread on collagen, as the radius increases the number of 
Btk clusters decreases (r= -0.995, p ≤ 0.01). Whereas, as the radius increases there is a 
positive correlation with cluster size and the number of localisations per cluster (p ≤ 0.05, 
r=0.98), Figure 6.3.5.C. This can be viewed in the representative image as when the 
cluster diameter is 25nm there are clusters that are close together that are different 
colours, whereas in the images with an increased in diameter such as 100nm, clusters 
are the same colour showing they have merged.  
As the size of the radius increase, the number of CLEC-2 clusters also decreased, Figure 
6.3.5.D. In contrast, the size of the CLEC-2 clusters and the number of localisations per 
cluster both strongly positively correlated with the increased radii size (r>0.95 and *p ≤ 
0.05 for both size of clusters and the number of localisations per cluster).  
Taken together, this suggests that Btk and CLEC-2 cluster in platelets spread on 
rhodocytin and that small clusters are localised near each other, that amalgamate with 






Figure 6.3.5 Btk and CLEC-2 cluster on rhodocytin 
Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes before 
fixation, permeabilization and staining with anti-Btk (magenta, A) and anti-CLEC-2 (green, 
B) followed by secondary staining with Alexa Fluor 647 conjugated donkey anti-rabbit and 
Alexa Fluor 555 conjugated donkey anti-mouse. Samples were imaged using a Nikon N-
STORM system in blinking buffer to induce fluorophore blinking. 20,000 frames of each 
colour were captured and reconstructed using Nikon NIS-Elements STORM analysis 
module, applying drift correction and gaussian rendering. ≥3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis. 
Cluster analysis was performed using the DBSCAN algorithm in LAMA software, with a 
cluster being defined as 10 localisations within 25nm, 50nm, 75nm and 100nm. 
Correlation analysis was performed using GraphPad Prism 8 with the R value of 
correlation being stated on the graph for (C) Btk clusters and (D) CLEC-2 clusters. Graph 
represents mean ± SEM *p ≤ 0.05, **p ≤ 0.01.  Scale bar represents 1µm. 
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6.3.1.6 Btk and LAT cluster when platelets spread on rhodocytin  
Btk and LAT were shown to cluster on collagen, and therefore this was investigated 
downstream of CLEC-2, on rhodocytin. Washed platelets were spread on rhodocytin 
(100nM) for 45 minutes. Platelets were then fixed, permeabilised, stained, imaged, and 
analysed as in Section 6.3.1.4. The representative images in Figure 6.3.6 show that both 
LAT and Btk form a punctate pattern which can be observed in Figure 6.3.6.A and B. 
As observed with platelets spread on collagen, the number of LAT clusters decreases as 
the defined radius of the cluster analysis increases, with a strong correlation (r=-0.995 p ≤ 
0.01), Figure 6.3.6.C. The cluster size, (r=0.951, p ≤ 0.05), and the number of 
localisations per cluster also increases as the radius increases (r=0.987, p ≤ 0.05). For 
Btk, as the radius increased, similarly to LAT, the number of clusters decreased with a 
strong negative correlation (r=-0.99, p ≤ 0.01). The cluster size and number of 
localisations per cluster has a strong positive correlation, as the radii increases (both 
r>0.99, p ≤ 0.01), Figure 6.3.6.D.  This suggests that for both LAT and Btk, smaller 






Figure 6.3.6 Btk and CLEC-2 cluster on rhodocytin 
Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes before 
fixation, permeabilization and staining with anti-LAT (magenta, A) and anti-Btk (green, B) 
followed by secondary staining with Alexa Fluor 647 conjugated donkey anti-rabbit and 
Alexa Fluor 555 donkey anti goat antibodies. Samples were imaged using a Nikon N-
STORM system in blinking buffer to induce fluorophore blinking. 20,000 frames of each 
colour were captured and reconstructed using NIS-Elements Nikon STORM analysis 
module, applying drift correction and gaussian rendering. ≥3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis. 
Cluster analysis was performed using the DBSCSAN algorithm in the LAMA software, 
with a cluster being defined as 10 localisations within 25nm, 50nm, 75nm and 100nm. 
Correlation analysis was performed using GraphPad Prism 8 with the R value of 
correlation being stated on the graph for LAT clusters (C) and Btk clusters (D). Graph 
represents mean ± SEM *P ≤ 0.05, **p ≤ 0.01.  Scale bar represents 5µm. 
301 
 
6.3.2 Colocalisation analysis using plot profile along a collagen 
fibre or line across a platelet  
Plot profile analysis  
Btk did not strongly localise with GPVI in TIRFM, however, it did look to form an inverse 
relationship along the fibre, with Btk puncta being present in areas where GPVI is absent 
(chapter 5, Figure 5.3.1). To assess the distribution of Btk and GPVI along the collagen 
fibre the plot profile function in Nikon NIS-Elements software was used. Plot profile 
displays the numerical output of the fluorescence converted into an arbitrary unit if 
fluorescence is present in either channel separately or together along a line within a 
reconstructed STORM images. To account for different length of collagen fibre these 
values were presented as a percentage of total localisations present at the fibre, 
excluding areas where no localisations were present. An example is shown in Figure 




Figure 6.3.7 Plot profile analysis method 
A reconstructed STORM image with Btk (magenta) and GPVI (green) staining of platelets 
spread on collagen is opened in Nikon NIS-Elements software. The DIC image is also 
opened (not shown) to confirm the location of the collagen fibre. The fluorescence profile 
of Btk and GPVI along the fibre is analysed by drawing along the fibre and a resulting 
graph is made (right hand panel of (A). This is then analysed in excel to quantify the % 
localisations of the fibre to normalise for the differences in fibre length across samples. 
(B) For nonfibrous ligands, a random cross Section through the platelet is taken.  
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6.3.2.1 Syk and GPVI colocalise to collagen fibres when evaluated using plot 
profile analysis 
Published (Dunster et al., 2020, Pallini et al., 2020) and previous work suggests that Syk 
and GPVI colocalise when imaged using TIRFM  (Chapter 5). The localisation of GPVI 
and Syk in relation to each other was investigated using STORM and analysed using plot 
profile analysis.   
Samples were prepared as described in Section 5.3.6. Platelets were then imaged using 
STORM and reconstructed (Section 6.3.1.1). The plot profile along the collagen fibre was 
used to assess recruitment and colocalisation of GPVI and Syk to the fibre. As seen in 
previous TIRFM experiments GPVI and Syk strongly localise to collagen fibre (Section 
5.3.6 and Figure 6.3.1.A). Syk is abundantly located but colocalisation with GPVI can be 
seen in the merged image, represented by white areas (Figure 6.3.8.A).  
GPVI alone makes up most of the localisations on the fibre (38.9% ± 2.3). However, a 
large proportion of GPVI is colocalised with Syk (32.2% ± 0.6) Figure 6.3.8.B. Together 






Figure 6.3.8 Syk and GPVI colocalise when spread on collagen and imaged in 
STORM 
(A) Washed platelets were spread on collagen for 45 minutes before being fixed, 
permeabilised and stained with anti-Syk (magenta) and anti-GPVI (green). Samples were 
secondary stained with Alexa Fluor 647 donkey anti rabbit and Alexa Fluor 555 goat anti 
mouse and imaged using a Nikon N-STORM system in blinking buffer to induce 
fluorophore blinking. 20,000 frames were captured and reconstructed using Nikon 
STORM analysis module, applying drift correction and gaussian rendering. 3 separate 
fields of view from 3 independent experiments were imaged. Individual fluorescent 
blinking events were filtered on photon count and only those with a count >400 was 
selected for further analysis. Scale bar represents 10μm.  Plot profile analysis was 
performed using Nikon NIS-Elements by selecting 3 random fibres to draw along. The 
resulting values were put into Excel to identify it there was fluorescent present in the Syk 
or GPVI channel or present in both at the same location. (B) The percentage of 
localisations was then calculated. Graph represents mean ± SEM, n=3. Statistical testing 
was performed using one-way ANOVA with Tukey’s multiple comparisons post-test. (C) A 




6.3.2.2 Btk and GPVI partly colocalise in STORM on collagen 
Plot profile was used to investigate the localisations of Btk and GPVI at the collagen fibre. 
Samples were prepared, imaged, and reconstructed as in Section 6.3.1.1. Plot profile 
analysis was performed as explained above in Section 6.3.2. 
The localisations along the fibre were predominantly made up of GPVI (Figure 6.3.9.E), 
with single GPVI localisations accounting for an average 65.8% (±9.9) of localisations at 
the fibre. Btk localisations made up less than 10% of the localisations (9.8% ± 5.1), 
suggesting that Btk is only present in small amounts in the absence of GPVI. Interestingly, 
Btk is largely present colocalised with GPVI, with Btk and GPVI colocalising along 
approximately 25% of the fibre’s length, as evident from Figure 6.3.9.C, where the slight 







Figure.6.3.9 Btk and GPVI colocalise along collagen fibres when imaged using 
STORM 
Washed platelets 2x10⁷ cells /mL were spread on 10µg/mL collagen for 45 minutes before 
fixation, permeabilization and staining with (B) anti-GPVI and (C) anti-Btk followed by 
secondary staining with Alexa Fluor 555 conjugated donkey anti-mouse and Alexa Fluor 
647 conjugated donkey anti-goat . Samples were imaged using (A) DIC to visualise the 
collagen fibres or (B, C) using a Nikon N-STORM system in blinking buffer to induce 
fluorophore blinking. 20,000 frames were captured and reconstructed using Nikon NIS-
Elements STORM analysis module, applying drift correction and gaussian rendering. 3 
fields of view from 3 independent experiments were imaged. Individual fluorescent 
blinking events were filtered on photon count and only those with a count >400 were 
selected for further analysis. Scale bar represents 10μm.  Plot profile analysis was 
performed using Nikon NIS-Elements and selecting 3 random collagen fibres per image 
identified using DIC (A) to draw along. The resulting values were put into excel to identify 
the presence of Btk, GPVI or both at each pixel along the fibre, converting the 
fluorescence into binary units (E) The % of localisations along the fibres were then 
calculated. (F) represents a Section of raw data before normalisation. Scale bar 10nm. 
Graph represents Mean ± SEM. Statistical testing was performed using one-way ANOVA 
with Tukey’s multiple comparisons post-test.
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6.3.2.3 Btk kinase inhibition does not change the amount of Btk and GPVI 
recruited to the collagen fibre  
As approximately 25% of the fibre’s localisations has Btk and GPVI colocalised, it was 
investigated if the recruitment of Btk was dependent on its kinase activity. Therefore, the 
recruitment of Btk to the collagen fibres in the presence of acalabrutinib was assessed 
using STORM and analysed using the plot profile approach described above.  This may 
provide further evidence for a scaffolding role for Btk. 
1μM blocks Btk’s kinase activity as determined by a loss of autophosphorylation using 
biochemical assays (Chapter 3). Therefore, 1μM and 0.1μM acalabrutinib were used to 
investigate the role of Btk kinase function in Btk recruitment to collagen fibres. Washed 
platelets were pre-treated with acalabrutinib before being spread on 10μg/mL collagen 
before fixation, permeabilization and staining as previously described (Section 6.3.1.3). 
Imaging and plot profile analysis was assessed as previously described.  
GPVI lines up along the collagen fibre. Interestingly in the representative image of the 
0.1μM acalabrutinib treated platelets, there appears to be a Section of Btk that looks to 
localise in a line near the fibre, but it does not overlap with GPVI in the merged image, 
Figure 6.3.10.C.  
Drug treatment does not alter the proportion of Btk and GPVI colocalising together along 
the fibre. However, 0.1μM acalabrutinib increases the proportion of Btk present at the 
fibre (p ≤ 0.05) and subsequently reduces the amount of GPVI present at the fibre (p ≤ 
0.05) when compared to the vehicle control. This shows that the fibre is made up of 
predominantly GPVI localizations, and Btk does not look to localise with GPVI but this 
does not change in the presence of Btk inhibitor. This further provides evidence for a 








Figure 6.3.10 Treatment with Btk inhibitors can change the location of Btk and GPVI 
when analysed using the plot profile method. 
 Washed platelets were treated with (A) vehicle control, (B) 1μM acalabrutinib or (C) 
0.1μM acalabrutinib and then spread on collagen for 45 minutes. Samples were fixed, 
permeabilised and stained with anti-Btk (magenta) and anti-GPVI (green) followed by 
secondary staining with Alexa Fluor 555 conjugated donkey anti-mouse and Alexa Fluor 
647 conjugated donkey anti-goat before being imaged. Samples were imaged using DIC 
or the Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 
frames per fluorophore were captured and reconstructed using Nikon NIS-Elements 
STORM analysis module, applying drift correction and gaussian rendering. 3 fields of view 
from 3 independent experiments were imaged. Individual fluorescent blinking events were 
filtered on photon count and only those with a count >400 were selected for further 
analysis. Scale bar represents 5μm.  Plot profile analysis was performed using Nikon NIS-
Elements selecting 3 random collagen fibres per image identified in the DIC image to 
draw over. The resulting values were put into excel to identify if fluorescence was present 
in the Btk, GPVI or both channels. (D) The percentage of localisations was then 
calculated. Graph represents Mean ± SEM. Statistical testing was performed using Two-












6.3.2.4 When assessed using plot profile analysis Btk and GPVI do not strongly 
colocalise in platelets spread of CRP-XL  
The data presented above demonstrated that GPVI is strongly localised to collagen fibres 
and that a proportion of Btk colocalises with GPVI.  To determine if GPVI and Btk 
colocalise on a non-fibrous GPVI ligand platelets were spread on CRP-XL and imaged 
using STORM and analysed using plot profile using a random cross-section through the 
middle of the platelet, an example is presented in Figure 6.3.7.B. 
Using this approach approximately 10% of localisations among the plot profile contained 
both GPVI and Btk (Figure 6.3.11.D).  GPVI and Btk are largely discretely present 












Figure 6.3.11 Plot profile assessment of Btk and GPVI colocalisation in platelets 
spread of CRP-XL 
Washed platelets were spread on CRP for 45 minutes before being fixed, permeabilised and 
stained with (A) anti-Btk (magenta) and (B) anti-GPVI (green) followed by secondary staining 
with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 488 conjugated goat 
anti-mouse. Samples were imaged using a Nikon N-STORM system in blinking buffer to 
induce fluorophore blinking. 20,000 frames were captured and reconstructed using Nikon 
NIS-Elements STORM analysis module, applying drift correction and gaussian rendering. 3 
fields of view from 3 independent experiments were imaged. Individual fluorescent blinking 
events were filtered on photon count and only those with a count >400 were selected for 
further analysis. Scale bar represents 5μm.  Plot profile analysis was performed using Nikon 
NIS-Elements and selecting 3 random cross Sections through the platelets (A). The resulting 
values were put into excel to identify pixels with fluorescence for Btk, GPVI or both. (E)The 
percentage of localisations was then calculated. Graph represents Mean ± SEM. Statistical 
testing was performed using one-way ANOVA with Tukey’s multiple comparisons post-test, 
*p ≤ 0.05. 
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6.3.2.5 Btk and LAT partially colocalise at collagen fibres when assessed using 
plot profile analysis 
Btk did not strongly colocalise with GPVI but it may interact with proteins further down 
the GPVI signalling pathway, for example LAT. Btk has been shown to co-
immunoprecipitate with LAT (Pasquet et al., 1999b). Therefore, STORM experiments 
were utilised to investigate if Btk colocalises with LAT along collagen fibres. 
Experiments were performed and analysed as previously described in Sections 6.3.1.4 
and 6.3.2. 
As Figure 6.3.12.B shows, Btk, looks to be recruited to the fibre in some parts of the 
image (Btk in magenta), but not wholly. When colocalisation at the fibre was assessed 
using plot profile analysis, the majority of Btk present was localising with LAT (43.1% ± 
5.4, p ≤ 0.05 comparing to Btk alone). A small proportion of the localisations were Btk 
alone (15.9% ±4.8), but a large amount of LAT was seemingly present along the fibre 
alone (41.% ±0.7), which is greater than the proportion of Btk (p ≤ 0.05). This suggests 











Figure 6.3.12 Btk can partially colocalise with LAT along collagen fibres when  
assessed using plot profile analysis 
 Washed platelets were spread on 10μg/mL collagen for 45 minutes before being fixed, permeabilised and stained with (B) anti-Btk (magenta), or (C) 
anti-LAT (green) and secondary stained with Alexa Fluor 647 conjugated donkey anti-rabbit and Alexa Fluor 555 donkey anti goat antibodies. 
Samples were imaged using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 frames of each colour were captured 
and reconstructed using Nikon NIS-Elements STORM analysis module, applying drift correction and gaussian rendering. ≥3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered on photon count and only those with a count >400 were 
selected for further analysis. Scale bar represents 10μm.  Plot profile analysis was performed using Nikon NIS-Elements by selecting 3 random 
collagen fibres identified using the DIC image (A). The resulting values were put into Excel to identify it there was fluorescent present in the Btk or 
GPVI channel or present in both at the same location. (E) The percentage of localisations was then calculated. Graph represents Mean ± SEM, n=3. 
Statistical testing was performed using one-way ANOVA with Tukey’s multiple comparisons post-test, *p ≤ 0.05. (F) shows a representative 
fluorescent intensity plot profile image.  
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6.3.2.6 Btk and CLEC-2 look to colocalise when spread on rhodocytin and 
examined using plot profile analysis 
Syk and SFK regulate CLEC-2 clustering (Pollitt et al., 2014). As Btk is involved in CLEC-
2 signalling (Chapter 3) and the relation of Btk to these tyrosine kinases (Li et al., 1997, 
Park et al., 1996, Wahl et al., 1997), it was hypothesized that  Btk may influence 
clustering of CLEC-2 and may be localised near it. Therefore, the localisation of the two 
proteins was assessed in relation to each other using plot profile analysis. 
Platelets were spread on rhodocytin (100nM) for 45 minutes before fixation, staining and 
imaging in STORM as previously described (Section 6.3.1.5). 
As the panel on the right in Figure 6.3.13.A shows that Btk is seemingly localised all 
throughout the platelet as observed on other agonists. In addition, CLEC-2 is also 
generally distributed throughout the platelet. The merged image does show areas of white 
suggesting that some Btk is colocalised with CLEC-2 when platelets spread on 
rhodocytin.  
The average percentage of localisations of Btk and CLEC-2 together was almost 40% 
(39.64 ± 1.4), which is approximately 10% more than Btk alone (29.14% ± 4.9). This 
suggests that a portion of Btk molecules in the platelet colocalise with CLEC-2 and vice 
versa. However, a high proportion of Btk does not localise with CLEC-2, and the 
proportion of Btk that localises with CLEC-2 is not significantly increased compared to the 
non-colocalised proportion. Therefore it is difficult to ascertain whether these values are 





Figure 6.3.13 Btk and CLEC-2 localise together in spread platelets on rhodocytin 
when analysed using plot profile analysis 
(A) Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes 
before fixation, permeabilization and staining with anti-Btk and anti-CLEC-2 before being 
imaged using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 
20,000 frames were captured and reconstructed using Nikon NIS-Elements STORM 
analysis module, applying drift correction and gaussian rendering. 3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis. 
Scale bar represents 10μm.  Plot profile analysis was performed using Nikon NIS-
Elements by selecting 3 random cross Sections through the middle of the platelet. The 
resulting values were put into Excel to identify if there was fluorescence present in the Btk 
or CLEC-2 channel individually or together. (B) The percentage of localisations was then 
calculated. Graph represents mean ± SEM, n=3. Statistical testing was performed using 
one-way ANOVA with Tukey’s multiple comparisons post-test with no significance found. 
(C) shows a representative fluorescence intensity image of a random cross Section 
through the middle of the imaged platelet before normalisation. 
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6.3.2.7 Btk and LAT look to colocalise when spread on rhodocytin and examined 
using plot profile analysis 
Initial work using TIRFM suggested that Btk and LAT colocalise when spread on 
rhodocytin. Therefore, plot profile was used to investigate if this colocalisation was 
maintained when imaged at a higher resolution using STORM.   
Samples were prepared, imaged, and reconstructed as previously described in Section 
6.3.1.5. Random cross Sections across the platelet were selected and the fluorescence 
intensity across the channels analysed (Figure 6.3.14.F). 
When spread on rhodocytin and imaged using STORM, Btk and LAT do not look to 
directly colocalise as shown in the lack of white colour in the merged image (Figure 
6.3.14.D). This is in direct contrast as to what was observed in TIRFM imaging. 
Furthermore, when the proportion of localisations across a random cross Section were 
analysed, there appears to be an approximately equal amount of Btk and LAT in separate 
areas. There is significantly more Btk localising on its own, than with LAT (p ≤ 0.05). This 
suggests that in STORM microscopy and assessment using plot profile analysis, Btk and 







Figure 6.3.14 Btk and LAT do not look to colocalise when assessed using plot 
profile when spread on rhodocytin 
(A-D) Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes 
before fixation, permeabilization and staining with (B) anti-Btk and (C) anti-LAT before 
being imaged using a Nikon N-STORM system in blinking buffer to induce fluorophore 
blinking. 20,000 frames were captured and reconstructed using Nikon NIS-Elements 
STORM analysis module, applying drift correction and gaussian rendering. 3 fields of view 
from 3 independent experiments were imaged. Individual fluorescent blinking events were 
filtered on photon count and only those with a count >400 were selected for further 
analysis (A). Scale bar represents 5μm.  Plot profile analysis was performed using Nikon 
NIS-E elements using 3 random cross Sections to analyse. The resulting values were put 
into Excel to identify it there was fluorescent present or absent in the Btk or LAT channel 
or present in both at the same location. (B)The percentage of all localisations was then 
calculated. Graph represents mean ± SEM, n=3. Statistical testing was performed using 
one-way ANOVA with Tukey’s multiple comparisons post-test with no significance found. 
(C) shows a representative fluorescence intensity image of a random cross Section 











6.3.3 Investigating the colocalisation of protein clusters  
Previous Sections in this Chapter have investigated the clustering of proteins in platelets 
and the amount of colocalisation along a fibre or along a cross Section.   The data above 
is analysed to determine if two molecules colocalise in a binary fashion.  To analyse how 
clusters of molecules interact with each other ClusDoc software was utilised to investigate 
cluster colocalisation. (Pageon et al., 2016). 
All samples were imaged and reconstructed as previously described in Sections 6.3.1. 
Co-ordinate files were loaded into ClusDoc which runs via MATLAB. Cluster parameters 
were set as a minimum of 10 points within a 50nm radius (epsilon) as described in Poulter 
et al. A CBC value of 0.4 or over was selected as a measurement of colocalisation 
according to recommendations from the literature (Pageon et al., 2016). 
 
 
6.3.3.1 Clusters of GPVI colocalise with Btk more than clusters of Btk with GPVI  
There is no significant difference in the number of clusters that are colocalised for Btk with 
GPVI when platelets are spread on collagen. However, there is a significant number of 
GPVI clusters that colocalise with Btk compared with GPVI without Btk, Figure 6.3.16.B (p 
≤ 0.01).   
GPVI clusters are much larger than Btk clusters (p ≤ 0.05). As DBSCAN analysis is 
propagative, the GPVI clusters are larger when associated with the collagen fibre. Indeed, 
the GPVI colocalised clusters are significantly less circular than their non-colocalised 
counterparts, suggesting colocalised clusters are along the fibre, Figure 6.3.16.E 
Furthermore, there is a significant increase in the size of GPVI clusters that colocalise 
with Btk compared to GPVI clusters which do not colocalise (p ≤ 0.05), Figure 6.3.16.D. 
This is also reflected in the increased number of localisations per colocalised GPVI cluster 





Figure 6.3.15 Cluster analysis of Btk and GPVI co-clusters 
Washed platelets 2x10⁷ cells /mL were spread on 10μg/mL collagen for 45 minutes before 
fixation, permeabilization and staining with anti-Btk and anti-GPVI before being imaged. 
Samples were imaged using a Nikon N-STORM system in blinking buffer to induce 
fluorophore blinking. 20,000 frames were captured and reconstructed using Nikon NIS-
Elements STORM analysis module, applying drift correction and gaussian rendering. 3 
fields of view from 3 independent experiments were imaged. Individual fluorescent 
blinking events were filtered on photon count and only those with a count >400 were 
selected for further analysis using ClusDoC. (A) Representative ROI from a reconstructed 
image with Btk in green and GPVI in red, with clusters of GPVI and Btk identified (cluster 
defined as ≥10 localisations within 50nm) (i),  the cluster density (ii) and the CBC plots 
(radius is also 50nm) (iii). Clusters with CBC values greater than 0.4 were analysed 
further and the (B) number of clusters (C) average area of a cluster, (D) circularity of a 
cluster and the € number of localisations per cluster were quantified. Graphs represent 
mean ± SEM, n=3. Statistical testing was performed using two-way ANOVA with 
Dunnett’s post-test, *p ≤ 0.05. 
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6.3.3.2 Btk kinase inhibition does not inhibit the number of GPVI or Btk clusters, or 
their colocalisation relative to each other.  
Using LAMA and DBSCAN in Section 6.3.1.3, it was identified that 1μM acalabrutinib 
increased the size of GPVI clusters.  ClusDoC was used to quantify the relationship 
between Btk and GPVI in the presence of the Btk inhibitor acalabrutinib. If Btk clusters 
and GPVI clusters colocalise when its kinase activity is inhibited, it would suggest a 
potential negative regulation as a scaffold in downstream of GPVI clustering.   
Compared to vehicle control, there is no significant difference in the number of clusters, 
the average area of a cluster, the circularity of a cluster or the number of localisations per 
cluster for drug treated platelets spread on collagen for GPVI clusters and Btk clusters 
which colocalise or not (Figure 6.3.17 Di-Hii).This suggests using this analysis that 
clustering of GPVI and Btk is not regulated by the catalytic activity of Btk in contrast to the 





Figure 6.3.16 Acalabrutinib does not alter clustering of Btk and GPVI using 
ClusDoC 
Washed platelets 2x10⁷ cells /mL were pre-treated with 1μM, 0.1μM acalabrutinib or 
vehicle control before being spread on 10μg/mL collagen for 45 minutes before fixation, 
permeabilization and staining with anti-Btk and anti-GPVI before being imaged using a 
Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 frames 
were captured and reconstructed using Nikon NIS-Element STORM analysis module, 
applying drift correction and gaussian rendering. 3 fields of view from 3 independent 
experiments were imaged. Individual fluorescent blinking events were filtered on photon 
count and only those with a count >400 were selected for further analysis using ClusDoC. 
Representative ROI from (A) vehicle (B) 1μM acalabrutinib and (C) 0.1μM acalabrutinib 
treated platelets; reconstructed image with Btk in green and GPVI in red, with clusters of 
GPVI and Btk identified (cluster defined as ≥10 localisations within 50nm) (i) the cluster 
density (ii) and the CBC plots (radius is also 50nm) (iii). Clusters with CBC values greater 
than 0.4 were analysed further and the number of clusters (Di, Ei) average area of a 
cluster, (Dii, Eii) circularity of a cluster and the (Diii, Eiii) number of localisations per 
cluster (Diiii, Eiiii) for Btk (Di-iii) and GPVI (Ei-iiii) were quantified. Graphs represent mean 
± SEM, n=3. Statistical testing was performed using two-way ANOVA with Dunnett’s post-







6.3.3.3 Btk and GPVI clusters do not colocalise on CRP-XL 
When platelets are spread on CRP-XL there are more clusters of GPVI than there are of 
Btk, with most of the GPVI clusters not associated with Btk (p ≤0 .001) (Figure 6.3.18.B). 
GPVI clusters that do not localise with Btk have more molecules per cluster than those 
which colocalise with Btk (p ≤ 0.05), Figure 6.3.18.F.  
Taken together this suggests, although there are less of them, the GPVI clusters that are 
colocalised with Btk are more compact. As the localisations per cluster increase, but the 
cluster area does not (Figure 6.3.18.C). More compact clusters may be a sign of 








Figure 6.3.17 Btk and GPVI do not localise when platelets are spread on CRP-XL 
Washed platelets 2x10⁷ cells /mL were spread on 1μg/mL CRP for 45 minutes before 
fixation, permeabilization and staining with anti-Btk and anti-GPVI before being imaged 
using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 
frames were captured and reconstructed using Nikon NIS-Elements STORM analysis 
module, applying drift correction and gaussian rendering. 3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis using 
ClusDoC. (A) Representative ROI from a reconstructed image with Btk in green and GPVI 
in red, with clusters of GPVI and Btk identified (cluster defined as ≥10 localisations within 
50nm) (i) the cluster density (ii) and the CBC plots (radius is also 50nm) (iii). Clusters with 
CBC values greater than 0.4 were analysed further and the (B) number of clusters (C) 
average area of a cluster, (D) circularity of a cluster and the (E) number of localisations 
per cluster were quantified.  Statistical testing was performed using two-way ANOVA with 













6.3.3.4 Btk preferentially localises with LAT when platelets spread on collagen.  
Coclustering of Btk and LAT were investigated using ClusDoC. There is an equal number 
of LAT clusters that form with and without Btk, Figure 6.3.19.B. However, there are 
significantly more clusters of Btk that have LAT present (colocalised) compared with non-
colocalised clusters, Figure 6.3.19.B, and these have significantly more localisations per 
cluster (Figure 6.3.19.E). Taken together, this suggests that Btk preferentially localises 
with LAT as there are more clusters of Btk that have LAT within them. These clusters of 
Btk with LAT have more localisations, suggesting more molecules present which may 





Figure 6.3.18 Btk preferentially colocalises with LAT 
Washed platelets 2x10⁷ cells/mL were spread on 10μg/mL collagen for 45 minutes before 
fixation, permeabilization and staining with anti-Btk and anti-LAT before being imaged 
using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 
frames were captured and reconstructed using Nikon NIS-Elements STORM analysis 
module, applying drift correction and gaussian rendering. 3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis using 
ClusDoC. (A) Representative ROI from a reconstructed image with Btk in red and LAT in 
green, with clusters of LAT and Btk identified (cluster defined as ≥10 localisations within 
50nm) (i) the cluster density (ii) and the CBC plots (radius is also 50nm) (iii). Clusters with 
CBC values greater than 0.4 were analysed further and the (B) number of clusters (C) 
average area of a cluster, (D) circularity of a cluster and the (E) number of localisations 
per cluster were quantified. Statistical testing was performed using two-way ANOVA with 













6.3.3.5 Btk and CLEC-2 do not colocalise when platelets spread on rhodocytin  
Using TIRFM and MCC and plot profile, Btk looks to colocalise with CLEC-2 more than 
GPVI, it was investigated to identify if clusters of Btk and CLEC-2 colocalise together.  
Most of the Btk clusters are not associated with CLEC-2. There is on average 
approximately 10x more clusters of Btk that do not seem to colocalise with CLEC-2 (74.59 
± 19.33, (p ≤ 0.01 when compared to colocalised Btk clusters. The Btk clusters that do 
colocalise with CLEC-2 are significantly larger than the clusters that do not.  However, for 
CLEC-2 clusters, there is no difference in the average cluster area if they are colocalised 
with Btk or not, (Figure 6.3.20.C).  
In addition to being larger, Btk clusters have more Btk localisations per cluster when they 
colocalises with CLEC-2.  This is consistent with the observations that Btk colocalises 





Figure 6.3.19 Btk and CLEC-2 do not strongly colocalise 
Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes before 
fixation, permeabilization and staining with anti-Btk and anti-CLEC-2 before being imaged 
using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 20,000 
frames were captured and reconstructed using Nikon NIS-Elements STORM analysis 
module, applying drift correction and gaussian rendering. 3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis using 
ClusDoC. (A) Representative ROI from a reconstructed image with Btk in green and 
CLEC-2 in red, with clusters of CLEC-2 and Btk identified (cluster defined as ≥10 
localisations within 50nm) (i) (, the cluster density (ii) and the CBC plots (radius is also 
50nm) (iii). Clusters with CBC values greater than 0.4 were analysed further and the (B) 
number of clusters (C) average area of a cluster, (D) circularity of a cluster and (E) 
number of localisations per cluster were quantified. Statistical testing was performed 
using two-way ANOVA with Dunnett’s post-test, *p ≤ 0.05, ***p ≤ 0.01. Graphs represent 













6.3.3.6 Btk partially colocalised with LAT when platelets spread on rhodocytin 
As Btk and LAT look to co-cluster when spread on collagen (Section 6.3.3.4), this was 
investigated on the CLEC-2 ligand, rhodocytin.  
Significantly more clusters of LAT are identified without the presence of Btk (p ≤ 0.05). 
Whereas there was similar number of clusters of Btk localising with and without LAT (18 ± 
3 and 19 ± 6 respectively), (Figure 6.3.21.B). Clusters of LAT that colocalise are 
approximately 5x larger than clusters that do not colocalise (p ≤ 0.05). There is no 
significant difference in the size of the clusters of Btk colocalised with LAT compared to 
without LAT. However, the number of localisations detected per cluster is significantly 
greater for Btk clusters colocalised with LAT that Btk clusters without LAT (p ≤ 0.01). This 
is also observed with LAT clusters (Figure 6.3.21.E), and LAT clusters which are 
significantly larger when colocalised with Btk than LAT clusters without Btk (p ≤ 0.05), 
(Figure 6.3.21.C). 
This suggests that colocalised clusters are of LAT are larger, even though there are fewer 
of them. In contrast, Btk clusters that are colocalised are the same size but denser than 
non-colocalised clusters. This suggests stronger recruitment of Btk to LAT than LAT to 







Figure 6.3.20 Btk partially colocalises with LAT when platelets are spread on 
rhodocytin 
 Washed platelets 2x10⁷ cells /mL were spread on 100nM rhodocytin for 45 minutes 
before fixation, permeabilization and staining with anti-Btk and anti-LAT before being 
imaged using a Nikon N-STORM system in blinking buffer to induce fluorophore blinking. 
20,000 frames were captured and reconstructed using Nikon NIA-Elements STORM 
analysis module, applying drift correction and gaussian rendering. 3 fields of view from 3 
independent experiments were imaged. Individual fluorescent blinking events were filtered 
on photon count and only those with a count >400 were selected for further analysis using 
ClusDoC. (A) Representative ROI from a reconstructed image with Btk in red and LAT in 
green, with clusters of LAT and Btk identified (cluster defined as ≥10 localisations within 
50nm) (i) (, the cluster density (ii) and the CBC plots (radius is also 50nm) (iii). Clusters 
with CBC values greater than 0.4 were analysed further and the (B) number of clusters 
(C) average area of a cluster, (D) circularity of a cluster and the (E) number of 
localisations per cluster were quantified.  Statistical testing was performed using two-way 













6.3.4 Results summary 
From the calculated plot profiles, the % localisations that appear together were taken and 
compared. As Figure 6.3.22.A shows, the percentage of localisations of Syk and GPVI 
together is significantly greater than the amount of Btk localising with GPVI spread on 
CRP-XL (p ≤ 0.01), but not on collagen. This suggests that Btk localises nearer to GPVI 
on collagen than it does on CRP-XL. Btk and CLEC-2 significantly localise together more 
than Btk and GPVI, independently of if it spread on collagen or CRP (*p ≤ 0.05, **p ≤ 
0.01). This suggests that Btk localises more with CLEC-2 than GPVI. The localisations of 
Btk with LAT were compared across ligands, and there is no significant difference 
between collagen and rhodocytin. This suggests that Btk is localising with LAT on both 
ligands.  
Heat maps to summarise the ClusDoC cluster output of Btk clusters colocalising with 
GPVI, LAT or CLEC-2 were calculated with red being areas of low. As Figure 6.3.22.C 





Figure 6.3.21 Btk and CLEC-2 colocalise more than Btk and GPVI and there is no 
difference in the localisation of Btk and LAT on either rhodocytin or collagen. 
(A) The amount of localizations together was plotted into a graph from plot profile analysis 
and compared using one-way ANOVA with Tukey's multiple comparisons test with 
significance taken at *p ≤ 0.05 and **p ≤ 0.01. Graph represents mean ± SEM, N=3. (B) 
plot profile analysis from Btk and LAT spread on collagen and rhodocytin were calculated. 
Statistical testing was performed using a two-way T – Test with no significance found.  (C) 
the mean number of colocalised clusters, (D) the average area of a colocalised cluster 
and (E) the number of localisations to a colocalised cluster were plotted into heat maps 
for Btk colocalising with GPVI on collagen and CRP-XL, LAT on rhodocytin and collagen 


















6.4.1 Aim - Investigate the localisation of Btk in relation to GPVI, 
LAT and CLEC-2  and  verify the colocalisation results in chapter 
5  
 
Btk and GPVI  
Using plot profile analysis drawing along the collagen fibre, as expected, most of the 
localisations present were GPVI (Figure 6.3.9). Some Btk can be found with GPVI at the 
fibre, but more GPVI is present alone. However, there is a proportion (approximately 
20%) where Btk and GPVI are localised together. This suggests that Btk is recruited to 
the collagen fibre to help mediate the signalling. 
In some images, Btk looks adjacent to the collagen fibre. The diameter of a collagen fibre 
is anywhere between 30 to 300nm, so it is possible that Btk may be localised at the fibre, 
however, the parameters selected in ClusDoC do not allow for appropriate analysis (Orgel 
et al., 2006). Using ClusDoC, there are similar number of Btk clusters that colocalise with 
GPVI as without GPVI, whereas there is trend of more GPVI clusters colocalising with 
Btk.  
When spread on CRP-XL, a smaller proportion of Btk and GPVI localise together when 
assessed using plot profile (around 10%), and when assessed using ClusDoc, indicated 
in a lighter shade of green in the heatmaps in Figure 6.3.22.C. When platelets are spread 
on collagen, there are significantly more clusters of Btk that localise with GPVI which is 
shown in the darker green in the heatmap (Figure 6.3.22.C). This suggests on a specific 
GPVI agonist that Btk does not localise as near to GPVI, as non an agonist for both GPVI 




Btk and CLEC-2 
Using plot profile, Btk looks to localise with CLEC-2 across a random cross Section of a 
platelet. However, colocalisation was assessed using ClusDoC, and significantly more Btk 
clusters form with no CLEC-2 present (Figure 6.3.20). This contrasts with the results 
obtained for plot profile (Figure 6.3.13). It is known that molecular partners with a common 
function do not always particularly congregate in clusters. This is observed in proteins 
involved in vesicle fusion, SNAP25 and Syntaxin 1. The clusters are located near each 
other, but are not arising in the same structure (Halemani et al., 2010). Therefore, this 
may explain why it looks that Btk and CLEC-2 colocalise using plot profile, but do not 
using ClusDoC.  
 
Btk and LAT 
There is no difference in localisation of Btk with LAT when spread on either GPVI agonist 
collagen or CLEC-2 agonist rhodocytin using plot profile (Figure 6.3.22.B). LAT is a key 
mediator in both pathways (Pasquet et al., 1999b, Suzuki-Inoue et al., 2006, Fuller et al., 
2007). Btk also does not look to strongly localise with GPVI, but does LAT. The TCR and 
LAT have been shown to form into distinct ‘protein islands’ in T cells (Lillemeier et al., 
2010), so Btk may not be localising with GPVI as it is at the LAT ‘protein island’.  
For Btk clusters which have LAT present, the sizes look similar (around 20,000nm2) on 
both ligands (Figure 6.3.19 and 6.3.21). However, for LAT clusters colocalising with Btk, 
the clusters are much larger on rhodocytin when compared to the colocalised clusters on 
collagen. It is possible that as Btk is localising near the larger clusters of LAT, it may also 
be near CLEC-2. Therefore, it may explain why Btk looks to localise more with CLEC-2 
than GPVI in plot profile analysis.   
The results showing that Btk localises with LAT in a spread platelet are unsurprising as 
Btk and LAT have been shown to interact biochemically when LAT is pulled down 
(Pasquet et al., 1999b). Interestingly, FcRɣ chain is also pulled down when LAT is 
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immunoprecipitated, so therefore it is not unreasonable to believe that the limit of 
resolution of ClusDoc and plot profile may be missing the interaction between GPVI and 
Btk.  
In Figure 6.3.19.Aiii, Btk and LAT look to form discrete protein complexes, however they 
seemingly have small contacts with each other which is demonstrated in areas of red. 
This fits with the hypothesis that protein complexes can form ‘islands’ and can likely 
interact with one another. Furthermore, protein clusters that are next to each other with 
some partial overlap can be observed in monocytes (Garcia-Parajo et al., 2014). 
Lymphocyte function-associated antigen-1 forms clusters approximately 70nm in 
diameter, and glycosylphosphatidylinositol-anchored proteins form clusters approximately 
10nm in diameter. These protein clusters are situated next to one another and interact to 
form a nanoplatform to mediate signalling (Garcia-Parajo et al., 2014). The interaction is 
only at the perimeters of the clusters, not total cluster integration of the proteins. This may 
explain the observed partial colocalisation of Btk and LAT, where it looks like part of Btk 
clusters interact with LAT clusters but not total overlap. 
 
6.4.2 Aim - To investigate the clustering of Btk on collagen, CRP-
XL and rhodocytin. 
In silico evidence has suggested that Btk undergoes clustering as one molecule of Btk is 
responsible for phosphorylating another molecule of Btk (Chung et al., 2019, Wang et al., 
2019b). No work has been published investigating if Btk undergoes clustering in platelets.  
Btk clustering on collagen  
At a range of radii, a number of clusters are detected on collagen, which suggests that 
indeed, Btk is undergoing clustering (Figure 6.3.1). There are more clusters of Btk on 
collagen then there are on CRP-XL (Figure 6.3.2). This suggests there may be a potential 
difference in the regulation of Btk on collagen compared to CRP-XL.  
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Less clusters of Btk on CRP-XL suggests there may be more free molecules of Btk (not in 
a cluster) in the spread CRP-XL platelet. A potential reason for this is Btk clustering may 
be a mechanism of reserve. Clustering of multiple proteins into stable entities would avoid 
loss of components from functional complexes, so would likely result in a sustained signal 
(Lang and Rizzoli, 2010). Keeping Btk in a cluster may prevent Btk from interacting with 
other proteins such as SHIP1 (Pasquet et al., 2000, Tomlinson et al., 2004a, Chari et al., 
2009). SHIP1 acts as a negative regulator on GPVI signalling, acting as a terminator 
(Chari et al., 2009). This may be more essential for collagen mediated activation 
compared to CRP-XL as it is known that collagen signalling is more sustained (Tomlinson 
et al., 2007).  
There is also another collagen receptor, α2β1. This binds the GFOGER sequence in 
collagen. There may be more clusters on collagen as opposed to CRP-XL due to Btk also 
undergoing clustering to help mediate signalling through this integrin. Experiments to 
investigate the localisation of α2β1 in relation to Btk should be performed to investigate 
this.  
Btk clustering on rhodocytin  
Compared to collagen ligands, there are fewer clusters of Btk when spread on rhodocytin 
(Figures 6.3.5 and 6.3.6). However, the number of clusters is similar on CRP-XL. The 
number of Btk clusters significantly decreases as the set cluster radius increases, 
suggesting smaller clusters are being incorporated into larger clusters due to the 
propagative analysis of DBSCAN (Malkusch and Heilemann, 2016). 
 
6.4.3 Aim – To confirm if Btk recruitment and clustering is 
independent of its kinase function downstream of GPVI.  
The clustering of GPVI is a level of regulation for the signalling (Poulter et al., 2017, 
Dunster et al., 2020, Pallini et al., 2020). Therefore, it would be interesting to identify what 
is regulating the clustering of GPVI to potentially target therapeutics to this mechanism. 
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As Btk is indirectly involved in the regulation of the clustering of the ITAM containing BCR, 
it was hypothesized that Btk could potentially be involved in the regulation of the 
clustering of the ITAM containing FcRɣ chain and GPVI. It is currently unknown what 
regulates the clustering of GPVI.  
Both the TIRFM (chapter 5) and STORM experiments (Figures 6.3.3 and 6.3.10), show 
that the localisation of Btk does not drastically change when treated with a Btk kinase 
inhibitor. In B cells and platelets, the recruitment of Btk is mediated by its PH domain and 
PIP3 interaction (Saito et al., 2001, Várnai et al., 1999, Salim et al., 1996). This 
mechanism is not believed to be kinase dependent, therefore it is consistent with the 
results in this study. 
In the plot profile experiments, interestingly, a lower concentration of acalabrutinib 
(0.1μM) increases the amount of Btk present at the fiber alone, and subsequently 
decreases the amount of GPVI present. This is unexpected, as 0.1μM acalabrutinib does 
not fully inhibit Btk phosphorylation. At lower concentrations of acalabrutinib, it was 
proposed by Bye et al., that there is increased SFK activity and the increased recruitment 
of Btk may be related to this. As SFK’s are responsible for phosphorylating Btk, if their 
activity is increased at this low concentration of acalabrutinib, it is possible that more Btk 
is present, being phosphorylated by SFK’s.  
Although plot profile analysis may not be the best for assessing recruitment to the fibre. 
Indeed, the results are converted into binary values and represent the proportion of all the 
localisations, disregarding areas which do not have any localisations. Therefore, it is likely 
not accurate for assessing the recruitment in the presence of drugs, as this may alter the 
amount of Btk or GPVI molecules present. Other methods of analysis should be 
performed to fully confirm this result. 
In the clustering experiments, 1μM acalabrutinib caused GPVI clusters to be significantly 
larger than vehicle treated samples (p ≤ 0.05). It also caused a significant reduction in the 
number of clusters compared to vehicle control. The clusters are only larger in terms of 
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area and not the number of localisations per cluster as this was not significantly different. 
This shows that 1μM acalabrutinib causes a more diffuse GPVI cluster. 
This more diffuse GPVI cluster caused by acalabrutinib is not related to Btk clustering. 
Consistent with TIRFM data of Btk puncta not changing, the clustering of Btk is not 
changed in the presence of acalabrutinib (Figure 6.3.3B-D)  
This more diffuse GPVI cluster observed in 1μM acalabrutinib treated samples may be 
related to the expected number of GPVI localisations present. The cluster should also be 
larger with more molecules of GPVI present (measured as by the increase of localisations 
per GPVI cluster). Although there is a trend of increase in 1μM samples, it is not 
significantly increased compared to vehicle treated samples (p = 0.08).  
A further reason may be due to the catalytic activity of Btk being involved in the regulation 
of GPVI clustering. Btk is implicated in being involved in the clustering of the BCR, as 
when the catalytic activity of Btk is inhibited , there is less BCR accumulation when 
assessed using fluorescence microscopy (Liu et al., 2011). This is due to Btk being 
responsible for regulation of WASP, which is involved in polymerisation of actin (Oda et 
al., 1998, Liu et al., 2011). It has been hypothesised that actin polymerisation may be 
playing a role in mediating the clustering of GPVI.  Actin dynamic inhibitors inhibited GPVI 
dimer formation at high concentrations, however at lower threshold inhibitory 
concentrations, there is still the formation of dimers (Poulter et al., 2017). Further 
evidence supporting the hypothesis of actin mediated GPVI clustering is that Rac1 (small 
GTPase that is involved in regulating actin) is required for proper GPVI signalling (Pleines 
et al., 2009). Therefore, the increased GPVI clustering in the presence of acalabrutinib 






Btk and GPVI do not colocalise when spread on CRP-XL. However, when spread on 
collagen, Btk and GPVI colocalise more. Btk and LAT do look to weakly colocalise when 
spread on collagen. More clusters of GPVI have Btk present within the cluster radius than 
molecules of Btk that have GPVI within the cluster radius when spread on collagen. Btk 
and CLEC-2 colocalise, and the clustering of Btk and CLEC-2 correlate to one another. 
Similarly, on rhodocytin, Btk and LAT look to colocalise and clustering may be regulated 


















7 General Discussion  
7.1 Summary of results  
This study uses the specific Btk inhibitor acalabrutinib, microscopy and a cell line model of 
CLEC-2 and GPVI signalling to investigate the role of Btk domains, with particular 
emphasis on the kinase domain, in GPVI and CLEC-2 mediated signalling.  
At concentrations of acalabrutinib where Btk phosphorylation (1μM) is lost, GPVI 
mediated aggregation, granule secretion and αIIbβ3 activation is unaffected, suggesting 
that it functions as a scaffold rather than a kinase (Figures 3.3.2 and 3.3.4). At 
intermediate concentrations of rhodocytin, Btk does not play a scaffolding role 
downstream of CLEC-2 as phosphorylation and platelet responses are lost when Btk 
phosphorylation is reduced (Figures 3.3.3 and 3.3.7).  Whereas at high concentrations of 
rhodocytin, Btk phosphorylation is lost, but aggregation is unaffected, suggesting Btk is 
playing a scaffolding role or it is not required for aggregation (Figure 3.3.6).  
In contrast to the work of Manne et al., we show that Btk is downstream of Syk in the 
CLEC-2 signalling cascade. Phosphorylation of Syk pY525, an indicator of active Syk, is 
only reduced at concentrations where Btk transphosphorylation (initial phosphorylation 
site) pY551 is lost (Figure 3.3.6 and 3.3.7). Also in contrast to the work of the Kunapali 
group and Martyanov et al., we show that fucoidan cannot mediate CLEC-2 mediated 
spreading, however, we show for the first time that platelets adhere to and spread on the 
CLEC-2 ligand rhodocytin. This is surprisingly unaffected  by Btk inhibition, although it 
may be explained by agonist being presented through a surface as opposed to in solution. 
Spreading on collagen is also unaffected by acalabrutinib and suggests a redundant role 
of Btk catalytic activity in platelet spreading on rhodocytin and collagen. 
To further investigate whether the catalytic activity of Btk is required for GPVI or CLEC-2 
mediated signalling, a cell line model was used. Downstream of CLEC-2, each functional 
domain of Btk was required to mediate signalling (Figures 4.3.5, 4.3.7 and 4.3.10). 
Whereas downstream of GPVI, Btk requires functional PH, SH3 and SH2 domains, but 
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Btk can mediate signalling independently of its kinase domain (Figures 4.3.4, 4.3.6 and 
4.3.9). This was shown using the over-expression of Btk mutants, with the additional use 
of  CRISPR-Cas9 gene editing to generate a Btk SH2 domain mutant cell line to verify the 
requirement of the Btk SH2 domain (Figures 4.3.17 and 4.3.18).  
As a potential role for Btk as a scaffold protein downstream of GPVI was identified, the 
localisation of Btk to areas of GPVI mediated signalling was investigated in the presence 
and absence of acalabrutinib. Using TIRFM, Btk does not strongly colocalise with GPVI 
when platelets are spread on CRP-XL (Figure 5.3.3). There is a suggestion of weak 
colocalization of Btk and GPVI on collagen and Btk may localise to areas of the collagen 
fibre in areas where GPVI is absent.  The mechanism of this segregation is unknown 
(Figure 5.3.1).  Btk and LAT appear to colocalise to a greater extent than Btk and GPVI 
on collagen (Figure 5.3.5). 
The resolution is limited at 200nm for TIRFM (Kudalkar et al., 2016). This may 
overestimate the level of true colocalization and therefore STORM, which has a resolution 
of 20-50nm (Rust et al., 2006) was utilised to investigate the suspected protein-protein 
interactions.  
Using STORM and quantified using plot profile and ClusDoC, Btk and GPVI do not 
colocalise when platelets spread on CRP-XL, consistent with the spreading data where 
Btk inhibition does not affect GPVI mediated spreading. However, when spread on 
collagen, Btk and GPVI colocalise to a greater extent (Figures 6.3.9 6.3.2.2 and 6.3.16). 
Btk and LAT colocalise when platelets spread on collagen showing an interaction 
between these proteins (Figure 6.3.12 and 6.3.19), which agrees with biochemical data 
previously published (Pasquet et al., 1999b). Btk inhibition increases the GPVI cluster 
size in platelets spread on collagen, suggesting a potential negative feedback role for Btk 
in GPVI clustering (Figure 6.3.3). This may be through Btk being unable to phosphorylate 
the negative regulator of platelet signalling, Platelet endothelial cell adhesion molecule-1, 
(PECAM-1) (Tourdot et al., 2013).   
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Compared to GPVI, at submaximal concentrations of rhodocytin, a functional Btk kinase 
domain is required to mediate signalling as shown using western blotting and cell line 
reporter assays. Therefore, it would be expected that it would localise near the receptor 
due to the requirement for its kinase domain. Indeed, when spread on rhodocytin, Btk 
appears to localise with CLEC-2 and LAT in TIRFM (Figures 5.3.7 and 5.3.8). This was 
confirmed using STORM (Figures 6.3.20, 6.3.21). However, platelets spread on 
rhodocytin are smaller, and the colocalisation may be an artefact due to a reduced 
surface area of the platelet.  
 
7.1.1 What domains are important for Btk signalling? 
7.1.1.1 The PH domain of Btk is required for GPVI and CLEC-2 signalling  
PH domains bind to phospholipids. Btk’s PH domain selectively binds to PIP3 rather than 
PIP2 (Salim et al., 1996). Using platelets, microscopy, and a cell line model this study 
show that the PH domain is required downstream of GPVI and CLEC-2  signalling. 
The formation of puncta of Btk is observed using TIRFM (Figure 5.3.5 and 5.3.6), may be 
a result of PIP3 production which is known to form clusters at the membrane (Wang and 
Richards, 2012). Indeed, in other cell types the recruitment of other Tec family kinases 
has been shown to be dependent on their PH domain (Kane and Watkins, 2005, Qi et al., 
2006). In future experiments, it would be interesting to label PIP3 in conjunction with Btk 
to identify if the puncta overlap in TIRFM and STORM.  
In a study of the PIP3 signalosome, Btk is one of the most common binding partners of 
the phospholipid (Durrant et al., 2017). Therefore, it is not surprising that in a cell line 
model of GPVI and CLEC-2 signalling the PH domain is required (Figures 4.3.6 and 
4.3.7). The PI3K inhibitor LY294002, to inhibit the formation for PIP3, was used to 
investigate PH requirement for GPVI mediated spreading (Figure 3.3.17).  However at the 
concentration used platelet spreading was greatly inhibited; it has been published that 
aggregation is not affected at this concentration of LY294002 although the agonist 
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concentration used by the authors was also greater than in this study (Pasquet et al., 
1999a).   
However, it should be noted that downstream of PI3K is Akt (Protein kinase B), which has 
been shown to be required in mediating the platelet response downstream of GPVI and 
CLEC-2 in ADP dependent and independent signalling pathways (Kim et al., 2009b, 
Badolia et al., 2017). Therefore, the inhibition of spreading seen with a PI3K inhibitor may 
be related to this rather than an effect on Btk activation. 
Therefore, future work to investigate spreading experiments in the presence of lower 
concentrations of LY294002 could be repeated, this would confirm the PH requirement of 
Btk in GPVI mediated signalling. 
An alternative way to investigate the function of Btk PH domain without inhibiting PI3K 
would be to target PTEN. Inhibiting PI3K may inhibit Akt, and this may inhibit the 
spreading response. Furthermore, as the hypothesis is that Btk can behave as a scaffold 
protein, Btk would need to be present at the signalosome to mediate signalling. Inhibiting 
PI3K is likely to inhibit recruitment of Btk due to the lack of PIP3. Alternatively PTEN could 
be targeted. PTEN is responsible for conversion of PIP3 to PIP2 and it has been shown in 
the Jurkat T cell model that PTEN deficiency increases the amount of Itk present at the 
cell membrane (Shan et al., 2000). Therefore it can be hypothesised that inhibition of 
PTEN would  result in increased Btk recruitment to the membrane, confirming the role of 
the Btk PH domain in GPVI and CLEC-2 mediated signalling. 
 
7.1.1.2 The SH3 domain is required for GPVI and CLEC-2 signalling  
SH3 domains bind to proline rich regions and are important for protein-protein interactions 
(Yang et al., 1995).  In this work, we show a functional SH3 domain is required to mediate 
GPVI and CLEC-2 signalling. Interestingly, this result contrasts with literature investigating 
the Tec SH3 domain.  In T cells, the SH3 domain of Tec is not required for TCR signal 
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transduction, with SH3 mutants of Tec able to mediate signalling (Tomlinson et al., 
2004b).  
The Btk SH3 domain is responsible for mediating the binding to BLNK (analogous to LAT) 
in B cells. Therefore, it is not unreasonable to hypothesise that the SH3 domain is 
mediating the interaction of LAT and Btk when spread on collagen and rhodocytin in 
Figures 5.3.5, 5.3.8 and 6.3.22. However, it would be difficult to investigate this further in 
platelets, therefore an in silico approach could be used. Indeed, using this approach, 
ankyrin repeat domain 54 (ANKRD54) has been proposed to preferentially select the Btk 
SH3 domain in an SH3 domain library (Gustafsson et al., 2017, Gustafsson et al., 2012). 
In B cells, ANKRD54 is involved in the nuclear translocation of Btk, and retention of Btk in 
the cytoplasm to mediate signalling. ANKRD5 has not been identified in platelets 
(Burkhart et al., 2012, Zeiler et al., 2014), but it shows potential mechanisms and 
functions of the SH3 domain.  
An approach to confirm the requirement of the Btk domain roles, and to avoid 
overexpression artefacts would be to continue to use CRISPR-Cas9 gene editing to 
knockin domain inactivating mutations in to the DT40 model. However as these do not 
endogenously express the platelet receptors CLEC-2 and GPVI  it would be interesting to 
move into a more physiologically relevant cell line. Candidates include iPS cells (Moreau 
et al., 2016). The KI of mutations into iPS cells has the potential to produce platelets 
expressing the domain mutations without the need to overexpress mutants. This would 
further help verify which domains of Btk are needed to mediate signalling. 
 
7.1.1.3 SH2 domain function is required for GPVI and CLEC-2 signalling 
Evidence that Btk requires a functional SH2 domain can be found in Chapter 4, along with 
further platelet evidence in vitro. In B cells, Btk has been shown to predominantly bind to 
BLNK via its SH2 domain following phosphorylation of BLNK by Syk (Hashimoto et al., 
1999a). As phosphorylation of both LAT and Btk are blocked downstream of a Syk 
inhibitor (Nicolson et al., 2020), it suggests that Btk and LAT may interact via the SH2 
357 
 
domains of Btk, however an interaction between Btk and LAT was not detected using 
immunoprecipitation.  
7.1.1.4 The kinase function of Btk downstream of GPVI is not required   
Downstream of GPVI, this thesis provides evidence that Btk acts as a scaffold protein as 
signalling can occur independently of its kinase function. At 1μM acalabrutinib, 
downstream of 1μg/mL CRP-XL, aggregation, granule release and αIIbβ3 activation are 
all normal compared to vehicle controls (Figure 3.3.2), but Btk pY223 and PLCγ2 pY759 
are lost (Figure 3.3.4). As these sites are lost but responses are normal, it suggests that 
the phosphorylation of these sites are not required for activation, suggesting a scaffolding 
role for Btk.  
Evidence that GPVI signalling is dependent on Btk, and that Btk is not a redundant protein 
in the GPVI signalling cascade can be found in Chapter 4.  Btk deficient DT40 cells are 
unable to reconstitute signalling downstream of GPVI (Figure 4.3.13, (Tomlinson et al., 
2007)). Platelets from  Btk KO mice do not undergo aggregation in response to CRP-XL 
(1μg/mL) (de Porto et al., 2019), similar to how human XLA patients platelets do not 
undergo aggregation at this agonist concentration (Quek et al., 1998).  
Chapter 4 also provides further evidence of a scaffolding role of Btk downstream of GPVI 
using a cell line model. A kinase dead Btk mutant was able to reconstitute signalling to a 
similar level as WT Btk in the DT40 cell model (Figure 4.3.4). This was also not blocked 
by high concentrations of acalabrutinib but, was in the presence of ibrutinib (Figure 4.3.6). 
The effect of ibrutinib was  due to off-target effects on SFK’s (Figure 3.3.7) and confirmed 
in the literature (Bye et al., 2017, Series et al., 2019, Nicolson et al., 2018).  
Btk partially colocalises with GPVI (Figures 6.3.2.4 and 6.3.3.2), however its localisation 
does not change in the presence of the kinase inhibitor. This provides further evidence 
that its role in GPVI signalling is kinase independent. To further confirm this result, 
microscopy studies using fluorescently labelled ibrutinib could be performed (Turetsky et 
al., 2014, Kim et al., 2015).  This would allow the Btk localisation to be followed in real 
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time in the presence of Btk kinase inhibition. If the fluorescently tagged ibrutinib was 
recruited to the fibre, it would provide further evidence that Btk can behave as a scaffold 
protein independently of its kinase domain.   
However, there is a suggestion that kinase activity may play a role in the negative 
regulation of GPVI signalling in platelets. Inhibition of Btk results in increased GPVI 
clustering (Figure 6.3.3). Although no potentiation was seen in the responses of GPVI 
signalling in aggregation or granule secretion, a trend towards potentiation was observed 
with spreading experiments, as higher concentrations of acalabrutinib caused slightly but 
not significantly increased number of platelets to adhere per field of view (Figure 3.3.16). 
Potentiation can also be seen in the cell line model, where once again there was a trend 
of increased signalling in cells treated with acalabrutinib (Figure 4.3.6).  
Potentiation of SFK phosphorylation was observed in the work of Bye et al., using 
ibrutinib, and it could be the role of SFK that is mediating this clustering.  SFK activity is 
negatively regulated by phosphorylation by C terminal Src kinase, Csk. The domain 
structure of Csk (SH3-SH2-Kinase) is structurally similar to Btk (Filippakopoulos et al., 
2009).  Ibrutinib has an IC50 value of 2.3nM for Csk (compared to an IC50 of 0.5nM for 
Btk), showing that it is a potent inhibitor of Csk (Bose et al., 2016, Barf et al., 2017). A 
recent study has also shown that the common ibrutinib side effect of atrial fibrillation is 
mediated through inhibition of Csk (Xiao et al., 2020). Therefore, as ibrutinib and 
acalabrutinib are similar in their binding to Cys481, the increase in GPVI clustering in the 
presence of acalabrutinib may be related to this. However, acalabrutinib is less likely to 
inhibit Csk, as acalabrutinib has a greater selectivity for Btk (Herman et al., 2015). 
Furthermore, it is not thought GPVI clustering is dependent on SFK’s (Poulter et al., 2017, 
Pallini et al., 2020) so this may suggest an alternative mechanism for increased GPVI 
clustering.  
In addition to SFK Lyn, both Csk and Btk are found downstream of PECAM-1 (Tourdot et 
al., 2013).  PECAM-1 is involved in the inhibition of GPVI signalling. It contains two 
immunoreceptor tyrosine-based inhibitory motifs, (ITIMs) and the C terminal ITIM is firstly 
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phosphorylated by Lyn (Tourdot et al., 2013). Then the subsequent N terminal ITIM is 
phosphorylated by either Btk or Csk when investigated using recombinant proteins. For 
Csk, the initial interaction is due to the Csk SH2 domain binding to the phosphorylated 
tyrosine in the C terminal ITIM, which then allows the Csk kinase domain to phosphorylate 
the N terminal ITIM. However, the interaction of Btk  with the N terminal ITIM is not wholly 
dependent on its SH2 domain (Tourdot et al., 2013). It has been shown that PI3K can co-
immunoprecipitate with PECAM-1 and the interaction between Btk’s kinase domain and 
PECAM-1 may be mediated through Btk’s PH domain mediated recruitment to PIP3 
(Moraes et al., 2010). In acalabrutinib treated platelets, Btk may be recruited to PECAM-1, 
but unable to phosphorylate the ITIM. This may potentially explain why an increase in 
GPVI clustering was observed.  
To confirm this, a further potential avenue is to investigate if Btk can colocalise with 
PECAM-1, and whether there is any change in the presence of acalabrutinib. It would be 
expected that Btk would be present in close proximity to the platelet inhibitory receptor, 
due to its proposed role in phosphorylating the N terminal ITIM of PECAM-1.  
In this study it cannot be ruled out that Tec phosphorylation is not mediating the signalling 
downstream of GPVI. However, this seems unlikely, as the use of acalabrutinib instead of 
ibrutinib is far more selective for Btk, and does not cause as strong Tec inhibition (Byrd et 
al., 2016). Further publications also suggest that Tec phosphorylation is only partially 
inhibited at concentrations of acalabrutinib  (0.5μM, and 2μM) where aggregation is 
normal downstream of GPVI (Figure 3.3.2) (Nicolson et al., 2018) or not inhibited at all 
(Bye et al., 2017).  Additionally, the concentration of agonist (1μg/mL CRP-XL) used in 
these studies is unlikely to have trigged the compensatory role of Tec. Only agonist 
concentrations at least 10-fold higher than the amount used in this study (10μg/mL and 
30μg/mL) induce aggregation in Btk-deficient platelets, demonstrating the compensatory 
role of Tec is only induced under high levels of GPVI ligation (Atkinson et al., 2003a).  
Future work to investigate the hypothesis of Btk potentially having a scaffolding role could 
include the use of patients with XLA. The patients used in the study by Nicolson et al. 
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2018 and 2020 were all deficient in Btk, which help prove that Btk is needed to mediate 
signalling. Indeed, many patients that have XLA are deficient in Btk. However, there are a 
subset of patients who have a ‘leaky’ phenotype (Gaspar et al., 2000). This describes 
patients who express catalytically inactive Btk and have a less severe immunodeficiency 
than patients who are deficient in Btk. Investigating their platelet function through 
aggregation, calcium mobilisation and phosphorylation downstream of GPVI could further 
help deduce the role of Btk in this pathway and determine the role of the catalytic activity 
without the use of inhibitors having off target effects.  
 
7.1.1.5 The kinase domain of Btk is required at low concentrations, but not at high 
concentrations of CLEC-2 ligation 
It is unclear whether the kinase domain is required downstream of CLEC-2.. At 
submaximal concentrations of rhodocytin (100nM, 50nM), it is known that downstream of 
CLEC-2, Btk kinase activity is required for aggregation (Figures 3.3.2, 3.3.7), calcium 
secretion (Figure 3.3.14) and mediation of the signalling in a cell line assay (Figure 4.3.5). 
In the cell line assay, only WT Btk can mediate CLEC-2 signalling (Figure 4.3.5). When 
both platelets and DT40’s are treated with acalabrutinib, there is in an inhibition of 
signalling, showing that at lower concentrations of rhodocytin (100nM and 50nM) 
concentrations of rhodocytin, Btk catalytic activity is required (Figures 3.3.7 and 4.3.7).  
Similar to GPVI, the presence of Btk is required to mediate signalling. Btk deficient DT40 
cells are unable to mediate CLEC-2 signalling (Chapter 4, (Fuller et al., 2007) and Btk 
deficient platelets do not aggregate in response to high concentrations of rhodocytin 
(Nicolson et al., 2020). This suggests that Btk expression is essential for CLEC-2 
signalling.  
However, at high concentrations of rhodocytin (300nM), platelet aggregation still occurs 
when Btk pY223 phosphorylation is lost due to acalabrutinib treatment, in both ADP 
insensitive and ADP sensitive platelets, as shown in Figures 3.3.6 and 3.3.12. There are 
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several reasons for this. The aggregation of ADP sensitive platelets observed with 300nM 
of rhodocytin suggests that the aggregation is mainly through secondary mediators. 
These platelets are prepared using a method that allows them to respond to ADP (Figure 
3.3.9) and does not interrupt the COX-1 signalling pathway during the washing process, 
removing the potential loss of thromboxane release.  Indeed, although there is no 
inhibition of aggregation at high concentrations of acalabrutinib, there is a delay compared 
to vehicle treated samples (Figure 3.3.7) suggesting that is due to the production and 
release of secondary mediators. To verify this, experiments assessing the release of ATP 
in conjunction with aggregation could be performed to elucidate the kinetics of 
aggregation.  
At high concentrations of rhodocytin, aggregation still occurs despite the loss of Btk 
pY223 and PLCγ2 pY759 phosphorylation. This suggests that at high concentrations of 
rhodocytin, this PLCγ2 phosphorylation site is not essential for mediating aggregation 
downstream of CLEC-2. As the concentration of rhodocytin was high, it may have been 
inducing a high level of CLEC-2 clustering, and therefore bypassing Btk to mediate 
signalling. This can be observed for several other proteins when they are genetically 
deleted, examples include LAT, where PLCγ2 phosphorylation is lost but the platelets are 
still able to aggregate to high concentrations of rhodocytin and CRP-XL (Hughes et al., 
2008, Judd et al., 2002), and SLP-76 where aggregation is not required downstream of 
rhodocytin, suggesting that there is a SLP-76 independent pathway of CLEC-2 activation 
(Suzuki-Inoue et al., 2006). However, this is only at high concentrations of agonist in vitro, 
and is surprising as SLP-76 deficient platelets exhibit the blood lymphatic mixing 
phenotype, suggesting that podoplanin present on lymphatic endothelial cells is not 
enough to bypass this signalling (Clements et al., 1999). Of note, LAT and SLP76 are 
both scaffolding proteins, further supporting the concept that Btk has dual roles, that of a 
scaffold and a kinase. 
An alternative hypothesis has been proposed in the work by Wist et. al., where 
catalytically inactive Btk (treated with acalabrutinib) can mediate BCR signalling. At higher 
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degrees of BCR activation, catalytically independent Btk functions come into effect such 
as scaffolding or shuttling between proteins  (Wist et al., 2020). Due to this, acalabrutinib 
acquires the property of a partially effective inhibitor. When CLEC-2 is ligated using a high 
concentration of rhodocytin, and no inhibition is observed, it may be related to the 
increased scaffolding role of Btk, and therefore there is only partial effectiveness of 
acalabrutinib inhibiting the amount of Btk that is catalytically active. This may explain why 
inhibition is observed in ADP insensitive platelets, but not ADP sensitive platelets.  
Moreover, Tec may be mediating CLEC-2 aggregation despite Btk inhibition at 300nM 
rhodocytin whereas it does not at lower concentrations of rhodocytin. This compensation 
at high concentrations is seen downstream of GPVI in mouse platelets where Tec can 
partially compensate for Btk; at high concentrations of CRP-XL (10μg/mL), Tec can 
compensate for Btk, whereas at lower concentrations (3μg/mL CRP-XL) it cannot 
(Atkinson et al., 2003a). Although this is unlikely, as at the concentrations of acalabrutinib 
where Btk phosphorylation is lost, it has been shown that Tec phosphorylation is also 
reduced in platelets (albeit downstream of GPVI) (Nicolson et al., 2018). However, due to 
the lack of phosphospecific antibodies for Tec, it is unknown whether the phosphorylation 
observed is the Src phosphorylation site, the autophosphorylation site or both. 
Nonetheless, it suggests that Tec is not playing a compensatory role.  
Future work using ‘leaky’ XLA patients could be performed to investigate the role of Btk 
kinase function downstream of CLEC-2, similarly to GPVI as described above. 
Furthermore, it would be interesting to investigate if there is a lower risk of diseases 
specifically related to CLEC-2 signalling dysfunction in these patients. It would be 
expected that these patients would have a reduced risk of CLEC-2 mediated disease 
such as DVT due to the disruption of its signalling. Population studies using XLA patients 
(who take intravenous IgG for treatment) compared to patients who also take intravenous 
IgG could be investigated to further confirm or deny this is, and would control for the 
intravenous immunoglobulin which has been proposed to have side effects.   
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One of the side effects for patients taking intravenous IgG is an increased risk of 
hemolytic anaemia (Berard et al., 2012). Hemolytic anaemia causes an increased risk of 
thrombotic events (Ruggeri and Rodeghiero, 2016), which could be attributed partly from 
the free heme activating the CLEC-2 receptor on platelets (Bourne et al., 2020). XLA 
patients are likely to be protected from this risk as they do not contain Btk, which is 
essential for CLEC-2 signalling at concentrations of heme present in the blood as shown 
in the work by Bourne et al., using a Btk inhibitor. Indeed, XLA patients do not seem to be 
at an increased risk for thrombus formation (Chen et al., 2016).  
 
7.1.2 The localisation of Btk, and differences between analysis 
methods 
In summary, when platelets spread on the GPVI ligand Btk and GPVI appear to partially 
colocalise, however there is stronger evidence that Btk colocalises with LAT. The 
localisation of Btk and LAT is also observed when platelets spread on rhodocytin.  
The results obtained from TIRFM and STORM imaging tend to be consistent with one 
another. For example, Btk appears to colocalise with LAT when spread on collagen, and 
this is mirrored in the plot profile experiments, where a large proportion of the localisations 
on the fibre are LAT and Btk together (Figures 5.3.5 and 6.3.12). This suggests that there 
is a stronger colocalisation of LAT and Btk when platelets spread on collagen that was 
unmasked using STORM.  
The puncta distribution of Btk observed in TIRFM was not changed in the presence of 
acalabrutinib (Figure 5.3.2). This suggests that Btk is clustered independent of its kinase 
activity, however TIRFM does not accurately allow for the quantification of clusters. 
Therefore, STORM was employed to quantify the distribution of Btk. In the presence of 
acalabrutinib when imaged in TIRFM or STORM, Btk clustering does not change showing 
consistency between the two methods of microscopy.  
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However, there are some differences in the results obtained in TIRFM and STORM. 
When spread on rhodocytin, Btk and LAT weakly colocalise in TIRFM, but do not appear 
to directly localise together in plot profile experiments. This highlights that there are 
differences in the results obtained by the methods of microscopy.  
Possible reasons to explain the observed differences is the resolution difference between 
STORM and TIRFM. The resolution, which is the distance of which the microscope can 
distinguish two separate molecules, is limited at 200nm for TIRFM (Kudalkar et al., 2016). 
However, for STORM, the optical resolution is higher at approximately 20-50nm (Rust et 
al., 2006). This allows for more accurate distinguishing of individual molecules, and 
therefore may explain why there is a difference in the results obtained with TIRFM and 
STORM.  
Further differences observed between TIRF and STORM may also be explained due to 
the differing resolution limits and experimental parameters. A primary antibody and a 
secondary antibody (where the blink (a localisation) is identified), can be up to 30nm long 
which may exclude localisations if the cluster diameter is set too small. To combat this, 
clustering experiments were performed over a range of diameters (Section 6.3.1)  (Ries et 
al., 2012). Experiments could be repeated with directly conjugated primary antibodies, 
nanobodies or aptamers to ensure the distance between the fluorophore and the protein 
of interest is smaller and would enable more accurate localisation precision (Opazo et al., 
2012). Alternatively, a clustering method where high density regions are identified, Super 
Resolution Optical Fluctuation, (SOFI), could be employed to analyse the clusters. This 
algorithm provides quantitative molecular density analysis of protein distributions 
independent of any user defined parameters (Lukeš et al., 2017). Clustering using LAMA 
which works via DBSCAN has an arbitrary cut off of 100nm which may not be appropriate 
for assessing clusters that are larger, such as the clusters of GPVI along a collagen fibre. 
The output of SOFI is the size in area, number and diameter of a high-density region and 
therefore is comparable to clustering.  
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Aside from the limitations due to resolution, there are some other limitations in regarding 
microscopy. STORM is often used to assess protein clustering; however, it may not be 
the most accurate. The fluorescent tag on the protein that is imaged, not the protein itself 
(which could only be imaged using fluorescently tagged proteins, unable to do in 
platelets). So therefore, clusters may appear larger than they are, or may give false 
positives. In addition, it has been proposed that antibody induced clustering can occur in 
the membrane even after fixation, particularly if the proteins are GPI-anchored membrane 
bound (Tanaka et al., 2010). However, the membrane bound proteins in this study (GPVI, 
CLEC-2 and LAT) are not anchored via Glycosylphosphatidylinositol.  
In a paper trying to identify whether Tetraspanins are involved in GPVI clustering, there 
was no significant difference in clustering using STORM, comparing wild type to knockout 
platelets, but there was an effect on lateral membrane diffusion suggesting a change in 
the movement of GPVI which could be only visualised in unfixed cells (Haining et al., 
2017b). This suggests that the sample preparation and imaging in STORM may obscure 
some of the dynamic changes that occur during receptor clustering.  
The use of an immobilised ligand to investigate protein clustering is also not 
representative of what may be happening in vivo. It has been shown that CLEC-2 
undergoes clustering, which has been  indirectly measured by assessing the clustering of 
podoplanin in a lipid bilayer model. Although CLEC-2 undergoes clustering, it is currently 
unclear whether that is mediated through podoplanin clustering or itself (Pollitt et al., 
2014). Therefore, the experiments using a static ligand of rhodocytin to investigate CLEC-
2 clustering may have not been physiologically relevant. In order to assess this in future 
experiments, a supported lipid bilayer model using podoplanin should be used to mimic a 
cell.  
Although, platelet spreading on immobilised ligands is widely used to investigate 
signalling pathways, it may be a good model of in vivo platelet substrate interactions. It is 
believed that platelets can sense the mechanical properties of the ligand they are 
spreading on, however it is unclear how this relates to protein cluster formation. Collagen 
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which is tagged to polyacrylamide gels of various thickness induce varying levels of 
platelet spreading (Kee et al., 2015). On stiffer collagen-gel substrates platelets are more 
coagulant as demonstrated by the increase in surface area and phosphatidyl serine 
exposure. Stiffer vessels are likely atherosclerotic / diseased vessels, and the 
experiments used in this study use collagen or rhodocytin coated glass wells or coverslips 
(Chapters 3,5,6). Glass is a solid medium and may therefore be representative of what 
would occur in a diseased vessel.  
Furthermore, signalling processes are dynamic and stoichiometry often plays a part. It 
has been shown that LAT is able to move within Z planes in a spreading T cell (Zhang et 
al., 2018, Balagopalan et al., 2018). The investigations in this study are at a fixed time 
point on a static ligand. It is known that interactions between signalling proteins can be 
transient, such as the nucleocytoplasmic shuttling of Btk in B cells (Mohamed et al., 
2000), and transient recruitment of Syk to the BCR (Zhou et al., 2006). Activation of 
platelets in solution over a time course may help to deduce the dynamic protein-protein 
interaction events.  
Furthermore, cell line studies could be used to investigate the clustering and localisation 
of Btk. The Yellow fluorescent protein (YFP)-based protein fragment complementation 
assay (PCA) technique for visualizing protein-protein interactions involves expressing a 
protein (Btk) tagged with YFP fragment 1 (first 158 amino acids of the protein) and 
expressing another plasmid of Btk tagged with YFP2 (latter half of the protein). Alone, 
these proteins would not be able to emit fluorescence. However, upon homo-
oligomerisation of the proteins, the two fragments would be in close proximity and 
complement together resulting in a functional protein capable of fluorescence that could 
be measured (Nyfeler et al., 2005). It has been demonstrated that Itk undergoes protein 
clustering using this method (Qi et al., 2006), and it could be extended to other proteins in 




7.2 Is Btk a psuedokinase or a scaffold protein? 
The definition of a classical scaffold protein is the absence of inherent catalytic activity 
required for signalling (Zeke et al., 2009). As Btk contains a functional kinase domain 
(Rawlings et al., 1996), it would be expected that Btk is unlikely to be a scaffold protein. 
However, there is the possibility that the kinase domain within Btk could be a 
psuedokinase downstream of GPVI and CLEC-2 at high agonist concentrations. A 
psuedokinase is an inactive enzyme in which catalytic activity cannot occur. Integrin 
linked kinase (ILK) and JAK2 (Saharinen et al., 2000) are psuedokinases in platelets. 
Psuedokinase domains have similar structures to catalytically active kinases so it is not 
unreasonable to hypothesise that Btk could be a psuedokinase. However when 
examined, the kinase domain of Btk and the psuedokinase domain of JAK2 share 41% of 
the same residues suggesting little similarity, when compared to the similarity of the 
kinase domains of Syk and Btk (Stothard, 2000). This result suggests that Btk is more 
similar to a classical kinase and it is unlikely that it is a psuedokinase. As Btk catalytic 
activity is required downstream of CLEC-2 at lower agonist concentrations, it suggests 
that it is unlikely that Btk is a psuedokinase. It is more likely that downstream of GPVI, Btk 
kinase function is not required. This is typical of an adaptor / scaffold protein and that Btk 
may be acting as one of these molecules.  
Using bioinformatic prediction approaches Hu et al., predicted scaffold proteins from 
protein-protein interaction data and kinase-substrate relationships. Of all the scaffold 
proteins predicted, 18.9% contained a kinase domain. Interestingly, Btk and Tec were 
predicted to be a scaffold protein within the Syk-PLCγ2 pathway (Hu et al., 2015). 
Although the study did verify some of their predicted scaffold proteins using in vitro 
experiments, Btk was not one selected.  
Btk has also been predicted to be a scaffold protein in another study based on the criteria 
that there is interaction between the scaffold and two other partner proteins, and they are 
facilitated through two separate domains (Oh and Yi, 2016). Downstream of both GPVI 
and CLEC-2 in a cell line model, it was shown that each of the domains of Btk were 
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required to mediate the signalling, suggesting the interactions that the domains mediate 
are required. Btk has been shown to interact with PIP3 through its PH domain, (Salim et 
al., 1996),  Phosphatidylinositol-4-phosphate 5- kinases (PIP5K) through its TH domain 
(Saito et al., 2001), PLCγ2 through its kinase domain (Kim et al., 2004) and Syk through 
its SH3 domain (Morrogh et al., 1999) and therefore this may be why it has been 
predicted as a scaffold protein. Although, these predictions are only theoretical due to 
limited validation against the known 78 scaffold proteins.   
Further in silico evidence for Btk being a scaffold protein is its size. Scaffolding proteins 
tend to be larger, with Hu et al., (2015) predicting an optimal size of 670 residues. Btk is 
659 amino acids (Rohrer et al., 1994), close to the predicted optimal size when compared 
to the median amino acid length of 375 (Brocchieri and Karlin, 2005). LAT however is 
much smaller than the optimal predicted size suggesting that this data modelling may 
need further validation.  
Btk forms a punctate pattern when platelets are spread on collagen or rhodocytin (Figures 
5.3.1 to 5.3.9). This observation is consistent with the punctate pattern of Tec (Tomlinson 
et al., 2004b) and Itk seen in Jurkat cells (Qi et al., 2006). Scaffold proteins often localise 
in a punctate pattern to increase the local concentration of signal components (Hu et al., 
2015), which may explain Btk’s punctate distribution. Furthermore, there is evidence in 
the literature that increased Itk clustering leads to a decrease in catalytic activity, as the 
kinase interacts with itself as opposed to its substrates, so the puncta formation of Btk 
provides further evidence that Btk may have a scaffolding role (Joseph and Andreotti, 
2009). The lack of change in the number or distribution of the Btk puncta / clusters in the 
presence of a Btk inhibitor also contributes to this concept (Figures 5.3.2 and 6.3.3).  
However, in contrast to the scaffolding hypothesis is the work of Chang et al. The authors 
propose that Btk clustering is required for catalytic activity and may explain the puncta 
and clusters observed in Chapters 5 and 6. Moreover, puncta can be observed when 
platelets spread on rhodocytin, where Btk pY223 phosphorylation and catalytic activity is 
required to mediate CLEC-2 signalling (Figure 3.3.7), providing evidence in favour of 
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Chang et al. This proposes an alternative argument suggesting that the punctate 
formation is linked to the catalytic activity of Btk rather than a scaffolding role.   
Signalosome studies have identified the adaptor proteins ELMO1 and DAAP1 along with 
Btk as proteins that are most commonly bound to PIP3 in platelets (Patel et al., 2019, 
Durrant et al., 2017). Both ELMO and DAAP1 are all implicated in the negative regulation 
of GPVI, as platelets from mouse models deficient in these proteins have enhanced GPVI 
signalling (Patel et al., 2019, Durrant et al., 2017). This suggests that binding of proteins 
PIP3 and subsequent interactions may be involved in the regulation and termination of 
GPVI signalling. Of note, both ELMO1 and DAAP1 are scaffolding proteins, further 
providing evidence that Btk may also have a potential scaffold role. 
Further evidence for the kinase/scaffolding role of Btk is the resistance to ibrutinib and 
acalabrutinib in B cell malignancies. Btk inhibitors which prevent Btk from being 
catalytically active can help control the disease by managing the excess BCR signalling 
(Akinleye et al., 2013, Burger et al., 2015), confirming the kinase role of Btk. Resistance 
can occur due to mutations in either Btk or PLCγ2 which overcome the kinase inhibition to 
restore signalling (Woyach et al., 2017, Woyach et al., 2014). Although mutations may 
occur in some PLCγ2 domains more than others, D993G has been identified as a 
prominent mutation in patients. This mutation is believed to promote the interaction of 
PLCγ2 with the membrane, bringing it closer to phosphoinisitol lipids (Liu et al., 2015) in 
order for conversion. As Btk would be catalytically inert, but able to recruit proteins its 
interaction with PLCγ2 suggests a scaffolding role.  
A similar increase in signalling due to increased recruitment to the membrane can be 
observed with SH2 domain-containing inositol 5-phosphatase (SHIP) deficient platelets. 
SHIP is responsible for the conversion of PIP3 into PIP2 (Damen et al., 2001), and 
therefore deficiency causes an increase in the membrane concentration of PIP3. SHIP is 
therefore an indirect negative regulator of Btk, as reducing PIP3 levels reduce the 
recruitment of the kinase to the membrane.  
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Indeed, SHIP deficient platelets have increased levels of PIP3 and Btk phosphorylation in 
basal samples. The calcium flux at basal levels are increased compared to WT mice, but 
the fold change in response to CRP-XL is similar between WT and SHIP deficient mice. In 
addition, the levels of the metabolite of DAG and IP3, phosphatidic acid were unchanged 
between SHIP KO and WT platelets downstream of GPVI, suggesting that PLCγ2 is not 
hyperactive. Finally, this was confirmed using total tyrosine phosphorylation of PLCγ2, 
where it was found to be normal. If Btk was an exclusive kinase, it would also be expected 
that PLCγ2 phosphorylation would be increased due to Btk phosphorylating its substrate.  
Obtaining resistance to Btk inhibitors ibrutinib and acalabrutinib via PLCγ2 mutation is 
rare compared to resistance via mutation of Btk (Lampson and Brown, 2018). The most 
common mutation to confer resistance is mutation of Btk Cys481 to a serine or arginine 
(Woyach et al., 2014, Ahn et al., 2017). The change in amino acid abolishes the thiol 
present on the kinase to which the inhibitor can no longer bind covalently, therefore 
allowing Btk to be more catalytically active than previously, suggesting that Btk still 
requires and favours (as more common than PLCγ2 resistance) a catalytic role in B cell 
malignancies.  
The potential mechanism for Btk’s scaffolding role has been proposed in B cells and is 
related to its interaction with lipid kinases and is shown in Figure 7.2.1. Btk interacts with 
PIP3 through its PH domain (Bolland et al., 1998, Durrant et al., 2017, Pasquet et al., 
2000). PIP3 can be converted to PIP2 via SHIP / PTEN (Pasquet et al., 2000, Myers et 
al., 1997). Btk can also interact with PIP5K, which is responsible for production of PIP2 
from PIP3 (Saito et al., 2003). PLCγ2 catalyses PIP2 into IP3 and DAG which result in 
calcium flux. As Btk brings PIP5K and therefore PIP2 to PLCγ2, IP3 and DAG can be 





Figure 7.2.1 Btk's interaction with phospholipid metabolism 
Btk and its domains are shown in green with the reference Btk at the top. Black arrows 
show phospholipid metabolisim, with the enzymes responsible being shown in pink. PIP is 
catalysed to PIP2 by PIP5K, which Btk can interact with via its proline rich regions in its 
TH domain. PIP2 can be converted to IP3 and DAG via PLCγ2, which Btk can 
phosphorylate downstream of low concentrations of CLEC-2. PIP2 can be converted to 
PIP3 via PI3K, which Btk interacts with through its SH3 domain. PIP3 recruits Btk via its 
PH domain. PIP3 can be converted to PIP2 via SHIP or PTEN, inhibition of both leads to 
an increase in Btk recruitment.  
7.3 Use of Btk inhibition in COVID-19 treatment  
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is the causative 
pathogen for the current coronavirus disease 2019 (COVID19) pandemic. The disease is 
caused by virus binding to the angiotensin converting enzyme 2 (ACE2) receptors on 
pulmonary epithelial cells, leading to viral pneumonia. A systemic inflammatory response 
follows this, leading to acute respiratory distress and multi organ failure. The systemic 
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inflammatory response is a cytokine storm, through excessive macrophage activation and 
release of interleukin-6. Patients with COVID19 have abnormal coagulation (increased 
prothrombin time) and abnormal thrombosis (Thachil et al., 2020). Both arterial and 
venous thrombosis are implicated in causing a more severe disease phenotype of 
COVID-19 as patients experience both myocardial infarctions and venous thrombosis, 
and therefore there is potential for Btk inhibition using acalabrutinib in order to cause a 
less severe disease.  
Acalabrutinib is a clinically safe drug with less severe side effects already approved for 
treatment. The occupancy level and tolerable dosage (without dangerous side effects) is 
already known (Barf et al., 2017, Wu et al., 2016, Byrd et al., 2016). The repurposing of 
drugs is far quicker than the development of new drugs and therefore is useful to use 
during a pandemic. 
COVID19 patients have altered coagulopathy, with increased thrombosis in the 
microvasculature of the lungs and other organs, reflected in increased D dimers (Goshua 
et al., 2020). These thrombi are likely a result of thromboinflammation, where 
inflammation triggers thrombus formation. Both GPVI and CLEC-2 have been implicated 
in thromboinflammatory conditions.  
GPVI has been implicated in thromboinflammation in ischemia-reperfusion injuries in a 
stroke model. The reperfusion of blood induces an inflammatory response which leads to 
microthrombi and infarcts through platelet activation, T cells and neutrophils (Boulaftali et 
al., 2018). Inhibiting GPVI signalling using a competitive antagonist, Revacept reduces 
the damage caused by the platelets and these cells, suggesting that in certain models, 
GPVI is responsible for mediating thromboinflammation.  
At high concentrations of rhodocytin, Btk signalling is not required for CLEC-2 mediated 
aggregation. However, this used the agonist rhodocytin, which is a snake venom and not 
present in the body. Rhodocytin likely induced a strong response which induces activation 
mainly through potentiation of secondary mediators. The endogenous ligands of CLEC-2 
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include podoplanin and heme. Rhodocytin induces a stronger aggregatory response than 
podoplanin (Suzuki-Inoue et al., 2007) but no studies comparing rhodocytin and heme 
have been published. As Btk inhibits more potently downstream of CLEC-2 at submaximal 
concentrations of rhodocytin, it is not unreasonable to believe that CLEC-2 mediated 
podoplanin signalling would be inhibited. It is beneficial to use acalabrutinib to inhibit 
podoplanin / heme induced CLEC-2 signalling, whilst likely sparing GPVI signalling. 
Although if the activation of CLEC-2 is very high, it may only have partial effectiveness. 
CLEC-2 has also been demonstrated to play a role in thromboinflammation. After infection 
with salmonella, tissue macrophages upregulate podoplanin on the surface in response to 
inflammation. This activates CLEC-2, leading to hepatic thrombus formation (Hitchcock et 
al., 2015). CLEC-2 is also implicated in playing a role in venous thrombosis, as CLEC-2 
KO mice are protected from venous thrombosis (Payne et al., 2017). Therefore inhibiting 
Btk, which is downstream of CLEC-2 may be beneficial in reducing the increased risk of 
VTE which COVID19 patients have (Chang et al., 2020, Al-Samkari et al., 2020).  
In vivo work using ibrutinib in a mouse model of protection of venous thrombosis has 
shown a trend towards inhibition, but no significant reduction (Nicolson et al., 2020). It 
may be that the mice may not have full pharmacological blockage throughout the 48 
hours required for the model, and that mouse CLEC-2 is not as critically dependent on Btk 
as human CLEC-2 signalling. Nonetheless, CLEC-2 does play a role in DVT, and as this 
is frequently seen in patients with COVID19, Btk is a potential therapeutic target.  
A case study followed a CLL patient who was taking ibrutinib prior to COVID-19. Upon 
admittance to the hospital, the ibrutinib therapy stopped, however the disease 
progressed, with elevated D-Dimers. Ibrutinib therapy was resumed whilst the patient was 
extubated, and the levels of D-Dimer dropped. This suggests that inhibition of Btk with 
ibrutinib may have a protective effect in thromboinflammatory COVID-19 (Lin et al., 2020).  
However, there is conflicting literature about whether CLEC-2 inhibition is suitable in all 
models of thromboinflammation. Absence of platelet CLEC-2 accelerates lung function 
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decline in a model of ARDS (Lax et al., 2017), and COVID19 involves damage of the 
lungs, so Btk inhibition downstream of CLEC-2 may further this lung damage. CLEC-2 
deletion results in a more severe phenotype of organ failure during sepsis, which is 
another thromboinflammatory condition (Rayes et al., 2017). Therefore, inhibition of the 
CLEC-2 signalling cascade with acalabrutinib may not be wholly beneficial. Of note, these 
experiments were performed using CLEC-2 KO mice. This total lack of signalling may 
explain the phenotype, therefore a partial inhibition of the CLEC-2 signalling pathway may 
not result in as severe phenotype as a knockout.  
Entry of virus is believed to occur  via angiotensin converting enzyme 2 (ACE2) and there 
is controversy whether this is present on platelets. One group has proposed that viral 
particles and COVID19 spike proteins can potentiate platelet activation in response to 
collagen and thrombin and this is through direct interaction of the virus with ACE2 (Zhang 
et al., 2020). The downstream signalling after ACE2 engagement is through MAPK, and 
Btk is not believed to play a role downstream of this pathway (Zhang et al., 2020). 
Therefore, inhibition of Btk would not yield any differing outcomes of disease. 
In contrast, it has been reported that ACE2 is not expressed in platelets, but viral entry 
can still occur (Manne et al., 2020). This group and others propose that there are 
alternate mechanisms for SARS-COV-2 to mediate entry into cells, and this may be 
through toll like receptors (Patra et al., 2020, Manne et al., 2020). Initially thought to only 
bind lipopolysaccharide and therefore bacteria, TLR4 has been shown to be activated by 
viral particles, such as dengue virus non-structural protein 1 (Olejnik et al., 2018, 
Modhiran et al., 2017). 
TLR4 is present on platelets, macrophages and monocytes, where it is known that Btk 
contributes to mediating the signalling resulting in increased cytokine release (Gilbert et 
al., 2003).  The cytokine storm produced by macrophages and monocytes contributes to 
lung damage (Krupa et al., 2014). It has been shown previously that silencing Btk using 
siRNA supresses the production of IL-6, Tumour necrosis factor α, (TNF-α) and results in 
less interstitial lung damage from LPS mediated sepsis (Zhou et al., 2014).  
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TLR4 is present in platelets, and signalling can occur through Myeloid differentiation 
factor-88- (MyD88-) dependent and independent pathways (Vallance et al., 2017). TLR4 
signalling through the MyD88- pathway results in production of TNF-α, contributing to the 
cytokine storm. In neutrophils, Btk has been seen to directly act with MyD88-  (Krupa et 
al., 2013), and therefore it is not unreasonable to believe that Btk could be involved in the 
MyD88- signalling pathway in platelets. Inhibiting Btk in platelets could inhibit release of 
TNF-α, reducing the pro-inflammatory effects seen in COVID19 patients.  
Furthermore, indirect evidence of platelet Btk being important downstream of TLR has 
been published. Platelet Btk is important for maintaining the lung integrity in 
Streptococcus pneumoniae induced pneumonia, but it is not required for host defence as 
the levels of colony forming units are similar in WT littermate controls. Platelets were less 
activated and as a result, there was an increase in the bleeding score and D-Dimers (de 
Porto et al., 2019).  However, platelet GPVI is not responsible for mediating the response 
of Streptococcus induced pneumococcal pneumonia (Claushuis et al., 2018, de Porto et 
al., 2019), so Btk must be required in another pathway. It is not known whether platelet 
Btk and its role in maintaining lung integrity is mediated through CLEC-2 signalling as the 
C type lectin receptor Mincle on macrophages has the ability to bind to this bacterium 
(Rabes et al., 2015), but platelet CLEC-2 has not yet been studied. However, 
Streptococcus pneumoniae has been shown to induce platelet aggregation via TLR 
activation, leading to initiation of PI3K signalling (Keane et al., 2010). This would 
subsequently involve Btk recruitment. Taken together, this suggests that Btk may be 
downstream of TLR signalling in platelets. 
However, these studies investigate the role of Btk and the aforementioned receptors 
downstream of bacteria, and not viruses using Btk deficient mice. The work in this thesis 
contributes the notion that Btk is required downstream of GPVI and CLEC-2, but catalytic 
activity is not, so the severe phenotype seen in the work of de Porto et al. may be related 
to a loss of a scaffolding role of Btk downstream of GPVI. Furthermore, as there is a 
difference in the platelet-host response between species of bacteria (de Porto et al., 2019, 
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Claushuis et al., 2018), it would be expected there would be differences between bacteria 
and virus. Therefore, although Btk inhibition may not be beneficial in response to bacteria, 
it could be in response to viral mediated inflammation.  
There are only limited reports, but both GPVI and CLEC-2 have been shown to interact 
with viruses. GPVI is reported to interact with the hepatitis C virus, and CLEC-2 with 
human immunodeficiency virus although the clinical significance is unknown (Chaipan et 
al., 2006, Zahn et al., 2006). Therefore, it is not wholly unreasonable that COVID19 could 
bind to these (hem)ITAM containing receptors. However, neither of these studies 
investigate intracellular tyrosine kinase signalling, so it is unclear if these viruses are 
causing activation of the platelet, and therefore using a Btk inhibitor may not be clinically 
beneficial.  
Furthermore, in a gene expression study, Btk gene expression is reduced in platelets from 
patients with COVID19. Reduced gene expression compared to healthy donors suggests 
that Btk is not essential in the platelet in promoting the inflammatory response (Manne et 
al., 2020). Furthermore, only 40% of CLL clinicians would continue patients on their 
current Btk inhibitor regime (Koffman et al., 2020). Further work with CLL patients 
identified that there were similar survival rates of COVID19 patients taking Btk inhibitors 
compared to patients who did not receive their Btk inhibitors (Mato et al., 2020). However, 
a large proportion of patients had their Btk inhibitor held when symptomatic for COVID19, 
suggesting that these survival rates may not be accurate.  
Further reasons why Btk inhibition would be an undesirable target in COVID19 are the 
development of immunity to the virus and/or a vaccine. Btk is responsible for mediating B 
cell maturity, and therefore the production of IgG, as XLA patients in Btk have low serum 
IgG (Conley, 1985). Inhibition of Btk with acalabrutinib would likely prevent the production 
of antibodies needed to build immunity to the virus, leading patients taking acalabrutinib to 
be more susceptible to disease. 
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Finally, although it is not reported that there is an increased risk of haemhorage for 
patients taking acalabrutinib, COVID19 patients do have an altered coagulopathy. One 
study identified that the percentage of COVID19 patients with venous thrombosis was 
similar to the number that experienced haemhorage (Al-Samkari et al., 2020), including 
one fatal bleed. Therefore using a platelet inhibitor such as acalabrutinib may result in 









7.4 Conclusion  
In this thesis, we show that the catalytic activity of Btk is not required downstream of GPVI 
mediated platelet responses and a cell line model of GPVI signalling (Figure 7.4.1, left 
panel). We also show that Btk catalytic activity is not required for its localisation or 
clustering, however we do show that it is involved in the regulation of GPVI clustering 
through an unknown mechanism. We also confirm published biochemical studies showing 
that Btk can interact with LAT, supporting its recruitment to the signalosome.   
Whereas, downstream of CLEC-2, at submaximal concentrations of CLEC-2 agonist, Btk 
is a  kinase as platelet responses are inhibited at concentrations where there is no 
evidence of Btk catalytic activity. This was also confirmed in a cell line model of CLEC-2 
signalling. Similarly to GPVI signalling, Btk and LAT colocalise when platelets spread on a 
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CLEC-2 agonist, showing that this interaction is similar across (hem)ITAM signalling 
(Summarised in Figure 7.4.1 middle panel). At high concentrations of rhodocytin, Btk 
activity is not required as CLEC-2 mediated signalling and aggregation can occur when 
phosphorylation of Btk is lost (Figure 7.4.1 right panel). The dependency of CLEC-2 









Figure 7.4.1 Overview of the role of Btk downstream of GPVI and CLEC-2 
At concentrations of CRP-XL used in this study (left panel), Btk mediates GPVI signalling through a scaffolding role, and it localises with LAT. 
At submaximal concentrations of rhodocytin (centre panel), Btk mediates CLEC-2 signalling through its kinase activity, as shown by the green 
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arrows (phosphorylation arrows are shown in green). Whereas at high concentrations (right panel), aggregation is independent on Btk and 
mediated through secondary mediators or scaffold function of Btk.  Independent of agonist, Btk localises with LAT (shown in orange), and 
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